Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2E)-2-[(4-hydroxy-3-methylphenyl)methylidene]-N-(5-sulfanylidene-4,5-dihydro-1,3,4-thiadiazol-2-yl)hydrazine-1-carboxamide
-
(2E)-2-[(4-hydroxyphenyl)methylidene]-N-(5-sulfanylidene-4,5-dihydro-1,3,4-thiadiazol-2-yl)hydrazine-1-carboxamide
-
(E)-3-iodo-1-styryl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
(R)-1-[4-(benzenesulfonyl)-2-benzylpiperazin-1-yl]ethan-1-one
-
(R)-17(R)-4-[2-benzyl-4-(4-sulfamoylbenzoyl)piperazine-1-carbonyl]benzene-1-sulfonamide
-
(R)-4-(2,4-dibenzylpiperazine-1-carbonyl)benzenesulfonamide
-
(R)-4-(2-benzyl-4-methanesulfonylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(R)-4-(2-benzyl-4-methylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(R)-4-(3,4-dibenzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(R)-4-(3-benzyl-4-methanesulfonylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(R)-4-(3-benzyl-4-methylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(R)-4-(3-benzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(R)-4-(4-acetyl-3-benzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(R)-4-(4-benzoyl-2-benzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(R)-4-(4-benzoyl-3-benzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(R)-4-[2-benzyl-4-(2-phenylacetyl)piperazine-1-carbonyl]benzene-1-sulfonamide
-
(R)-4-[3-benzyl-4-(2-phenylacetyl)piperazine-1-carbonyl]benzene-1-sulfonamide
-
(R)-4-[4-(benzenesulfonyl)-2-benzylpiperazine-1-carbonyl]benzene-1-sulfonamide
-
(R)-4-[4-(benzenesulfonyl)-3-benzylpiperazine-1-carbonyl]benzene-1-sulfonamide
-
(S)-1-[4-(benzenesulfonyl)-2-benzylpiperazin-1-yl]ethan-1-one
-
(S)-2-(2-ammoniopropanamido)-4-methylbenzo[d]thiazol-3-ium di-2,2,2-trifluoroacetate
-
(S)-4-(2,4-dibenzylpiperazine-1-carbonyl)benzenesulfonamide
-
(S)-4-(2-benzyl-4-methanesulfonylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(S)-4-(2-benzyl-4-methylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(S)-4-(3,4-dibenzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(S)-4-(3-benzyl-4-methanesulfonylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(S)-4-(3-benzyl-4-methylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(S)-4-(3-benzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(S)-4-(4-acetyl-3-benzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(S)-4-(4-benzoyl-2-benzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(S)-4-(4-benzoyl-3-benzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(S)-4-[2-benzyl-4-(2-phenylacetyl)piperazine-1-carbonyl]benzene-1-sulfonamide
-
(S)-4-[2-benzyl-4-(4-sulfamoylbenzoyl)piperazine-1-carbonyl]benzene-1-sulfonamide
-
(S)-4-[3-benzyl-4-(2-phenylacetyl)piperazine-1-carbonyl]benzene-1-sulfonamide
-
(S)-4-[4-(benzenesulfonyl)-2-benzylpiperazine-1-carbonyl]benzene-1-sulfonamide
-
(S)-4-[4-(benzenesulfonyl)-3-benzylpiperazine-1-carbonyl]benzene-1-sulfonamide
-
(S)-benzyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxopropan-2-yl)carbamate
-
(S)-benzyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate
-
(S)-tert-butyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate
-
(S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate
-
(S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate
-
(S)-tert-butyl (1-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate
-
1,3-bis(4-bromobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
1,3-dimethylpyrimidine-2,4(1H,3H)-dione
inhibition of isozyme hCA I
1-(3-cyanobenzyl)-3-(2,3,4,5,6-pentamethyl-benzyl)-3H-benzoimidazol-1-ium bromide
inhibitory to carbonic anhydrase, alpha-glycosidase, butyrylcholinesterase, and acetylcholinesterase
1-(3-cyanobenzyl)-3-(2,3,5,6-tetramethyl-benzyl)-3H-benzoimidazol-1-ium bromide
inhibitory to carbonic anhydrase, alpha-glycosidase, butyrylcholinesterase, and acetylcholinesterase
1-(3-cyanobenzyl)-3-(2,4,6-trimethyl-benzyl)-3H-benzoimidazol-1-ium bromide
inhibitory to carbonic anhydrase, alpha-glycosidase, butyrylcholinesterase, and acetylcholinesterase
1-(3-cyanobenzyl)-3-(2-methylbenzyl)-3H-benzoimidazol-1-ium bromide
inhibitory to carbonic anhydrase, alpha-glycosidase, butyrylcholinesterase, and acetylcholinesterase
1-(3-cyanobenzyl)-3-(4-methylbenzyl)-3H-benzoimidazol-1-ium bromide
inhibitory to carbonic anhydrase, alpha-glycosidase, butyrylcholinesterase, and acetylcholinesterase
1-(3-fluorobenzyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
1-(4-chlorobenzyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
1-(4-methoxyphenyl)-2-methyl-3-nitro-1-H-indol-6-ol
ID-8
1-anilino-3-[(oxolan-2-yl)methoxy]propane-2-thiol
inhibits carbonic anhydrase, acetylcholinesterase and alpha-glycosidase
1-anilino-4,4,5,5-tetrafluoropentane-2-thiol
inhibits carbonic anhydrase, acetylcholinesterase and alpha-glycosidase
1-benzyl-3-(2,4,6-trimethoxybenzyl)-2-methylimidazolium chloride
-
1-benzyl-3-(N-methyphthalimide)-2-methylimidazolium bromide
-
1-benzyl-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
1-benzyl-3-[2-(4-hydroxyphenyl)ethyl]-2-methylimidazolium bromide
-
1-butyl-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
1-decyl-3-(2,4,6-trimethoxybenzyl)-2-methylimidazolium chloride
-
1-decyl-3-(N-methyphthalimide)-2-methylimidazolium bromide
-
1-decyl-3-[2-(4-hydroxyphenyl)ethyl]-2-methylimidazolium bromide
-
1-methoxy-3-(3-methylanilino)propane-2-thiol
inhibits carbonic anhydrase, acetylcholinesterase and alpha-glycosidase
2,2'-(1-(4-bromophenyl)ethane-1,1-diyl)bis(sulfanediyl)diacetic acid
inhibits acetylcholinesterase, butyrylcholinesterase, and carbonic anhydrase
2,2'-(1-(4-methoxyphenyl)ethane-1,1-diyl)bis(sulfanediyl)bis(N-(pyridin-2-yl)acetamide)
inhibits acetylcholinesterase, butyrylcholinesterase, and carbonic anhydrase
2,2'-(1-(4-methoxyphenyl)ethane-1,1-diyl)bis(sulfanediyl)diacetic acid
inhibits acetylcholinesterase, butyrylcholinesterase, and carbonic anhydrase
2,2'-(1-(4-nitrophenyl)ethane-1,1-diyl)bis(sulfanediyl)bis(N-(pyridin-2-yl)acetamide)
inhibits acetylcholinesterase, butyrylcholinesterase, and carbonic anhydrase
2,2'-(1-phenylethane-1,1-diyl)bis(sulfanediyl)bis(N-benzylacetamide)
inhibits acetylcholinesterase, butyrylcholinesterase, and carbonic anhydrase
2,2'-(1-phenylethane-1,1-diyl)bis(sulfanediyl)bis(N-p-tolylacetamide)
inhibits acetylcholinesterase, butyrylcholinesterase, and carbonic anhydrase
2-((2,6-dichlorobenzyl)thio)-6-phenyl-5-(piperidin-1-ylmethyl) imidazo[2,1-b][1,3,4]-thiadiazole
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
2-((2,6-dichlorobenzyl)thio)-6-phenyl-5-(pyrrolidin-1-ylmethyl) imidazo[2,1-b][1,3,4]-thiadiazole
-
2-((2,6-dichlorobenzyl)thio)-6-phenylimidazo[2,1-b][1,3,4] thiadiazole
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
2-((2,6-difluorobenzyl)thio)-6-phenylimidazo[2,1-b][1,3,4] thiadiazole
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
2-((2-chloro-6-fluorobenzyl)thio)-6-(3,4-dichlorophenyl)imidazo [2,1-b][1,3,4]thiadiazole
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
2-((2-chloro-6-fluorobenzyl)thio)-6-(4-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazole
noncompetitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
2-((2-chloro-6-fluorobenzyl)thio)-6-(4-fluorophenyl)imidazo[2,1-b][1,3,4]thiadiazole
competitive. competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
2-((2-chloro-6-fluorobenzyl)thio)-6-(4-methoxyphenyl)imidazo [2,1-b][1,3,4]thiadiazole
noncompetitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
2-((2-chloro-6-fluorobenzyl)thio)-6-phenylimidazo[2,1-b][1,3,4] thiadiazole
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
2-(3-methoxypropyl)-4-(methylamino)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 -
2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA I
2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA I
2-[(ethylsulfanyl)(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]malononitrile
inhibits carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and alpha-glycosidase
3-imino-1-ethylsulfanyl-5,6,7,8-tetrahydro-3H-pyrrolo[1,2-a]indole-2-carboxamide
inhibits carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and alpha-glycosidase
3-iodo-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
3-iodo-1-(prop-2-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
3-iodo-1-phenethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
3-iodo-1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
4,5-dichloro-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA I, i.e. daranide
4-((2-((2,6-dichlorobenzyl)thio)-6-phenylimidazo[2,1-b][1,3,4] thiadiazol-5-yl)methyl)-morpholine
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
4-((2-((2,6-difluorobenzyl)thio)-6-phenylimidazo[2,1-b][1,3,4] thiadiazol-5-yl)methyl)-morpholine
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
4-((2-((2-chloro-6-fluorobenzyl)thio)-6-phenylimidazo[2,1-b] [1,3,4]thiadiazol-5-yl)methyl)morpholine
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
4-(2-((2-chloro-6-fluorobenzyl)thio)imidazo[2,1-b][1,3,4] thiadiazol-6-yl)benzonitrile
noncompetitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
4-(2-methylphenyl)benzene-1-sulfonamide
-
4-(3-formylphenyl)benzene-1-sulfonamide
-
4-(3-quinolinyl)benzene-1-sulfonamide
-
4-benzyl-6-(thiophen-2-yl)pyrimidin-2-amine
inhibits carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and alpha-glycosidase
4-phenylbenzene-1-sulfonamide
-
4-[(2R)-2-benzylpiperazine-1-carbonyl]benzene-1-sulfonamide
-
4-[(2S)-2-benzylpiperazine-1-carbonyl]benzene-1-sulfonamide
-
4-[(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl]-2-methoxyphenyl methanesulfonate
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
4-[(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl]phenylmethanesulfonate
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
5,6-diamino-1,3-dimethyluracil
inhibition of isozyme hCA I
5-(hydroxymethyl)pyrimidine-2,4(1H,3H)-dione
inhibition of isozyme hCA I
5-bromo-1-(4-methylbenzene-1-sulfonyl)pyrimidine-2,4(1H,3H)-dione
inhibition of isozyme hCA I
5-bromo-1-(methanesulfonyl)pyrimidine-2,4(1H,3H)-dione
inhibition of isozyme hCA I
6-(4-bromophenyl)-2-((2-chloro-6-fluorobenzyl)thio)imidazo[2,1-b][1,3,4]thiadiazole
noncompetitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
6-([1,1'-biphenyl]-4-yl)-2-((2-chloro-6-fluorobenzyl)thio)imidazo [2,1-b][1,3,4]thiadiazole
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
6-amino-1,3-dimethyluracil
inhibition of isozyme hCA I
6-chloro-4-amino-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA I
6-methyl-4-(methylamino)-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 -
6-methylpyrimidine-2,4(1H,3H)-dione
inhibition of isozyme hCA I
6-trifluoromethyl-4-aminobenzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA I
benzene-1,2-diol
inhibition of isozyme hCA I
benzene-1,3-diol
inhibition of isozyme hCA I
Benzyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate
-
benzyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate
-
benzyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate
-
brinzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA I
Cu-GGHSLN
time-dependent inactivation of carbonic anhydrase I activity, within 3 h carbonic anhydrase I activity is eliminated at 0.005 mM Cu-GGHSLN
-
dorzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA I
ethyl 5-phenyl-1H-pyrrole-2-carbodithioate
inhibits carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and alpha-glycosidase
-
Furosemide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA I
H2NSO2NH2
isoenzyme hCA I
hydrochlorothiazide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA I
Isoorotic acid
inhibition of isozyme hCA I
methyl 2-[(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl]-3-nitrobenzoate
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
N'-[(1Z)-1-(5-chlorothiophen-3-yl)ethylidene]butane-1-sulfonohydrazide
good inhibitor of alpha-glycosidase, human carbonic anhydrase I and II isoforms and acetylcholinesterase enzyme
N'-[(1Z)-1-(furan-3-yl)ethylidene]butane-1-sulfonohydrazide
good inhibitor of alpha-glycosidase, human carbonic anhydrase I and II isoforms and acetylcholinesterase enzyme
N'-[(1Z)-1-(thiophen-3-yl)ethylidene]butane-1-sulfonohydrazide
good inhibitor of alpha-glycosidase, human carbonic anhydrase I and II isoforms and acetylcholinesterase enzyme
N'-[(Z)-(1H-indol-3-yl)methylidene]butane-1-sulfonohydrazide
good inhibitor of alpha-glycosidase, human carbonic anhydrase I and II isoforms and acetylcholinesterase enzyme
N-(1-(2-hydroxyphenylamino)-3-methyl-1-oxobutan-2-ylcarbamothioyl)benzamide
i.e. NK-154, binding structure, overview
N-(1-(2-hydroxyphenylamino)-4-methyl-1-oxopentan-2-ylcarbamothioyl) benzamide
i.e. NK-168, binding structure, overview
N-hydroxysulfamide
isoenzyme hCA I
N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 -
Orotic acid
inhibition of isozyme hCA I
sulthiame
isoenzyme hCA I
tert-butyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate
-
tert-butyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)-carbamate
-
tert-butyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate
-
topiramate
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA I
tris(2-pyridyl)phosphine selenide
inhibits carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and alpha-glycosidase
tris(2-pyridyl)phosphine sulfide
inhibits carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and alpha-glycosidase
zonisamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA I
[Co(1-benzyl-2-methylimidazole)2Cl2]
-
[Hg(1-benzyl-2-methylimidazole)2Cl2]
-
[Zn(1-benzyl-2-methylimidazole)2Cl2]
-
[[(eta5-C5H4)-C(CH3)=N-N(H)-C6H4-4-SO2NH2]]FeCp
-
-
[[(eta5-C5H4)-C(CH3)=N-N(H)-C6H4-4-SO2NH2]]Mn(CO)3
-
-
[[(eta5-C5H4)-C(CH3)=N-N(H)-C6H4-4-SO2NH2]]re(CO)3
-
-
[[(eta5-C5H4)-CH=N-N(H)-C6H4-4-SO2NH2]]FeCp
-
-
[[(eta5-C5H4)-CH=N-N(H)-C6H4-4-SO2NH2]]Mn(CO)3
-
-
[[(eta5-C5H4)-CH=N-N(H)-C6H4-4-SO2NH2]]re(CO)3
-
-
(2,4,6-triisopropylphenyl)sulfonylsulfamic acid
-
-
(2,4,6-tripropylphenyl)sulfonylsulfamic acid
-
-
(2,5-dichlorophenyl)sulfonylsulfamic acid
-
-
(2-nitrophenyl)sulfonylsulfamic acid
-
-
(2E)-2-[(4-hydroxy-3-methylphenyl)methylidene]-N-(5-sulfanylidene-4,5-dihydro-1,3,4-thiadiazol-2-yl)hydrazine-1-carboxamide
-
(2E)-2-[(4-hydroxyphenyl)methylidene]-N-(5-sulfanylidene-4,5-dihydro-1,3,4-thiadiazol-2-yl)hydrazine-1-carboxamide
-
(2E)-4-methoxy-4-oxobut-2-enoic acid
-
-
(2E)-but-2-enedioic acid
-
-
(2R)-3-(3-chloro-4-hydroxyphenyl)-2-[[(2E)-4-methoxy-4-oxobut-2-enoyl]amino]propanoic acid
-
-
(2S)-3-(3-chloro-4-hydroxyphenyl)-2-[[(2E)-4-methoxy-4-oxobut-2-enoyl]amino]propanoic acid
-
-
(3,5-dichloro-2-hydroxyphenyl)sulfonylsulfamic acid
-
-
(3-chloro-4-hydroxyphenyl)acetic acid
-
-
(3-chloro-4-nitrophenyl)sulfonylsulfamic acid
-
-
(3-chlorophenyl)acetic acid
-
-
(3-nitrophenyl)sulfonylsulfamic acid
-
-
(3aR,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl sulfamate
-
-
(4-acetylphenyl)sulfonylsulfamic acid
-
-
(4-bromophenyl)sulfonylsulfamic acid
-
-
(4-chlorophenyl)sulfonylsulfamic acid
-
-
(4-fluorophenyl)sulfonylsulfamic acid
-
-
(4-hydroxyphenyl)acetic acid
-
-
(4-iodophenyl)sulfonylsulfamic acid
-
-
(4-methoxyphenyl)sulfonylsulfamic acid
-
-
(4-methylphenyl)sulfonylsulfamic acid
-
-
(4-nitrophenyl)sulfonylsulfamic acid
-
-
(5Z)-2-amino-5-(3,4-dihydroxybenzylidene)-3,5-dihydro-4H-imidazol-4-one
-
-
(5Z)-2-amino-5-(4-hydroxy-3-methoxybenzylidene)-3,5-dihydro-4H-imidazol-4-one
-
-
(E)-3-iodo-1-styryl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
(heptadecafluorooctyl)sulfonylsulfamic acid
-
-
(nonafluorobutyl)sulfonylsulfamic acid
-
-
(pentafluorophenyl)sulfonylsulfamic acid
-
-
(R)- 4-(2-benzyl-4-methylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(R)- 4-(4-benzoyl-2-benzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(R)-1-[4-(benzenesulfonyl)-2-benzylpiperazin-1-yl]ethan-1-one
-
(R)-17(R)-4-[2-benzyl-4-(4-sulfamoylbenzoyl)piperazine-1-carbonyl]benzene-1-sulfonamide
-
(R)-4-(2,4-dibenzylpiperazine-1-carbonyl)benzenesulfonamide
-
(R)-4-(2-benzyl-4-methanesulfonylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(R)-4-(3,4-dibenzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(R)-4-(3-benzyl-4-methanesulfonylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(R)-4-(3-benzyl-4-methylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(R)-4-(3-benzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(R)-4-(4-acetyl-3-benzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(R)-4-(4-benzoyl-3-benzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(R)-4-[2-benzyl-4-(2-phenylacetyl)piperazine-1-carbonyl]benzene-1-sulfonamide
-
(R)-4-[3-benzyl-4-(2-phenylacetyl)piperazine-1-carbonyl]benzene-1-sulfonamide
-
(R)-4-[4-(benzenesulfonyl)-2-benzylpiperazine-1-carbonyl]benzene-1-sulfonamide
-
(R)-4-[4-(benzenesulfonyl)-3-benzylpiperazine-1-carbonyl]benzene-1-sulfonamide
-
(S)- 4-(2-benzyl-4-methylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(S)- 4-(4-benzoyl-2-benzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(S)-1-[4-(benzenesulfonyl)-2-benzylpiperazin-1-yl]ethan-1-one
-
(S)-4-(2,4-dibenzylpiperazine-1-carbonyl)benzenesulfonamide
-
(S)-4-(2-benzyl-4-methanesulfonylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(S)-4-(3,4-dibenzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(S)-4-(3-benzyl-4-methanesulfonylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(S)-4-(3-benzyl-4-methylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(S)-4-(3-benzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(S)-4-(4-acetyl-3-benzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(S)-4-(4-benzoyl-3-benzylpiperazine-1-carbonyl)benzene-1-sulfonamide
-
(S)-4-[2-benzyl-4-(2-phenylacetyl)piperazine-1-carbonyl]benzene-1-sulfonamide
-
(S)-4-[2-benzyl-4-(4-sulfamoylbenzoyl)piperazine-1-carbonyl]benzene-1-sulfonamide
-
(S)-4-[3-benzyl-4-(2-phenylacetyl)piperazine-1-carbonyl]benzene-1-sulfonamide
-
(S)-4-[4-(benzenesulfonyl)-2-benzylpiperazine-1-carbonyl]benzene-1-sulfonamide
-
(S)-4-[4-(benzenesulfonyl)-3-benzylpiperazine-1-carbonyl]benzene-1-sulfonamide
-
(S)-benzyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxopropan-2-yl)carbamate
-
(trichloromethyl)sulfonylsulfamic acid
-
-
(trifluoromethyl)sulfonylsulfamic acid
-
-
1,1,1-trifluoromethanesulfonamide
-
1,1,2,2,3,3,4,4 octafluoro-n-butane-1-4-bissulfonamide
-
-
1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluoro-n-hexane-1-sulfonamide
-
-
1,1,2,2,3,3,4,4,5,5,6,6,7,7,7-pentadecafluoro-n-heptane-1-sulfonamide
-
-
1,1-dimethyl-4-(7-sulfamoyl-4H-[1,2,3]thiadiazolo[3,4-a]benzimidazol-3-yl)piperazin-1-ium iodide
-
1,2,4-trimethoxybenzene
-
-
1,2-bis[(2,4-dichloro-5-sulfonamidobenzamide)ethoxy]ethane
-
-
1,2-bis[(2,4-dichloro-5-sulfonamidobenzoate)-ethoxy]ethane
-
-
1,2-bis[(4-sulfonamidobenzamide)ethoxy]ethane
-
-
1,2-bis[(4-sulfonamidobenzoate)ethoxy]ethane
-
-
1,2:3,4-di-O-isopropylidene-alpha-D-galactopyranose 6-sulfamate
-
-
1,2:5,6-di-O-isopropylidene-alpha-D-glucofuranose 3-sulfamate
-
-
1,3-bis(4-bromobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
1,3-dimethylpyrimidine-2,4(1H,3H)-dione
inhibition of isozyme hCA II
1,3-dioxolan-2-yl-N-(2-propenyl)-2-thiophene-sulfonamide
-
-
1-(1,2-benzoxazol-3-yl)methanesulfonamide
-
-
1-(3-cyanobenzyl)-3-(2,3,4,5,6-pentamethyl-benzyl)-3H-benzoimidazol-1-ium bromide
inhibitory to carbonic anhydrase, alpha-glycosidase, butyrylcholinesterase, and acetylcholinesterase
1-(3-cyanobenzyl)-3-(2,3,5,6-tetramethyl-benzyl)-3H-benzoimidazol-1-ium bromide
inhibitory to carbonic anhydrase, alpha-glycosidase, butyrylcholinesterase, and acetylcholinesterase
1-(3-cyanobenzyl)-3-(2,4,6-trimethyl-benzyl)-3H-benzoimidazol-1-ium bromide
inhibitory to carbonic anhydrase, alpha-glycosidase, butyrylcholinesterase, and acetylcholinesterase
1-(3-cyanobenzyl)-3-(2-methylbenzyl)-3H-benzoimidazol-1-ium bromide
inhibitory to carbonic anhydrase, alpha-glycosidase, butyrylcholinesterase, and acetylcholinesterase
1-(3-cyanobenzyl)-3-(4-methylbenzyl)-3H-benzoimidazol-1-ium bromide
inhibitory to carbonic anhydrase, alpha-glycosidase, butyrylcholinesterase, and acetylcholinesterase
1-(3-fluorobenzyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
1-(4-chlorobenzyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
1-(4-methoxyphenyl)-2-methyl-3-nitro-1-H-indol-6-ol
ID-8
1-anilino-3-[(oxolan-2-yl)methoxy]propane-2-thiol
inhibits carbonic anhydrase, acetylcholinesterase and alpha-glycosidase
1-anilino-4,4,5,5-tetrafluoropentane-2-thiol
inhibits carbonic anhydrase, acetylcholinesterase and alpha-glycosidase
1-benzyl-3-(2,4,6-trimethoxybenzyl)-2-methylimidazolium chloride
-
1-benzyl-3-(N-methyphthalimide)-2-methylimidazolium bromide
-
1-benzyl-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
1-benzyl-3-[2-(4-hydroxyphenyl)ethyl]-2-methylimidazolium bromide
-
1-butyl-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
1-cyclohexyl-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamide
-
1-cyclopentyl-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamide
-
1-cyclopropyl-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamide
-
1-decyl-3-(2,4,6-trimethoxybenzyl)-2-methylimidazolium chloride
-
1-decyl-3-(N-methyphthalimide)-2-methylimidazolium bromide
-
1-decyl-3-[2-(4-hydroxyphenyl)ethyl]-2-methylimidazolium bromide
-
1-methoxy-3-(3-methylanilino)propane-2-thiol
inhibits carbonic anhydrase, acetylcholinesterase and alpha-glycosidase
1-n-butyl-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamide
-
1-naphthylsulfonylsulfamic acid
-
-
1-[(2-oxo-2H-chromen-6-yl)methyl]-3,5,7-triaza-1-azoniatricyclo[3.3.1.13,7]decane
-
1-[2-(1H-imidazol-5-yl)ethyl]-4-methyl-2,6-di(propan-2-yl)pyridin-1-ium hexafluorophosphate
-
1H,1H,2H,2H-perfluorodecyl sulfamate
-
-
1H,1H,2H,2H-perfluorooctyl sulfamate
-
-
1H,1H-perfluoroethyl sulfamate
-
-
1H-perfluoroisopropyl sulfamate
-
-
2,2'-(1-(4-bromophenyl)ethane-1,1-diyl)bis(sulfanediyl)diacetic acid
inhibits acetylcholinesterase, butyrylcholinesterase, and carbonic anhydrase
2,2'-(1-(4-methoxyphenyl)ethane-1,1-diyl)bis(sulfanediyl)bis(N-(pyridin-2-yl)acetamide)
inhibits acetylcholinesterase, butyrylcholinesterase, and carbonic anhydrase
2,2'-(1-(4-methoxyphenyl)ethane-1,1-diyl)bis(sulfanediyl)diacetic acid
inhibits acetylcholinesterase, butyrylcholinesterase, and carbonic anhydrase
2,2'-(1-(4-nitrophenyl)ethane-1,1-diyl)bis(sulfanediyl)bis(N-(pyridin-2-yl)acetamide)
inhibits acetylcholinesterase, butyrylcholinesterase, and carbonic anhydrase
2,2'-(1-phenylethane-1,1-diyl)bis(sulfanediyl)bis(N-benzylacetamide)
inhibits acetylcholinesterase, butyrylcholinesterase, and carbonic anhydrase
2,2'-(1-phenylethane-1,1-diyl)bis(sulfanediyl)bis(N-p-tolylacetamide)
inhibits acetylcholinesterase, butyrylcholinesterase, and carbonic anhydrase
2,3,4,5,6-pentafluorobenzene-1-sulfonamide
VD10-9
2,3,4,6-tetra-O-acetyl-N-sulfamoyl-beta-D-galactopyranosylamine
-
-
2,3,4,6-tetra-O-acetyl-N-sulfamoyl-beta-D-glucopyranosylamine
-
-
2,3,4,6-tetra-O-acetyl-N-sulfamoyl-beta-D-mannopyranosylamine
-
-
2,3,4-tri-O-acetyl-6-deoxy-N-sulfamoyl-alpha-L-glucopyranosylamine
-
-
2,3,5,6-tetrafluoro-4-(2-hydroxyethanesulfonyl)benzene-1-sulfonamide
VD10-35
2,3,5,6-tetrafluoro-4-(2-phenylethanesulfonyl)benzene-1-sulfonamide
2,3,5,6-tetrafluoro-4-(morpholin-4-yl)benzene-1-sulfonamide
VD10-12
2,3,5,6-tetrafluoro-4-(phenylsulfanyl)benzene-1-sulfonamide
VD10-18
2,3,5,6-tetrafluoro-4-(propylsulfanyl)benzene-1-sulfonamide
VD12-05
2,3,5,6-tetrafluoro-4-hydrazinylbenzene-1-sulfonamide
VD10-14
2,3,5,6-tetrafluoro-4-[(2-hydroxyethyl)sulfanyl]benzene-1-sulfonamide
VD10-13
2,3,5,6-tetrafluoro-4-[(2-phenylethyl)sulfanyl]benzene-1-sulfonamide
VD11-09
2,3,5-trifluoro-4-[(2-phenylethyl)sulfanyl]-6-[(propan-2-yl)amino]benzene-1-sulfonamide
VD11-71
2,3,5-trifluoro-6-(morpholin-4-yl)-4-[(2-phenylethyl)sulfanyl]benzene-1-sulfonamide
VD11-67
2,3,6-trifluoro-4-(2-hydroxyethanesulfonyl)-5-[[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]amino]benzene-1-sulfonamide
-
2,3,6-trifluoro-5-[[(1R,2R)-2-hydroxy-1,2-diphenylethyl]amino]-4-(2-phenylethanesulfonyl)benzene-1-sulfonamide
VD11-39
2,4,6-trichlorophenyl sulfamate
-
-
2,4-bis(4-hydroxyphenyl)-5H-indeno[1,2-b]pyridin-5-one
-
-
2,6-dimethoxybenzoic acid
-
-
2-((2,6-dichlorobenzyl)thio)-6-phenyl-5-(piperidin-1-ylmethyl) imidazo[2,1-b][1,3,4]-thiadiazole
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
2-((2,6-dichlorobenzyl)thio)-6-phenyl-5-(pyrrolidin-1-ylmethyl) imidazo[2,1-b][1,3,4]-thiadiazole
-
2-((2,6-dichlorobenzyl)thio)-6-phenylimidazo[2,1-b][1,3,4] thiadiazole
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
2-((2,6-difluorobenzyl)thio)-6-phenylimidazo[2,1-b][1,3,4] thiadiazole
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
2-((2-chloro-6-fluorobenzyl)thio)-6-(3,4-dichlorophenyl)imidazo [2,1-b][1,3,4]thiadiazole
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
2-((2-chloro-6-fluorobenzyl)thio)-6-(4-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazole
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
2-((2-chloro-6-fluorobenzyl)thio)-6-(4-fluorophenyl)imidazo[2,1-b][1,3,4]thiadiazole
competitive. competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
2-((2-chloro-6-fluorobenzyl)thio)-6-(4-methoxyphenyl)imidazo [2,1-b][1,3,4]thiadiazole
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
2-((2-chloro-6-fluorobenzyl)thio)-6-phenylimidazo[2,1-b][1,3,4] thiadiazole
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
2-(1-methylethyl)-3-[(2-propynylamino)methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
-
-
2-(1-methylethyl)-3-[(4-morpholinyl)methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
-
-
2-(2-hydroxyethyl)-N-(1,1-dimethylethyl)-2H-thieno[3,2-e-]-1,2-thiazine-6-sulfonamide 1,1-dioxide
-
-
2-(2-methoxyethyl)-3-[(4-morpholinyl)methyl]-2-(2-propenyl)-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
-
-
2-(2-methoxyethyl)-3-[[bis(2-methoxyethyl)amino]methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide hydrochloride
-
-
2-(3,4-dimethoxyphenyl)-3-[(4-morpholinyl)methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide hydrochloride
-
-
2-(3-chloro-4-hydroxyphenyl)-N-(2-methoxyethyl)acetamide
-
-
2-(3-chloro-4-hydroxyphenyl)-N-(2-phenylethyl)acetamide
-
-
2-(3-chloro-4-hydroxyphenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]acetamide
-
-
2-(3-chloro-4-hydroxyphenyl)-N-[2-(3-methoxyphenyl)ethyl]acetamide
-
-
2-(3-chloro-4-hydroxyphenyl)-N-[2-(4-sulfamoylphenyl)ethyl]acetamide
-
-
2-(3-chloro-4-hydroxyphenyl)acetamide
-
-
2-(3-hydroxyphenyl)-3-(4-morpholinylmethyl)-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
-
-
2-(3-hydroxyphenyl)-3-[(2-propynylamino)methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide hydrochloride
-
-
2-(3-hydroxypropyl)-3-(4-morpholinylmethyl)-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
-
-
2-(3-methoxyphenyl)-3-[(2-hydroxyethylamino)methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide hydrochloride
-
-
2-(3-methoxyphenyl)-3-[(4-morpholinyl)methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide hydrochloride
-
-
2-(3-methoxypropyl)-3-[(4-morpholinyl)methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
-
-
2-(3-methoxypropyl)-3-[(4-morpholinyl)methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide hydrochloride
-
-
2-(3-methoxypropyl)-4-(methylamino)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
2-(4-hydroxybenzylidene)-2H-indene-1,3-dione
-
-
2-(4-hydroxyphenyl)acetamide
-
-
2-(benzenesulfonamido-N-benzyl)-5-[N,Ndibenzylsulfonamido]-l,3,4-thiadiazole
-
-
2-(benzylamino)-3,5,6-trifluoro-4-(2-hydroxyethanesulfonyl)benzene-1-sulfonamide
VD10-39b
2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide
2-(p-toluenesulfonamido)-l,3,4-thiadiazole-5-sulfonamide
-
-
2-(phenylethynyl)benzenesulfonamide
-
-
2-adamantylethyl 7-methoxy-2-oxo-2H-chromene-8-carboxylate
-
-
2-amino-1-benzothiophen-3(2H)-one 1,1-dioxide
-
-
2-aminobenzenesulfonamide
2-benzene-sulfonamido-l,3,4-thiadiazole-5-sulfonamide
-
-
2-chloro-3-[[(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)sulfanyl]acetyl]benzene-1-sulfonamide
E11-18
2-chloro-3-[[(5-ethylpyrimidin-2-yl)sulfanyl]acetyl]benzene-1-sulfonamide
E11-12
2-chloro-3-[[(5-propylpyrimidin-2-yl)sulfanyl]acetyl]benzene-1-sulfonamide
E11-14
2-chloro-4-[(phenylsulfanyl)acetyl]benzene-1-sulfonamide
E11-6
2-chloro-4-[2-[(prop-2-en-1-yl)amino]-1,3-thiazol-4-yl]benzene-1-sulfonamide
E11-64
2-cyclohexyl-3-[(4-morpholinyl)methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
-
-
2-cyclopropylmethyl-3-[(4-morpholinyl)methyl]-2-(2-propenyl)-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
-
-
2-ethyl-3-[(4-morpholinyl)methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide hydrochloride
-
-
2-ethyl-3-[[bis(2-hydroxyethyl)amino]methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide hydrochloride
-
-
2-ethyl-3-[[bis(2-methoxyethyl)amino]methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide hydrochloride
-
-
2-hydrazinobenzenesulfonamide
2-hydroxycinnamic acid
-
-
2-methyl-2H-thieno[2,3-e]-1,2-thiazine-3-methanol 1,1-dioxide
-
-
2-methyl-2H-thieno[3,2-e]-1,2-thiazine-3-methanol 1,1-dioxide
-
-
2-methyl-3-(4-morpholinylmethyl)-2H-thieno[2,3-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide
-
-
2-methyl-3-(4-morpholinylmethyl)-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide hydrochloride
-
-
2-methyl-3-[(4-morpholinyl)methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
-
-
2-methyl-3-[[N-(2-methoxyethyl)-N-(2-propenyl)amino]methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
-
-
2-methyl-3-[[N-(2-methoxyethyl)-N-(3-methoxypropyl)-amino]methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
-
-
2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide
2-N-(4-sulfamoylphenyl)-thioformyl-L-Ala
-
-
2-N-(4-sulfamoylphenyl)-thioformyl-L-Asn
-
-
2-N-(4-sulfamoylphenyl)-thioformyl-L-Gln
-
-
2-N-(4-sulfamoylphenyl)-thioformyl-L-Ile
-
-
2-N-(4-sulfamoylphenyl)-thioformyl-L-Leu
-
-
2-N-(4-sulfamoylphenyl)-thioformyl-L-Met
-
-
2-N-(4-sulfamoylphenyl)-thioformyl-L-Phe
-
-
2-N-(4-sulfamoylphenyl)-thioformyl-L-Pro
-
-
2-N-(4-sulfamoylphenyl)-thioformyl-L-Trp
-
-
2-N-(4-sulfamoylphenyl)-thioformyl-L-Val
-
-
2-naphthylsulfonylsulfamic acid
-
-
2-nitrobenzenesulfonamide
-
-
2-Nitrophenol
-
product inhibition
2-oxo-2H-chromene-3-carboxylic acid
-
2-oxo-2H-thiochromene-3-carboxylic acid
-
2-phenylethyl sulfamate
-
-
2-propyl-3-[(2-propynylamino)methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
-
-
2-[(4-methoxyphenyl)methyl]-3-[(4-morpholinyl)methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
-
-
2-[(4-methoxyphenyl)methyl]-3-[(4-morpholinyl)methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide hydrochloride
-
-
2-[(4-morpholinyl)phenyl]-3-[(4-morpholinyl)methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide hydrochloride
-
-
2-[(ethylsulfanyl)(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]malononitrile
inhibits carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and alpha-glycosidase
2-[(p-toluenesulfonamido)-N-methyl]-5-[N,N-dimethylsulfonamide]-l,3,4-thiadiazole
-
-
2-[2-(4-morpholinyl)ethyl]-2H-thieno[3,2-e-]-1,2-thiazine-6-sulfonamide 1,1-dioxide hydrochloride
-
-
2-[2-(acetoxy)ethyl]-N-(1,1-dimethylethyl)-4-hydroxy-2H-thieno[3,2-e-]-1,2-thiazine-6-sulfonamide 1,1-dioxide
-
-
2-[2-(propylamino)ethyl]-2H-thieno[3,2-e-]-1,2-thiazine-6-sulfonamide 1,1-dioxide hydrochloride
-
-
2-[2-[4-acetyl-(1-piperazinyl)]ethyl]-2H-thieno[3,2-e-]-1,2-thiazine-6-sulfonamide 1,1-dioxide
-
-
2-[2-[bis(2-methoxyethyl)amino]ethyl]-2H-thieno[3,2-e-]-1,2-thiazine-6-sulfonamide 1,1-dioxide hydrochloride
-
-
2-[4-(4-morpholinyl)-2-butenyl]-2H-thieno[3,2-e-]-1,2-thiazine-6-sulfonamide 1,1-dioxide hydrochloride
-
-
2-[benzenesulfonamido-N-(n-propyl)]-l,3,4-thiadiazole-5-sulfonamide
-
-
2-[[(3,4-dimethoxyphenyl)methyl]amino]-3,5,6-trifluoro-4-[(2-hydroxyethyl)sulfanyl]benzene-1-sulfonamide
VD12-17
2-[[(3,4-dimethoxyphenyl)methyl]amino]-3,5,6-trifluoro-4-[(2-phenylethyl)sulfanyl]benzene-1-sulfonamide
VD12-04
3,3,4,4,5,5,6,6,6-nonafluoro-n-hexanesulfonamide
-
-
3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-n-octanesulfonamide
-
-
3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro-n-decanesulfonamide
-
-
3,4,6-tri-O-acetyl-2-deoxy-N-sulfamoyl-beta-D-arabino-hexopyranosylamine
-
-
3,4,6-tri-O-acetyl-2-deoxy-N-sulfamoyl-beta-D-lyxo-hexopyranosylamine
-
-
3,4-dihydroisoquinoline-2(1H)-sulfonamide
-
3,4-dihydroxybenzoic acid
-
-
3,4-dimethoxybenzoic acid
-
-
3,5-dibromo-2-(1,3-dioxalan-2-yl)-thiophene
-
-
3,5-Dihydroxybenzoic acid
-
-
3-(1,3-dioxolan-2-yl)-N-(2-methoxyethyl)-2-thiophenesulfonamide
-
-
3-(1,3-dioxolan-2-yl)-N-(3,4-dimethoxyphenyl)-2-thiophenesulfonamide
-
-
3-(1,3-dioxolan-2-yl)-N-(3-methoxyphenyl)-2-thiophenesulfonamide
-
-
3-(1,3-dioxolan-2-yl)-N-(4-(4-morpholinyl)phenyl)-2-thiophenesulfonamide
-
-
3-(1,3-dioxolan-2-yl)-N-cyclohexyl-2-thiophenesulfonamide
-
-
3-(1,3-dioxolan-2-yl)-N-[4-(4-morpholinyl)phenyl]-2-thiophenesulfonamide
-
-
3-(4-methylpiperazin-1-yl)-4H-[1,2,3]thiadiazolo[3,4-a]benzimidazole-7-sulfonamide
-
3-(benzylamino)-2,5,6-trifluoro-4-(2-hydroxyethanesulfonyl)benzene-1-sulfonamide
-
3-(benzylamino)-2,5,6-trifluoro-4-(2-phenylethanesulfonyl)benzene-1-sulfonamide
VD11-28
3-(cyclooctylamino)-2,5,6-trifluoro-4-(2-hydroxyethanesulfonyl)benzene-1-sulfonamide
VD11-4-2
3-(methylsulfanyl)-4H-[1,2,3]thiadiazolo[3,4-a]benzimidazole-7-sulfonamide
-
3-(methylsulfonyl)-4H-[1,2,3]thiadiazolo[3,4-a]benzimidazole-7-sulfonamide
-
3-(phenylethynyl)benzenesulfonamide
-
-
3-(phenylsulfanyl)-4H-[1,2,3]thiadiazolo[3,4-a]benzimidazole-7-sulfonamide
-
3-3-(1,3-dioxolan-2-yl)-N-(1-methylethyl)-2-thiophene-sulfonamide
-
-
3-chloro-4H-[1,2,3]thiadiazolo[3,4-a]benzimidazole-7-sulfonamide
-
3-chloromethyl-N-(1,1-dimethylethyl)-2-(3-methoxyphenyl)-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
-
-
3-chloropropyl sulfamate
-
-
3-Hydroxybenzoic acid
-
-
3-hydroxymethyl 2-methyl-2H-thieno[2,3-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide
-
-
3-hydroxymethyl-2-methyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide
-
-
3-imino-1-ethylsulfanyl-5,6,7,8-tetrahydro-3H-pyrrolo[1,2-a]indole-2-carboxamide
inhibits carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and alpha-glycosidase
3-iodo-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
3-iodo-1-(prop-2-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
3-iodo-1-phenethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
3-iodo-1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
3-methylphenylsulfamate
-
-
3-methylsalicylic acid
-
noncompetitive inhibition of isozyme carbonic anhydrase I and uncompetitive inhibition of isozyme carbonic anhydrase II
3-morpholin-4-yl-4H-[1,2,3]thiadiazolo[3,4-a]benzimidazole-7-sulfonamide
-
3-phenylprop-2-ene-1-sulfonamide
-
-
3-phenylpropanenitrile
-
-
3-tributylgermylpropanamine
-
-
3-triethylgermylpropanamine
-
-
3-triethylsilylpropanamine
-
-
3-triphenylgermylpropanamine
-
-
3-[(1-imidazolyl)methyl]-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
-
-
3-[(1H-benzimidazol-1-yl)acetyl]-2-chlorobenzene-1-sulfonamide
E11-36
3-[(1H-benzimidazol-1-yl)acetyl]benzene-1-sulfonamide
E11-37
3-[(2,3,5,6-tetrafluoro-4-sulfamoylphenyl)sulfanyl]propanoic acid
VD11-56
3-[(2,3-dihydro-1H-inden-2-yl)amino]-2,5,6-trifluoro-4-(2-phenylethanesulfonyl)benzene-1-sulfonamide
VD11-16
3-[(2-benzyl-1H-benzimidazol-1-yl)acetyl]-2-chlorobenzene-1-sulfonamide
E11-52
3-[(2-benzyl-1H-benzimidazol-1-yl)acetyl]benzene-1-sulfonamide
E11-53
3-[(3-fluorophenyl)ethynyl]benzenesulfonamide
-
-
3-[(3-methoxyphenyl)ethynyl]benzenesulfonamide
-
-
3-[(4-methylphenyl)ethynyl]benzenesulfonamide
-
-
3-[(4-morpholinyl)methyl]-2-(2-propenyl)-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
-
-
3-[(4-morpholinyl)methyl]-2-propyl-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide hydrochloride
-
-
3-[(adamantan-2-yl)amino]-2,5,6-trifluoro-4-(2-phenylethanesulfonyl)benzene-1-sulfonamide
VD11-17
3-[(anilinocarbonyl)amino]benzenesulfonamide
-
3-[(cyclopropylamino)methyl]-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide hydrochloride
-
-
3-[(sulfoamino)sulfonyl]benzoic acid
-
-
3-[1,3-dioxolan-2-yl]-N-(2-methoxyethyl)-2-thiophenesulfonamide
-
-
3-[1,3-dioxolan-2-yl]-N-(3,4-dimethoxyphenyl)-2-thiophenesulfonamide
-
-
3-[9-borabicyclo[1.3.3.]nonane]-1-bromopropane
-
-
3-[9-borabicyclo[1.3.3.]nonane]-1-propylsulfonic acid sodium salt
-
-
3-[[(1,3-benzothiazol-2-yl)sulfanyl]acetyl]benzene-1-sulfonamide
E11-57
3-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-2,5,6-trifluoro-4-(2-hydroxyethanesulfonyl)benzene-1-sulfonamide
-
3-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-2,5,6-trifluoro-4-(2-phenylethanesulfonyl)benzene-1-sulfonamide
-
3-[[(3,4-dimethoxyphenyl)methyl]amino]-2,5,6-trifluoro-4-(2-hydroxyethanesulfonyl)benzene-1-sulfonamide
-
3-[[(4,6-dimethylpyrimidin-2-yl)sulfanyl]acetyl]benzene-1-sulfonamide
E11-11
3-[[(5-propylpyrimidin-2-yl)sulfanyl]acetyl]benzene-1-sulfonamide
E11-15
3-[[(aminosulfonyl)amino]sulfonyl]benzoic acid
-
-
3-[[bis(2-methoxyethyl)amino]methyl]-2-propyl-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide hydrochloride
-
-
3-[[N-(2-methoxyethyl)-N-(2-propenyl)amino]methyl]-2-methyl-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide hydrochloride
-
-
3-[[N-(2-methoxyethyl)-N-(3-methoxypropyl)amino]methyl]-2-methyl-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide hydrochloride
-
-
3-[[N-(2-methoxyethyl)-N-methylamino]methyl]-2-methyl-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
-
-
3alpha,12alpha-diacetoxy-5beta-cholan-24-oic acid
-
-
3alpha,7alpha,12alpha-triacetoxy-5beta-cholan-24-oic acid
-
-
3alpha-acetoxy-5beta-cholan-24-oic acid
-
-
4,4'-thiodipyridine-3-sulfonamide
-
-
4,4'-[(1R,2R,3S,4S)-3,4-dimethylcyclobutane-1,2-diyl]bis(2-methoxyphenol)
-
-
4,4'-[(1R,2S,3R,4S)-3,4-dimethylcyclobutane-1,2-diyl]bis(2-methoxyphenol)
-
-
4,4'-[(2R,3R)-2,3-dimethylbutane-1,4-diyl]bis(2-methoxyphenol)
-
-
4,5-dichloro-benzene-1,3-disulfonamide
4,5-dichlorobenzene-1,3-disulfonamide
-
-
4,6-dinitrosalicylic acid
-
noncompetitive inhibition of isozymes carbonic anhydrase I and II
4-((2-((2,6-dichlorobenzyl)thio)-6-phenylimidazo[2,1-b][1,3,4] thiadiazol-5-yl)methyl)-morpholine
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
4-((2-((2,6-difluorobenzyl)thio)-6-phenylimidazo[2,1-b][1,3,4] thiadiazol-5-yl)methyl)-morpholine
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
4-((2-((2-chloro-6-fluorobenzyl)thio)-6-phenylimidazo[2,1-b] [1,3,4]thiadiazol-5-yl)methyl)morpholine
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
4-(1,3,4-thiadiazol-2-ylthio)pyridine-3-sulfonamide
-
-
4-(1-methyl-5-tetrazolylthio)pyridine-3-sulfonamide
-
-
4-(1-[2-[2-(3-bromobenzylidene)hydrazino]-2-oxoethyl]-3-methyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)-N'-[(3-bromophenyl)methylene]benzohydrazide
-
-
4-(1-[2-[2-(4-bromo-2-hydroxybenzylidene)hydrazino]-2-oxoethyl]-3-methyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)-N'-[(4-bromo-2-ydroxyphenyl)methylene]benzohydrazide
-
-
4-(1-[2-[2-(4-bromobenzylidene)hydrazino]-2-oxoethyl]-3-methyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)-N'-[(4-bromophenyl)methylene]benzohydrazide
-
-
4-(1-[2-[2-(4-chlorobenzylidene)hydrazino]-2-oxoethyl]-3-methyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)-N'-[(4-chlorophenyl)methylene]benzohydrazide
-
-
4-(1-[2-[2-(4-methoxybenzylidene)hydrazino]-2-oxoethyl]-3-methyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)-N'-[(4-methoxyphenyl)methylene]benzohydrazide
-
-
4-(1-[2-[2-benzylidenehydrazino]-2-oxoethyl]-3-methyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)-N'-[phenylmethylene]benzohydrazide
-
-
4-(2-((2-chloro-6-fluorobenzyl)thio)imidazo[2,1-b][1,3,4] thiadiazol-6-yl)benzonitrile
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
4-(2-aminoethyl)benzenesulfonamide
4-(2-hydroxyethyl)benzenesulfonamide
4-(2-hydroxyethyl)phenol
-
-
4-(2-methyl-8-quinolinoxy)-3-pyridinesulfonamide
-
-
4-(2-methylphenyl)benzene-1-sulfonamide
-
4-(2-phenylacetamido)-3-bromobenzenesulfonamide
4-(2-phenylacetamido)-3-chlorobenzenesulfonamide
4-(2-phenylacetamido)-3-fluorobenzenesulfonamide
4-(2-phenylacetamido)benzenesulfonamide
4-(2-phenylacetamidoethyl)benzenesulfonamide
4-(2-phenylacetamidomethyl)benzenesulfonamide
4-(2-propynylthio)pyridine-3-sulfonamide
-
-
4-(2-pyridin-2-ylacetamido)benzenesulfonamide
4-(2-pyridin-4-ylacetamido)benzenesulfonamide
4-(2-pyridin-4-ylacetamidoethyl)benzenesulfonamide
4-(3-formylphenyl)benzene-1-sulfonamide
-
4-(3-quinolinyl)benzene-1-sulfonamide
-
4-(4'-dimethylaminophenyl)diazenylbenzenesulfonamide
-
-
4-(4'-hydroxyphenyl)diazenylbenzene-N,N-dimethylsulfonamide
-
-
4-(4'-hydroxyphenyl)diazenylbenzene-N-methylsulfonamide
-
-
4-(4'-hydroxyphenyl)diazenylbenzenesulfonamide
-
-
4-(4'-methoxyphenyl)diazenylbenzene-N,N-dimethylsulfonamide
-
-
4-(4-cyanophenoxy)-3-pyridinesulfonamide
-
-
4-(4-fluorophenoxy)-3-pyridinesulfonamide
-
-
4-(4-hydroxyphenyl)-2-(3-hydroxyphenyl)-5H-indeno[1,2-b]pyridin-5-one
-
-
4-(4-hydroxyphenyl)-2-(4-bromophenyl)-5H-indeno[1,2-b]pyridin-5-one
-
-
4-(4-hydroxyphenyl)-2-(4-chlorophenyl)-5H-indeno[1,2-b]pyridin-5-one
-
-
4-(4-hydroxyphenyl)-2-(4-fluorophenyl)-5H-indeno[1,2-b]pyridin-5-one
-
-
4-(4-hydroxyphenyl)-2-(4-methoxyphenyl)-5H-indeno[1,2-b]pyridin-5-one
-
-
4-(4-hydroxyphenyl)-2-p-tolyl-5H-indeno[1,2-b]pyridin-5-one
-
-
4-(4-hydroxyphenyl)-2-phenyl-5H-indeno[1,2-b]pyridin-5-one
-
-
4-(5-methyl-2-pyrazolino)-3-pyridinesulfonamide
-
-
4-(6-nitrobenzothiazol-2-ylthio)pyridine-3-sulfonamide
-
-
4-(allylamino)-3-pyridinesulfonamide
-
-
4-(aminomethyl)benzenesulfonamide
4-(aminosulfonyl)-N-[2-[4-(aminosulfonyl)phenyl]ethyl]benzamide
-
4-(aminosulfonyl)-N-{2-[4-(aminosulfonyl)phenyl]ethyl}benzamide
-
4-(aminosulfonyl)benzoic acid
4-(benzenesulfonyl)-2,3,5,6-tetrafluorobenzene-1-sulfonamide
VD11-51
4-(benzylamino)-2,3,5,6-tetrafluorobenzene-1-sulfonamide
VD10-16
4-(benzylsulfanyl)-2,3,5,6-tetrafluorobenzene-1-sulfonamide
VD11-61
4-(carbamoylmethylthio)pyridine-3-sulfonamide
-
-
4-(cyanomethylthio)pyridine-3-sulfonamide
-
-
4-(hydroxymethyl)benzenesulfonamide
4-(methylhydrazino)-3-pyridinesulfonamide
-
-
4-(N-oxide-2-pyridylthio)pyridine-3-sulfonamide
-
-
4-(phenylethynyl)benzenesulfonamide
-
-
4-(propylsulfanyl)benzene-1-sulfonamide
VD12-10
4-(quinolinoxy)-3-pyridinesulfonamide
-
-
4-acetyl-N-(aminosulfonyl)benzenesulfonamide
-
-
4-acetylamidophenyl sulfamate
-
-
4-amino-3,5-dibromobenzenesulfonamide
-
4-amino-3-bromobenzenesulfonamide
-
4-amino-3-chlorobenzenesulfonamide
4-amino-3-fluoro-5-iodobenzenesulfonamide
-
4-amino-3-fluorobenzenesulfonamide
4-amino-3-iodobenzenesulfonamide
-
4-amino-6-(trifluoromethyl)benzene-1,3-disulfonamide
4-amino-6-chlorobenzene-1,3-disulfonamide
4-amino-N-[4-(aminosulfonyl)benzyl]benzenesulfonamide
4-amino-N-{2-[4-(aminosulfonyl)phenyl]ethyl}benzenesulfonamide
4-Aminobenzenesulfonamide
4-aminoethylbenzenesulfonamide
-
4-aminosalicylic acid
-
noncompetitive inhibition of isozymes carbonic anhydrase I and II
4-benzyl-6-(thiophen-2-yl)pyrimidin-2-amine
inhibits carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and alpha-glycosidase
4-benzythiopyridine-3-sulfonamide
-
-
4-bromo-5-(1,3-dioxalan-2-yl)-N-(1,1-dimethylethyl)-thiophene-2-sulfonamide
-
-
4-bromobenzenesulfonamide
-
-
4-bromophenyl sulfamate
-
-
4-chlorobenzenesulfonamide
-
-
4-chlorophenyl sulfamate
-
best CA IX inhibitor
4-cyanophenyl sulfamate
-
-
4-ethoxy-3-pyridinesulfonamide
-
-
4-ethynylbenzenesulfonamide
-
-
4-fluorobenzenesulfonamide
-
4-hydrazino-3-pyridinesulfonamide
-
-
4-hydrazinobenzenesulfonamide
-
4-hydroxybenzenesulfonamide
-
-
4-iodobenzenesulfonamide
-
-
4-iodophenyl sulfamate
-
-
4-methoxy-3-pyridinesulfonamide
-
-
4-methoxyphenyl sulfamate
-
-
4-methylbenzenesulfonamide
4-methylphenyl sulfamate
-
-
4-methylthiopyridine-3-sulfonamide
-
-
4-nitrobenzenesulfonamide
-
-
4-nitrophenyl sulfamate
-
-
4-phenoxyphenyl sulfamate
-
-
4-phenylbenzene-1-sulfonamide
-
4-phenylphenyl sulfamate
-
-
4-S-isobutylamino-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
-
binds 800 times more strongly to carbonic anhydrase II than to carbonic anhydrase I
4-sulfosalicylic acid
-
uncompetitive inhibition of isozyme carbonic anhydrase I and competitive inhibition of isozyme carbonic anhydrase II
4-t-butylphenyl sulfamate
-
-
4-trichloromethylphenyl sulfamate
-
-
4-[(1,3-benzothiazol-2-yl)sulfanyl]-2,3,5,6-tetrafluorobenzene-1-sulfonamide
VD10-49
4-[(2-aminopyrimidin-4-yl)amino]benzenesulfonamide
4-[(2-hydroxyethyl)sulfanyl]benzene-1-sulfonamide
VD11-31
4-[(2-phenylethyl)sulfanyl]benzene-1-sulfonamide
VD11-36
4-[(2R)-2-benzylpiperazine-1-carbonyl]benzene-1-sulfonamide
-
4-[(2S)-2-benzylpiperazine-1-carbonyl]benzene-1-sulfonamide
-
4-[(3-fluorophenyl)ethynyl]benzenesulfonamide
-
-
4-[(3-hydroxyphenyl)ethynyl]benzenesulfonamide
-
-
4-[(3-methoxyphenyl)ethynyl]benzenesulfonamide
-
-
4-[(4,5-diphenyl-1H-imidazol-2-yl)sulfanyl]-2,3,5,6-tetrafluorobenzene-1-sulfonamide
VD10-45
4-[(4,6-dimethylpyrimidin-2-yl)sulfanyl]-2,3,5,6-tetrafluorobenzene-1-sulfonamide
VD10-50
4-[(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl]-2-methoxyphenyl methanesulfonate
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
4-[(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl]phenylmethanesulfonate
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
4-[(4-methylphenyl)ethynyl]benzenesulfonamide
-
-
4-[(acetyloxy)amino]-N-[4-(aminosulfonyl)phenyl]benzenesulfonamide
-
4-[(anilinocarbonyl)amino]-6-chlorobenzene-1,3-disulfonamide
-
4-[(methylsulfonyl)amino]benzenesulfonamide
-
4-[(phenylsulfonyl)amino]benzenesulfonamide
-
4-[(sulfoamino)sulfonyl]benzoic acid
-
-
4-[2-(2-thienyl)acetamidoethyl]benzenesulfonamide
4-[2-(2-thienyl)acetamidomethyl]benzenesulfonamide
4-[2-(2-thienyl)acetamido]-3-bromobenzenesulfonamide
4-[2-(2-thienyl)acetamido]-3-chlorobenzenesulfonamide
4-[2-(2-thienyl)acetamido]-3-fluorobenzenesulfonamide
4-[2-(2-thienyl)acetamido]benzenesulfonamide
4-[2-(4-sulfamoylphenyl)ethylamino]-3-pyridinosulfonamide
-
-
4-[2-[(anilinocarbonothioyl)amino]ethyl]benzenesulfonamide
-
4-[2-[(anilinocarbonyl)amino]ethyl]benzenesulfonamide
-
4-[2-[([[4-(aminosulfonyl)phenyl]amino]carbonothioyl)amino]ethyl]benzenesulfonamide
-
4-[4-(aminosulfonyl)phenyl]-1-(2',3',4',6'-tetra-O-acetyl-alpha-D-mannopyranosyl)-1H-1,2,3-triazole
-
-
4-[4-(aminosulfonyl)phenyl]-1-(2',3',4',6'-tetra-O-acetyl-beta-D-galactopyranosyl)-1H-1,2,3-triazole
-
-
4-[4-(aminosulfonyl)phenyl]-1-(2',3',4',6'-tetra-O-acetyl-beta-D-glucopyranosyl)-1H-1,2,3-triazole
-
-
4-[4-(aminosulfonyl)phenyl]-1-(2',3',4'-tri-O-acetyl-alpha-D-arabinopyranosyl)-1H-1,2,3-triazole
-
-
4-[4-(aminosulfonyl)phenyl]-1-(2',3',4'-tri-O-acetyl-beta-D-glucuronic acid methyl ester)-1H-1,2,3-triazole
-
-
4-[4-(aminosulfonyl)phenyl]-1-(2',3',5'-tri-O-benzoyl-beta-D-ribofuranosyl)-1H-1,2,3-triazole
-
-
4-[4-(aminosulfonyl)phenyl]-1-(2'-acetamido-2'-deoxy'-3',4',6'-tri-O-acetyl-beta-D-glucopyranosyl)-1H-1,2,3-triazole
-
-
4-[4-(aminosulfonyl)phenyl]-1-(2'-acetamido-2'-deoxy-beta-D-glucopyranosyl)-1H-1,2,3-triazole
-
-
4-[4-(aminosulfonyl)phenyl]-1-(alpha-D-arabinopyranosyl)-1H-1,2,3-triazole
-
-
4-[4-(aminosulfonyl)phenyl]-1-(alpha-D-mannopyranosyl)-1H-1,2,3-triazole
-
-
4-[4-(aminosulfonyl)phenyl]-1-(beta-D-galactopyranosyl)-1H-1,2,3-triazole
-
-
4-[4-(aminosulfonyl)phenyl]-1-(beta-D-glucopyranosyl)-1H-1,2,3-triazole
-
-
4-[4-(aminosulfonyl)phenyl]-1-(beta-D-glucuronic acid methyl ester)-1H-1,2,3-triazole
-
-
4-[4-(aminosulfonyl)phenyl]-1-(beta-D-maltopyranosyl)-1H-1,2,3-triazole
-
-
4-[4-(aminosulfonyl)phenyl]-1-(beta-D-ribofuranosyl)-1H-1,2,3-triazole
-
-
4-[4-(aminosulfonyl)phenyl]-1-(hepta-O-acetyl-beta-D-maltopyranosyl)-1H-1,2,3-triazole
-
-
4-[4-(methylsulfonyl)phenyl]-3-phenyldihydrofuran-2(3H)-one
-
-
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
-
-
4-[N'-(1,1-dioxopyrido[4,3-e]-1,4,2-dithiazin-3-yl)hydrazino]-3-pyridinesulfonamide
-
-
4-[N'-(6-chloro-7-cyano-1,1-dioxo-1,4,2-benzodithiazin-3-yl)hydrazino]-3-pyridinesulfonamide
-
-
4-[N'-(6-chloro-7-methyl-1,1-dioxo-1,4,2-benzodithiazin-3-yl)hydrazino]-3-pyridinesulfonamide
-
-
4-[[(aminosulfonyl)amino]sulfonyl]benzoic acid
-
-
4-[[(anilinocarbonothioyl)amino]methyl]benzenesulfonamide
-
4-[[(phenylsulfonyl)amino]methyl]benzenesulfonamide
-
4H-[1,2,3]thiadiazolo[3,4-a]benzimidazole-7-sulfonamide
-
5,6-diamino-1,3-dimethyluracil
inhibition of isozyme hCA II
5-(2-chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide
5-(2-phenylacetamido)-1,3,4-thiadiazole-2-sulfonamide
5-(3,7,12-trioxo-5beta-cholanamido)-1,3,4-thiadiazole-2-sulfonamide
-
-
5-(3alpha,12alpha-dihydroxy-5beta-cholanamido)-1,3,4-thiadiazole-2-sulfonamide
-
-
5-(3alpha,7alpha,12alpha-triacetoxy-5beta-cholanamido)-1,3,4-thiadiazole-2-sulfonamide
-
-
5-(3alpha,7alpha,12alpha-trihydroxy-5beta-cholanamido)-1,3,4-thiadiazole-2-sulfonamide
-
-
5-(3alpha-acetoxy-5beta-cholanamido)-1,3,4-thiadiazole-2-sulfonamide
-
-
5-(3alpha-hydroxy-5beta-cholanamido)-1,3,4-thiadiazole-2-sulfonamide
-
-
5-(formylamino)-1,3,4-thiadiazole-2-sulfonamide
-
-
5-(hydroxymethyl)pyrimidine-2,4(1H,3H)-dione
-
5-acetamido-1,3,4-thiadiazole-2-sulfonamide
5-amino-1,3,4-thiadiazole-2-sulfonamide
5-bromo-1-(4-methylbenzene-1-sulfonyl)pyrimidine-2,4(1H,3H)-dione
inhibition of isozyme hCA II
5-bromo-1-(methanesulfonyl)pyrimidine-2,4(1H,3H)-dione
inhibition of isozyme hCA II
5-chlorosalicylic acid
-
uncompetitive inhibition of isozymes carbonic anhydrase I and II
5-imino-4-methyl-4,5-dihydro-1,3,4-thiadiazole-2-sulfonamide
5-pentylresorcinylsulfamate
-
-
5-sulfosalicylic acid
-
competitive inhibition of isozyme carbonic anhydrase I and noncompetitive inhibition of isozyme carbonic anhydrase II
5-[(2-phenylethyl)(phenylsulfonyl)amino]-1,3,4-thiadiazole-2-sulfonamide
-
-
5-[(benzylsulfonyl)(2,4-dichlorobenzyl)amino]-1,3,4-thiadiazole-2-sulfonamide
-
-
5-[(benzylsulfonyl)(2-methylpropyl)amino]-1,3,4-thiadiazole-2-sulfonamide
-
-
5-[(benzylsulfonyl)(3,4,5-trimethoxybenzyl)amino]-1,3,4-thiadiazole-2-sulfonamide
-
-
5-[(benzylsulfonyl)(4-chlorobenzyl)amino]-1,3,4-thiadiazole-2-sulfonamide
-
-
5-[(benzylsulfonyl)(4-methoxybenzyl)amino]-1,3,4-thiadiazole-2-sulfonamide
-
-
5-[(benzylsulfonyl)(butyl)amino]-1,3,4-thiadiazole-2-sulfonamide
-
-
5-[(benzylsulfonyl)(dodecyl)amino]-1,3,4-thiadiazole-2-sulfonamide
-
-
5-[(benzylsulfonyl)(pentyl)amino]-1,3,4-thiadiazole-2-sulfonamide
-
-
5-[(benzylsulfonyl)(propan-2-yl)amino]-1,3,4-thiadiazole-2-sulfonamide
-
-
5-[2-(2-thienyl)acetamido]-1,3,4-thiadiazole-2-sulfonamide
5-[benzyl(phenylsulfonyl)amino]-1,3,4-thiadiazole-2-sulfonamide
-
-
5-[ethyl(phenylsulfonyl)amino]-1,3,4-thiadiazole-2-sulfonamide
-
-
5-[methyl(phenylsulfonyl)amino]-1,3,4-thiadiazole-2-sulfonamide
-
-
5-[[(4-bromophenyl)sulfonyl]amino]-1,3,4-thiadiazole-2-sulfonamide
-
5-[[(4-nitrophenyl)sulfonyl]amino]-1,3,4-thiadiazole-2-sulfonamide
-
5-{(2,4-dichlorobenzyl)[(4-methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
5-{(4-bromobenzyl)[(4-methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
5-{(4-chlorobenzyl)[(4-methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
5-{(4-fluorobenzyl)[(4-methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
5-{(4-methoxybenzyl)[(4-methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
5-{(4-methylbenzyl)[(4-methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
5-{(benzylsulfonyl)[2-(4-bromophenyl)ethyl]amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
5-{benzyl[(4-methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
5-{butyl[(4-methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
5-{dodecyl[(4-methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
5-{ethyl[(4-methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
5-{methyl[(4-methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
5-{[(4-amino-3-chloro-5-fluorophenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide
-
5-{[(4-aminophenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide
5-{[(4-methylphenyl)sulfonyl](2-methylpropyl)amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
5-{[(4-methylphenyl)sulfonyl](2-phenylethyl)amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
5-{[(4-methylphenyl)sulfonyl](3,4,5-trimethoxybenzyl)amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
5-{[(4-methylphenyl)sulfonyl](pentyl)amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
5-{[(4-methylphenyl)sulfonyl](propan-2-yl)amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
5-{[(4-methylphenyl)sulfonyl](propyl)amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
5-{[2-(4-bromophenyl)ethyl][(4-methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
5-{[3-(2-methoxyphenyl)propyl][(4-methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide
-
-
6,7-dimethoxy-1-ethyl-3,4-dihydroisoquinoline-2(1H)-sulfonamide
-
6,7-dimethoxy-1-isopropyl-3,4-dihydroisoquinoline-2(1H)-sulfonamide
-
6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline-2(1H)-sulfonamide
-
6,7-dimethoxy-1-phenyl-3,4-dihydroisoquinoline-2(1H)-sulfonamide
-
6,7-dimethoxy-1-propyl-3,4-dihydroisoquinoline-2(1H)-sulfonamide
-
6-((1S)-hydroxy-3-methylbutyl)-7-methoxy-2H-chromen-2-one
-
6-(1-hydroxy-3-methylbutyl)-7-methoxy-2H-chromen-2-one
-
-
6-(4-bromophenyl)-2-((2-chloro-6-fluorobenzyl)thio)imidazo[2,1-b][1,3,4]thiadiazole
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
6-(aminomethyl)-2H-chromen-2-one
-
6-(hydroxymethyl)-2-oxo-2H-chromene-3-carboxylic acid
-
6-(hydroxymethyl)-2H-chromen-2-one
-
6-([1,1'-biphenyl]-4-yl)-2-((2-chloro-6-fluorobenzyl)thio)imidazo [2,1-b][1,3,4]thiadiazole
competitive. Potent acetylcholinesterase and non-classical carbonic anhydrase inhibitor
6-acetyl-7-(benzyloxy)-2H-chromen-2-one
-
-
6-acetyl-7-adamantylethoxy-2H-chromen-2-one
-
-
6-acetyl-7-butoxy-2H-chromen-2-one
-
-
6-acetyl-7-ethoxy-2H-chromen-2-one
-
-
6-acetyl-7-hydroxy-2H-chromen-2-one
-
-
6-acetyl-7-methoxy-2H-chromen-2-one
-
-
6-acetyl-7-propoxy-2H-chromen-2-one
-
-
6-amino-1,3-dimethyluracil
inhibition of isozyme hCA II
6-chloro-4-amino-benzene-1,3-disulfonamide
6-deoxy-N-sulfamoyl-alpha-L-glucopyranosylamine
-
-
6-ethoxy-1,3-benzothiazole-2-sulfonamide
-
-
6-hydroxy-1,3-benzothiazole-2-sulfonamide
-
6-methoxy-2-oxo-2H-chromene-3-carboxylic acid
-
6-methyl-2-oxo-2H-chromene-3-carboxylic acid
-
6-methyl-4-(methylamino)-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
6-methylpyrimidine-2,4(1H,3H)-dione
-
6-trifluoromethyl-4-aminobenzene-1,3-disulfonamide
7-(2-phenylethoxy)-2H-chromen-2-one
-
7-(benzyloxy)-2H-chromen-2-one
-
7-alpha-hydroxydehydroepiandrosterone sulfamate
-
-
7-butoxy-2H-chromen-2-one
-
7-ethoxy-2H-chromen-2-one
-
7-ethoxy-8-propanoyl-2H-chromen-2-one
-
-
7-hydroxy-1-methoxy-3-methyl-9-oxo-9,9a-dihydro-4aH-xanthene-8-carboxylic acid
-
-
7-hydroxy-3-(hydroxymethyl)-1-methoxy-9-oxo-9,9a-dihydro-4aH-xanthene-8-carboxylic acid
-
-
7-hydroxy-6-propanoyl-2H-chromen-2-one
-
-
7-hydroxy-8-propanoyl-2H-chromen-2-one
-
-
7-methoxy-2-oxo-2H-chromene-4-carboxylic acid
-
7-methoxy-2H-chromen-2-one
-
7-methoxy-8-propanoyl-2H-chromen-2-one
-
-
7-oxodehydroepiandrosterone sulfamate
-
-
7-propoxy-2H-chromen-2-one
-
7alpha-hydroxyepiandrosterone sulfamate
-
-
8-acetyl-7-(benzyloxy)-2H-chromen-2-one
-
-
8-acetyl-7-butoxy-2H-chromen-2-one
-
-
8-acetyl-7-ethoxy-2H-chromen-2-one
-
-
8-acetyl-7-hydroxy-2H-chromen-2-one
-
-
8-acetyl-7-methoxy-2H-chromen-2-one
-
-
8-acetyl-7-propoxy-2H-chromen-2-one
-
-
8-methoxy-2-oxo-2H-chromene-3-carboxylic acid
-
8-propanoyl-7-propoxy-2H-chromen-2-one
-
-
acetaldehyde
-
modification of carbonic anhydrase II with acetaldehyde leads to decreased enzyme activity, acetaldehyde (100 mM) in the presence of NaBH3(CN) causes 23.7% reduction in CA II activity, in the absence of NaBH3(CN) the activity is only slightly reduced
Acetylsalicylic acid
-
noncompetitive inhibition of isozymes carbonic anhydrase I and II
allylamine hydrochloride
-
-
allylsulfonamide hydrochloride
-
-
allylsulfonyl chloride
-
-
amikacin sulfate
noncompetitive inhibition
amoxicillin
uncompetitive inhibition
ampicillin
uncompetitive inhibition
Benzyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate
-
benzylsulfonylsulfamic acid
-
-
catechin
-
a competitive inhibitor with 4-nitrophenylacetate as substrate
cefazolin
uncompetitive inhibition
cefoperazone
uncompetitive inhibition
ceftriaxone
noncompetitive inhibition
cefuroxime
uncompetitive inhibition
Chlorthalidone
chlorthalidone is a medium potency CA I, II, and IV inhibitor, a very effective inhibitor of CA VB, CA VII, CA IX, CA XII, and CA XIII and an ineffective inhibitor of isozymes CA III, VA, VI, and XIV
chlorzolamide
potent inhibitor
cholesteryl sulfamate
-
-
Cl-
-
relatively resistant to
clindamycin phosphate
uncompetitive inhibition
-
cyclopentyl sulfamate
-
-
D-phenylalanyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-alloisoleucinamide
-
-
D-phenylalanyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-leucinamide
-
-
D-phenylalanyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-methioninamide
-
-
D-phenylalanyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-phenylalaninamide
-
-
dehydroepiandrosterone sulfamate
diflunisal
-
noncompetitive inhibition of isozymes carbonic anhydrase I and II
dimethylsilyl para-toluenesulfonamidoborane
-
-
dimethylsilyl-diphenylaminoborane
-
-
dimethylsilyl-N-methyl-N-phenylaminoborane
-
-
dimethylsilylaminoborane
-
-
dimethylsilylboronic acid
-
-
dimethylsilylfluoroborane
-
-
dimethylsilylsulfonamidoborane
-
-
dinitrosalicylic acid
-
-
EMD 486019
EMD 486019 acts as a strong inhibitor of isozymes carbonic anhydrase II, VB, VII, IX, XII, and XIV
estradiol 17 beta-sulfamate
-
-
estradiol 3,17 beta-disulfamate
ethoxazolamide
-
systemic carbonic anhydrase inhibitor
ethyl 2-methyl-2H-thieno[2,3-e]-1,2-thiazine-3-carboxylate 1,1-dioxide
-
-
ethyl 2-methyl-2H-thieno[3,2-e]-1,2-thiazine-3-carboxylate 1,1-dioxide
-
-
ethyl 2-[[2-(4-chloro-3-sulfamoylphenyl)-2-oxoethyl]sulfanyl]-6-oxo-1,6-dihydropyrimidine-5-carboxylate
E46
ethyl 3,4-dihydro-4-hydroxy-2H-thieno[3,2-e]-1,2-thiazine-3-carboxylate 1,1-dioxide
-
-
ethyl 5-phenyl-1H-pyrrole-2-carbodithioate
inhibits carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and alpha-glycosidase
-
ethyl 6-(hydroxymethyl)-2-oxo-2H-chromene-3-carboxylate
-
ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate
-
fluorenylmethyl sulfamate
-
-
gentamicin sulfate
uncompetitive inhibition
hydrogen sulfide
best inhibitor
indapamide
indapamide is a quite ineffective inhibitor of isozymes CA I, II, III, VA, VI, and XIV, a medium potency CA IV and CA VB inhibitor, and a very effective inhibitor of isozymes CA VII, IX, XII, and XIII
Isoorotic acid
inhibition of isozyme hCA II
isopropylsulfonylsulfamic acid
-
-
kanamycin sulfate
competitive inhibition
Lincomycin
competitive inhibition
methyl (3-chloro-4-hydroxyphenyl)acetate
-
-
methyl 2-[(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl]-3-nitrobenzoate
inhibitor of acetylcholinesterase and the human carbonic anhydrase isoforms I and II
methyl 6-(hydroxymethyl)-2-oxo-2H-chromene-3-carboxylate
-
methyl N-[(2,3,4,6-Tetra-O-acetyl-beta-D-glucosyl)sulfonyl]-L-4'-sulfamoylprolinate
-
methyl N-[(2,3,4,6-tetra-O-acetyl-beta-D-glucosyl)sulfonyl]-L-sulfamoylserinate
-
methylsulfonylsulfamic acid
-
-
N'',N'''-bis[(E)-(2,3,4-trihydroxyphenyl)methylidene]carbonic dihydrazide
-
N'',N'''-bis[(E)-(2,3-dihydroxyphenyl)methylidene]carbonic dihydrazide
-
N'',N'''-bis[(E)-(2,4,6-trihydroxyphenyl)methylidene]carbonic dihydrazide
-
N'',N'''-Bis[(E)-(2,4-dichlorophenyl)methylidene]carbonic dihydrazide
-
N'',N'''-bis[(E)-(2,5-dihydroxyphenyl)methylidene]carbonic dihydrazide
-
N'',N'''-bis[(E)-(2,6-dichlorophenyl)methylidene]carbonic dihydrazide
mixed-type inhibition
N'',N'''-bis[(E)-(2-bromophenyl)methylidene]carbonic dihydrazide
-
N'',N'''-bis[(E)-(2-chloro-5-nitrophenyl)methylidene]carbonic dihydrazide
mixed-type inhibition
N'',N'''-bis[(E)-(2-chlorophenyl)methylidene]carbonic dihydrazide
mixed-type inhibition
N'',N'''-bis[(E)-(2-fluorophenyl)methylidene]carbonic dihydrazide
-
N'',N'''-bis[(E)-(2-hydroxy-3-methoxyphenyl)methylidene]carbonic dihydrazide
-
N'',N'''-bis[(E)-(2-hydroxy-5-methoxyphenyl)methylidene]carbonic dihydrazide
-
N'',N'''-bis[(E)-(2-hydroxyphenyl)methylidene]carbonic dihydrazide
-
N'',N'''-bis[(E)-(2-methoxyphenyl)methylidene]carbonic dihydrazide
-
N'',N'''-bis[(E)-(2-nitrophenyl)methylidene]carbonic dihydrazide
mixed-type inhibition
N'',N'''-bis[(E)-(3,4-dimethoxyphenyl)methylidene]carbonic dihydrazide
-
N'',N'''-bis[(E)-(3-ethoxy-2-hydroxyphenyl)methylidene]carbonic dihydrazide
-
N'',N'''-bis[(E)-(3-hydroxyphenyl)methylidene]carbonic dihydrazide
-
N'',N'''-bis[(E)-(3-methoxyphenyl)methylidene]carbonic dihydrazide
-
N'',N'''-bis[(E)-(4-bromophenyl)methylidene]carbonic dihydrazide
mixed-type inhibition
N'',N'''-bis[(E)-(4-chlorophenyl)methylidene]carbonic dihydrazide
-
N'',N'''-bis[(E)-(4-fluorophenyl)methylidene]carbonic dihydrazide
-
N'',N'''-bis[(E)-(4-hydroxyphenyl)methylidene]carbonic dihydrazide
-
-
N'',N'''-bis[(E)-(4-methoxyphenyl)methylidene]carbonic dihydrazide
-
N'',N'''-bis[(E)-(4-nitrophenyl)methylidene]carbonic dihydrazide
mixed-type inhibition
N'',N'''-bis[(E)-(5-bromo-2-hydroxyphenyl)methylidene]carbonic dihydrazide
-
N'',N'''-bis[(E)-phenylmethylidene]carbonic dihydrazide
-
N'-[(1Z)-1-(5-chlorothiophen-3-yl)ethylidene]butane-1-sulfonohydrazide
good inhibitor of alpha-glycosidase, human carbonic anhydrase I and II isoforms and acetylcholinesterase enzyme
N'-[(1Z)-1-(furan-3-yl)ethylidene]butane-1-sulfonohydrazide
good inhibitor of alpha-glycosidase, human carbonic anhydrase I and II isoforms and acetylcholinesterase enzyme
N'-[(1Z)-1-(thiophen-3-yl)ethylidene]butane-1-sulfonohydrazide
good inhibitor of alpha-glycosidase, human carbonic anhydrase I and II isoforms and acetylcholinesterase enzyme
N'-[(Z)-(1H-indol-3-yl)methylidene]butane-1-sulfonohydrazide
good inhibitor of alpha-glycosidase, human carbonic anhydrase I and II isoforms and acetylcholinesterase enzyme
N,N'-biphosphoryl-4,5-dichloro-1,3-benzenesulfonamide
-
-
N,N'-bis(benzylsulfonyl)allylamine
-
-
N,N'-bis(styrenesulfonyl)allylamine
-
-
N,N-dimethylamidimidodisulfuric acid
-
-
N,N-dimethylimidodisulfuric diamide
-
-
N-(1,1-dimethylethyl)-2-(3-methoxyphenyl)-3-[(2-propylaminol)methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
-
-
N-(1,1-dimethylethyl)-2-(3-methoxyphenyl)-3-[(4-morpholinyl)methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide
-
-
N-(1,1-dimethylethyl)-2-[4-(4-morpholinyl)-2-butenyl]-2H-thieno[3,2-e-]-1,2-thiazine-6-sulfonamide 1,1-dioxide
-
-
N-(1-(2-hydroxyphenylamino)-3-methyl-1-oxobutan-2-ylcarbamothioyl)benzamide
i.e. NK-154, binding structure, overview
N-(1-(2-hydroxyphenylamino)-4-methyl-1-oxopentan-2-ylcarbamothioyl) benzamide
i.e. NK-168, binding structure, overview
N-(2-fluoro-4-sulfamoylphenyl)-2-(thiophen-2-yl)acetamide
-
-
N-(4-sulfamoylphenyl)-2-(thiophen-2-yl)acetamide
-
-
N-(4-[(E)-[(aminosulfonyl)imino]methyl]phenyl)acetamide
-
-
N-(4-[[(aminosulfonyl)amino]sulfonyl]phenyl)acetamide
-
-
N-(5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl)acetamide
-
-
N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide
-
-
N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)furan-2-carboxamide
-
N-(allylsulfonyl)allylamine
-
-
N-(allysulfonyl)-3-triethylsilylpropanamine
-
-
N-(aminosulfonyl)-1,1,1-trichloromethanesulfonamide
-
-
N-(aminosulfonyl)-1,1,1-trifluoromethanesulfonamide
-
-
N-(aminosulfonyl)-1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonamide
-
-
N-(aminosulfonyl)-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonamide
-
-
N-(aminosulfonyl)-1-(7,7-dimethylbicyclo[2.2.1]hept-1-yl)methanesulfonamide
-
-
N-(aminosulfonyl)-1-phenylmethanesulfonamide
-
-
N-(aminosulfonyl)-2,3,4,5,6-pentafluorobenzenesulfonamide
-
-
N-(aminosulfonyl)-2,4,6-triisopropylbenzenesulfonamide
-
-
N-(aminosulfonyl)-2,4,6-tripropylbenzenesulfonamide
-
-
N-(aminosulfonyl)-2,5-dichlorobenzenesulfonamide
-
-
N-(aminosulfonyl)-2-nitrobenzenesulfonamide
-
-
N-(aminosulfonyl)-3,5-dichloro-2-hydroxybenzenesulfonamide
-
-
N-(aminosulfonyl)-3-(trifluoromethyl)benzenesulfonamide
-
-
N-(aminosulfonyl)-3-chloro-4-nitrobenzenesulfonamide
-
-
N-(aminosulfonyl)-3-nitrobenzenesulfonamide
-
-
N-(aminosulfonyl)-4-bromobenzenesulfonamide
-
-
N-(aminosulfonyl)-4-chlorobenzenesulfonamide
-
-
N-(aminosulfonyl)-4-fluorobenzenesulfonamide
-
-
N-(aminosulfonyl)-4-iodobenzenesulfonamide
-
-
N-(aminosulfonyl)-4-methoxybenzenesulfonamide
-
-
N-(aminosulfonyl)-4-methylbenzenesulfonamide
-
-
N-(aminosulfonyl)-4-nitrobenzenesulfonamide
-
-
N-(aminosulfonyl)-5-(dimethylamino)naphthalene-1-sulfonamide
-
-
N-(aminosulfonyl)benzenesulfonamide
-
-
N-(aminosulfonyl)methanesulfonamide
-
-
N-(aminosulfonyl)naphthalene-1-sulfonamide
-
-
N-(aminosulfonyl)naphthalene-2-sulfonamide
-
-
N-(aminosulfonyl)propane-2-sulfonamide
-
-
N-(aminosulfonyl)quinoline-8-sulfonamide
-
-
N-(aminosulfonyl)thiophene-2-sulfonamide
-
-
N-(benzylsulfonyl)-3-tributylgermylpropanamine
-
-
N-(benzylsulfonyl)-3-triethylsilylpropanamine
-
-
N-(benzylsulfonyl)allylamine
-
-
N-(cyclopropylmethyl)-3-(1,3-dioxolan-2-yl)thiophene-2-sulfonamide
-
-
N-(dimesilylboro)allylsulfonamide
-
-
N-(styrenesulfonyl)-3-triethylsilylpropanamine
-
-
N-(tert-butoxycarbonyl)-D-phenylalanyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-alloisoleucinamide
-
-
N-(tert-butoxycarbonyl)-D-phenylalanyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-leucinamide
-
-
N-(tert-butoxycarbonyl)-D-phenylalanyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-methioninamide
-
-
N-(tert-butoxycarbonyl)-D-phenylalanyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-phenylalaninamide
-
-
N-(tert-butoxycarbonyl)-D-phenylalanyl-N-[2-(4-sulfamoylphenyl)ethyl]glycinamide
-
-
N-(trans-styrenesulfonyl)allylamine
-
-
N-2'-sulfamoylethyl-S-(2,3,4,6-tetra-O-acetyl-1-thio-beta-D-glucopyranosyl)sulfonamide
-
N-3'-R-sulfamoylpyrrolidinyl-S-(1-thio-beta-D-glucopyranosyl)sulfonamide
-
N-3'-R-sulfamoylpyrrolidinyl-S-(2,3,4,6-tetra-O-acetyl-1-thio-beta-D-glucopyranosyl)sulfonamide
-
N-3'-sulfamoylpropyl-S-(1-thio-beta-D-glucopyranosyl)sulfonamide
-
N-3'-sulfamoylpropyl-S-(2,3,4,6-tetra-O-acetyl-1-thio-beta-D-glucopyranosyl)sulfonamide
-
N-4'-sulfamoylpiperidinyl-S-(1-thio-beta-D-glucopyranosyl)sulfonamide
-
N-4'-sulfamoylpiperidinyl-S-(2,3,4,6-tetra-O-acetyl-1-thio-beta-D-glucopyranosyl)sulfonamide
-
N-4-methoxyphenylsulfonyl-N-2-nitrobenzyl-L-alanine hydroxamate
-
-
N-4-methoxyphenylsulfonyl-N-benzyl-L-valine hydroxamate
-
-
N-5'-sulfamoylpentyl-S-(1-thio-beta-D-glucopyranosyl)sulfonamide
-
N-5'-sulfamoylpentyl-S-(2,3,4,6-tetra-O-acetyl-1-thio-beta-D-glucopyranosyl)sulfonamide
-
N-allyl-1-phenylmethanesulfonamide
-
-
N-allylsulfonyl-3-[9-borabicyclo[1.3.3.]nonane]propanamine
-
-
N-benzyl-2-(3-chloro-4-hydroxyphenyl)acetamide
-
-
N-butyl-2-(3-chloro-4-hydroxyphenyl)acetamide
-
-
N-cyclohexyl-N-[(3-formyl-thien-2-yl)sulfonyl]-glycine methyl ester
-
-
N-cyclopropylmethyl-3-(1,3-dioxolan-2-yl)-2-thiophenesulfonamide
-
-
n-hexadecyl sulfamate
-
-
N-n-perfluorobutylsulfonyl-alanine hydroxamate
-
-
n-octadecyl sulfamate
-
-
N-pentafluorophenylsulfonyl-glycine
-
-
N-pentafluorophenylsulfonyl-glycine hydroxamate
-
-
N-pentafluorophenylsulfonyl-N-4-nitrobenzyl-glycine hydroxamate
-
-
N-phosphoryl-4-carboxy-benzenesulfonamide
-
-
N-phosphoryl-6-nitro-benzothiazole-2-sulfonamide
-
-
N-phosphoryl-benzothiazole -2-sulfonamide
-
-
N-salicylidene-sulfanilic acid amide
-
-
N-salicylidene-sulfanilic acid amide cobalt acetate complex
-
-
N-salicylidene-sulfanilic acid amide cobalt chloride complex
-
-
N-salicylidene-sulfanilic acid amide cobalt nitrate complex
-
-
N-salicylidene-sulfanilic acid amide cobalt sulfate complex
-
-
N-salicylidene-sulfanilic acid amide copper chloride complex
-
-
N-salicylidene-sulfanilic acid amide copper nitrate complex
-
-
N-salicylidene-sulfanilic acid amide nickel acetate complex
-
-
N-salicylidene-sulfanilic acid amide nickel chloride complex
-
-
N-salicylidene-sulfanilic acid amide nickel nitrate complex
-
-
N-salicylidene-sulfanilic acid amide nickel sulfate complex
-
-
N-sulfamoyl-beta-D-galactopyranosylamine
-
-
N-sulfamoyl-beta-D-glucopyranosylamine
-
-
N-sulfamoyl-beta-D-mannopyranosylamine
-
-
N-tert-butyl-2-(3-chloro-4-hydroxyphenyl)acetamide
-
-
N-trimethylsilylallylsulfonamide
-
-
N-[(1E)-(1-methyl-1H-pyrrol-2-yl)methylene]sulfamide
-
-
N-[(1E)-(3,4,5-trimethoxyphenyl)methylene]sulfamide
-
-
N-[(1E)-(3-nitrophenyl)methylene]sulfamide
-
-
N-[(1E)-(4-methoxyphenyl)methylene]sulfamide
-
-
N-[(1E)-(4-methylphenyl)methylene]sulfamide
-
-
N-[(1E)-(4-nitrophenyl)methylene]sulfamide
-
-
N-[(1E)-(5-methylthien-2-yl)methylene]sulfamide
-
-
N-[(1E)-phenylmethylene]sulfamide
-
-
N-[(1E)-thien-2-ylmethylene]sulfamide
-
-
N-[(1E)-[4-(dimethylamino)phenyl]methylene]sulfamide
-
-
N-[(3-formyl-2-thienyl)sulfonyl]-glycine ethyl ester
-
-
N-[(3-formyl-thien-2-yl)sulfonyl]-N-(2-methoxyethyl)-glycine ethyl ester
-
-
N-[(3aR,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]sulfamic amide
-
-
N-[(benzyloxy)carbonyl]-D-alanyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-alaninamide
-
-
N-[(benzyloxy)carbonyl]-D-alanyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-methioninamide
-
-
N-[(benzyloxy)carbonyl]-D-alanyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-phenylalaninamide
-
-
N-[(benzyloxy)carbonyl]-D-alanyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-valinamide
-
-
N-[(benzyloxy)carbonyl]-D-alanyl-N-[2-(4-sulfamoylphenyl)ethyl]glycinamide
-
-
N-[(benzyloxy)carbonyl]-D-alanyl-S-benzyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-cysteinamide
-
-
N-[(benzyloxy)carbonyl]-D-methionyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-alaninamide
-
-
N-[(benzyloxy)carbonyl]-D-methionyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-methioninamide
-
-
N-[(benzyloxy)carbonyl]-D-methionyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-phenylalaninamide
-
-
N-[(benzyloxy)carbonyl]-D-methionyl-N-[2-(4-sulfamoylphenyl)ethyl]glycinamide
-
-
N-[(benzyloxy)carbonyl]-D-phenylalanyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-alaninamide
-
-
N-[(benzyloxy)carbonyl]-D-phenylalanyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-isoleucinamide
-
-
N-[(benzyloxy)carbonyl]-D-phenylalanyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-leucinamide
-
-
N-[(benzyloxy)carbonyl]-D-phenylalanyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-methioninamide
-
-
N-[(benzyloxy)carbonyl]-D-phenylalanyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-phenylalaninamide
-
-
N-[(benzyloxy)carbonyl]-D-phenylalanyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-valinamide
-
-
N-[(benzyloxy)carbonyl]-D-phenylalanyl-N-[2-(4-sulfamoylphenyl)ethyl]glycinamide
-
-
N-[(benzyloxy)carbonyl]-D-phenylalanyl-S-benzyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-cysteinamide
-
-
N-[(benzyloxy)carbonyl]glycyl-N-[2-(4-sulfamoylphenyl)ethyl]-D-methioninamide
-
-
N-[(benzyloxy)carbonyl]glycyl-N-[2-(4-sulfamoylphenyl)ethyl]glycinamide
-
-
N-[4-(aminosulfonyl)phenyl]-2,2,2-trifluoroacetamide
-
N-[4-(aminosulfonyl)phenyl]-2,2-dimethylpropanamide
-
N-[4-(aminosulfonyl)phenyl]-2-methylpropanamide
-
N-[4-(aminosulfonyl)phenyl]acetamide
-
N-[4-(aminosulfonyl)phenyl]benzamide
-
N-[4-(aminosulfonyl)phenyl]butanamide
-
N-[4-(aminosulfonyl)phenyl]pentanamide
-
N-[4-(aminosulfonyl)phenyl]propanamide
-
N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide
N-[[2-(1,3-dioxalan-2-yl)-3-thienyl]sulfonyl]-N-methylglycine ethyl ester
-
-
N-[[3-(1,3-dioxolan-2-yl)-2-thienyl]sulfonyl]-glycine ethyl ester
-
-
N-[[3-(1,3-dioxolan-2-yl)thien-2-yl]sulfonyl]-N-(1-methylethyl)-glycine ethyl ester
-
-
N-[[3-(1,3-dioxolan-2-yl)thien-2-yl]sulfonyl]-N-(2-propenyl)-glycine ethyl ester
-
-
N-[[3-(1,3-dioxolan-2-yl)thien-2-yl]sulfonyl]-N-(3-methoxyethyl)-glycine ethyl ester
-
-
N-[[3-(1,3-dioxolan-2-yl)thien-2-yl]sulfonyl]-N-ethylglycine ethyl ester
-
-
N-[[3-(1,3-dioxolan-2-yl)thien-2-yl]sulfonyl]-N-methylcyclopropyl-glycine ethyl ester
-
-
N-[[3-(1,3-dioxolan-2-yl)thien-2-yl]sulfonyl]-N-methylglycine ethyl ester
-
-
N-[[3-(1,3-dioxolan-2-yl)thien-2-yl]sulfonyl]-N-propylglycine ethyl ester
-
-
N-[[3-(1,3-dioxolan-2-yl)thien-2-yl]sulfonyl]-N-[(3,4-dimethoxyphenyl)methyl]-glycine ethyl ester
-
-
N-[[3-(1,3-dioxolan-2-yl)thien-2-yl]sulfonyl]-N-[(3-methoxyphenyl)methyl]-glycine ethyl ester
-
-
N-[[3-(1,3-dioxolan-2-yl)thien-2-yl]sulfonyl]-N-[(4-methoxyphenyl)methyl]-glycine ethyl ester
-
-
N-[[3-(1,3-dioxolan-2-yl)thien-2-yl]sulfonyl]-N-[4-(morpholin-4-yl)phenyl]-glycine methyl ester
-
-
N-[[5-(aminosulfonyl)-2-formyl-thiophen-3-yl]sulfonyl]-N-methyl-glycine ethyl ester
-
-
N-[[[4-(aminosulfonyl)phenyl]amino]thioxomethyl]-L-alanine
-
-
N-[[[4-(aminosulfonyl)phenyl]amino]thioxomethyl]-L-asparagine
-
-
N-[[[4-(aminosulfonyl)phenyl]amino]thioxomethyl]-L-glutamine
-
-
N-[[[4-(aminosulfonyl)phenyl]amino]thioxomethyl]-L-isoleucine
-
-
N-[[[4-(aminosulfonyl)phenyl]amino]thioxomethyl]-L-leucine
-
-
N-[[[4-(aminosulfonyl)phenyl]amino]thioxomethyl]-L-methionine
-
-
N-[[[4-(aminosulfonyl)phenyl]amino]thioxomethyl]-L-phenylalanine
-
-
N-[[[4-(aminosulfonyl)phenyl]amino]thioxomethyl]-L-proline
-
-
N-[[[4-(aminosulfonyl)phenyl]amino]thioxomethyl]-L-tryptophan
-
-
N-[[[4-(aminosulfonyl)phenyl]amino]thioxomethyl]-L-valine
-
-
Orotic acid
inhibition of isozyme hCA II
p-(aminomethyl)-benzene-sulfonamide
a CAII inhibitor
p-biphenylmethyl sulfamate
-
-
p-methylbenzyl sulfamate
-
-
pentachlorophenyl sulfamate
-
-
pentafluorophenyl sulfamate
-
-
perfluorobutanesulfonamide
-
-
phenylarsonic acid
weak inhibitor
phenylboronic acid
weak inhibitor
phenylsulfamate
-
best CA I inhibitor
phenylsulfonylsulfamic acid
-
-
piperacillin
noncompetitive inhibition
prop-2-ene-1-sulfonamide
-
-
quinolin-8-ylsulfonylsulfamic acid
-
-
rifamycin
strongest competitive inhibition
SCN-
-
inhibits 4-nitrophenyl acetate hydrolase activity
SDS
the wild-type enzyme is inactivated at 0.4% w/v, the mutant enzymes are more stable showing residual activity at that concentration
silymarin
-
a competitive inhibitor with 4-nitrophenylacetate as substrate
sodium (butylsulfonyl)azanide
-
-
sodium (hexylsulfonyl)azanide
-
-
sodium (octylsulfonyl)azanide
-
-
sulfasalazine
-
noncompetitive inhibition of isozymes carbonic anhydrase I and II
Sulfonamides
-
affinity of carbonic anhydrase IV for sulfonamides is decreased up to 65fold compared to carbonic anhydrase II
teicoplanin
noncompetitive inhibition
tert-butyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate
-
tert-butyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate
-
tert-butyl 3-[[(aminosulfonyl)amino]sulfonyl]phenylcarbamate
-
-
tert-butyl 4-[[(aminosulfonyl)amino]sulfonyl]phenylcarbamate
-
-
tert-butyl 5-[[(aminosulfonyl)amino]sulfonyl]-2-hydroperoxyphenylcarbamate
-
-
thien-2-ylsulfonylsulfamic acid
-
-
tobramycin
uncompetitive inhibition
trifluoromethanesulfonamide
tris(2-pyridyl)phosphine selenide
inhibits carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and alpha-glycosidase
tris(2-pyridyl)phosphine sulfide
inhibits carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and alpha-glycosidase
Vancomycin
noncompetitive inhibition
[(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate
-
-
[(7,7-dimethylbicyclo[2.2.1]hept-1-yl)methyl]sulfonylsulfamic acid
-
-
[3-(trifluoromethyl)phenyl]sulfonylsulfamic acid
-
-
[3-[(tert-butoxycarbonyl)amino]-4-hydroperoxyphenyl]sulfonylsulfamic acid
-
-
[3-[(tert-butoxycarbonyl)amino]phenyl]sulfonylsulfamic acid
-
-
[4-(acetylamino)phenyl]sulfonylsulfamic acid
-
-
[4-[(tert-butoxycarbonyl)amino]phenyl]sulfonylsulfamic acid
-
-
[5-(dimethylamino)-1-naphthyl]sulfonylsulfamic acid
-
-
[Co(1-benzyl-2-methylimidazole)2Cl2]
-
[Hg(1-benzyl-2-methylimidazole)2Cl2]
-
[Zn(1-benzyl-2-methylimidazole)2Cl2]
-
[[(2-methylphenyl)sulfonyl]amino]carbonylsulfamic acid
-
-
[[(2-methylphenyl)sulfonyl]amino]carbonylsulfamic amide
-
-
[[(4-chlorophenyl)sulfonyl]amino]carbonylsulfamic acid
-
-
[[(4-chlorophenyl)sulfonyl]amino]carbonylsulfamic amide
-
-
[[(4-fluorophenyl)sulfonyl]amino]carbonylsulfamic acid
-
-
[[(4-fluorophenyl)sulfonyl]amino]carbonylsulfamic amide
-
-
[[(4-methylphenyl)sulfonyl]amino]carbonylsulfamic acid
-
-
[[(4-methylphenyl)sulfonyl]amino]carbonylsulfamic amide
-
-
[[(eta5-C5H4)-C(CH3)=N-N(H)-C6H4-4-SO2NH2]]FeCp
-
-
[[(eta5-C5H4)-C(CH3)=N-N(H)-C6H4-4-SO2NH2]]Mn(CO)3
-
-
[[(eta5-C5H4)-C(CH3)=N-N(H)-C6H4-4-SO2NH2]]re(CO)3
-
-
[[(eta5-C5H4)-CH=N-N(H)-C6H4-4-SO2NH2]]FeCp
-
-
[[(eta5-C5H4)-CH=N-N(H)-C6H4-4-SO2NH2]]Mn(CO)3
-
-
[[(eta5-C5H4)-CH=N-N(H)-C6H4-4-SO2NH2]]re(CO)3
-
-
acetazolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA I
acetazolamide
i.e. 5-acetamido-1,3,4-thiadiazole-2-sulfonamide
acetazolamide
AAZ, a sulfonamide inhibitor
catechol
-
ethoxzolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA I
ethoxzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA I
phenol
inhibition of isozyme hCA I
resorcinol
-
2,3,5,6-tetrafluoro-4-(2-phenylethanesulfonyl)benzene-1-sulfonamide
-
2,3,5,6-tetrafluoro-4-(2-phenylethanesulfonyl)benzene-1-sulfonamide
VD11-10
2-(3-methoxypropyl)-4-(methylamino)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 -
2-(3-methoxypropyl)-4-(methylamino)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VA
2-(3-methoxypropyl)-4-(methylamino)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VB
2-(3-methoxypropyl)-4-(methylamino)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VI
2-(3-methoxypropyl)-4-(methylamino)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IX
2-(3-methoxypropyl)-4-(methylamino)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XII
2-(3-methoxypropyl)-4-(methylamino)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XIV
2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA II
2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA III
2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IV
2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VA
2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VB
2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VI
2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VII
2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IX
2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XII
2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XIV catalytic domain
2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide
efficient inhibitor of only isozymes CA I and II
2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide
-
2-aminobenzenesulfonamide
-
2-aminobenzenesulfonamide
-
2-hydrazinobenzenesulfonamide
-
2-hydrazinobenzenesulfonamide
-
2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA II
2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA III
2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IV
2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VA
2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VB
2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VI
2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VII
2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IX
2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XII
2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XIV
4,5-dichloro-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA II, i.e. daranide
4,5-dichloro-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA III, i.e. daranide
4,5-dichloro-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IV, i.e. daranide
4,5-dichloro-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VA, i.e. daranide
4,5-dichloro-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VB, i.e. daranide
4,5-dichloro-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VI, i.e. daranide
4,5-dichloro-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VII, i.e. daranide
4,5-dichloro-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IX, i.e. daranide
4,5-dichloro-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XII, i.e. daranide
4,5-dichloro-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XIV, i.e. daranide
4-(2-aminoethyl)benzenesulfonamide
-
4-(2-aminoethyl)benzenesulfonamide
-
4-(2-aminoethyl)benzenesulfonamide
-
-
4-(2-hydroxyethyl)benzenesulfonamide
-
4-(2-hydroxyethyl)benzenesulfonamide
-
4-(2-hydroxyethyl)benzenesulfonamide
-
-
4-(2-phenylacetamido)-3-bromobenzenesulfonamide
-
-
4-(2-phenylacetamido)-3-bromobenzenesulfonamide
-
4-(2-phenylacetamido)-3-chlorobenzenesulfonamide
-
-
4-(2-phenylacetamido)-3-chlorobenzenesulfonamide
-
4-(2-phenylacetamido)-3-fluorobenzenesulfonamide
-
-
4-(2-phenylacetamido)-3-fluorobenzenesulfonamide
-
4-(2-phenylacetamido)benzenesulfonamide
-
-
4-(2-phenylacetamido)benzenesulfonamide
-
4-(2-phenylacetamidoethyl)benzenesulfonamide
-
-
4-(2-phenylacetamidoethyl)benzenesulfonamide
-
4-(2-phenylacetamidomethyl)benzenesulfonamide
-
-
4-(2-phenylacetamidomethyl)benzenesulfonamide
-
4-(2-pyridin-2-ylacetamido)benzenesulfonamide
-
-
4-(2-pyridin-2-ylacetamido)benzenesulfonamide
-
4-(2-pyridin-4-ylacetamido)benzenesulfonamide
-
-
4-(2-pyridin-4-ylacetamido)benzenesulfonamide
-
4-(2-pyridin-4-ylacetamidoethyl)benzenesulfonamide
-
-
4-(2-pyridin-4-ylacetamidoethyl)benzenesulfonamide
-
4-(aminomethyl)benzenesulfonamide
-
4-(aminomethyl)benzenesulfonamide
-
4-(aminosulfonyl)benzoic acid
-
4-(aminosulfonyl)benzoic acid
-
4-(hydroxymethyl)benzenesulfonamide
-
4-(hydroxymethyl)benzenesulfonamide
-
4-amino-3-chlorobenzenesulfonamide
-
4-amino-3-chlorobenzenesulfonamide
-
4-amino-3-fluorobenzenesulfonamide
-
4-amino-3-fluorobenzenesulfonamide
-
4-amino-3-fluorobenzenesulfonamide
-
-
4-amino-6-(trifluoromethyl)benzene-1,3-disulfonamide
-
4-amino-6-(trifluoromethyl)benzene-1,3-disulfonamide
-
4-amino-6-chlorobenzene-1,3-disulfonamide
-
4-amino-6-chlorobenzene-1,3-disulfonamide
-
4-amino-6-chlorobenzene-1,3-disulfonamide
-
-
4-amino-N-[4-(aminosulfonyl)benzyl]benzenesulfonamide
-
4-amino-N-[4-(aminosulfonyl)benzyl]benzenesulfonamide
-
4-amino-N-{2-[4-(aminosulfonyl)phenyl]ethyl}benzenesulfonamide
-
4-amino-N-{2-[4-(aminosulfonyl)phenyl]ethyl}benzenesulfonamide
-
4-Aminobenzenesulfonamide
-
-
4-Aminobenzenesulfonamide
-
4-Aminobenzenesulfonamide
-
4-Aminobenzenesulfonamide
-
-
4-methylbenzenesulfonamide
-
4-methylbenzenesulfonamide
-
4-[(2-aminopyrimidin-4-yl)amino]benzenesulfonamide
-
4-[(2-aminopyrimidin-4-yl)amino]benzenesulfonamide
-
4-[2-(2-thienyl)acetamidoethyl]benzenesulfonamide
-
-
4-[2-(2-thienyl)acetamidoethyl]benzenesulfonamide
-
4-[2-(2-thienyl)acetamidomethyl]benzenesulfonamide
-
-
4-[2-(2-thienyl)acetamidomethyl]benzenesulfonamide
-
4-[2-(2-thienyl)acetamido]-3-bromobenzenesulfonamide
-
-
4-[2-(2-thienyl)acetamido]-3-bromobenzenesulfonamide
-
4-[2-(2-thienyl)acetamido]-3-chlorobenzenesulfonamide
-
-
4-[2-(2-thienyl)acetamido]-3-chlorobenzenesulfonamide
-
4-[2-(2-thienyl)acetamido]-3-fluorobenzenesulfonamide
-
-
4-[2-(2-thienyl)acetamido]-3-fluorobenzenesulfonamide
-
4-[2-(2-thienyl)acetamido]benzenesulfonamide
-
-
4-[2-(2-thienyl)acetamido]benzenesulfonamide
-
5-(2-chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide
-
-
5-(2-chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide
-
5-(2-chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide
-
5-(2-phenylacetamido)-1,3,4-thiadiazole-2-sulfonamide
-
-
5-(2-phenylacetamido)-1,3,4-thiadiazole-2-sulfonamide
-
5-acetamido-1,3,4-thiadiazole-2-sulfonamide
-
5-acetamido-1,3,4-thiadiazole-2-sulfonamide
-
-
5-amino-1,3,4-thiadiazole-2-sulfonamide
-
-
5-amino-1,3,4-thiadiazole-2-sulfonamide
-
5-amino-1,3,4-thiadiazole-2-sulfonamide
-
5-amino-1,3,4-thiadiazole-2-sulfonamide
-
-
5-fluorouracil
-
5-imino-4-methyl-4,5-dihydro-1,3,4-thiadiazole-2-sulfonamide
-
5-imino-4-methyl-4,5-dihydro-1,3,4-thiadiazole-2-sulfonamide
-
5-[2-(2-thienyl)acetamido]-1,3,4-thiadiazole-2-sulfonamide
-
-
5-[2-(2-thienyl)acetamido]-1,3,4-thiadiazole-2-sulfonamide
-
5-{[(4-aminophenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide
-
5-{[(4-aminophenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide
-
6-chloro-4-amino-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA II
6-chloro-4-amino-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA III
6-chloro-4-amino-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IV
6-chloro-4-amino-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VA
6-chloro-4-amino-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VB
6-chloro-4-amino-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VI
6-chloro-4-amino-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VII
6-chloro-4-amino-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IX
6-chloro-4-amino-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XII
6-chloro-4-amino-benzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XIV
6-methyl-4-(methylamino)-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 -
6-methyl-4-(methylamino)-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA III
6-methyl-4-(methylamino)-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VA
6-methyl-4-(methylamino)-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VB
6-methyl-4-(methylamino)-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VI
6-methyl-4-(methylamino)-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IX
6-methyl-4-(methylamino)-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XII
6-methyl-4-(methylamino)-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XIV
6-trifluoromethyl-4-aminobenzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA II
6-trifluoromethyl-4-aminobenzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA III
6-trifluoromethyl-4-aminobenzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IV
6-trifluoromethyl-4-aminobenzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VA
6-trifluoromethyl-4-aminobenzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VB
6-trifluoromethyl-4-aminobenzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VI
6-trifluoromethyl-4-aminobenzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VII
6-trifluoromethyl-4-aminobenzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IX
6-trifluoromethyl-4-aminobenzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XII
6-trifluoromethyl-4-aminobenzene-1,3-disulfonamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XIV
acetazolamide
-
-
acetazolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA II
acetazolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA III
acetazolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IV
acetazolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VA
acetazolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VB
acetazolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VI
acetazolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VII
acetazolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IX
acetazolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XII
acetazolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XIV
acetazolamide
-
i.e. 5-acetamido-1,3,4-thiadiazole-2-sulfonamide
acetazolamide
-
systemic carbonic anhydrase inhibitor
acetazolamide
promiscuous inhibitor of all isozymes except CA III
acetazolamide
i.e. 5-acetamido-1,3,4-thiadiazole-2-sulfonamide
acetazolamide
AAZ, a sulfonamide inhibitor
acetazolamide
i.e. 5-acetamido-1,3,4-thiadiazole-2-sulfonamide
benzolamide
-
-
bicarbonate
-
brinzolamide
-
-
brinzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA II
brinzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA III
brinzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IV
brinzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VA
brinzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VB
brinzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VI
brinzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VII
brinzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IX
brinzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XII
brinzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XIV catalytic domain
brinzolamide
-
potent inhibitor of isozymes CA II
catechol
inhibition of isozyme hCA II
celecoxib
-
curcumin
-
a competitive inhibitor with 4-nitrophenylacetate as substrate
dehydroepiandrosterone sulfamate
-
-
dehydroepiandrosterone sulfamate
-
CA II inhibitor
dichlorophenamide
-
-
dichlorophenamide
-
systemic carbonic anhydrase inhibitor
dobutamin
-
a competitive inhibitor with 4-nitrophenylacetate as substrate
dorzolamide
-
-
dorzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA II
dorzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA III
dorzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IV
dorzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VA
dorzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VB
dorzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VI
dorzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VII
dorzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IX
dorzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XII
dorzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XIV catalytic domain
dorzolamide
-
potent inhibitor of isozymes CA II
estradiol 3,17 beta-disulfamate
-
CA II inhibitor
estradiol 3,17 beta-disulfamate
-
-
ethoxzolamide
-
-
ethoxzolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA II
ethoxzolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA III
ethoxzolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IV
ethoxzolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VA
ethoxzolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VB
ethoxzolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VI
ethoxzolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VII
ethoxzolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IX
ethoxzolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XII
ethoxzolamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XIV
ethoxzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA II
ethoxzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA III
ethoxzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IV
ethoxzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VA
ethoxzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VB
ethoxzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VI
ethoxzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VII
ethoxzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IX
ethoxzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XII
ethoxzolamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XIV catalytic domain
ethoxzolamide
promiscuous inhibitor of all isozymes except CA III
ethoxzolamide
strong binding, U-shaped pH-dependence of the Gibbs energy of binding, the affinity is greatest in the near neutral pH region and diminished towards both the acidic and alkaline regions
Furosemide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA II
Furosemide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA III
Furosemide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IV
Furosemide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VA
Furosemide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VB
Furosemide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VI
Furosemide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VII
Furosemide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IX
Furosemide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XII
Furosemide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XIV
H2NSO2NH2
isoenzyme hCA II
H2NSO2NH2
isoenzyme hCA IX
H2NSO2NH2
isoenzyme hCA XII
H2NSO3H
isoenzyme hCA II
H2NSO3H
isoenzyme hCA XII
hydrochlorothiazide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA II
hydrochlorothiazide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA III
hydrochlorothiazide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IV
hydrochlorothiazide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VA
hydrochlorothiazide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VB
hydrochlorothiazide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VI
hydrochlorothiazide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VII
hydrochlorothiazide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IX
hydrochlorothiazide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XII
hydrochlorothiazide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XIV
I-
-
inhibits 4-nitrophenyl acetate hydrolase activity
I-
-
relatively resistant to
indisulam
-
indisulam
-
potent inhibitor of CA IX
methazolamide
-
-
methazolamide
-
systemic carbonic anhydrase inhibitor
methazolamide
promiscuous inhibitor of all isozymes except CA III
n-decyl sulfamate
-
CA II inhibitor
N-hydroxysulfamide
the inhibitor coordinates to the active site zinc ion by the ionized primary amino group, participating in an extended network of hydrogen bonds with amino acid residues Thr199, Thr200 and two water molecules, isoenzyme hCA II
N-hydroxysulfamide
isoenzyme hCA IX
N-hydroxysulfamide
isoenzyme hCA XII
n-octyl sulfamate
-
-
n-octyl sulfamate
-
inhibition of hCA I, hCA II, and hCA IX
n-tetradecyl sulfamate
-
most potent CA I inhibitor
n-tetradecyl sulfamate
-
-
N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 -
N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA III
N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VA
N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VB
N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VI
N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IX
N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XII
N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XIV
nitrate
-
-
nitrate
mutants M3 and M4 are more resistent against inhibition by nitrate compared to wild-type and mutants M1 and M2
phenol
-
-
phenol
inhibition of isozyme hCA II
resorcinol
inhibition of isozyme hCA II
resveratrol
-
a competitive inhibitor with 4-nitrophenylacetate as substrate
salicylic acid
-
noncompetitive inhibition of isozymes carbonic anhydrase I and II
sulfamic acid
-
-
sulfamide
-
sulfanilamide
-
-
sulpiride
-
sulthiame
isoenzyme hCA II
sulthiame
isoenzyme hCA III
sulthiame
isoenzyme hCA IV
sulthiame
isoenzyme hCA VA
sulthiame
isoenzyme hCA VB
sulthiame
isoenzyme hCA VI
sulthiame
isoenzyme hCA VII
sulthiame
isoenzyme hCA IX
sulthiame
isoenzyme hCA XIV
thiocyanate
-
-
thiocyanate
best inhibitor
topiramate
-
-
topiramate
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA II
topiramate
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA III
topiramate
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IV
topiramate
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VA
topiramate
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VB
topiramate
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VI
topiramate
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VII
topiramate
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IX
topiramate
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XII
topiramate
Q9ULX7, O43570, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XIV
topiramate
-
powerful inhibitor of CA II
trifluoromethanesulfonamide
U-shaped pH-dependence of the Gibbs energy of binding, the affinity is greatest in the near neutral pH region and diminished towards both the acidic and alkaline regions
trifluoromethanesulfonamide
-
valdecoxib
-
zonisamide
-
zonisamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA II
zonisamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA III
zonisamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IV
zonisamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VA
zonisamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VB
zonisamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VI
zonisamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA VII
zonisamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA IX
zonisamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XII
zonisamide
O14939, Q9ULX7, Q16790, P00918, P07451, P00915, P22748, P35218, Q9Y2D0, P23280, P43166 isoenzyme hCA XIV catalytic domain
additional information
synthesis, X-ray structure, in silico calculation, and carbonic anhydrase inhibitory properties of benzylimidazole metal complexes, i.e. three coordination compounds of formula [M(bmim)2Cl2], crystal structures of metal complexes, overview. Each complex incorporates 1-benzyl-2-methylimidazole (bmim) as ligand. The coordination polyhedron around the metal center for all complexes has a quasi-regular tetragonal geometry. In the 1-benzyl-2-methylimidazole ligand, imidazole moiety is connected to phenyl cycle via a methylene linker. Density functional theory calculations are carried out on the title compounds, with Co2+, Zn2+, and Hg2+, and as well on hypothetical complexes (with Cu2+, Ni2+) in order to elucidate their electronic and molecular structure. Only compound [Hg(bmim)2Cl2] exhibits a modest inhibitory effect against enzyme hCA I, probably due to the affinity of Hg(II) for His residues at the entrance of the active site cavity
-
additional information
synthesis, X-ray structure, in silico calculation, and carbonic anhydrase inhibitory properties of benzylimidazole metal complexes, i.e. three coordination compounds of formula [M(bmim)2Cl2], crystal structures of metal complexes, overview. Each complex incorporates 1-benzyl-2-methylimidazole (bmim) as ligand. The coordination polyhedron around the metal center for all complexes has a quasi-regular tetragonal geometry. In the 1-benzyl-2-methylimidazole ligand, imidazole moiety is connected to phenyl cycle via a methylene linker. Density functional theory calculations are carried out on the title compounds, with Co2+, Zn2+, and Hg2+, and as well on hypothetical complexes (with Cu2+, Ni2+) in order to elucidate their electronic and molecular structure. Only compound [Hg(bmim)2Cl2] exhibits a modest inhibitory effect against enzyme hCA I, probably due to the affinity of Hg(II) for His residues at the entrance of the active site cavity
-
additional information
some uracil derivatives have carbonic anhydrase inhibitory properties, overview
-
additional information
some uracil derivatives have carbonic anhydrase inhibitory properties, overview
-
additional information
-
some uracil derivatives have carbonic anhydrase inhibitory properties, overview
-
additional information
benzothiazole derivative inhibitor synthesis, overview
-
additional information
benzothiazole derivative inhibitor synthesis, overview
-
additional information
benzothiazole derivative inhibitor synthesis, overview
-
additional information
benzothiazole derivative inhibitor synthesis, overview
-
additional information
-
benzothiazole derivative inhibitor synthesis, overview
-
additional information
inhibitor synthesis and isozyme in silico docking study using enzyme structure, PDB ID 2FW4, modeling
-
additional information
inhibitor synthesis and isozyme in silico docking study using enzyme structure, PDB ID 2FW4, modeling
-
additional information
inhibitor synthesis and isozyme in silico docking study using enzyme structure, PDB ID 2FW4, modeling
-
additional information
-
inhibitor synthesis and isozyme in silico docking study using enzyme structure, PDB ID 2FW4, modeling
-
additional information
2-benzylpiperazine is a scaffold for potent human carbonic anhydrase inhibitors, compounds synthesis, enzyme inhibition, and enantioselectivity, overview
-
additional information
2-benzylpiperazine is a scaffold for potent human carbonic anhydrase inhibitors, compounds synthesis, enzyme inhibition, and enantioselectivity, overview
-
additional information
2-benzylpiperazine is a scaffold for potent human carbonic anhydrase inhibitors, compounds synthesis, enzyme inhibition, and enantioselectivity, overview
-
additional information
2-benzylpiperazine is a scaffold for potent human carbonic anhydrase inhibitors, compounds synthesis, enzyme inhibition, and enantioselectivity, overview
-
additional information
-
2-benzylpiperazine is a scaffold for potent human carbonic anhydrase inhibitors, compounds synthesis, enzyme inhibition, and enantioselectivity, overview
-
additional information
structure-activity relationships of benzenesulfonamide-based inhibitors towards carbonic anhydrase isoform specificity, inhibition of different human isozymes, in silico modeling of inhibitors in CA I, oveview
-
additional information
structure-activity relationships of benzenesulfonamide-based inhibitors towards carbonic anhydrase isoform specificity, inhibition of different human isozymes, in silico modeling of inhibitors in CA I, oveview
-
additional information
structure-activity relationships of benzenesulfonamide-based inhibitors towards carbonic anhydrase isoform specificity, inhibition of different human isozymes, in silico modeling of inhibitors in CA I, oveview
-
additional information
structure-activity relationships of benzenesulfonamide-based inhibitors towards carbonic anhydrase isoform specificity, inhibition of different human isozymes, in silico modeling of inhibitors in CA I, oveview
-
additional information
isozyme hCA I is inhibited by flavonoids, poor inhibition by pelargonin
-
additional information
isozyme hCA I is inhibited by flavonoids, poor inhibition by pelargonin
-
additional information
-
isozyme hCA I is inhibited by flavonoids, poor inhibition by pelargonin
-
additional information
-
insensitive to bromopyruvate
-
additional information
-
overview
-
additional information
overview
-
additional information
-
NaClO4 is not inhibitory
-
additional information
-
not inhibited by acetazolamide
-
additional information
no inhibition of HCA II by citrate and no conformational changes of amino-acid side chains as a result of the use of citrate at pH 6.0-11.0
-
additional information
-
no inhibition of HCA II by citrate and no conformational changes of amino-acid side chains as a result of the use of citrate at pH 6.0-11.0
-
additional information
-
carbonic anhydrases are inhibited by sulfonamides, inorganic anions, phenols, coumarins (acting as prodrugs) and polyamines. Development of hydroxy-, methoxy-substituted benzoic acids as well as di-, tri-methoxy benzenes as submicromolar-low micromolar inhibitors of carbonic anhydrase isozymes, molecular docking and inhibition mechanism, overview
-
additional information
-
an additional 3-fluoro substituent on the 4-amino-benzenesulfonamide scaffold of inhibitors alters the inhibition profiles against the cytosolic isozymes hCA I, II, III, VII and XIII, interaction analysis, overview. The binding differences render the inhibitors more isozyme-specific. Docking studies, overview
-
additional information
-
synthesis of 2-[(p-toluenesulfonamido)-N-yl]-l,3,4-thiadiazole-5-sulfonamide inhibitors, inhibitory potencies versus isozymes CAII, docking study, overview
-
additional information
-
synthesis of two series of disubstituted coumarins incorporating ether and acetyl/propionyl moieties in positions 6,7 and 7,8 of the heterocyclic ring. The compounds are very weak or ineffective as inhibitors of the housekeeping, offtarget isozymes CA I and CA II. The 6,7-disubstituted series show ineffective inhibition also for the transmembrane tumor-associated isoforms CA IX and XII, whereas the corresponding isomeric 7,8-disubstituted coumarins show nanomolar/subnanomolar inhibition of CA IX/XII, overview. No inhibition by 12 and 13
-
additional information
-
N-beta-glycosyl sulfamides are selective inhibitors of the cancer-associated carbonic anhydrase isoforms IX and XII
-
additional information
-
some natural phenols show effective hCA II inhibitory effects, in the same range as the clinically used sulfonamide acetazolamide, and might be used as leads for generating enzyme inhibitors possibly targeting other CA isozymes
-
additional information
-
development and synthesis of a series of compounds incorporating regioisomeric phenylethynylbenzenesulfonamide moieties, analysis of potential as inhibitors of the four human isozymes, hCA I, hCA II, hCA IX, and hCA XII. The position of the sulfamoyl group with respect to the alkyne functionality, and the nature of the moieties substituting the second aromatic ring are the principal structural features influencing CA inhibition. The para-sulfamoyl-substituted derivatives are effective inhibitors of CA IX and XII, the meta-substituted regioisomers of CA I, X and XII, whereas the ortho-substituted sulfonamides ae weak inhibitors of CA I, II and IX, but inhibit ignificantly CA XII, structure-activity relationship study, overview
-
additional information
synthesis, X-ray structure, in silico calculation, and carbonic anhydrase inhibitory properties of benzylimidazole metal complexes, i.e. three coordination compounds of formula [M(bmim)2Cl2], crystal structures of metal complexes, overview. Each complex incorporates 1-benzyl-2-methylimidazole (bmim) as ligand. The coordination polyhedron around the metal center for all complexes has a quasi-regular tetragonal geometry. In the 1-benzyl-2-methylimidazole ligand, imidazole moiety is connected to phenyl cycle via a methylene linker. Density functional theory calculations are carried out on the title compounds, with Co2+, Zn2+, and Hg2+, and as well on hypothetical complexes (with Cu2+, Ni2+) in order to elucidate their electronic and molecular structure. All three complxes do not inhibit the enzyme significantly
-
additional information
synthesis, X-ray structure, in silico calculation, and carbonic anhydrase inhibitory properties of benzylimidazole metal complexes, i.e. three coordination compounds of formula [M(bmim)2Cl2], crystal structures of metal complexes, overview. Each complex incorporates 1-benzyl-2-methylimidazole (bmim) as ligand. The coordination polyhedron around the metal center for all complexes has a quasi-regular tetragonal geometry. In the 1-benzyl-2-methylimidazole ligand, imidazole moiety is connected to phenyl cycle via a methylene linker. Density functional theory calculations are carried out on the title compounds, with Co2+, Zn2+, and Hg2+, and as well on hypothetical complexes (with Cu2+, Ni2+) in order to elucidate their electronic and molecular structure. All three complxes do not inhibit the enzyme significantly
-
additional information
some uracil derivatives have carbonic anhydrase inhibitory properties, overview
-
additional information
some uracil derivatives have carbonic anhydrase inhibitory properties, overview
-
additional information
-
some uracil derivatives have carbonic anhydrase inhibitory properties, overview
-
additional information
benzothiazole derivative inhibitor synthesis, overview. No inhibition by benzyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, (S)-tert-butyl (1-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, (S)-tert-butyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)-carbamate, (S)-benzyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, and (S)-2-(2-ammoniopropanamido)-4-methylbenzo[d]thiazol-3-ium di-2,2,2-trifluoroacetate
-
additional information
benzothiazole derivative inhibitor synthesis, overview. No inhibition by benzyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, (S)-tert-butyl (1-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, (S)-tert-butyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)-carbamate, (S)-benzyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, and (S)-2-(2-ammoniopropanamido)-4-methylbenzo[d]thiazol-3-ium di-2,2,2-trifluoroacetate
-
additional information
benzothiazole derivative inhibitor synthesis, overview. No inhibition by benzyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, (S)-tert-butyl (1-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, (S)-tert-butyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)-carbamate, (S)-benzyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, and (S)-2-(2-ammoniopropanamido)-4-methylbenzo[d]thiazol-3-ium di-2,2,2-trifluoroacetate
-
additional information
benzothiazole derivative inhibitor synthesis, overview. No inhibition by benzyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, (S)-tert-butyl (1-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, (S)-tert-butyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)-carbamate, (S)-benzyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, and (S)-2-(2-ammoniopropanamido)-4-methylbenzo[d]thiazol-3-ium di-2,2,2-trifluoroacetate
-
additional information
-
benzothiazole derivative inhibitor synthesis, overview. No inhibition by benzyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, (S)-tert-butyl (1-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, (S)-tert-butyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)-carbamate, (S)-benzyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, and (S)-2-(2-ammoniopropanamido)-4-methylbenzo[d]thiazol-3-ium di-2,2,2-trifluoroacetate
-
additional information
benzothiazole derivative inhibitor synthesis, overview. No inhibition by benzyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, (S)-tert-butyl (1-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, (S)-benzyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)-carbamate, (S)-benzyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, and (S)-2-(2-ammoniopropanamido)-4-methylbenzo[d]thiazol-3-ium di-2,2,2-trifluoroacetate
-
additional information
benzothiazole derivative inhibitor synthesis, overview. No inhibition by benzyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, (S)-tert-butyl (1-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, (S)-benzyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)-carbamate, (S)-benzyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, and (S)-2-(2-ammoniopropanamido)-4-methylbenzo[d]thiazol-3-ium di-2,2,2-trifluoroacetate
-
additional information
benzothiazole derivative inhibitor synthesis, overview. No inhibition by benzyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, (S)-tert-butyl (1-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, (S)-benzyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)-carbamate, (S)-benzyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, and (S)-2-(2-ammoniopropanamido)-4-methylbenzo[d]thiazol-3-ium di-2,2,2-trifluoroacetate
-
additional information
benzothiazole derivative inhibitor synthesis, overview. No inhibition by benzyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, (S)-tert-butyl (1-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, (S)-benzyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)-carbamate, (S)-benzyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, and (S)-2-(2-ammoniopropanamido)-4-methylbenzo[d]thiazol-3-ium di-2,2,2-trifluoroacetate
-
additional information
-
benzothiazole derivative inhibitor synthesis, overview. No inhibition by benzyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, (S)-tert-butyl (1-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, (S)-benzyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)-carbamate, (S)-benzyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, and (S)-2-(2-ammoniopropanamido)-4-methylbenzo[d]thiazol-3-ium di-2,2,2-trifluoroacetate
-
additional information
inhibitor synthesis, overview. No inhibition by benzyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, (S)-tert-butyl (1-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, (S)-benzyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)-carbamate, (S)-benzyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, and (S)-2-(2-ammoniopropanamido)-4-methylbenzo[d]thiazol-3-ium di-2,2,2-trifluoroacetate
-
additional information
inhibitor synthesis, overview. No inhibition by benzyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, (S)-tert-butyl (1-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, (S)-benzyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)-carbamate, (S)-benzyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, and (S)-2-(2-ammoniopropanamido)-4-methylbenzo[d]thiazol-3-ium di-2,2,2-trifluoroacetate
-
additional information
inhibitor synthesis, overview. No inhibition by benzyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, (S)-tert-butyl (1-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, (S)-benzyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)-carbamate, (S)-benzyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, and (S)-2-(2-ammoniopropanamido)-4-methylbenzo[d]thiazol-3-ium di-2,2,2-trifluoroacetate
-
additional information
inhibitor synthesis, overview. No inhibition by benzyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, (S)-tert-butyl (1-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, (S)-benzyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)-carbamate, (S)-benzyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, and (S)-2-(2-ammoniopropanamido)-4-methylbenzo[d]thiazol-3-ium di-2,2,2-trifluoroacetate
-
additional information
-
inhibitor synthesis, overview. No inhibition by benzyl (2-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, (S)-tert-butyl (1-((6-(methylsulfonyl)benzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-2-oxoethyl)carbamate, (S)-benzyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, benzyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)carbamate, tert-butyl (2-((4-methylbenzo[d]thiazol-2-yl)amino)-2-oxoethyl)-carbamate, (S)-benzyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxopropan-2-yl)carbamate, (S)-tert-butyl (1-((4-methylbenzo[d]thiazol-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate, and (S)-2-(2-ammoniopropanamido)-4-methylbenzo[d]thiazol-3-ium di-2,2,2-trifluoroacetate
-
additional information
inhibitor synthesis and isozyme in silico docking study using enzyme structure, PDB ID 5AML, modeling
-
additional information
inhibitor synthesis and isozyme in silico docking study using enzyme structure, PDB ID 5AML, modeling
-
additional information
inhibitor synthesis and isozyme in silico docking study using enzyme structure, PDB ID 5AML, modeling
-
additional information
-
inhibitor synthesis and isozyme in silico docking study using enzyme structure, PDB ID 5AML, modeling
-
additional information
inhibitor synthesis and isozyme in silico docking study using enzyme structure, PDB ID 3IAI, modeling. No inhibition by pyrogallol
-
additional information
inhibitor synthesis and isozyme in silico docking study using enzyme structure, PDB ID 3IAI, modeling. No inhibition by pyrogallol
-
additional information
inhibitor synthesis and isozyme in silico docking study using enzyme structure, PDB ID 3IAI, modeling. No inhibition by pyrogallol
-
additional information
-
inhibitor synthesis and isozyme in silico docking study using enzyme structure, PDB ID 3IAI, modeling. No inhibition by pyrogallol
-
additional information
presence of D2O reduces catalysis, but does not change how it proceeds
-
additional information
presence of D2O reduces catalysis, but does not change how it proceeds
-
additional information
-
presence of D2O reduces catalysis, but does not change how it proceeds
-
additional information
structure-activity relationships of benzenesulfonamide-based inhibitors towards carbonic anhydrase isoform specificity, inhibition of different human isozymes, overview
-
additional information
structure-activity relationships of benzenesulfonamide-based inhibitors towards carbonic anhydrase isoform specificity, inhibition of different human isozymes, overview
-
additional information
structure-activity relationships of benzenesulfonamide-based inhibitors towards carbonic anhydrase isoform specificity, inhibition of different human isozymes, overview
-
additional information
structure-activity relationships of benzenesulfonamide-based inhibitors towards carbonic anhydrase isoform specificity, inhibition of different human isozymes, overview
-
additional information
2-benzylpiperazine is a scaffold for potent human carbonic anhydrase inhibitors, compounds synthesis, enzyme inhibition, and enantioselectivity, overview
-
additional information
2-benzylpiperazine is a scaffold for potent human carbonic anhydrase inhibitors, compounds synthesis, enzyme inhibition, and enantioselectivity, overview
-
additional information
2-benzylpiperazine is a scaffold for potent human carbonic anhydrase inhibitors, compounds synthesis, enzyme inhibition, and enantioselectivity, overview
-
additional information
2-benzylpiperazine is a scaffold for potent human carbonic anhydrase inhibitors, compounds synthesis, enzyme inhibition, and enantioselectivity, overview
-
additional information
-
2-benzylpiperazine is a scaffold for potent human carbonic anhydrase inhibitors, compounds synthesis, enzyme inhibition, and enantioselectivity, overview
-
additional information
3-[[(3,4-dimethoxyphenyl)methyl]amino]-2,5,6-trifluoro-4-(2-hydroxyethanesulfonyl)benzene-1-sulfonamide does not exhibit selectivity for CA XIV
-
additional information
-
3-[[(3,4-dimethoxyphenyl)methyl]amino]-2,5,6-trifluoro-4-(2-hydroxyethanesulfonyl)benzene-1-sulfonamide does not exhibit selectivity for CA XIV
-
additional information
development and synthesis of a class of CA IX inhibitors that comprise a sulfamate as the zinc binding group, a variable linker, and a carbohydrate tail moiety
-
additional information
isozyme hCA II is inhibited by flavonoids, poor inhibition by pelargonin
-
additional information
isozyme hCA II is inhibited by flavonoids, poor inhibition by pelargonin
-
additional information
-
isozyme hCA II is inhibited by flavonoids, poor inhibition by pelargonin
-
additional information
-
not inhibited by neostigmine
-
additional information
not inhibited by ciprofloxacin, levofloxacin, metronidazole, moxifloxacin, netilmicin, ofloxacin, and ornidazole
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Achlorhydria
Achlorhydria induced changes in gastrin, somatostatin, H+/K(+)-ATPase and carbonic anhydrase in the sheep.
Acid-Base Imbalance
BLOOD CARBONIC ANHYDRASE ACTIVITY-A POSSIBLE ROLE IN THE PRODUCTION OF ACID-BASE IMBALANCE IN CHILDREN AND INFANTS.
Acid-Base Imbalance
Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin.
Acidosis
: Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates.
Acidosis
A Case of Carbonic Anhydrase Type 2 Deficiency Syndrome with Autistic Disorder.
Acidosis
A Multifunctional Graphene Oxide Platform for Targeting Cancer.
Acidosis
A novel homozygous nonsense mutation in the CA2 gene (c.368G>A, p.W123X) linked to carbonic anhydrase II deficiency syndrome in a Chinese family.
Acidosis
A splice junction mutation in intron 2 of the carbonic anhydrase II gene of osteopetrosis patients from Arabic countries.
Acidosis
Acetazolamide and exercise in sojourners to 6,300 meters--a preliminary study.
Acidosis
Acetazolamide on the ventral medulla of the cat increases phrenic output and delays the ventilatory response to CO2.
Acidosis
Acetazolamide, alternate carbonic anhydrase inhibitors and hypoglycaemic agents: comparing enzymatic with diuresis induced metabolic acidosis following intraocular surgery in diabetes.
Acidosis
Acetazolamide, metabolic acidosis, and intraocular pressure.
Acidosis
Acetylcholine-induced intracellular acidosis in rabbit salivary gland acinar cells.
Acidosis
Acid pH increases carbonic anhydrase II and calcitonin receptor mRNA expression in mature osteoclasts.
Acidosis
Acid-base status determines the renal expression of Ca2+ and mg2+ transport proteins.
Acidosis
Acid-base status in the toad Bufo viridis in vivo.
Acidosis
Acidosis inhibits the hypocalcemic effect of acetazolamide.
Acidosis
Adaptive changes of H+ and/or bicarbonate transport in chronic metabolic acidosis: its quantitative evaluation by using isolated perfused kidney.
Acidosis
Aqueous humor flow in human eyes treated with dorzolamide and different doses of acetazolamide.
Acidosis
Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models.
Acidosis
Association of acetazolamide infusion with headache and cranial artery dilation in healthy volunteers.
Acidosis
Autoantibodies against carbonic anhydrase II are increased in renal tubular acidosis associated with Sjogren syndrome.
Acidosis
Axial skeletal malformations induced by acetazolamide in rabbits.
Acidosis
Bicarbonate transport in collecting tubules from outer stripe of outer medulla of rabbit kidneys.
Acidosis
Binding of carbonic anhydrase IX to 45S rDNA genes is prevented by exportin-1 in hypoxic cells.
Acidosis
Body water and electrolyte responses to acetazolamide in humans.
Acidosis
Brain carbonic acid acidosis after acetazolamide.
Acidosis
CA IX Stabilizes Intracellular pH to Maintain Metabolic Reprogramming and Proliferation in Hypoxia.
Acidosis
Carbonic anhydrase 2 deficiency leads to increased pyelonephritis susceptibility.
Acidosis
Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer.
Acidosis
Carbonic anhydrase II (CA II) deficiency in Maghrebian patients: evidence for founder effect and genomic recombination at the CA II locus.
Acidosis
Carbonic anhydrase II and IV mRNA in rabbit nephron segments: stimulation during metabolic acidosis.
Acidosis
Carbonic anhydrase II deficiency a novel mutation.
Acidosis
Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.
Acidosis
Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.
Acidosis
Carbonic Anhydrase II Deficiency in a Saudi Woman.
Acidosis
Carbonic anhydrase II deficiency syndrome (osteopetrosis with renal tubular acidosis and brain calcification): novel mutations in CA2 identified by direct sequencing expand the opportunity for genotype-phenotype correlation.
Acidosis
Carbonic anhydrase II deficiency syndrome--clinico-pathological, biochemical and molecular studies.
Acidosis
Carbonic anhydrase II deficiency syndrome: recessive osteopetrosis with renal tubular acidosis and cerebral calcification.
Acidosis
Carbonic anhydrase II deficiency.
Acidosis
Carbonic anhydrase II deficiency: a rare autosomal recessive disorder of osteopetrosis, renal tubular acidosis, and cerebral calcification.
Acidosis
Carbonic Anhydrase II Deficiency: A Rare Case of Severe Obstructive Sleep Apnea.
Acidosis
Carbonic anhydrase II deficiency: diagnosis and carrier detection using differential enzyme inhibition and inactivation.
Acidosis
Carbonic anhydrase II deficiency: report of a novel mutation.
Acidosis
Carbonic anhydrase II deficiency: single-base deletion in exon 7 is the predominant mutation in Caribbean Hispanic patients.
Acidosis
Carbonic anhydrase II in the developing and adult human brain.
Acidosis
Carbonic anhydrase II mRNA is induced in rabbit kidney cortex during chronic metabolic acidosis.
Acidosis
Carbonic anhydrase in the scleractinian coral Stylophora pistillata: characterization, localization, and role in biomineralization.
Acidosis
Carbonic Anhydrase Inhibition Ameliorates Inflammation and Experimental Pulmonary Hypertension.
Acidosis
Carbonic anhydrase inhibition improves pulmonary artery reactivity and nitric oxide-mediated relaxation in sugen-hypoxia model of pulmonary hypertension.
Acidosis
Carbonic anhydrase inhibition. IV. The effects of metabolic acidosis on the response to diamox.
Acidosis
Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstructive pulmonary disease.
Acidosis
Carbonic anhydrase inhibitors suppress seizures in a rat model of birth asphyxia.
Acidosis
Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
Acidosis
Carbonic anhydrase isoenzyme B in erythrocytes of subjects with chronic acidosis.
Acidosis
Carbonic anhydrase isozymes IV and II in urinary membranes from carbonic anhydrase II-deficient patients.
Acidosis
Carbonic Anhydrase IX as an Anticancer therapy Target: Preclinical Evaluation of Internalizing Monoclonal Antibody Directed to Catalytic Domain.
Acidosis
Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis.
Acidosis
Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain.
Acidosis
Carbonic anhydrase IX is a critical determinant of pulmonary microvascular endothelial cell pH regulation and angiogenesis during acidosis.
Acidosis
Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors.
Acidosis
Carbonic anhydrase IX: A hypoxia-controlled "catalyst" of cell migration.
Acidosis
Carnosine inhibits carbonic anhydrase IX-mediated extracellular acidosis and suppresses growth of HeLa tumor xenografts.
Acidosis
Case report 668. Carbonic anhydrase II deficiency syndrome (osteopetrosis associated with renal tubular acidosis and cerebral calcification).
Acidosis
Cerebral calcification, osteopetrosis and renal tubular acidosis: is it carbonic anhydrase-II deficiency?
Acidosis
Cerebrospinal fluid ions in metabolic acidosis in dogs: effects of acetazolamide.
Acidosis
Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis.
Acidosis
Clinical and molecular findings in a family with the carbonic anhydrase II deficiency syndrome.
Acidosis
Clinical and molecular heterogeneity in carbonic anhydrase II deficiency and prenatal diagnosis in an Italian family.
Acidosis
Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions.
Acidosis
CO(2)/H(+) chemoreception in the cat pre-Bötzinger complex in vivo.
Acidosis
CO2 retention as a basis for increased toxicity of salicylate with acetazolamide: avoidance of increased toxicity with benzolamide.
Acidosis
Comparison of carbonic anhydrase in neonatal and maternal red blood cells with different levels of acidosis in newborn calves.
Acidosis
Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform.
Acidosis
Concomitant treatment with topiramate and ketogenic diet in pediatric epilepsy.
Acidosis
Contractile function of papillary muscles with carbonic anhydrase inhibitors.
Acidosis
Correction of renal tubular acidosis in carbonic anhydrase II-deficient mice with gene therapy.
Acidosis
CSF bicarbonate regulation in respiratory acidosis and alkalosis.
Acidosis
Determination of carbonic anhydrase C and beta 2-microglobulin by radioimmunoassay in urine of heavy-metal-exposed subjects and patients with renal tubular acidosis.
Acidosis
Diuretic complications.
Acidosis
Diuretic therapy and exercise performance.
Acidosis
Diuretics and disorders of calcium homeostasis.
Acidosis
Does Aerobic Respiration Produce Carbon Dioxide or Hydrogen Ion and Bicarbonate?
Acidosis
Drug and chemical-induced metabolic acidosis.
Acidosis
Drug-induced acid-base disorders.
Acidosis
Effect of acetazolamide on susceptibility to central sleep apnea in chronic spinal cord injury.
Acidosis
Effect of carbonic anhydrase inhibitors and acidosis in choroid plexus epithelial cell sodium and potassium.
Acidosis
Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients.
Acidosis
Effect of metabolic acidosis on glucose reabsorption in rats with acute hyperglycemia.
Acidosis
Effect of metabolic acidosis on hydrogen ion excretion in a pigtail macaque with erythrocyte carbonic anhydrase I deficiency.
Acidosis
Effects of acidosis and carbonic anhydrase inhibition in the elasmobranch rectal gland.
Acidosis
Effects of chronic acetazolamide administration on fluid flux from the pulmonary vasculature at rest and during exercise in horses.
Acidosis
Effects of the selective cyclooxygenase-2 inhibitor analgesic celecoxib on renal carbonic anhydrase enzyme activity: a randomized, controlled trial.
Acidosis
Elimination of CO2 in patients with carbonic anhydrase II deficiency, with studies of respiratory function at rest.
Acidosis
Enzymatically inactive red cell carbonic anhydrase B in a family with renal tubular acidosis.
Acidosis
Evaluation of carbonic anhydrase isozymes in disorders involving osteopetrosis and/or renal tubular acidosis.
Acidosis
Expression of carbonic anhydrase IV in carbonic anhydrase II-deficient mice.
Acidosis
Expression of carbonic anhydrase IV in mouse placenta.
Acidosis
Expression of carbonic anhydrase IV mRNA in rabbit kidney: stimulation by metabolic acidosis.
Acidosis
Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia.
Acidosis
Extrinsic acidosis suppresses glycolysis and migration while increasing network formation in pulmonary microvascular endothelial cells.
Acidosis
Focal CO2/H+ alters phrenic motor output response to chemical stimulation of cat pre-Botzinger complex in vivo.
Acidosis
Generation of nitric oxide from nitrite by carbonic anhydrase: A possible link between metabolic activity and vasodilation.
Acidosis
Genetic mutation of Kcnj16 identifies Kir5.1-containing channels as key regulators of acute and chronic pH homeostasis.
Acidosis
High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC.
Acidosis
Histopathological Determinants of Tumor Resistance: a Special Look to The Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers.
Acidosis
Hypercarbia and acidosis associated with carbonic anhydrase inhibition: a hazard of topical mafenide acetate use in renal failure.
Acidosis
Hyperkalaemia induced by carbonic anhydrase inhibitor.
Acidosis
Hypokalaemia and Renal Tubular Acidosis due to Abuse of Nurofen Plus.
Acidosis
Hypokalemia and suspected renal tubular acidosis associated with topical carbonic anhydrase inhibitor therapy in a cat.
Acidosis
Hypoxia and energetic tumour metabolism.
Acidosis
Hypoxia related carbonic anhydrase IX expression is associated with unfavourable response to first-line therapy in classical Hodgkin's lymphoma.
Acidosis
Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH.
Acidosis
Hypoxia-inducible carbonic anhydrase IX expression is insufficient to alleviate intracellular metabolic acidosis in the muscle of zebrafish, Danio rerio.
Acidosis
Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression.
Acidosis
Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates.
Acidosis
Identification of a novel mutation in an Indian patient with CAII deficiency syndrome.
Acidosis
Inactive form of erythrocyte carbonic anhydrase B in patients with primary renal tubular acidosis.
Acidosis
Indirect evidence for the presence of non-specific anion channels in rabbit mandibular salivary gland acinar cells.
Acidosis
Induction of anti-carbonic-anhydrase-II antibody causes renal tubular acidosis in a mouse model of Sjogren's syndrome.
Acidosis
Influence of alterations in acid-base conditions on intracellular pH of intact renal cortex.
Acidosis
Influence of carbonic anhydrase inhibition on renal effects of acute respiratory alkalosis and acidosis in human subjects.
Acidosis
Inhibition of Carbonic Anhydrase IX by Ureidosulfonamide Inhibitor U104 Reduces Prostate Cancer Cell Growth, But Does Not Modulate Daunorubicin or Cisplatin Cytotoxicity.
Acidosis
Intracellular carbonic anhydrase activity and its role in GABA-induced acidosis in isolated rat hippocampal pyramidal neurones.
Acidosis
Knock-down of hypoxia-induced carbonic anhydrases IX and XII radiosensitizes tumor cells by increasing intracellular acidosis.
Acidosis
Mapping of the cerebral response to acetazolamide using graded asymmetric spin echo EPI.
Acidosis
Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis.
Acidosis
Metabolic acidosis and anaemia associated with dorzolamide in a patient with impaired renal function.
Acidosis
Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function.
Acidosis
Metabolic acidosis stimulates carbonic anhydrase activity in rabbit proximal tubule and medullary collecting duct.
Acidosis
Metabolic Acidosis with Ophthalmic Dorzolamide in a Neonate.
Acidosis
Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors.
Acidosis
Molecular basis of human carbonic anhydrase II deficiency.
Acidosis
Molecular Modelling and Dynamics of CA2 Missense Mutations Causative to Carbonic Anhydrase 2 Deficiency Syndrome.
Acidosis
Nephrolithiasis and Nephrocalcinosis From Topiramate Therapy in Children With Epilepsy.
Acidosis
Ocular and systemic effects of acetazolamide in nephrectomized rabbits.
Acidosis
Optic nerve pH and PO2: the effects of carbonic anhydrase inhibition, and metabolic and respiratory acidosis.
Acidosis
Osteoclastic acid transport: mechanism and implications for physiological and pharmacological regulation.
Acidosis
Osteopetrosis: some unusual radiological features with a short review.
Acidosis
Overexpression of the transmembrane carbonic anhydrase isoforms IX and XII in the inflamed synovium.
Acidosis
Paralysis Episodes in Carbonic Anhydrase II Deficiency.
Acidosis
Pathogenic mechanism, prophylaxis, and therapy of symptomatic acidosis induced by acetazolamide.
Acidosis
Phenotypic Characteristics of Bone in Carbonic Anhydrase II-Deficient Mice.
Acidosis
Polymorphic gene for human carbonic anhydrase II: a molecular disease marker located on chromosome 8.
Acidosis
Postnatal disappearance of type A intercalated cells in carbonic anhydrase II-deficient mice.
Acidosis
Promoter activity of carbonic anhydrase II regulatory regions in cultured renal proximal tubular cells.
Acidosis
Proton NMR spectra of urine as indicators of renal damage. Mercury-induced nephrotoxicity in rats.
Acidosis
Quantitative high resolution 1H NMR urinalysis studies on the biochemical effects of cadmium in the rat.
Acidosis
Recent developments in the understanding of the pathophysiology of osteopetrosis.
Acidosis
Red blood cell carbonic anhydrase activity in children with distal renal tubular acidosis.
Acidosis
Remodeling the cellular profile of collecting ducts by chronic carbonic anhydrase inhibition.
Acidosis
Renal and systemic pH imaging by contrast-enhanced MRI.
Acidosis
Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency.
Acidosis
Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency: pathogenesis of impaired acidification.
Acidosis
Renal Tubular Acidosis, Osteopetrosis, and Cerebral Calcification: A Rare Syndrome Caused by Carbonic Anhydrase II Deficiency.
Acidosis
Report of Another Mutation Proven Case of Carbonic Anhydrase II Deficiency.
Acidosis
Resistance of hippocampal synaptic transmission to hypoxia in carbonic anhydrase II-deficient mice.
Acidosis
Retinal pH and Acid Regulation During Metabolic Acidosis.
Acidosis
S0859, an N-cyanosulphonamide inhibitor of sodium-bicarbonate cotransport in the heart.
Acidosis
Severe metabolic acidosis and disturbances of calcium metabolism induced by acetazolamide in patients on haemodialysis.
Acidosis
Severe mixed acidosis by combined therapy with acetazolamide and timolol eyedrops.
Acidosis
Sjögren's syndrome--study of autoantigens and autoantibodies.
Acidosis
Stimulation of renal sulfate secretion by metabolic acidosis requires Na+/H+ exchange induction and carbonic anhydrase.
Acidosis
Subgroups of Sjögren syndrome patients according to serological profiles.
Acidosis
The effect of acetazolamide and carbonic anhydrase inhibition on erythrocyte 2,3-diphosphoglycerate content and metabolism.
Acidosis
The effect of antiepileptic drugs on the kidney function and structure.
Acidosis
The neurology of carbonic anhydrase type II deficiency syndrome.
Acidosis
The renal excretion of hydrogen ion in renal tubular acidosis. II. Quantitative response to the carbonic anhydrase inhibitor, acetazolamide.
Acidosis
The role of carbonic anhydrase in gastric mucosal protection with special reference to H+ back diffusion and concomitant metabolic acidosis induced by acetazolamide.
Acidosis
The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond.
Acidosis
The vasodilating effect of acetazolamide and dorzolamide involves mechanisms other than carbonic anhydrase inhibition.
Acidosis
Therapeutic Interference With Vascular Calcification-Lessons From Klotho-Hypomorphic Mice and Beyond.
Acidosis
Time course of the response to recombinant growth hormone in acidotic mice.
Acidosis
Topiramate and metabolic acidosis in infants and toddlers.
Acidosis
Topiramate and metabolic acidosis in pediatric epilepsy.
Acidosis
Topiramate and metabolic acidosis: a case series and review of the literature.
Acidosis
Topiramate and metabolic acidosis: an evolving story.
Acidosis
Topiramate and severe metabolic acidosis: case report.
Acidosis
Topiramate in Migraine Prevention: A 2016 Perspective.
Acidosis
Topiramate induces type 3 renal tubular acidosis by inhibiting renal carbonic anhydrase.
Acidosis
Topiramate Overdose: Clinical and Laboratory Features.
Acidosis
Topiramate-induced nephrolithiasis.
Acidosis
Transaldolase is essential for maintenance of the mitochondrial transmembrane potential and fertility of spermatozoa.
Acidosis
Transfusion of carbonic anhydrase-replete erythrocytes fails to correct the acidification defect in the syndrome of osteopetrosis, renal tubular acidosis, and cerebral calcification (carbonic anhydrase-II deficiency).
Acidosis
Transgenic Expression of Carbonic Anhydrase III in Cardiac Muscle Demonstrates A Mechanism to Tolerate Acidosis.
Acidosis
Treatment of "permanent" muscle weakness in familial Hypokalemic Periodic Paralysis.
Acidosis
Two novel CAII mutations causing carbonic anhydrase II deficiency syndrome in two unrelated Chinese families.
Acidosis
Use of diuretics in chronic renal failure.
Acidosis
[Carbonic anhydrase II deficiency: osteopetrosis, renal tubular acidosis and intracranial calcifications. Review of the literature and 3 cases]
Acidosis
[Comparison between the effects of metabolic acidosis due to ammonium chloride and carbon anhydrase inhibitors in patients with chronic respiratory insufficiency. I. Ventilation, gas exchange, and gas tension in the blood, at rest and during muscular exercise of various intensity]
Acidosis
[Comparison between the effects of metabolic acidosis due to ammonium chloride and carbon anhydrase inhibitors, in patients with chronic respiratory insufficiency. II. Tissue oxygenation and anerobic metabolism during muscular exercise]
Acidosis
[Effect of purinergic agents on ion movement in submaxillary glands]
Acidosis
[Effects of carbonic anhydrase inhibition and of acidosis due to ammonium chloride on the ventilatory response to CO2 in chronic respiratory insufficiency]
Acidosis
[Inhibition of renal carbonic anhydrase as a respiratory stimulant-- an obsolete indication?]
Acidosis
[Osteopetrosis and renal acidosis: a new case of this rare syndrome]
Acidosis
[Osteopetrosis with carbonic anhydrase II deficiency: report of 24 cases]
Acidosis
[Recent progress in molecular biology of inherited tubular transport abnormalities]
Acidosis
[Renal acidosis with aminoaciduria following inhibition of carbonic anhydrase with diamox.]
Acidosis
[Syndrome associating: osteopetrosis, tubular acidosis, mental retardation and cerebral calcifications due to carbonic anhydrase II deficiency. Apropos of 3 cases in the siblings]
Acidosis
[The role of carbonic anhydrase IX in the progression of malignant tumors - a potential therapeutic target?]
Acidosis
[Two cases of urolithiasis induced by topiramate].
Acidosis
[Ventilatory action of acetazolamide. IV. Effects of extracellular acidosis & alkalosis on inhibition of globular anhydrase by acetazolamide.]
Acidosis, Lactic
Carbonic anhydrase 2 (CAII) supports tumor blood endothelial cell survival under lactic acidosis in the tumor microenvironment.
Acidosis, Lactic
Drug-induced acid-base disorders.
Acidosis, Lactic
Proton NMR spectra of urine as indicators of renal damage. Mercury-induced nephrotoxicity in rats.
Acidosis, Lactic
Two cases of carbonic anhydrase VA deficiency-An ultrarare metabolic decompensation syndrome presenting with hyperammonemia, lactic acidosis, ketonuria, and good clinical outcome.
Acidosis, Renal Tubular
A Case of Carbonic Anhydrase Type 2 Deficiency Syndrome with Autistic Disorder.
Acidosis, Renal Tubular
A novel homozygous nonsense mutation in the CA2 gene (c.368G>A, p.W123X) linked to carbonic anhydrase II deficiency syndrome in a Chinese family.
Acidosis, Renal Tubular
A splice junction mutation in intron 2 of the carbonic anhydrase II gene of osteopetrosis patients from Arabic countries.
Acidosis, Renal Tubular
Autoantibodies against carbonic anhydrase II are increased in renal tubular acidosis associated with Sjogren syndrome.
Acidosis, Renal Tubular
Carbonic anhydrase II (CA II) deficiency in Maghrebian patients: evidence for founder effect and genomic recombination at the CA II locus.
Acidosis, Renal Tubular
Carbonic anhydrase II deficiency a novel mutation.
Acidosis, Renal Tubular
Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.
Acidosis, Renal Tubular
Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.
Acidosis, Renal Tubular
Carbonic Anhydrase II Deficiency in a Saudi Woman.
Acidosis, Renal Tubular
Carbonic anhydrase II deficiency syndrome (osteopetrosis with renal tubular acidosis and brain calcification): novel mutations in CA2 identified by direct sequencing expand the opportunity for genotype-phenotype correlation.
Acidosis, Renal Tubular
Carbonic anhydrase II deficiency syndrome--clinico-pathological, biochemical and molecular studies.
Acidosis, Renal Tubular
Carbonic anhydrase II deficiency syndrome: recessive osteopetrosis with renal tubular acidosis and cerebral calcification.
Acidosis, Renal Tubular
Carbonic anhydrase II deficiency.
Acidosis, Renal Tubular
Carbonic anhydrase II deficiency: a rare autosomal recessive disorder of osteopetrosis, renal tubular acidosis, and cerebral calcification.
Acidosis, Renal Tubular
Carbonic Anhydrase II Deficiency: A Rare Case of Severe Obstructive Sleep Apnea.
Acidosis, Renal Tubular
Carbonic anhydrase II deficiency: diagnosis and carrier detection using differential enzyme inhibition and inactivation.
Acidosis, Renal Tubular
Carbonic anhydrase II deficiency: report of a novel mutation.
Acidosis, Renal Tubular
Carbonic anhydrase II deficiency: single-base deletion in exon 7 is the predominant mutation in Caribbean Hispanic patients.
Acidosis, Renal Tubular
Carbonic anhydrase II in the developing and adult human brain.
Acidosis, Renal Tubular
Carbonic anhydrase isozymes IV and II in urinary membranes from carbonic anhydrase II-deficient patients.
Acidosis, Renal Tubular
Case report 668. Carbonic anhydrase II deficiency syndrome (osteopetrosis associated with renal tubular acidosis and cerebral calcification).
Acidosis, Renal Tubular
Cerebral calcification, osteopetrosis and renal tubular acidosis: is it carbonic anhydrase-II deficiency?
Acidosis, Renal Tubular
Clinical and molecular findings in a family with the carbonic anhydrase II deficiency syndrome.
Acidosis, Renal Tubular
Clinical and molecular heterogeneity in carbonic anhydrase II deficiency and prenatal diagnosis in an Italian family.
Acidosis, Renal Tubular
Correction of renal tubular acidosis in carbonic anhydrase II-deficient mice with gene therapy.
Acidosis, Renal Tubular
Determination of carbonic anhydrase C and beta 2-microglobulin by radioimmunoassay in urine of heavy-metal-exposed subjects and patients with renal tubular acidosis.
Acidosis, Renal Tubular
Drug-induced acid-base disorders.
Acidosis, Renal Tubular
Enzymatically inactive red cell carbonic anhydrase B in a family with renal tubular acidosis.
Acidosis, Renal Tubular
Evaluation of carbonic anhydrase isozymes in disorders involving osteopetrosis and/or renal tubular acidosis.
Acidosis, Renal Tubular
Hypokalaemia and Renal Tubular Acidosis due to Abuse of Nurofen Plus.
Acidosis, Renal Tubular
Hypokalemia and suspected renal tubular acidosis associated with topical carbonic anhydrase inhibitor therapy in a cat.
Acidosis, Renal Tubular
Identification of a novel mutation in an Indian patient with CAII deficiency syndrome.
Acidosis, Renal Tubular
Inactive form of erythrocyte carbonic anhydrase B in patients with primary renal tubular acidosis.
Acidosis, Renal Tubular
Induction of anti-carbonic-anhydrase-II antibody causes renal tubular acidosis in a mouse model of Sjogren's syndrome.
Acidosis, Renal Tubular
Molecular basis of human carbonic anhydrase II deficiency.
Acidosis, Renal Tubular
Molecular Modelling and Dynamics of CA2 Missense Mutations Causative to Carbonic Anhydrase 2 Deficiency Syndrome.
Acidosis, Renal Tubular
Nephrolithiasis and Nephrocalcinosis From Topiramate Therapy in Children With Epilepsy.
Acidosis, Renal Tubular
Osteopetrosis: some unusual radiological features with a short review.
Acidosis, Renal Tubular
Paralysis Episodes in Carbonic Anhydrase II Deficiency.
Acidosis, Renal Tubular
Phenotypic Characteristics of Bone in Carbonic Anhydrase II-Deficient Mice.
Acidosis, Renal Tubular
Polymorphic gene for human carbonic anhydrase II: a molecular disease marker located on chromosome 8.
Acidosis, Renal Tubular
Promoter activity of carbonic anhydrase II regulatory regions in cultured renal proximal tubular cells.
Acidosis, Renal Tubular
Quantitative high resolution 1H NMR urinalysis studies on the biochemical effects of cadmium in the rat.
Acidosis, Renal Tubular
Recent developments in the understanding of the pathophysiology of osteopetrosis.
Acidosis, Renal Tubular
Red blood cell carbonic anhydrase activity in children with distal renal tubular acidosis.
Acidosis, Renal Tubular
Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency.
Acidosis, Renal Tubular
Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency: pathogenesis of impaired acidification.
Acidosis, Renal Tubular
Renal Tubular Acidosis, Osteopetrosis, and Cerebral Calcification: A Rare Syndrome Caused by Carbonic Anhydrase II Deficiency.
Acidosis, Renal Tubular
Report of Another Mutation Proven Case of Carbonic Anhydrase II Deficiency.
Acidosis, Renal Tubular
Sjögren's syndrome--study of autoantigens and autoantibodies.
Acidosis, Renal Tubular
Subgroups of Sjögren syndrome patients according to serological profiles.
Acidosis, Renal Tubular
The effect of antiepileptic drugs on the kidney function and structure.
Acidosis, Renal Tubular
The neurology of carbonic anhydrase type II deficiency syndrome.
Acidosis, Renal Tubular
The renal excretion of hydrogen ion in renal tubular acidosis. II. Quantitative response to the carbonic anhydrase inhibitor, acetazolamide.
Acidosis, Renal Tubular
Topiramate and severe metabolic acidosis: case report.
Acidosis, Renal Tubular
Topiramate induces type 3 renal tubular acidosis by inhibiting renal carbonic anhydrase.
Acidosis, Renal Tubular
Two novel CAII mutations causing carbonic anhydrase II deficiency syndrome in two unrelated Chinese families.
Acidosis, Renal Tubular
[Carbonic anhydrase II deficiency: osteopetrosis, renal tubular acidosis and intracranial calcifications. Review of the literature and 3 cases]
Acidosis, Renal Tubular
[Recent progress in molecular biology of inherited tubular transport abnormalities]
Acidosis, Renal Tubular
[Two cases of urolithiasis induced by topiramate].
Acidosis, Respiratory
Adaptation to respiratory acidosis in the turtle bladder.
Acidosis, Respiratory
Carbonic anhydrase isoenzyme B in erythrocytes of subjects with chronic acidosis.
Acidosis, Respiratory
CO2 retention as a basis for increased toxicity of salicylate with acetazolamide: avoidance of increased toxicity with benzolamide.
Acidosis, Respiratory
Drug-induced acid-base disorders.
Acidosis, Respiratory
Dual contribution theory of regulation of CSF HCO3 in respiratory acidosis.
Acidosis, Respiratory
Effect of carbonic anhydrase on carbon dioxide tension of urine and plasma during respiratory acidosis.
Acidosis, Respiratory
Effects of acidosis and carbonic anhydrase inhibition in the elasmobranch rectal gland.
Acidosis, Respiratory
Effects of acute and chronic acetazolamide on resting ventilation and ventilatory responses in men.
Acidosis, Respiratory
Effects of carbonic anhydrase inhibition on the acid base status in lamprey and trout.
Acidosis, Respiratory
Effects of the carbonic anhydrase inhibitor "6063" (diamox) on respiration and electrolyte metabolism of patients with respiratory acidosis.
Acidosis, Respiratory
Influence of alterations in acid-base conditions on intracellular pH of intact renal cortex.
Acidosis, Respiratory
Optic nerve pH and PO2: the effects of carbonic anhydrase inhibition, and metabolic and respiratory acidosis.
Acidosis, Respiratory
Respiratory acidosis in carbonic anhydrase II-deficient mice.
Acidosis, Respiratory
Respiratory and renal effects of a carbonic anhydrase inhibitor (diamox) on acid-base balance in normal man and in patients with respiratory acidosis.
Acidosis, Respiratory
Roles of gill and red cell carbonic anhydrase in elasmobranch HCO3- and CO2 excretion.
Acidosis, Respiratory
The apparent buffer value of cerebrospinal fluid in acute hypercapnia.
Acidosis, Respiratory
The CSF HCO3 increase in hypercapnia relationshp to HCO3, glutamate, glutamine and NH3 in brain.
Acidosis, Respiratory
The effects of the carbonic anhydrase inhibitor 6063 on electrolytes and acid-base balance in two normal subjects and two patients with respiratory acidosis.
Acidosis, Respiratory
The effects of the carbonic anhydrase inhibitor acetazoleamide on chronic respiratory acidosis.
Acidosis, Respiratory
The treatment of respiratory acidosis with a potent carbonic anhydrase inhibitor (dichlorphenamide).
Acidosis, Respiratory
[Acid-base equilibrium and the brain]
Acidosis, Respiratory
[CARBONIC ANHYDRASE INHIBITORS IN THE TREATMENT OF RESPIRATORY ACIDOSIS.]
Acidosis, Respiratory
[The role of carbonic anhydrase in the buffer mechanism of cerebrospinal fluid in acute respiratory acidosis (author's transl)]
Acidosis, Respiratory
[Trial of a carbonic anhydrase inhibitor, dichlorphenamide, in the treatment of respiratory acidosis.]
Acquired Immunodeficiency Syndrome
Carbonic Anhydrase Activators. Part 19 Spectroscopic and Kinetic Investigations for the Interaction of Isozymes I and II With Primary Amines.
Acquired Immunodeficiency Syndrome
Design of miniproteins by the transfer of active sites onto small-size scaffolds.
Acquired Immunodeficiency Syndrome
Gas transfer in dogfish: a unique model of CO2 excretion.
Acquired Immunodeficiency Syndrome
Leaf Proteome Analysis Reveals Prospective Drought and Heat Stress Response Mechanisms in Soybean.
Acquired Immunodeficiency Syndrome
Synergistic role of bacterial urease and carbonic anhydrase in carbonate mineralization.
Acute Kidney Injury
Relationship of renal prostaglandins to three diuretics.
Acute Kidney Injury
Renal handling and plasma elimination kinetics of carbonic anhydrase isoenzymes I, II and III in the rat.
Acute Lung Injury
Carbonic anhydrase inhibitor attenuates ischemia-reperfusion induced acute lung injury.
Acute Lung Injury
Carbonic anhydrase IX is a critical determinant of pulmonary microvascular endothelial cell pH regulation and angiogenesis during acidosis.
Addison Disease
The effects of carbonic anhydrase inhibitor in Addison's disease.
Adenocarcinoma
1,3-Dipolar Cycloaddition, HPLC Enantioseparation, and Docking Studies of Saccharin/Isoxazole and Saccharin/Isoxazoline Derivatives as Selective Carbonic Anhydrase IX and XII Inhibitors.
Adenocarcinoma
A Rare Case of Synchronous Esophageal and Pancreatic Malignancy.
Adenocarcinoma
A Versatile Carbonic Anhydrase IX Targeting Ligand-Functionalized Porous Silicon Nanoplatform for Dual Hypoxia Cancer Therapy and Imaging.
Adenocarcinoma
Association of increased radiocurability of murine carcinomas with low constitutive expression of p21(WAF1/CIP1) protein.
Adenocarcinoma
Biologic instability of pancreatic cancer xenografts in the nude mouse.
Adenocarcinoma
Carbonic anhydrase II gene expression in cell lines from human pancreatic adenocarcinoma.
Adenocarcinoma
Carbonic anhydrase II gene expression in mouse pancreatic duct cells.
Adenocarcinoma
Carbonic anhydrase isozymes II, IX, and XII in uterine tumors.
Adenocarcinoma
Carbonic anhydrase IX expression in prostate cancer.
Adenocarcinoma
Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma.
Adenocarcinoma
Carbonic anhydrase IX is strongly overexpressed in adenocarcinoma in situ of the cervix uteri.
Adenocarcinoma
Carbonic anhydrase type IX expression in lobular endocervical glandular hyperplasia and gastric-type adenocarcinoma of the uterine cervix.
Adenocarcinoma
CuZnSOD and MnSOD inhibit metabolic stress-induced necrosis and multicellular tumour spheroid growth.
Adenocarcinoma
Establishment of a new human pancreatic adenocarcinoma cell line, MDAPanc-3.
Adenocarcinoma
Expression of Carbonic Anhydrase IX (CA IX), a Hypoxia-Related Protein, Rather Than Vascular-Endothelial Growth Factor (VEGF), a Pro-Angiogenic Factor, Correlates With an Extremely Poor Prognosis in Esophageal and Gastric Adenocarcinomas.
Adenocarcinoma
HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3.
Adenocarcinoma
Hypoxia in human colorectal adenocarcinoma: Comparison between extrinsic and potential intrinsic hypoxia markers.
Adenocarcinoma
Immunohistochemical localization of sodium-potassium-stimulated adenosine triphosphatase and carbonic anhydrase in human colon and colonic neoplasms.
Adenocarcinoma
Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas.
Adenocarcinoma
Paxillin and Carbonic Anhydrase IX are prognostic markers in gallbladder squamous cell/adenosquamous carcinomas and adenocarcinomas.
Adenocarcinoma
Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.
Adenocarcinoma
Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer.
Adenocarcinoma
Sinonasal renal cell-like adenocarcinomas: robust carbonic anhydrase expression.
Adenocarcinoma
Stromal expression of hypoxia regulated proteins is an adverse prognostic factor in colorectal carcinomas.
Adenocarcinoma
Synchronous primary carcinoid tumor and primary adenocarcinoma arising within mature cystic teratoma of horseshoe kidney: a unique case report and review of the literature.
Adenocarcinoma
The potential role of fecal carbonic anhydrase II in screening for colorectal cancer.
Adenocarcinoma
The significance of carbonic anhydrase expression in human colorectal cancer.
Adenocarcinoma
Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia.
Adenocarcinoma
Tumor necrosis factor-alpha induces the expression of carbonic anhydrase II in pancreatic adenocarcinoma cells.
Adenocarcinoma
[Clinicopathological significance of the expression of carbonic anhydrase I and II in human pancreatic cancer].
Adenocarcinoma of Lung
Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions.
Adenocarcinoma of Lung
Association of Carbonic Anhydrase 9 Polymorphism and the Epithelial Growth Factor Receptor Mutations in Lung Adenocarcinoma Patients.
Adenocarcinoma of Lung
Carbonic Anhydrase 4 serves as a Clinicopathological Biomarker for Outcomes and Immune Infiltration in Renal Cell Carcinoma, Lower Grade Glioma, Lung Adenocarcinoma and Uveal Melanoma.
Adenocarcinoma of Lung
Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma.
Adenocarcinoma of Lung
Carbonic anhydrase-related protein VIII increases invasiveness of non-small cell lung adenocarcinoma.
Adenocarcinoma of Lung
Effect of carbonic anhydrase-related protein VIII expression on lung adenocarcinoma cell growth.
Adenocarcinoma of Lung
Prognostic significance of carbonic anhydrase IX expression by cancer-associated fibroblasts in lung adenocarcinoma.
Adenocarcinoma, Mucinous
The Expression of Glut-1, CAIX, and MCT4 in Mucinous Carcinoma.
Adenoma
Carbonic anhydrase isozymes IX and XII in gastric tumors.
Adenoma
Histogenetic stereological reconstruction of rat basophilic, clear, and oncocytic neoplastic renal cell lesions using carbonic anhydrase type II-PAS double-stained sections.
Adenoma
Histological features of advanced colorectal adenomas detected by endoscopy and fecal immunochemical test.
Adenoma
Immunohistochemical localization of sodium-potassium-stimulated adenosine triphosphatase and carbonic anhydrase in human colon and colonic neoplasms.
Adenoma
Immunohistochemical study of carbonic anhydrase in mixed tumours and adenomas of sweat and sebaceous glands.
Adenoma
RT-PCR detection of fibronectin EDA+ and EDB+ mRNA isoforms: molecular markers for hepatocellular carcinoma.
Adenoma
Serrated adenoma of the colorectum undergoes a proliferation versus differentiation process: new conceptual interpretation of morphogenesis.
Adenoma, Oxyphilic
Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.
Adenoma, Oxyphilic
Immunohistochemical localization of two types of carbonic anhydrase isozymes in oncocytoma and oncocytic epithelial cells.
Adenoma, Oxyphilic
Role of carbonic anhydrase IX, ?-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: a tissue microarray immunohistochemical study.
Adenoma, Pleomorphic
[Histogenesis of pleomorphic adenomas of the salivary glands]
Adenomatous Polyposis Coli
Analysis of protein profiling studies of ?-thalassemia/Hb E disease.
Adrenocortical Adenoma
Carbonic anhydrases in the human adrenal gland and its disorders: Immunohistochemical and biochemical studies of the enzymes.
Adrenoleukodystrophy
Carbonic anhydrase and 2',3' cyclic nucleotide 3'-phosphohydrolase activity in normal human brain and in demyelinating diseases.
Ageusia
Efficacy of exogenous oral zinc in treatment of patients with carbonic anhydrase VI deficiency.
Agranulocytosis
Topiramate induced agranulocytosis.
Albuminuria
Renal dysfunction and podocyturia in pre-eclampsia may be explained by increased urinary VEGF.
Alkalosis
Acetazolamide Use in Severe Chronic Obstructive Pulmonary Disease. Pros and Cons.
Alkalosis
Acetazolamide: a second wind for a respiratory stimulant in the intensive care unit?
Alkalosis
Carbon dioxide elimination after acetazolamide in patients with chronic obstructive pulmonary disease and metabolic alkalosis.
Alkalosis
Carbonic anhydrase 2-like and Na?-K?-ATPase ? gene expression in medaka (Oryzias latipes) under carbonate alkalinity stress.
Alkalosis
Carbonic anhydrase inhibitors in patients with respiratory failure and metabolic alkalosis: a systematic review and meta-analysis of randomized controlled trials.
Alkalosis
Disturbance of CO2 elimination in the lungs by carbonic anhydrase inhibition.
Alkalosis
Drug-induced acid-base disorders.
Alkalosis
Effects of acetazolamide on cerebrospinal fluid ions in metabolic alkalosis in dogs.
Alkalosis
Functional interaction of carbonic anhydrase and chloride/bicarbonate exchange in human platelets.
Alkalosis
Influence of alterations in acid-base conditions on intracellular pH of intact renal cortex.
Alkalosis
Metabolic alkalosis.
Alkalosis
Proximal tubular acidification in metabolic alkalosis.
Alkalosis
Roles of gill and red cell carbonic anhydrase in elasmobranch HCO3- and CO2 excretion.
Alkalosis
The effect of metabolic alkalosis, hypotension and inhibitors of carbonic anhydrase on fluid secretion by rat testes.
Alkalosis
The Warburg Effect and the Hallmarks of Cancer.
Alkalosis
Trial sequential analysis suggested the potential overestimated effect of carbonic anhydrase inhibitor for respiratory failure and metabolic alkalosis.
Alkalosis
V-H+ -ATPase translocation during blood alkalosis in dogfish gills: interaction with carbonic anhydrase and involvement in the postfeeding alkaline tide.
Alkalosis
[Diuretics; their characteristics and future development]
Alkalosis
[Ventilatory action of acetazolamide. IV. Effects of extracellular acidosis & alkalosis on inhibition of globular anhydrase by acetazolamide.]
Alkalosis, Respiratory
Acetazolamide suppresses the prevalence of augmented breaths during exposure to hypoxia.
Alkalosis, Respiratory
Gymnocypris przewalskii decreases cytosolic carbonic anhydrase expression to compensate for respiratory alkalosis and osmoregulation in the saline-alkaline lake Qinghai.
Alkalosis, Respiratory
Influence of carbonic anhydrase inhibition on renal effects of acute respiratory alkalosis and acidosis in human subjects.
alpha-Thalassemia
The occurrence of hemoglobins Bart's and F associated with carbonic anhydrase deficiency in a patient with alpha-thalassemia and malignant thymoma.
Altitude Sickness
Acetazolamide during acute hypoxia improves tissue oxygenation in the human brain.
Altitude Sickness
Acetazolamide impairs fear memory consolidation in rodents.
Altitude Sickness
Acute Mountain Sickness Symptom Severity at the South Pole: The Influence of Self-Selected Prophylaxis with Acetazolamide.
Altitude Sickness
Anuric Acute Kidney Injury Induced by Acute Mountain Sickness Prophylaxis With Acetazolamide.
Altitude Sickness
Benzolamide improves oxygenation and reduces acute mountain sickness during a high-altitude trek and has fewer side effects than acetazolamide at sea level.
Altitude Sickness
Bioavailability, tissue distribution, and excretion characteristics of the novel carbonic anhydrase inhibitor tolsultazolamide in rats.
Altitude Sickness
Carbonic anhydrase inhibitors and high altitude illnesses.
Altitude Sickness
Carbonic anhydrase inhibitors and hypoxic pulmonary vasoconstriction.
Altitude Sickness
Carbonic Anhydrase Inhibitors suppress platelet procoagulant responses and in vivo thrombosis.
Altitude Sickness
Determination of acetazolamide in human serum by enzymatic assay.
Altitude Sickness
Diuretic therapy and exercise performance.
Altitude Sickness
Effect of acetazolamide and methazolamide on diaphragm and dorsiflexor fatigue: a randomized controlled trial.
Altitude Sickness
Effect of low-dose acetazolamide on the ventilatory CO2 response during hypoxia in the anaesthetized cat.
Altitude Sickness
Evaluating off-label uses of acetazolamide.
Altitude Sickness
Heterocyclic compounds as carbonic anhydrase inhibitor.
Altitude Sickness
High hopes at high altitudes: pharmacotherapy for acute mountain sickness and high-altitude cerebral and pulmonary oedema.
Altitude Sickness
In vitro inhibition of ?-carbonic anhydrase isozymes by some phenolic compounds.
Altitude Sickness
Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness.
Altitude Sickness
NO-releasing esters show carbonic anhydrase inhibitory action against human isoforms I and II.
Altitude Sickness
Novel application of acetazolamide to reduce cerebrospinal fluid production in patients undergoing thoracoabdominal aortic surgery.
Altitude Sickness
Pharmacology of acute mountain sickness: old drugs and newer thinking.
Altitude Sickness
Relationship of altitude mountain sickness and smoking: a Catalan traveller's cohort study.
Altitude Sickness
Synthesis and characterization of novel substituted thiophene derivatives and discovery of their carbonic anhydrase and acetylcholinesterase inhibition effects.
Altitude Sickness
Synthesis and evaluation of 4-(1,3,4-oxadiazol-2-yl)-benzenesulfonamides as potent carbonic anhydrase inhibitors.
Altitude Sickness
Usual clinical dose of acetazolamide does not alter cerebral blood flow velocity.
Altitude Sickness
[Inhibition of renal carbonic anhydrase as a respiratory stimulant-- an obsolete indication?]
Alzheimer Disease
Activation of Two Different Drugs Used in Alzheimer's Disease Treatment on Human Carbonic Anhydrase Isozymes I and II Activity: an In Vitro Study.
Alzheimer Disease
Carbonic anhydrase activation profile of indole-based derivatives.
Alzheimer Disease
Carbonic anhydrase activators: activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines.
Alzheimer Disease
Carbonic anhydrase gating of attention: memory therapy and enhancement.
Alzheimer Disease
Cholinesterases, ?-glycosidase, and carbonic anhydrase inhibition properties of 1H-pyrazolo[1,2-b]phthalazine-5,10-dione derivatives: Synthetic analogues for the treatment of Alzheimer's disease and diabetes mellitus.
Alzheimer Disease
Five- and Six-Membered Nitrogen-Containing Compounds as Selective Carbonic Anhydrase Activators.
Alzheimer Disease
Indazole, Pyrazole, and Oxazole Derivatives Targeting Nitric Oxide Synthases and Carbonic Anhydrases.
Alzheimer Disease
Investigation of inhibitory properties of some hydrazone compounds on hCA I, hCA II and AChE enzymes.
Alzheimer Disease
Novel sulfamate derivatives of menthol: Synthesis, characterization, and cholinesterases and carbonic anhydrase enzymes inhibition properties.
Alzheimer Disease
Plasma carbonic anhydrase II protein is elevated in Alzheimer's disease.
Alzheimer Disease
Probing the chemical interaction space governed by 4-aminosubstituted benzenesulfonamides and carbonic anhydrase isoforms.
Alzheimer Disease
Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and ?-glycosidase inhibitors.
Alzheimer Disease
Synthesis of novel bis-sulfone derivatives and their inhibition properties on some metabolic enzymes including carbonic anhydrase, acetylcholinesterase, and butyrylcholinesterase.
Alzheimer Disease
Synthesis of novel tris-chalcones and determination of their inhibition profiles against some metabolic enzymes.
Alzheimer Disease
The green synthesis and molecular docking of novel N-substituted rhodanines as effective inhibitors for carbonic anhydrase and acetylcholinesterase enzymes.
Alzheimer Disease
[Study on mechanisms of anti-Alzheimer's disease action of absorbed components of Gardeniae Fructus based on network pharmacology].
Ameloblastoma
Immunohistochemical expression of GLUT-1, GLUT-3, and carbonic anhydrase IX in benign odontogenic lesions.
Amyotrophic Lateral Sclerosis
Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: relationship with creatine kinase.
Amyotrophic Lateral Sclerosis
Development of a highly sensitive enzyme-immunoassay for serum carbonic anhydrase-III.
Amyotrophic Lateral Sclerosis
Muscle-specific carbonic anhydrase III is a more sensitive marker of muscle damage than creatine kinase in neuromuscular disorders.
Amyotrophic Lateral Sclerosis
Serum carbonic anhydrase III in neuromuscular disorders and in healthy persons after a long-distance run.
Amyotrophic Lateral Sclerosis
Synthesis and human/bacterial carbonic anhydrase inhibition with a series of sulfonamides incorporating phthalimido moieties.
Anaphylaxis
Characterization of two strains of selectively bred guinea-pigs. I. Skin transplantation experiments and screening for erythrocyte enzyme polymorphism.
Anemia
Anti-carbonic anhydrase antibodies in iron deficiency anemia.
Anemia
Blood carbonic anhydrase activity in anemia, with a note on polycythemia vera.
Anemia
Carbonic andydrase isoenzyme B in erythrocytes of subjects with different types of anemia.
Anemia
Carbonic anhydrase activity in sickle cell anemia, sickle cell trait, and pernicious anemia.
Anemia
Differential expression of carbonic anhydrase isoenzymes in various types of anemia.
Anemia
EFFECT OF A CARBONIC ANHYDRASE INHIBITOR (DICHLORPHENAMIDE) ON SICKLE CELL ANEMIA.
Anemia
Evaluation of carbonic anhydrase isozymes in disorders involving osteopetrosis and/or renal tubular acidosis.
Anemia
Possible correlation between the zinc and copper concentrations involved in the pathogenesis of various forms of anemia.
Anemia
Significance of blood carbonic anhydrase activity in anemia.
Anemia
The pattern of carbon dioxide excretion in the rainbow trout Salmo gairdneri.
Anemia
Zinc deficiency states and carbonic anhydrase isozyme in experimental hemolytic and bleeding anemia of rabbits.
Anemia
[Erythrocyte carbonic anhydrase in subjects on periodic hemodialysis]
Anemia
[Erythrocyte carbonic anhydrase isozymes in patients with iron deficiency anemia and their clinical significances (author's transl)]
Anemia, Aplastic
Antibodies against Carbonic Anhydrase in Patients with Aplastic Anemia.
Anemia, Aplastic
Aplastic anemia resulting from the use of carbonic anhydrase inhibitors.
Anemia, Aplastic
Identification of carbonic anhydrase I immunodominant epitopes recognized by specific autoantibodies which indicate an improved prognosis in patients with malignancy after autologous stem cell transplantation.
Anemia, Aplastic
Overlap of epitopes recognized by anti-carbonic anhydrase I IgG in patients with malignancy-related aplastic anemia-like syndrome and in patients with aplastic anemia.
Anemia, Aplastic
Presence of serum carbonic anhydrase autoantibodies in patients relapsed after autologous stem cell transplantation indicates an improved prognosis.
Anemia, Hemolytic
Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors.
Anemia, Iron-Deficiency
Anti-carbonic anhydrase antibodies in iron deficiency anemia.
Anemia, Iron-Deficiency
Differential expression of carbonic anhydrase isoenzymes in various types of anemia.
Anemia, Iron-Deficiency
[Erythrocyte carbonic anhydrase isozymes in patients with iron deficiency anemia and their clinical significances (author's transl)]
Anemia, Megaloblastic
Red-cell carbonic anhydrase isoenyzmes in megaloblastic anaemia.
Anemia, Pernicious
Carbonic anhydrase activity in sickle cell anemia, sickle cell trait, and pernicious anemia.
Anemia, Pernicious
Zinc and carbonic anhydrase content of red cells in normals and in pernicious anemia.
Anemia, Sickle Cell
Carbonic anhydrase activity in sickle cell anemia, sickle cell trait, and pernicious anemia.
Anemia, Sickle Cell
EFFECT OF A CARBONIC ANHYDRASE INHIBITOR (DICHLORPHENAMIDE) ON SICKLE CELL ANEMIA.
Angina Pectoris
The chemistry and pharmacology of alkaloids and allied nitrogen compounds from Artemisia species: A review.
Angiomatosis
Hereditary heparin cofactor II deficiency and thrombosis: report of six patients belonging to two separate kindreds.
Angiomyolipoma
Activation of the ER stress and calcium signaling in angiomyolipoma.
Anthracosis
[Blood carbonic anhydrase activity in anthracosis (anthracosilicosis) and pulmonary emphysema]
Anuria
Acute renal failure from the use of acetazolamide (Diamox).
Aortic Aneurysm, Abdominal
Autoantigenicity of carbonic anhydrase 1 in patients with abdominal aortic aneurysm, revealed by proteomic surveillance.
Aortic Valve Stenosis
Carbonic anhydrase XII in valve interstitial cells promotes the regression of calcific aortic valve stenosis.
Apnea
Independent associations between arterial bicarbonate, apnea severity and hypertension in obstructive sleep apnea.
Arterial Occlusive Diseases
Heparin cofactor II: a simple assay method and results of its clinical application.
Arthralgia
Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function.
Arthritis
7-Acylamino-3H-1,2-benzoxathiepine 2,2-dioxides as new isoform-selective carbonic anhydrase IX and XII inhibitors.
Arthritis
AHR-15010--a novel anti-arthritic agent.
Arthritis
Carbonic anhydrase inhibitors are antiarthritic in the rat.
Arthritis
Discovery of new 2, 5-disubstituted 1,3-selenazoles as selective human carbonic anhydrase IX inhibitors with potent anti-tumor activity.
Arthritis
Effects of New NSAID-CAI Hybrid Compounds in Inflammation and Lung Fibrosis.
Arthritis
Evaluation of selenide, diselenide and selenoheterocycle derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
Arthritis
Exploring structure-activity relationship of S-substituted 2-mercaptoquinazolin-4(3H)-one including 4-ethylbenzenesulfonamides as human carbonic anhydrase inhibitors.
Arthritis
First evaluation of organotellurium derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
Arthritis
Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: Three for the price of one.
Arthritis
Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin.
Arthritis, Rheumatoid
Bioisosteric Development of Multitarget Nonsteroidal Anti-Inflammatory Drug-Carbonic Anhydrases Inhibitor Hybrids for the Management of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Carbonic anhydrase II autoantibody and oxidative stress in rheumatoid arthritis.
Arthritis, Rheumatoid
Carbonic anhydrase III is insufficient in muscles of myasthenia gravis patients.
Arthritis, Rheumatoid
Carbonic anhydrases III and IV autoantibodies in rheumatoid arthritis, systemic lupus erythematosus, diabetes, hypertensive renal disease, and heart failure.
Arthritis, Rheumatoid
Changes in zinc and zinc-dependent enzymes in rheumatoid patients during penicillamine treatment.
Arthritis, Rheumatoid
Design and Synthesis of Novel Nonsteroidal Anti-Inflammatory Drugs and Carbonic Anhydrase Inhibitors Hybrids (NSAIDs-CAIs) for the Treatment of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Discovery of Novel Nonsteroidal Anti-Inflammatory Drugs and Carbonic Anhydrase Inhibitors Hybrids (NSAIDs-CAIs) for the Management of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Improved serological detection of rheumatoid arthritis: a highly antigenic mimotope of carbonic anhydrase III selected in a murine model by phage display.
Arthritis, Rheumatoid
In pursuit of B-cell synovial autoantigens in rheumatoid arthritis: Confirmation of citrullinated fibrinogen, detection of vimentin, and introducing carbonic anhydrase as a possible new synovial autoantigen.
Arthritis, Rheumatoid
Pain Relieving Effect of-NSAIDs-CAIs Hybrid Molecules: Systemic and Intra-Articular Treatments against Rheumatoid Arthritis.
Arthritis, Rheumatoid
Synthesis and Evaluation of Carbonic Anhydrase Inhibitors with Carbon Monoxide Releasing Properties for the Management of Rheumatoid Arthritis.
Ascariasis
Ascaris lumbricoides ? carbonic anhydrase: a potential target enzyme for treatment of ascariasis.
Ascariasis
Homology modeling and molecular dynamics dimulation study of ? carbonic anhydrase of Ascaris lumbricoides.
Asthma
A comparison of the effects of inhaled furosemide and ethacrynic acid on sodium-metabisulfite-induced bronchoconstriction in subjects with asthma.
Asthma
The effect of inhaled furosemide and acetazolamide on bronchoconstriction induced by deep inspiration in asthma.
Astrocytoma
Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy.
Astrocytoma
Carbonic anhydrase related protein expression in astrocytomas and oligodendroglial tumors.
Astrocytoma
Differential expression of HIF-1 in glioblastoma multiforme and anaplastic astrocytoma.
Astrocytoma
Distinct Tumor Microenvironment at Tumor Edge as a Result of Astrocyte Activation Is Associated With Therapeutic Resistance for Brain Tumor.
Astrocytoma
Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis.
Astrocytoma
Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX.
Astrocytoma
Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo.
Astrocytoma
Hsp27 and its expression pattern in diffusely infiltrating astrocytomas.
Astrocytoma
Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas.
Astrocytoma
Immunohistochemical demonstration of human carbonic anhydrase isoenzyme II in brain tumours.
Astrocytoma
The expressions of carbonic anhydrase 9 and vascular endothelial growth factor in astrocytic tumors predict a poor prognosis.
Ataxia
Aberrant IP3 receptor activities revealed by comprehensive analysis of pathological mutations causing spinocerebellar ataxia 29.
Ataxia
Acetazolamide acts directly on the human skeletal muscle chloride channel.
Ataxia
Acetazolamide-responsive ataxia.
Ataxia
Episodic ataxia: a case report and review of literature.
Ataxia
RNAi silencing of P/Q-type calcium channels in Purkinje neurons of adult mouse leads to episodic ataxia type 2.
Ataxia
Roles of inositol 1,4,5-trisphosphate receptors in spinocerebellar ataxias.
Ataxia
Use of Acetazolamide in Sulfonamide-Allergic Patients With Neurologic Channelopathies.
Ataxia
[Treatment options for nystagmus].
Atherosclerosis
Atherosclerosis: The carbonic anhydrase, carbon dioxide, calcium concerted theory.
Atherosclerosis
Carbonic Anhydrase 1-Mediated Calcification Is Associated With Atherosclerosis, and Methazolamide Alleviates Its Pathogenesis.
Atherosclerosis
Strong association of glaucoma with atherosclerosis.
Atherosclerosis
The effects of cardiac drugs on human erythrocyte carbonic anhydrase I and II isozymes.
Atrial Fibrillation
Re-expression of alpha skeletal actin as a marker for dedifferentiation in cardiac pathologies.
Atypical Squamous Cells of the Cervix
"Equivocal" High-Risk HPV DNA Tests Performed on ThinPrep Specimens After ASC-US Diagnoses Are Associated With an Increased Incidence of CIN3: A Cytologic/Histologic Review of 315 Cases.
Atypical Squamous Cells of the Cervix
Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL.
Atypical Squamous Cells of the Cervix
Detection of high risk human papillomavirus cervical infections by the hybrid capture in Asunción, Paraguay.
Atypical Squamous Cells of the Cervix
Detection of HPV DNA in cervical specimens collected in cytologic solution by ligation-dependent PCR.
Atypical Squamous Cells of the Cervix
High-risk human papillomavirus detection: a split-sample comparison of hybrid capture and chromogenic in situ hybridization.
Autoimmune Diseases
A study of anti-carbonic anhydrase II antibodies in rheumatic autoimmune diseases.
Autoimmune Diseases
Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia.
Autoimmune Diseases
Autoimmune pancreatitis.
Autoimmune Diseases
Carbonic anhydrase antibody in sera from patients with endometriosis.
Autoimmune Diseases
Carbonic anhydrase III is insufficient in muscles of myasthenia gravis patients.
Autoimmune Diseases
Carbonic anhydrase III: a new target for autoantibodies in autoimmune diseases.
Autoimmune Diseases
Detection of autoantibody against carbonic anhydrase II in various liver diseases by enzyme-linked immunosorbent assay using appropriate conditions.
Autoimmune Diseases
Increased serum anti-carbonic anhydrase II antibodies in patients with Graves' disease.
Autoimmune Diseases
Serum carbonic anhydrase I and II autoantibodies in patients with chronic lymphocytic leukaemia.
Autoimmune Pancreatitis
Anti-carbonic anhydrase II antibody in autoimmune pancreatitis and tubulointerstitial nephritis.
Autoimmune Pancreatitis
Antibodies to carbonic anhydrase and IgG4 levels in idiopathic chronic pancreatitis: relevance for diagnosis of autoimmune pancreatitis.
Autoimmune Pancreatitis
Autoimmune chronic pancreatitis.
Autoimmune Pancreatitis
Autoimmune pancreatitis.
Autoimmune Pancreatitis
Differentiation of autoimmune pancreatitis from pancreas cancer: utility of anti-amylase and anti-carbonic anhydrase II autoantibodies.
Autoimmune Pancreatitis
Experimental immune-mediated pancreatitis in neonatally thymectomized mice immunized with carbonic anhydrase II and lactoferrin.
Autoimmune Pancreatitis
Helicobacter pylori and autoimmune pancreatitis: role of carbonic anhydrase via molecular mimicry?
Autoimmune Pancreatitis
Helicobacter pylori and pancreatic diseases.
Autoimmune Pancreatitis
Low-avidity antibodies to carbonic anhydrase-I and -II in autoimmune chronic pancreatitis.
Autoimmune Pancreatitis
Potential for differential diagnosis of autoimmune pancreatitis and pancreatic cancer using carbonic anhydrase II antibody.
Autoimmune Pancreatitis
Serum antibodies to carbonic anhydrase IV in patients with autoimmune pancreatitis.
Autoimmune Pancreatitis
Serum antibody to carbonic anhydrase II in patients with chronic viral hepatitis: a review of its prevalence in liver diseases.
Autoimmune Pancreatitis
Utility of serum IgG, IgG4 and carbonic anhydrase II antibodies in distinguishing autoimmune pancreatitis from pancreatic cancer and chronic pancreatitis.
Autoimmune Pancreatitis
Value of anti-plasminogen binding peptide, anti-carbonic anhydrase II, immunoglobulin G4, and other serological markers for the differentiation of autoimmune pancreatitis and pancreatic cancer.
Autoimmune Pancreatitis
What are the useful biological and functional markers of early-stage chronic pancreatitis?
Autoimmune Pancreatitis
[Autoimmune pancreatitis: inflammatory pseudotumor, multifocal fibrosclerosis, portal hypertension, and long-term outcome]
Azotemia
Use of diuretics in chronic renal failure.
Babesiosis
Plasma levels of zinc, copper, copper/zinc ratio, and activity of carbonic anhydrase in equine piroplasmosis.
Bacteremia
Capnophilic Enterobacteriaceae.
Bacterial Infections
Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type-2 inflammation: a patent evaluation (WO2017/058370).
beta-Thalassemia
Differential expression of carbonic anhydrase isoenzymes in various types of anemia.
beta-Thalassemia
Thalassemic erythrocytes release microparticles loaded with hemichromes by redox activation of p72Syk kinase.
Blepharitis
Comparative cost evaluation of brand name and generic ophthalmology medications in Ontario.
Blister
[Encapsulated filtering blebs--incidence and methods of treatment]
Bone Diseases
Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders.
Bone Diseases
Enzymatically synthesized inorganic polymers as morphogenetically active bone scaffolds: application in regenerative medicine.
Bone Diseases, Developmental
Report of Another Mutation Proven Case of Carbonic Anhydrase II Deficiency.
Bone Diseases, Metabolic
A proteomic study of protein variation between osteopenic and age-matched control bone tissue.
Bone Resorption
1 alpha,25-dihydroxyvitamin D3 regulates the transcription of carbonic anhydrase II mRNA in avian myelomonocytes.
Bone Resorption
17 beta-estradiol suppresses gene expression of tartrate-resistant acid phosphatase and carbonic anhydrase II in ovariectomized rats.
Bone Resorption
A comparison of the effects of inhibitors of carbonic anhydrase on osteoclastic bone resorption and purified carbonic anhydrase isozyme II.
Bone Resorption
A facilitative role for carbonic anhydrase activity in matrix vesicle mineralization.
Bone Resorption
Acid pH increases carbonic anhydrase II and calcitonin receptor mRNA expression in mature osteoclasts.
Bone Resorption
Bone resorption induced by parathyroid hormone and dibutyryl cyclic AMP: role of carbonic anhydrase.
Bone Resorption
Bone resorptive activity of human peripheral blood mononuclear cells after fusion with polyethylene glycol.
Bone Resorption
Bone-targeted carbonic anhydrase inhibitors: effect of a proinhibitor on bone resorption in vitro.
Bone Resorption
Carbonic anhydrase activity in fetal rat bone resorbing cells: inhibition by acetazolamide infusion.
Bone Resorption
Carbonic anhydrase and bone remodeling: sulfonamide inhibition of bone resorption in organ culture.
Bone Resorption
Carbonic anhydrase and bone resorption.
Bone Resorption
Carbonic anhydrase II and H+ -ATPase in osteoclasts of four osteopetrotic mutations in the rat.
Bone Resorption
Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.
Bone Resorption
Carbonic anhydrase II deficiency.
Bone Resorption
Carbonic anhydrase II gene transcript in cultured osteoclasts from neonatal rats: effect of calcitonin.
Bone Resorption
Carbonic anhydrase II is induced in HL-60 cells by 1,25-dihydroxyvitamin D3: a model for osteoclast gene regulation.
Bone Resorption
Carbonic anhydrase II plays a major role in osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca2+.
Bone Resorption
Carbonic anhydrase inhibition by flurbiprofen and related agents.
Bone Resorption
Carbonic anhydrase inhibitors are antiarthritic in the rat.
Bone Resorption
Cholera toxin-stimulated bone resorption in cultured mouse calvarial bones not inhibited by calcitonin: a possible interaction at the stimulatory G protein.
Bone Resorption
Detection of mRNA for carbonic anhydrase II in human osteoclast-like cells by in situ hybridization.
Bone Resorption
Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts.
Bone Resorption
Dual carbonic anhydrase/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors.
Bone Resorption
Effect of chronic carbonic anhydrase inhibitor therapy on bone mineral density in white women.
Bone Resorption
Effects of a potent carbonic anhydrase inhibitor on bone resorption in organ culture.
Bone Resorption
Effects of heterocyclic sulfonamides on bone metabolism.
Bone Resorption
Evaluation of carbonic anhydrase isozymes in disorders involving osteopetrosis and/or renal tubular acidosis.
Bone Resorption
Forskolin-induced bone resorption in neonatal mouse calvaria in vitro.
Bone Resorption
High active isoenzyme of carbonic anhydrase in rat calvaria osteoclasts. Immunohistochemical study.
Bone Resorption
Hydrochlorothiazide inhibits osteoclastic bone resorption in vitro.
Bone Resorption
In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation.
Bone Resorption
In vitro resorptive activity of isolated chick osteoclasts: effects of carbonic anhydrase inhibition.
Bone Resorption
Increased expression of fibroblast growth factor 23 is the signature of a deteriorated Ca/P balance in ageing laying hens.
Bone Resorption
Increased oxidation-related glutathionylation and carbonic anhydrase activity in endometriosis.
Bone Resorption
Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H(+)-ATPase.
Bone Resorption
Inhibitory mechanisms of H(+)-ATPase inhibitor bafilomycin A1 and carbonic anhydrase II inhibitor acetazolamide on experimental bone resorption.
Bone Resorption
miR-506-3p alleviates uncontrolled osteoclastogenesis via repression of RANKL/NFATc1 signaling pathway.
Bone Resorption
Osteoclastic acid transport: mechanism and implications for physiological and pharmacological regulation.
Bone Resorption
Osteogenic activity of yellow flag iris (Iris pseudacorus) extract modulating differentiation of osteoblasts and osteoclasts.
Bone Resorption
Potential anti-osteoporotic activity of low-molecular weight hyaluronan by attenuation of osteoclast cell differentiation and function in vitro.
Bone Resorption
Proton channel part of vacuolar H(+)-ATPase and carbonic anhydrase II expression is stimulated in resorbing osteoclasts.
Bone Resorption
Regression of medial elastocalcinosis in rat aorta: a new vascular function for carbonic anhydrase.
Bone Resorption
Role of carbonic anhydrase in bone resorption induced by 1,25 dihydroxyvitamin D3 in vitro.
Bone Resorption
Role of carbonic anhydrase in bone resorption induced by prostaglandin E2 in vitro.
Bone Resorption
Role of carbonic anhydrase in bone resorption: effect of acetazolamide on basal and parathyroid hormone-induced bone metabolism.
Bone Resorption
Targeted disruption of the Cl-/HCO3- exchanger Ae2 results in osteopetrosis in mice.
Bone Resorption
The cellular physiology of carbonic anhydrases.
Bone Resorption
The effect of carbonic anhydrase inhibition on calcium and bone homeostasis in healthy postmenopausal women.
Bone Resorption
The expression of carbonic anhydrase in canine mammary gland and mammary gland tumor.
Bone Resorption
The migration of purified osteoclasts through collagen is inhibited by matrix metalloproteinase inhibitors.
Bone Resorption
Treat ankylosing spondylitis with methazolamide.
Bone Resorption
Treatment of humoral hypercalcemia of malignancy in rats with inhibitors of carbonic anhydrase.
Bone Resorption
Vitamin D and genomic stability.
Bradycardia
Cardiorespiratory effects induced by acetazolamide on the ventromedullary surface of the cat.
Bradycardia
New glaucoma medications in the geriatric population: efficacy and safety.
Brain Diseases
Brain carbonic anhydrase activity in rats in experimental hepatogenic encephalopathy.
Brain Diseases
Carbonic anhydrase VA deficiency: a very rare case of hyperammonemic encephalopathy.
Brain Diseases
Mitochondrial carbonic anhydrase VA deficiency in three Indian infants manifesting early metabolic crisis.
Brain Diseases
Pronounced reversible hyperammonemic encephalopathy associated with combined valproate-topiramate therapy in a 7-year-old girl.
Brain Diseases
Small-molecule suppression of misfolding of mutated human carbonic anhydrase II linked to marble brain disease.
Brain Diseases
Thermodynamic interrogation of a folding disease. Mutant mapping of position 107 in human carbonic anhydrase II linked to marble brain disease.
Brain Diseases
Valproate-induced hyperammonemic encephalopathy in the presence of topiramate.
Brain Edema
[Treatment of increase of the cerebral volume with electrolyte substitution and inhibition of carbonic anhydrase. With a contribution to the genesis of cerebral edema.]
Brain Infarction
Carbonic anhydrase II in the cerebrospinal fluid: its value as a disease marker.
Brain Injuries
Inhibition of carbonic anhydrase reduces brain injury after intracerebral hemorrhage.
Brain Ischemia
Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors.
Brain Ischemia
Extracellular pH changes during spreading depression and cerebral ischemia: mechanisms of brain pH regulation.
Brain Ischemia
Network pharmacology study on the active components of Pterocypsela elata and the mechanism of their effect against cerebral ischemia.
Brain Ischemia
Role of Carbonic Anhydrase in Cerebral Ischemia and Carbonic Anhydrase Inhibitors as Putative Protective Agents.
Brain Neoplasms
Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy.
Brain Neoplasms
Carbonic anhydrase IX in oligodendroglial brain tumors.
Brain Neoplasms
Carbonic anhydrase XII functions in health and disease.
Brain Neoplasms
Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells.
Brain Neoplasms
Distinct Tumor Microenvironment at Tumor Edge as a Result of Astrocyte Activation Is Associated With Therapeutic Resistance for Brain Tumor.
Brain Neoplasms
Expression of hypoxia-inducible carbonic anhydrases in brain tumors.
Brain Neoplasms
Expression of Myoglobin in Normal and Cancer Brain Tissues: Correlation With Hypoxia Markers.
Brain Neoplasms
Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma.
Brain Neoplasms
Immunohistochemical demonstration of human carbonic anhydrase isoenzyme II in brain tumours.
Brain Neoplasms
Intrinsic thermodynamics of trifluoromethanesulfonamide and ethoxzolamide binding to human carbonic anhydrase VII.
Brain Neoplasms
Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer.
Brain Neoplasms
Prognostic Significance of Osteopontin and Carbonic Anhydrase 9 in Human Brain Tumors: A Meta-Analysis.
Brain Neoplasms
Quinazolinones as Competitive Inhibitors of Carbonic Anhydrase-II (Human and Bovine): Synthesis, in-vitro, in-silico, Selectivity, and Kinetics Studies.
Brain Neoplasms
Substituted (E)-2-(2-benzylidenehydrazinyl)-4-methylthiazole-5-carboxylates as dual inhibitors of 15-lipoxygenase & carbonic anhydrase II: synthesis, biochemical evaluation and docking studies.
Brain Neoplasms
The Expression of Carbonic Anhydrases II, IX and XII in Brain Tumors.
Brain Neoplasms
Topiramate induces acute intracellular acidification in glioblastoma.
Breast Neoplasms
A non-catalytic function of carbonic anhydrase IX contributes to the glycolytic phenotype and pH regulation in human breast cancer cells.
Breast Neoplasms
A surface proton antenna in carbonic anhydrase II supports lactate transport in cancer cells.
Breast Neoplasms
An inhibitory antibody targeting carbonic anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo.
Breast Neoplasms
Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer.
Breast Neoplasms
Anti-breast cancer action of carbonic anhydrase IX inhibitor 4-[4-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-benzylidene-hydrazinocarbonyl]-benzenesulfonamide (BSM-0004): in vitro and in vivo studies.
Breast Neoplasms
Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts.
Breast Neoplasms
Application of carbonic anhydrase inhibitors to increase the penetration of doxorubicin and its liposomal formulation into 2D and 3D triple negative breast cancer cell cultures.
Breast Neoplasms
Benzofuran-Based Carboxylic Acids as Carbonic Anhydrase Inhibitors and Antiproliferative Agents against Breast Cancer.
Breast Neoplasms
Betulin Sulfonamides as Carbonic Anhydrase Inhibitors and Anticancer Agents in Breast Cancer Cells.
Breast Neoplasms
Blood Oxygenation Level-dependent Magnetic Resonance Imaging of Breast Cancer: Correlation with Carbonic Anhydrase IX and Vascular Endothelial Growth Factor.
Breast Neoplasms
CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
Breast Neoplasms
CA IX is upregulated in CoCl2-induced hypoxia and associated with cell invasive potential and a poor prognosis of breast cancer.
Breast Neoplasms
CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells.
Breast Neoplasms
CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy.
Breast Neoplasms
Carbonic Anhydrase 1-Mediated Calcification Is Associated With Atherosclerosis, and Methazolamide Alleviates Its Pathogenesis.
Breast Neoplasms
Carbonic anhydrase 13 suppresses bone metastasis in breast cancer.
Breast Neoplasms
Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline.
Breast Neoplasms
Carbonic anhydrase inhibitors based on sorafenib scaffold: Design, synthesis, crystallographic investigation and effects on primary breast cancer cells.
Breast Neoplasms
Carbonic anhydrase inhibitors--Part 94. 1,3,4-thiadiazole-2-sulfonamidederivatives as antitumor agents?
Breast Neoplasms
Carbonic anhydrase inhibitors. Biphenylsulfonamides with inhibitory action towards the transmembrane, tumor-associated isozymes IX possess cytotoxic activity against human colon, lung and breast cancer cell lines.
Breast Neoplasms
Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials.
Breast Neoplasms
Carbonic anhydrase IX expression is more predictive than prognostic in breast cancer.
Breast Neoplasms
Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.
Breast Neoplasms
Carbonic Anhydrase IX Promotes Myeloid-Derived Suppressor Cell Mobilization and Establishment of a Metastatic Niche by Stimulating G-CSF Production.
Breast Neoplasms
Carbonic anhydrase IX: A promising diagnostic and prognostic biomarker in breast carcinoma.
Breast Neoplasms
Carbonic anhydrase XII expression is linked to suppression of Sonic hedgehog ligand expression in triple negative breast cancer cells.
Breast Neoplasms
Carbonic Anhydrase XII Expression Is Modulated during Epithelial Mesenchymal Transition and Regulated through Protein Kinase C Signaling.
Breast Neoplasms
Carbonic anhydrase XII functions in health and disease.
Breast Neoplasms
Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma.
Breast Neoplasms
Carbonic anhydrase XII promotes invasion and migration ability of MDA-MB-231 breast cancer cells through the p38 MAPK signaling pathway.
Breast Neoplasms
Carcinoma arising in microglandular adenosis of the breast: triple negative phenotype with variable morphology.
Breast Neoplasms
Catalysis and pH control by membrane-associated carbonic anhydrase IX in MDA-MB-231 breast cancer cells.
Breast Neoplasms
Catalytic activity of human carbonic anhydrase isoform IX is displayed both extra- and intracellularly.
Breast Neoplasms
Cellular and radiobiological effects of carbonic anhydrase IX in human breast cancer cells.
Breast Neoplasms
Chemometric modeling of breast cancer associated carbonic anhydrase IX inhibitors belonging to the ureido-substituted benzene sulfonamide class.
Breast Neoplasms
Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.
Breast Neoplasms
Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Breast Neoplasms
Combined 3-O-acetylbetulin treatment and carbonic anhydrase IX inhibition results in additive effects on human breast cancer cells.
Breast Neoplasms
Correction: Signaling Pathways of ESE-16, an Antimitotic and Anticarbonic Anhydrase Estradiol Analog, in Breast Cancer Cells.
Breast Neoplasms
Correlation between carbonic anhydrase IX (CA-9), XII (CA-12) and hypoxia inducible factor-2? (HIF-2?) in breast cancer.
Breast Neoplasms
Correlation of carbonic anhydrase IX expression with clinico-morphological parameters, hormonal receptor status and HER-2 expression in breast cancer.
Breast Neoplasms
Cutaneous breast cancer deposits show distinct growth patterns with different degrees of angiogenesis, hypoxia and fibrin deposition.
Breast Neoplasms
Depletion of carbonic anhydrase IX abrogates hypoxia-induced overexpression of stanniocalcin-1 in triple negative breast cancer cells.
Breast Neoplasms
Designing carbonic anhydrase inhibitors for the treatment of breast cancer.
Breast Neoplasms
Differential expression and function of CAIX and CAXII in breast cancer: A comparison between tumorgraft models and cells.
Breast Neoplasms
Discovery of novel artemisinin-sulfonamidehybrids as potential carbonicanhydraseIX inhibitors with improved antiproliferative activities.
Breast Neoplasms
Dynamic surveillance of tamoxifen-resistance in ER-positive breast cancer by CAIX-targeted ultrasound imaging.
Breast Neoplasms
Endogenous myoglobin in breast cancer is hypoxia-inducible by alternative transcription and functions to impair mitochondrial activity: a role in tumor suppression?
Breast Neoplasms
Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype.
Breast Neoplasms
Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer.
Breast Neoplasms
Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.
Breast Neoplasms
Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models.
Breast Neoplasms
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial.
Breast Neoplasms
Expression and Activity of Carbonic Anhydrase IX Is Associated With Metabolic Dysfunction in MDA-MB-231 Breast Cancer Cells.
Breast Neoplasms
Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2.
Breast Neoplasms
Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.
Breast Neoplasms
Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner.
Breast Neoplasms
Germinal center hypoxia in tumor-draining lymph nodes negatively regulates tumor-induced humoral immune responses in mouse models of breast cancer.
Breast Neoplasms
GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression.
Breast Neoplasms
Glycoprotein profiles of human breast cells demonstrate a clear clustering of normal/benign versus malignant cell lines and basal versus luminal cell lines.
Breast Neoplasms
Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors.
Breast Neoplasms
Granulocyte Colony Stimulating Factor Expression in Breast Cancer and Its Association with Carbonic Anhydrase IX and Immune Checkpoints.
Breast Neoplasms
Harnessing Induced Essentiality: Targeting Carbonic Anhydrase IX and Angiogenesis Reduces Lung Metastasis of Triple Negative Breast Cancer Xenografts.
Breast Neoplasms
HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
Breast Neoplasms
High expression of carbonic anhydrase 12 (CA12) is associated with good prognosis in breast cancer.
Breast Neoplasms
Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX.
Breast Neoplasms
Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients.
Breast Neoplasms
Hypoxia-induced carbonic anhydrase IX facilitates lactate flux in human breast cancer cells by non-catalytic function.
Breast Neoplasms
Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer.
Breast Neoplasms
Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer.
Breast Neoplasms
Identification of potential breast cancer markers in nipple discharge by protein profile analysis using two-dimensional nano-liquid chromatography/nanoelectrospray ionization-mass spectrometry.
Breast Neoplasms
In vitro and in vivo BNCT investigations using a carborane containing sulfonamide targeting CAIX epitopes on malignant pleural mesothelioma and breast cancer cells.
Breast Neoplasms
Inclusion of a 5-fluorouracil moiety in nitrogenous bases derivatives as human carbonic anhydrase IX and XII inhibitors produced a targeted action against MDA-MB-231 and T47D breast cancer cells.
Breast Neoplasms
Influence of Paclitaxel and Doxorubicin Therapy of ßIII-Tubulin, Carbonic Anhydrase IX, and Survivin in Chemically Induced Breast Cancer in Female Rat.
Breast Neoplasms
Inhibition of Carbonic Anhydrase Using SLC-149: Support for a Noncatalytic Function of CAIX in Breast Cancer.
Breast Neoplasms
Inhibition of smoothened in breast cancer cells reduces CAXII expression and cell migration.
Breast Neoplasms
Interaction of HIF-1? and Notch3 Is Required for the Expression of Carbonic Anhydrase 9 in Breast Carcinoma Cells.
Breast Neoplasms
Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma.
Breast Neoplasms
Investigation of acetylcholinesterase and mammalian DNA topoisomerases, carbonic anhydrase inhibition profiles, and cytotoxic activity of novel bis(?-aminoalkyl)phosphinic acid derivatives against human breast cancer.
Breast Neoplasms
Metabolic Effect of Estrogen Receptor Agonists on Breast Cancer Cells in the Presence or Absence of Carbonic Anhydrase Inhibitors.
Breast Neoplasms
Metabolism-Related Proteins Are Differentially Expressed according to the Molecular Subtype of Invasive Breast Cancer Defined by Surrogate Immunohistochemistry.
Breast Neoplasms
Modulation of markers associated with aggressive phenotype in MDA-MB-231 breast carcinoma cells by sulforaphane.
Breast Neoplasms
Necrosis and hypoxia in invasive breast carcinoma.
Breast Neoplasms
New selective carbonic anhydrase IX inhibitors: Synthesis and pharmacological evaluation of diarylpyrazole-benzenesulfonamides.
Breast Neoplasms
New strategies for targeting the hypoxic tumour microenvironment in breast cancer.
Breast Neoplasms
Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-alpha expression but decrease functional transcriptional activity, DNA binding, and degradation.
Breast Neoplasms
Overexpression of CA1 mRNA and the CA I Protein in Tumor Cells Does Not Change the Gene Expression of the ECM Proteins.
Breast Neoplasms
Overexpression of Carbonic Anhydrase IX is a Dismal Prognostic Marker in Breast Carcinoma in Egyptian Patients.
Breast Neoplasms
p300 and p53 levels determine activation of HIF-1 downstream targets in invasive breast cancer.
Breast Neoplasms
p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres.
Breast Neoplasms
Paraneoplastic cerebellar degeneration in a patient with breast cancer associated with carbonic anhydrase-related protein VIII autoantibodies.
Breast Neoplasms
PEG Linker Length Strongly Affects Tumor Cell Killing by PEGylated Carbonic Anhydrase Inhibitors in Hypoxic Carcinomas Expressing Carbonic Anhydrase IX.
Breast Neoplasms
Peroxisome proliferator activated receptor-?/hypoxia inducible factor-1? interplay sustains carbonic anhydrase IX and apoliprotein E expression in breast cancer stem cells.
Breast Neoplasms
Perspectives on the Classical Enzyme Carbonic Anhydrase and the Search for Inhibitors.
Breast Neoplasms
PPAR? and RXR Ligands Disrupt the Inflammatory Cross-talk in the Hypoxic Breast Cancer Stem Cells Niche.
Breast Neoplasms
Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells.
Breast Neoplasms
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.
Breast Neoplasms
Prognostic Significance of Carbonic Anhydrase IX (CA-IX), Endoglin (CD105) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in Breast Cancer Patients.
Breast Neoplasms
Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
Breast Neoplasms
Pyrazolo[4,3-e][1,2,4]triazine sulfonamides as carbonic anhydrase inhibitors with antitumor activity.
Breast Neoplasms
Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer.
Breast Neoplasms
Renewed interests in carbonic anhydrase IX in relevance to breast cancer treatment.
Breast Neoplasms
Repression of protocadherin 17 is correlated with elevated angiogenesis and hypoxia markers in female patients with breast cancer.
Breast Neoplasms
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.
Breast Neoplasms
Role of hypoxia and EGF on expression, activity, localization and phosphorylation of carbonic anhydrase IX in MDA-MB-231 breast cancer cells.
Breast Neoplasms
Selective inhibition of carbonic anhydrase IX over carbonic anhydrase XII in breast cancer cells using benzene sulfonamides: Disconnect between activity and growth inhibition.
Breast Neoplasms
Selective inhibition of human carbonic anhydrase IX in Xenopus oocytes and MDA-MB-231 breast cancer cells.
Breast Neoplasms
Signaling pathways of ESE-16, an antimitotic and anticarbonic anhydrase estradiol analog, in breast cancer cells.
Breast Neoplasms
Subcellular FIH-1 expression patterns in invasive breast cancer in relation to HIF-1? expression.
Breast Neoplasms
Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation.
Breast Neoplasms
Synthesis of 4-(thiazol-2-ylamino)-benzenesulfonamides with carbonic anhydrase I, II and IX inhibitory activity and cytotoxic effects against breast cancer cell lines.
Breast Neoplasms
Synthesis of novel tellurides bearing benzensulfonamide moiety as carbonic anhydrase inhibitors with antitumor activity.
Breast Neoplasms
Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.
Breast Neoplasms
Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors.
Breast Neoplasms
Tellurides bearing benzensulfonamide as carbonic anhydrase inhibitors with potent antitumor activity.
Breast Neoplasms
TFAP2C regulates carbonic anhydrase XII in human breast cancer.
Breast Neoplasms
The basal-like breast carcinoma phenotype is regulated by SLUG gene expression.
Breast Neoplasms
The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
Breast Neoplasms
The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer.
Breast Neoplasms
The Expression of Carbonic Anhydrase (CA) IX/ XII and Lymph Node Metastasis in Early Breast Cancer.
Breast Neoplasms
The Hypoxic Response Expression as a Survival Biomarkers in Treatment-Naive Advanced Breast Cancer.
Breast Neoplasms
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy.
Breast Neoplasms
The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis.
Breast Neoplasms
The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1? and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
Breast Neoplasms
Ureido-Substituted Benzenesulfonamides Potently Inhibit Carbonic Anhydrase IX and Show Antimetastatic Activity in a Model of Breast Cancer Metastasis.
Breast Neoplasms
Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines.
Breast Neoplasms
Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer.
Breast Neoplasms
[Expression of carbonic anhydrase IX in the breast carcinomas].
Breast Neoplasms
[Hypoxia induces down-regulation of estrogen receptor alpha in human breast cancer.]
Breast Neoplasms
[Significance of carbonic anhydrase IX protein expression in molecular subtyping of breast cancers].
Breast Neoplasms
[Significance of carbonic anhydrase IX protein in fibrotic foci of mammary invasive ductal carcinomas].
Breast Neoplasms, Male
Fibrotic focus and hypoxia in male breast cancer.
Brucellosis
Brucella suis carbonic anhydrases and their inhibitors: Towards alternative antibiotics?
Brucellosis
Design and development of novel therapeutics for brucellosis treatment based on carbonic anhydrase inhibition.
Calcinosis
The role of carbonic anhydrase in the pathogenesis of vascular calcification in humans.
carbonic anhydrase deficiency
A novel homozygous nonsense mutation in the CA2 gene (c.368G>A, p.W123X) linked to carbonic anhydrase II deficiency syndrome in a Chinese family.
carbonic anhydrase deficiency
A point mutation in exon 3 (His 107-->Tyr) in two unrelated Japanese patients with carbonic anhydrase II deficiency with central nervous system involvement.
carbonic anhydrase deficiency
A splice junction mutation in intron 2 of the carbonic anhydrase II gene of osteopetrosis patients from Arabic countries.
carbonic anhydrase deficiency
A unique mutation underlying carbonic anhydrase II deficiency syndrome in patients of Arab descent.
carbonic anhydrase deficiency
Altered gene expression in the lower respiratory tract of Car6 (-/-) mice.
carbonic anhydrase deficiency
Bone marrow transplantation corrects osteopetrosis in the carbonic anhydrase II deficiency syndrome.
carbonic anhydrase deficiency
Bone marrow transplantation demonstrates that carbonic anhydrase II deficiency limited to bone marrow-derived cells affects ammonium chloride tolerance in mice.
carbonic anhydrase deficiency
Brain calcification in Kallman's syndrome. Computed tomographic appearance.
carbonic anhydrase deficiency
Brain phenotype of carbonic anhydrase IX-deficient mice.
carbonic anhydrase deficiency
Carbonic anhydrase 2 deficiency leads to increased pyelonephritis susceptibility.
carbonic anhydrase deficiency
Carbonic anhydrase deficiency with persistence of foetal haemoglobin: a new syndrome.
carbonic anhydrase deficiency
Carbonic anhydrase II (CA II) deficiency in Maghrebian patients: evidence for founder effect and genomic recombination at the CA II locus.
carbonic anhydrase deficiency
Carbonic anhydrase II deficiency a novel mutation.
carbonic anhydrase deficiency
Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.
carbonic anhydrase deficiency
Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.
carbonic anhydrase deficiency
Carbonic anhydrase II deficiency in a Japanese patient produced by a nonsense mutation (TAT-->TAG) at Tyr-40 in exon 2, (Y40X).
carbonic anhydrase deficiency
Carbonic Anhydrase II Deficiency in a Saudi Woman.
carbonic anhydrase deficiency
Carbonic anhydrase II deficiency in three unrelated Japanese patients.
carbonic anhydrase deficiency
Carbonic anhydrase II deficiency syndrome (osteopetrosis with renal tubular acidosis and brain calcification): novel mutations in CA2 identified by direct sequencing expand the opportunity for genotype-phenotype correlation.
carbonic anhydrase deficiency
Carbonic anhydrase II deficiency syndrome in a Belgian family is caused by a point mutation at an invariant histidine residue (107 His----Tyr): complete structure of the normal human CA II gene.
carbonic anhydrase deficiency
Carbonic anhydrase II deficiency syndrome--clinico-pathological, biochemical and molecular studies.
carbonic anhydrase deficiency
Carbonic anhydrase II deficiency syndrome: recessive osteopetrosis with renal tubular acidosis and cerebral calcification.
carbonic anhydrase deficiency
Carbonic anhydrase II deficiency.
carbonic anhydrase deficiency
Carbonic anhydrase II deficiency: a rare autosomal recessive disorder of osteopetrosis, renal tubular acidosis, and cerebral calcification.
carbonic anhydrase deficiency
Carbonic Anhydrase II Deficiency: A Rare Case of Severe Obstructive Sleep Apnea.
carbonic anhydrase deficiency
Carbonic anhydrase II deficiency: diagnosis and carrier detection using differential enzyme inhibition and inactivation.
carbonic anhydrase deficiency
Carbonic anhydrase II deficiency: report of a novel mutation.
carbonic anhydrase deficiency
Carbonic anhydrase II deficiency: single-base deletion in exon 7 is the predominant mutation in Caribbean Hispanic patients.
carbonic anhydrase deficiency
Carbonic anhydrase II in the developing and adult human brain.
carbonic anhydrase deficiency
Carbonic anhydrase isozyme-II-deficient mice lack the duodenal bicarbonate secretory response to prostaglandin E2.
carbonic anhydrase deficiency
Carbonic anhydrase isozymes IV and II in urinary membranes from carbonic anhydrase II-deficient patients.
carbonic anhydrase deficiency
Carbonic anhydrase VA deficiency: a very rare case of hyperammonemic encephalopathy.
carbonic anhydrase deficiency
Carbonic anhydrase XIV deficiency produces a functional defect in the retinal light response.
carbonic anhydrase deficiency
Carbonic Anhydrase-Deficient Mutant of Chlamydomonas reinhardii Requires Elevated Carbon Dioxide Concentration for Photoautotrophic Growth.
carbonic anhydrase deficiency
Carbonic anhydrase-related protein VIII deficiency is associated with a distinctive lifelong gait disorder in waddles mice.
carbonic anhydrase deficiency
Case report 668. Carbonic anhydrase II deficiency syndrome (osteopetrosis associated with renal tubular acidosis and cerebral calcification).
carbonic anhydrase deficiency
Case report 718. Osteopetrosis with carbonic anhydrase II deficiency.
carbonic anhydrase deficiency
Cerebral calcification, osteopetrosis and renal tubular acidosis: is it carbonic anhydrase-II deficiency?
carbonic anhydrase deficiency
Clinical and molecular findings in a family with the carbonic anhydrase II deficiency syndrome.
carbonic anhydrase deficiency
Clinical and molecular heterogeneity in carbonic anhydrase II deficiency and prenatal diagnosis in an Italian family.
carbonic anhydrase deficiency
Clinical quiz. Osteopetrosis with carbonic anhydrase II deficiency.
carbonic anhydrase deficiency
Combined inherited protein S and heparin co-factor II deficiency in a patient with upper limb thrombosis: a family study.
carbonic anhydrase deficiency
Defective hepatic bicarbonate production due to carbonic anhydrase VA deficiency leads to early-onset life-threatening metabolic crisis.
carbonic anhydrase deficiency
Developmental changes in seizure susceptibility in carbonic anhydrase II-deficient mice and normal littermates.
carbonic anhydrase deficiency
Disturbances of growth hormone-insulin-like growth factor axis and response to growth hormone in acidosis.
carbonic anhydrase deficiency
Effect of disease-linked mutations on the structure, function, stability and aggregation of human carbonic anhydrase II.
carbonic anhydrase deficiency
Effect of metabolic acidosis on hydrogen ion excretion in a pigtail macaque with erythrocyte carbonic anhydrase I deficiency.
carbonic anhydrase deficiency
Efficacy of exogenous oral zinc in treatment of patients with carbonic anhydrase VI deficiency.
carbonic anhydrase deficiency
Elimination of CO2 in patients with carbonic anhydrase II deficiency, with studies of respiratory function at rest.
carbonic anhydrase deficiency
ERRATUM: Defective hepatic bicarbonate production due to carbonic anhydrase VA deficiency leads to early-onset life-threatening metabolic crisis.
carbonic anhydrase deficiency
Evaluation of carbonic anhydrase isozymes in disorders involving osteopetrosis and/or renal tubular acidosis.
carbonic anhydrase deficiency
Expression of carbonic anhydrase IX in mouse tissues.
carbonic anhydrase deficiency
Failure of acetazolamide to decrease intraocular pressure in patients with carbonic anhydrase II deficiency.
carbonic anhydrase deficiency
Fatal metabolic decompensation in carbonic anhydrase VA deficiency despite early treatment and control of hyperammonemia.
carbonic anhydrase deficiency
Gastric carbonic anhydrase IX deficiency: At base, it is all about acid.
carbonic anhydrase deficiency
Gene therapy for renal diseases.
carbonic anhydrase deficiency
Global transcriptional response to carbonic anhydrase IX deficiency in the mouse stomach.
carbonic anhydrase deficiency
Heparin cofactor II deficiency in renal allograft recipients: no correlation with the development of thrombosis.
carbonic anhydrase deficiency
Heparin cofactor II, antithrombin and protein C in plasma from term and preterm infants.
carbonic anhydrase deficiency
Hereditary heparin cofactor II deficiency and coronary artery disease.
carbonic anhydrase deficiency
Hereditary heparin cofactor II deficiency and the risk of development of thrombosis.
carbonic anhydrase deficiency
Hereditary heparin cofactor II deficiency and thrombosis: report of six patients belonging to two separate kindreds.
carbonic anhydrase deficiency
Herpes simplex virus as a model vector system for gene therapy in renal disease.
carbonic anhydrase deficiency
Human carbonic anhydrases and carbonic anhydrase deficiencies.
carbonic anhydrase deficiency
Intracranial calcification in children with osteopetrosis caused by carbonic anhydrase II deficiency.
carbonic anhydrase deficiency
Kinetic analysis of a mutant (His107-->Tyr) responsible for human carbonic anhydrase II deficiency syndrome.
carbonic anhydrase deficiency
Liposome-mediated gene therapy in the kidney.
carbonic anhydrase deficiency
Long-term follow up of carbonic anhydrase II deficiency syndrome.
carbonic anhydrase deficiency
Mitochondrial carbonic anhydrase VA deficiency in three Indian infants manifesting early metabolic crisis.
carbonic anhydrase deficiency
Mitochondrial Carbonic Anhydrase VA Deficiency Resulting from CA5A Alterations Presents with Hyperammonemia in Early Childhood.
carbonic anhydrase deficiency
Molecular basis of human carbonic anhydrase II deficiency.
carbonic anhydrase deficiency
Molecular mechanism of type I congenital heparin cofactor (HC) II deficiency caused by a missense mutation at reactive P2 site: HC II Tokushima.
carbonic anhydrase deficiency
Molecular Modelling and Dynamics of CA2 Missense Mutations Causative to Carbonic Anhydrase 2 Deficiency Syndrome.
carbonic anhydrase deficiency
N-ethyl-N-nitrosourea-induced null mutation at the mouse Car-2 locus: an animal model for human carbonic anhydrase II deficiency syndrome.
carbonic anhydrase deficiency
Natural History and Clinical Manifestations of Hyponatremia and Hyperchlorhidrosis due to Carbonic Anhydrase XII Deficiency.
carbonic anhydrase deficiency
Nephrocalcinosis and urolithiasis in carbonic anhydrase II deficiency syndrome.
carbonic anhydrase deficiency
Oligodendrocytes express a normal phenotype in carbonic anhydrase II-deficient mice.
carbonic anhydrase deficiency
Osteoclastic acid transport: mechanism and implications for physiological and pharmacological regulation.
carbonic anhydrase deficiency
Osteopetrosis, renal tubular acidosis without urinary concentration abnormality, cerebral calcification and severe mental retardation in three Turkish brothers.
carbonic anhydrase deficiency
Osteopetrosis: some unusual radiological features with a short review.
carbonic anhydrase deficiency
Paralysis Episodes in Carbonic Anhydrase II Deficiency.
carbonic anhydrase deficiency
Polymorphic gene for human carbonic anhydrase II: a molecular disease marker located on chromosome 8.
carbonic anhydrase deficiency
Positive renal response to intravenous acetazolamide in patients with carbonic anhydrase II deficiency.
carbonic anhydrase deficiency
Prevalence of heparin cofactor II deficiency in patients with a history of venous thrombosis.
carbonic anhydrase deficiency
Proteomic Profiling of the First Human Dental Pulp Mesenchymal Stem/Stromal Cells from Carbonic Anhydrase II Deficiency Osteopetrosis Patients.
carbonic anhydrase deficiency
Purification and characterization of human salivary carbonic anhydrase.
carbonic anhydrase deficiency
Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency.
carbonic anhydrase deficiency
Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency: pathogenesis of impaired acidification.
carbonic anhydrase deficiency
Renal Tubular Acidosis, Osteopetrosis, and Cerebral Calcification: A Rare Syndrome Caused by Carbonic Anhydrase II Deficiency.
carbonic anhydrase deficiency
Report of Another Mutation Proven Case of Carbonic Anhydrase II Deficiency.
carbonic anhydrase deficiency
Respiratory acidosis in carbonic anhydrase II-deficient mice.
carbonic anhydrase deficiency
Seven novel mutations in carbonic anhydrase II deficiency syndrome identified by SSCP and direct sequencing analysis.
carbonic anhydrase deficiency
Siblings with renal tubular acidosis and nerve deafness. The first family in Japan.
carbonic anhydrase deficiency
Small-molecule suppression of misfolding of mutated human carbonic anhydrase II linked to marble brain disease.
carbonic anhydrase deficiency
The occurrence of hemoglobins Bart's and F associated with carbonic anhydrase deficiency in a patient with alpha-thalassemia and malignant thymoma.
carbonic anhydrase deficiency
Time course of the response to recombinant growth hormone in acidotic mice.
carbonic anhydrase deficiency
Transfusion of carbonic anhydrase-replete erythrocytes fails to correct the acidification defect in the syndrome of osteopetrosis, renal tubular acidosis, and cerebral calcification (carbonic anhydrase-II deficiency).
carbonic anhydrase deficiency
Two novel CAII mutations causing carbonic anhydrase II deficiency syndrome in two unrelated Chinese families.
carbonic anhydrase deficiency
Unfolding a folding disease: folding, misfolding and aggregation of the marble brain syndrome-associated mutant H107Y of human carbonic anhydrase II.
carbonic anhydrase deficiency
Up-regulation of carbonic anhydrase isozyme IV in CNS myelin of mice genetically deficient in carbonic anhydrase II.
carbonic anhydrase deficiency
Variable clinical presentation of carbonic anhydrase deficiency: evidence for heterogeneity?
carbonic anhydrase deficiency
[Carbonic anhydrase II deficiency and Fanconi syndrome]
carbonic anhydrase deficiency
[Carbonic anhydrase II deficiency: osteopetrosis, renal tubular acidosis and intracranial calcifications. Review of the literature and 3 cases]
carbonic anhydrase deficiency
[Carbonic anhydrase II deficiency]
carbonic anhydrase deficiency
[Constitutional dysfunction of heparin cofactor II with a tendency for venous thrombosis]
carbonic anhydrase deficiency
[Juvenile cerebral infarction associated with heparin cofactor II abnormality. A case report]
carbonic anhydrase deficiency
[Kidney tubular transport disorders. Carbonic anhydrase II deficiency]
carbonic anhydrase deficiency
[Osteopetrosis with carbonic anhydrase II deficiency: report of 24 cases]
carbonic anhydrase deficiency
[Recessive osteopetrosis. Identification of a form of medium severity]
carbonic anhydrase deficiency
[Syndrome associating: osteopetrosis, tubular acidosis, mental retardation and cerebral calcifications due to carbonic anhydrase II deficiency. Apropos of 3 cases in the siblings]
Carcinogenesis
A class of carbonic anhydrase IX/XII - selective carboxylate inhibitors.
Carcinogenesis
An update on anticancer drug development and delivery targeting carbonic anhydrase IX.
Carcinogenesis
Attachment of carbohydrates to methoxyaryl moieties leads to highly selective inhibitors of the cancer associated carbonic anhydrase isoforms IX and XII.
Carcinogenesis
Carbonic anhydrase II: a novel biomarker for pseudomyxoma peritonei.
Carcinogenesis
Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors.
Carcinogenesis
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides.
Carcinogenesis
Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies.
Carcinogenesis
Carbonic anhydrase IX inhibitors in cancer therapy: an update.
Carcinogenesis
Carbonic anhydrase IX is highly expressed in hereditary nonpolyposis colorectal cancer.
Carcinogenesis
Carbonic anhydrase IX: a new druggable target for the design of antitumor agents.
Carcinogenesis
Carbonic anhydrase IX: a regulator of pH and participant in carcinogenesis.
Carcinogenesis
Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target.
Carcinogenesis
Carbonic Anhydrase XII as an Independent Prognostic Factor in Advanced Esophageal Squamous Cell Carcinoma.
Carcinogenesis
COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents.
Carcinogenesis
Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX.
Carcinogenesis
Development of 3-(4-aminosulphonyl)-phenyl-2-mercapto-3H-quinazolin-4-ones as inhibitors of carbonic anhydrase isoforms involved in tumorigenesis and glaucoma.
Carcinogenesis
Developments of small molecules as inhibitors for carbonic anhydrase isoforms.
Carcinogenesis
Dickkopf-1 (DKK-1) interrupts FAK/PI3K/mTOR pathway by interaction of carbonic anhydrase IX (CA9) in tumorigenesis.
Carcinogenesis
Down regulation of CAII is associated with tumor differentiation and poor prognosis in patients with pancreatic cancer.
Carcinogenesis
Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors.
Carcinogenesis
Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
Carcinogenesis
Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2.
Carcinogenesis
Expression of carbonic anhydrases IX and XII during mouse embryonic development.
Carcinogenesis
Expression of hypoxia-induced proteins in ductal carcinoma in situ and invasive cancer of the male breast.
Carcinogenesis
Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors.
Carcinogenesis
Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours.
Carcinogenesis
G250: a carbonic anhydrase IX monoclonal antibody.
Carcinogenesis
High expression of carbonic anhydrase IX is significantly associated with glandular lesions in gastroesophageal junction and with tumorigenesis markers BMI1, MCM4 and MCM7.
Carcinogenesis
Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma.
Carcinogenesis
Identification of Carbonic Anhydrase IX as a Novel Target for Endoscopic Molecular Imaging of Human Bladder Cancer.
Carcinogenesis
Increased oxidation-related glutathionylation and carbonic anhydrase activity in endometriosis.
Carcinogenesis
Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro.
Carcinogenesis
Inhibition of carbonic anhydrase IX: a new strategy against cancer.
Carcinogenesis
Is serous cystadenoma of the pancreas a model of clear-cell-associated angiogenesis and tumorigenesis?
Carcinogenesis
LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen.
Carcinogenesis
N-?-Glycosyl sulfamides are selective inhibitors of the cancer associated carbonic anhydrase isoforms IX and XII.
Carcinogenesis
PIMT Binding to C-Terminal Ala459 of CAIX Is Involved in Inside-Out Signaling Necessary for Its Catalytic Activity.
Carcinogenesis
Quantitative assessment of specific carbonic anhydrase inhibitors effect on hypoxic cells using electrical impedance assays.
Carcinogenesis
Selective carbonic anhydrase IX inhibitors based on coumarin scaffold as promising antimetastatic agents: WO2012070024.
Carcinogenesis
Serendipitous fragment-based drug discovery: ketogenic diet metabolites and statins effectively inhibit several carbonic anhydrases.
Carcinogenesis
Synthesis of coumarin-sulfonamide derivatives and determination of their cytotoxicity, carbonic anhydrase inhibitory and molecular docking studies.
Carcinogenesis
Targeting tumor-associated carbonic anhydrase IX in cancer therapy.
Carcinogenesis
The cellular physiology of carbonic anhydrases.
Carcinoid Tumor
Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines.
Carcinoid Tumor
Hypoxia stimulates CXCR4 signalling in ileal carcinoids.
Carcinoid Tumor
Pdcd4 inhibits growth of tumor cells by suppression of carbonic anhydrase type II.
Carcinoid Tumor
Synchronous primary carcinoid tumor and primary adenocarcinoma arising within mature cystic teratoma of horseshoe kidney: a unique case report and review of the literature.
Carcinoma
'Image and treat': an individualized approach to urological tumors.
Carcinoma
A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo.
Carcinoma
A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX((R))) and interferon-alpha-2a in metastatic renal cell carcinoma patients.
Carcinoma
A new PCR-based assay amplifies the E6-E7 genes of most mucosal human papillomaviruses (HPV).
Carcinoma
A Novel Fully-Human Potency-Matched Dual Cytokine-Antibody Fusion Protein Targets Carbonic Anhydrase IX in Renal Cell Carcinomas.
Carcinoma
A potential for tissue restrictive gene therapy in renal cell carcinoma using MN/CA IX promoter.
Carcinoma
A Rare Case of Synchronous Esophageal and Pancreatic Malignancy.
Carcinoma
Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma.
Carcinoma
Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
Carcinoma
Agreement between carcinoma experiments in vivo and low-energy x-ray irradiation of the metalloprotein carbonic anhydrase.
Carcinoma
An evaluation of cytosolic erythrocyte carbonic anhydrase and catalase in carcinoma patients: an elevation of carbonic anhydrase activity.
Carcinoma
An Intrarenal Adrenocortical Carcinoma Arising in an Adrenal Rest.
Carcinoma
Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice.
Carcinoma
Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma.
Carcinoma
Association between carbonic anhydrase 9 expression and poor prognosis in sinonasal squamous cell carcinoma.
Carcinoma
Association of increased radiocurability of murine carcinomas with low constitutive expression of p21(WAF1/CIP1) protein.
Carcinoma
Association of the Gross Appearance of Intratumoral Vascularity at MDCT With the Carbonic Anhydrase IX Score in Clear Cell Renal Cell Carcinoma.
Carcinoma
Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia.
Carcinoma
Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma.
Carcinoma
CA9 Silencing Promotes Mitochondrial Biogenesis, Increases Putrescine Toxicity and Decreases Cell Motility to Suppress ccRCC Progression.
Carcinoma
CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Carcinoma
Calcifying epithelioma of Malherbe with ossification. Special reference to lectin binding and immunohistochemistry of ossified sites.
Carcinoma
Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy.
Carcinoma
Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix.
Carcinoma
Carbonic Anhydrase 4 serves as a Clinicopathological Biomarker for Outcomes and Immune Infiltration in Renal Cell Carcinoma, Lower Grade Glioma, Lung Adenocarcinoma and Uveal Melanoma.
Carcinoma
Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival.
Carcinoma
Carbonic anhydrase 9 in clear cell renal cell carcinoma: A marker for diagnosis, prognosis and treatment.
Carcinoma
Carbonic anhydrase expression in kidney and renal cancer: implications for diagnosis and treatment.
Carcinoma
Carbonic Anhydrase III Promotes Cell Migration and Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma.
Carcinoma
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
Carcinoma
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
Carcinoma
Carbonic anhydrase isozymes IX and XII in gastric tumors.
Carcinoma
Carbonic anhydrase IX (CA9) expression in multiple renal epithelial tumour subtypes.
Carcinoma
Carbonic anhydrase IX (CAIX) does not differentiate between benign and malignant mesothelium.
Carcinoma
Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
Carcinoma
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Carcinoma
Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies.
Carcinoma
Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma.
Carcinoma
Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma.
Carcinoma
Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma.
Carcinoma
Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)?
Carcinoma
Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma.
Carcinoma
Carbonic anhydrase IX as a specific biomarker for clear cell renal cell carcinoma: comparative study of Western blot and immunohistochemistry and implications for diagnosis.
Carcinoma
Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs.
Carcinoma
Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy.
Carcinoma
Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies.
Carcinoma
Carbonic anhydrase IX expression in clear cell renal cell carcinomas negatively correlates with the proportion of the granular cell component.
Carcinoma
Carbonic anhydrase IX expression is associated with favorable prognostic factors in small intestinal carcinoma.
Carcinoma
Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma.
Carcinoma
Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas.
Carcinoma
Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells.
Carcinoma
Carbonic anhydrase IX immunohistochemistry has potential to predict renal cell carcinoma outcomes: A systematic review and meta-analyses.
Carcinoma
Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker.
Carcinoma
Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management.
Carcinoma
Carbonic Anhydrase IX in Renal Cell Carcinoma: Implications for Prognosis, Diagnosis, and Therapy.
Carcinoma
Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma.
Carcinoma
Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer.
Carcinoma
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Carcinoma
Carbonic anhydrase IX is expressed in mesothelioma and metastatic clear cell renal cell carcinoma of the lung.
Carcinoma
Carbonic Anhydrase IX is Not a Predictor of Outcomes in Non-Metastatic Clear Cell Renal Cell Carcinoma - A Digital Analysis of Tissue Microarray.
Carcinoma
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma.
Carcinoma
Carbonic anhydrase IX overexpression regulates the migration and progression in oral squamous cell carcinoma.
Carcinoma
Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder.
Carcinoma
Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density.
Carcinoma
Carbonic anhydrase IX: A promising diagnostic and prognostic biomarker in breast carcinoma.
Carcinoma
Carbonic anhydrase VI: a novel marker for salivary serous acinar differentiation and its application to discriminate acinic cell carcinoma from mammary analogue secretory carcinoma of the salivary gland.
Carcinoma
Carbonic Anhydrase XII as an Independent Prognostic Factor in Advanced Esophageal Squamous Cell Carcinoma.
Carcinoma
CAXII Is a sero-diagnostic marker for lung cancer.
Carcinoma
Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells.
Carcinoma
Characterization of carbonic anhydrase IX interactome reveals proteins assisting its nuclear localization in hypoxic cells.
Carcinoma
Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis.
Carcinoma
Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers.
Carcinoma
Clear Cell Renal Cell Carcinoma Metastatic to the Gynecologic Tract: A Clinicopathologic Analysis of 17 Cases.
Carcinoma
Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Carcinoma
Clinicopathological significance of carbonic anhydrase 9, glucose transporter-1, Ki-67 and p53 expression in oral squamous cell carcinoma.
Carcinoma
Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients.
Carcinoma
COILED COIL PEPTIDES AS UNIVERSAL LINKERS FOR THE ATTACHMENT OF RECOMBINANT PROTEINS TO POLYMER THERAPEUTICS.
Carcinoma
Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma.
Carcinoma
Colonic and small-intestinal phenotypes in gastric cancers: relationships with clinicopathological findings.
Carcinoma
Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients.
Carcinoma
Comparative evaluation of Affibody molecules for radionuclide imaging of in vivo expression of carbonic anhydrase IX.
Carcinoma
Computational discovery of plant-based inhibitors against human carbonic anhydrase IX and molecular dynamics simulation.
Carcinoma
Correlation of carbonic anhydrase 9 (CA9) with pathological T-stage and prognosis in patients with oral tongue squamous cell carcinoma.
Carcinoma
Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX.
Carcinoma
Current status and future directions of molecular markers in renal cell carcinoma.
Carcinoma
Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer.
Carcinoma
Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma.
Carcinoma
Detection of carbonic anhydrase 9-expressing tumor cells in the lymph nodes of vulvar carcinoma patients by RT-PCR.
Carcinoma
Diagnostic Algorithmic Proposal Based on Comprehensive Immunohistochemical Evaluation of 297 Invasive Endocervical Adenocarcinomas.
Carcinoma
Diagnostic and prognostic molecular markers in renal cell carcinoma.
Carcinoma
Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis.
Carcinoma
Diagnostic Challenges of Kidney Cancer: A Systematic Review of the Role of Positron Emission Tomography-Computerized Tomography.
Carcinoma
Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.
Carcinoma
Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients.
Carcinoma
Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation.
Carcinoma
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
Carcinoma
Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma.
Carcinoma
Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2.
Carcinoma
Establishment of patient-derived three-dimensional organoid culture in renal cell carcinoma.
Carcinoma
Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma.
Carcinoma
Evaluation of morphologically unclassified renal cell carcinoma with electron microscopy and novel renal markers: implications for tumor reclassification.
Carcinoma
Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110.
Carcinoma
Exosomes expressing carbonic anhydrase 9 promote angiogenesis.
Carcinoma
Expression and diagnostic implications of carbonic anhydrase IX in several tumours with predominantly clear cell morphology.
Carcinoma
Expression of CA IX in dysplasia adjacent to surgical resection margins of oral squamous cell carcinoma.
Carcinoma
Expression of CA-IX is associated with advanced stage tumors and poor survival in oral squamous cell carcinoma patients.
Carcinoma
Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma.
Carcinoma
Expression of carbonic anhydrase IX in genitourinary and adrenal tumours.
Carcinoma
Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma.
Carcinoma
Expression of carbonic anhydrases I/II and the correlation to clinical aspects of oral squamous cell carcinoma analyzed using tissue microarray.
Carcinoma
Expression of MaTu-MN protein in human tumor cultures and in clinical specimens.
Carcinoma
Expression of new prognostic markers, peripheral-type benzodiazepine receptor and carbonic anhydrase IX, in human breast and ovarian carcinoma cell lines.
Carcinoma
Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast.
Carcinoma
Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors.
Carcinoma
Expression of TMPRSS4 in non-small cell lung cancer and its modulation by hypoxia.
Carcinoma
Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours.
Carcinoma
Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours.
Carcinoma
Expression Pattern of Carbonic Anhydrase IX in Medullary Thyroid Carcinoma Supports a Role for RET-Mediated Activation of the HIF Pathway.
Carcinoma
Fabrication of mAb G250-SPIO molecular magnetic resonance imaging nanoprobe for the specific detection of renal cell carcinoma in vitro.
Carcinoma
Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with 111In-girentuximab.
Carcinoma
Generation of anti-tumour immune response using dendritic cells pulsed with carbonic anhydrase IX-Acinetobacter baumannii outer membrane protein A fusion proteins against renal cell carcinoma.
Carcinoma
Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9.
Carcinoma
Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer.
Carcinoma
Glycolysis-related protein expression in thyroid cancer.
Carcinoma
Hemoglobin level predicts outcome for vulvar cancer patients independent of GLUT-1 and CA-IX expression in tumor tissue.
Carcinoma
HIF-1? and CA-IX as predictors of locoregional control for determining the optimal treatment modality for early-stage laryngeal carcinoma.
Carcinoma
HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
Carcinoma
High stromal carbonic anhydrase IX expression is associated with nodal metastasis and decreased survival in patients with surgically-treated oral cavity squamous cell carcinoma.
Carcinoma
High-Throughput Image Cytometry Detection Method for CAR-T Transduction, Cell Proliferation, and Cytotoxicity Assays.
Carcinoma
HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3.
Carcinoma
Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
Carcinoma
Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers.
Carcinoma
Hypoxia in larynx carcinomas assessed by pimonidazole binding and the value of CA-IX and vascularity as surrogate markers of hypoxia.
Carcinoma
Hypoxia-inducible expression of tumor-associated carbonic anhydrases.
Carcinoma
Hypoxic marker CA IX and adhesion mediator ?-catenin are downregulated by lymphocytic choriomeningitis virus persistent infection.
Carcinoma
Identification of proteins that regulate radiation-induced apoptosis in murine tumors with wild type p53.
Carcinoma
Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor.
Carcinoma
Immune responses to transgene and retroviral vector in patients treated with ex vivo engineered T cells.
Carcinoma
Immunoaffinity Enrichment and Liquid Chromatography-Selected Reaction Monitoring Mass Spectrometry for Quantitation of Carbonic Anhydrase 12 in Cultured Renal Carcinoma Cells.
Carcinoma
Immunohistochemical distinction of metastases of renal cell carcinoma to the adrenal from primary adrenal nodules, including oncocytic tumor.
Carcinoma
Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma.
Carcinoma
Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma.
Carcinoma
Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment.
Carcinoma
Immunohistochemical marker panel differentiates between the three most common subtypes of renal cell carcinoma independent from histomorphologic criteria.
Carcinoma
Immunohistochemical Panel for Differentiating Renal Cell Carcinoma with Clear and Papillary Features.
Carcinoma
Immunohistochemical panel for differentiating renal cell carcinoma with clear and papillary features.
Carcinoma
ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.
Carcinoma
Immunostimulatory Activity of Dendritic cells pulsed with carbonic anhydrase IX and Acinetobacter baumannii outer membrane protein A.
Carcinoma
Immunotargeting of human cervical carcinoma xenograft expressing CA IX tumor-associated antigen by 125I-labeled M75 monoclonal antibody.
Carcinoma
Impact of tumoral carbonic anhydrase IX and Ki-67 expression on survival in oral squamous cell carcinoma patients.
Carcinoma
Impacts of CA9 gene polymorphisms and environmental factors on oral-cancer susceptibility and clinicopathologic characteristics in Taiwan.
Carcinoma
Impacts of CA9 gene polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic characteristics in Taiwan.
Carcinoma
Increased expression of carbonic anhydrase IX in oral submucous fibrosis and oral squamous cell carcinoma.
Carcinoma
Indium-111-labeled Girentuximab ImmunoSPECT as a Diagnostic Tool in Clear Cell Renal Cell Carcinoma.
Carcinoma
Inhibition of carbonic anhydrase IX (CA9) sensitizes renal cell carcinoma to ionizing radiation.
Carcinoma
Inhibition of carbonic anhydrase IX: a new strategy against cancer.
Carcinoma
Intercalated cells as a probable source for the development of renal oncocytoma.
Carcinoma
Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma.
Carcinoma
Intracellular distribution of hepatic carbonic anhydrase in mice bearing Ehrlich ascites carcinoma or with spontaneous mammary carcinoma.
Carcinoma
Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas.
Carcinoma
Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and (124)I-cG250 PET/CT.
Carcinoma
Investigation of the Prognostic Role of Carbonic Anhydrase 9 (CAIX) of the Cellular mRNA/Protein Level or Soluble CAIX Protein in Patients with Oral Squamous Cell Carcinoma.
Carcinoma
Knock-down of hypoxia-induced carbonic anhydrases IX and XII radiosensitizes tumor cells by increasing intracellular acidosis.
Carcinoma
LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen.
Carcinoma
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Carcinoma
Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study.
Carcinoma
Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.
Carcinoma
Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas.
Carcinoma
Metabolic correlates of tumour hypoxia in malignant canine mammary carcinoma.
Carcinoma
Metastatic instability of murine tumor metastases: dependence on tumor type.
Carcinoma
Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines.
Carcinoma
Microsatellite alterations in head and neck squamous cell carcinoma and relation to expression of pimonidazole, CA IX and GLUT-1.
Carcinoma
Modulation of Tumor Microenvironment to Enhance Radiotherapy Efficacy in Esophageal Squamous Cell Carcinoma by Inhibiting Carbonic Anhydrase IX.
Carcinoma
Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma.
Carcinoma
Monoclonal antibody G250 targeting CA ?: Binding specificity, internalization and therapeutic effects in a non-renal cancer model.
Carcinoma
Mucin 5B, carbonic anhydrase 9 and claudin 18 are potential theranostic markers of gallbladder carcinoma.
Carcinoma
Novel antibody to a carbonic anhydrase: patent evaluation of WO2011138279A1.
Carcinoma
Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
Carcinoma
Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
Carcinoma
Optimizing Lutetium 177-Anti-Carbonic Anhydrase IX Radioimmunotherapy in an Intraperitoneal Clear Cell Renal Cell Carcinoma Xenograft Model.
Carcinoma
Overexpression of carbonic anhydrase IX induces cell motility by activating matrix metalloproteinase-9 in human oral squamous cell carcinoma cells.
Carcinoma
Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis.
Carcinoma
Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy.
Carcinoma
PAI-1, CAIX, and VEGFA expressions as prognosis markers in oral squamous cell carcinoma.
Carcinoma
Pairwise comparison of (89)Zr- and (124)I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.
Carcinoma
Paxillin and Carbonic Anhydrase IX are prognostic markers in gallbladder squamous cell/adenosquamous carcinomas and adenocarcinomas.
Carcinoma
Pazopanib-associated posterior reversible encephalopathy syndrome with intracerebral haemorrhage.
Carcinoma
PEG Linker Length Strongly Affects Tumor Cell Killing by PEGylated Carbonic Anhydrase Inhibitors in Hypoxic Carcinomas Expressing Carbonic Anhydrase IX.
Carcinoma
PEGylated Bis-Sulfonamide Carbonic Anhydrase Inhibitors Can Efficiently Control the Growth of Several Carbonic Anhydrase IX-Expressing Carcinomas.
Carcinoma
PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.
Carcinoma
Phase 1 Radioimmunotherapy Study with Lutetium 177-labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.
Carcinoma
Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.
Carcinoma
Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma.
Carcinoma
Plasmatic exosomes from prostate cancer patients show increased carbonic anhydrase IX expression and activity and low pH.
Carcinoma
Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype.
Carcinoma
Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion.
Carcinoma
Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-alpha.
Carcinoma
Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
Carcinoma
Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review.
Carcinoma
Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma.
Carcinoma
Prognostic impact of LY6K and CDCA1 expression for patients with esophageal squamous cell carcinoma.
Carcinoma
Prognostic significance of HIF-1a, CA-IX, and OPN in T1-T2 laryngeal carcinoma treated with radiotherapy.
Carcinoma
Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma.
Carcinoma
Prognostic value of CAIX expression in oral squamous cell carcinoma: a systematic review and meta-analysis.
Carcinoma
Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue.
Carcinoma
Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma.
Carcinoma
Prognostic value of carbonic anhydrase IX expression in penile squamous cell carcinoma: A pilot study.
Carcinoma
Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.
Carcinoma
Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.
Carcinoma
Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.
Carcinoma
Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin.
Carcinoma
Pyridinium derivatives of 3-aminobenzenesulfonamide are nanomolar-potent inhibitors of tumor-expressed carbonic anhydrase isozymes CA IX and CA XII.
Carcinoma
Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials.
Carcinoma
Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer.
Carcinoma
Quantitative image analysis of immunohistochemical stains using a CMYK color model.
Carcinoma
Quinazolinones as Competitive Inhibitors of Carbonic Anhydrase-II (Human and Bovine): Synthesis, in-vitro, in-silico, Selectivity, and Kinetics Studies.
Carcinoma
Radionuclide and fluorescence imaging of clear cell renal cell carcinoma using dual-labeled anti-Carbonic Anhydrase IX antibody G250.
Carcinoma
Re: carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
Carcinoma
Redox state and carbonic anhydrase isozyme IX expression in human renal cell carcinoma: biochemical and morphological investigations.
Carcinoma
Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor.
Carcinoma
Renal cell carcinoma-associated G250 methylation and expression: in vivo and in vitro studies.
Carcinoma
Renal cell carcinoma: new prognostic factors?
Carcinoma
Role of carbonic anhydrase IX, ?-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: a tissue microarray immunohistochemical study.
Carcinoma
Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence.
Carcinoma
Salivary gland-type mammary carcinoma arising in microglandular adenosis: A case report and clinicopathological review of the literature.
Carcinoma
Sarcomatoid Renal Cell Carcinoma With Unusual Metastasis to the Small Intestine Manifesting as Perforated Appendicitis.
Carcinoma
Serum adenosine deaminase, catalase, and carbonic anhydrase activities in patients with renal cell carcinoma.
Carcinoma
Serum carbonic anhydrase I and II autoantibodies in patients with chronic lymphocytic leukaemia.
Carcinoma
Significant variation of immunohistochemical marker expression in paired primary and metastatic clear cell renal cell carcinomas.
Carcinoma
Single nucleotide polymorphisms and haplotypes of carbonic anhydrase 9 can predict invasive squamous cell carcinoma of uterine cervix.
Carcinoma
Sinonasal renal cell-like adenocarcinomas: robust carbonic anhydrase expression.
Carcinoma
Small renal masses: current concepts regarding the natural history and reflections on the American Urological Association guidelines.
Carcinoma
Soluble carbonic anhydrase IX is not an independent prognostic factor in human renal cell carcinoma.
Carcinoma
Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract.
Carcinoma
Sortase-Mediated Site-Specific Modification of Interleukin-2 for the Generation of a Tumor-Targeting Acetazolamide-Cytokine Conjugate.
Carcinoma
Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma.
Carcinoma
Subnormal level of carbonic anhydrase in blood of carcinoma patients?
Carcinoma
Substituted (E)-2-(2-benzylidenehydrazinyl)-4-methylthiazole-5-carboxylates as dual inhibitors of 15-lipoxygenase & carbonic anhydrase II: synthesis, biochemical evaluation and docking studies.
Carcinoma
T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.
Carcinoma
T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.
Carcinoma
Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study.
Carcinoma
Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.
Carcinoma
The choroid plexus carcinomas of childhood: histopathology, immunocytochemistry and clinicopathological correlations.
Carcinoma
The human chromophobe cell renal carcinoma: its probable relation to intercalated cells of the collecting duct.
Carcinoma
The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis.
Carcinoma
The prognostic impact of a combined carbonic anhydrase IX and Ki67 signature in oral squamous cell carcinoma.
Carcinoma
The prognostic value of immunohistochemical markers for oral tongue squamous cell carcinoma.
Carcinoma
The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy.
Carcinoma
The relevance of RT-PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes.
Carcinoma
The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths.
Carcinoma
The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder.
Carcinoma
The role of carbonic anhydrase IX overexpression in kidney cancer.
Carcinoma
Tissue Expression of Carbonic Anhydrase IX Correlates to More Aggressive Phenotype of Basal Cell Carcinoma.
Carcinoma
Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy.
Carcinoma
Transcriptional regulation of carbonic anhydrase II by retinoic acid in the human pancreatic tumor cell line DANG.
Carcinoma
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.
Carcinoma
Tumor M2-Pyruvate Kinase, Matrix Carbonic Anhydrase IX, and Metalloproteinase 9 - Novel Prognostic Markers of Renal Cell Carcinoma.
Carcinoma
Tumor-associated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis.
Carcinoma
Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study.
Carcinoma
Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology.
Carcinoma
Useful immunohistochemical panel for differentiating clear cell papillary renal cell carcinoma from its mimics.
Carcinoma
Utility of multiphasic multidetector computed tomography in discriminating between clear cell renal cell carcinomas with high and low carbonic anhydrase-IX expression.
Carcinoma
Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma.
Carcinoma
VHL-gene Deletion in Single Renal Tubular Epithelial Cells and Renal Tubular Cysts: Further Evidence for a Cyst-dependent Progression Pathway of Clear Cell Renal Carcinoma in von Hippel-Lindau Disease.
Carcinoma
Words of wisdom. Re: Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Stillebroer AB, Mulders PFA, Boerman DC, Oyen WJG, Oosterwijk. E Eur Urol. In press. DOI: 10.1016/j.eururo.2010.03.015.
Carcinoma
Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology, immunohistochemistry, and FISH analysis.
Carcinoma
[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma.
Carcinoma
[A preliminary study on the relationship between GLUT-1?MCT-4 and CA? in laryngeal squamous cell carcinoma].
Carcinoma
[Clinical significance for detection of circulating cancer cells in renal cell carcinoma]
Carcinoma
[Clinicopathologic features of mammary microglandular adenosis with carcinoma: a study of 5 cases].
Carcinoma
[Detection of carbonic anhydrase IX gene expression in renal cell carcinoma with reverse transcription-PCR]
Carcinoma
[Evaluation of genotyping of human papilomavirus by a new DNA liquid chip based on Luminex XMAP]
Carcinoma
[Expression and clinical pathological implications of carbonic anhydrase 9 and P glycoprotein in laryngeal squamous cell carcinoma].
Carcinoma
[Hypoxia induces down-regulation of estrogen receptor alpha in human breast cancer.]
Carcinoma
[Progress in the study of carbonic anhydrase inhibitors as potential anticancer drugs].
Carcinoma in Situ
Expression of CA IX in dysplasia adjacent to surgical resection margins of oral squamous cell carcinoma.
Carcinoma in Situ
HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
Carcinoma, Acinar Cell
Carbonic anhydrase VI: a novel marker for salivary serous acinar differentiation and its application to discriminate acinic cell carcinoma from mammary analogue secretory carcinoma of the salivary gland.
Carcinoma, Adenosquamous
Association of increased radiocurability of murine carcinomas with low constitutive expression of p21(WAF1/CIP1) protein.
Carcinoma, Adenosquamous
Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas.
Carcinoma, Adenosquamous
Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas.
Carcinoma, Basal Cell
Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype.
Carcinoma, Basal Cell
Tissue Expression of Carbonic Anhydrase IX Correlates to More Aggressive Phenotype of Basal Cell Carcinoma.
Carcinoma, Ductal
Correlation of carbonic anhydrase IX expression with clinico-morphological parameters, hormonal receptor status and HER-2 expression in breast cancer.
Carcinoma, Ductal
Expression of hypoxia-induced proteins in ductal carcinoma in situ and invasive cancer of the male breast.
Carcinoma, Ductal
Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Carcinoma, Ductal
Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast.
Carcinoma, Ductal
Necrosis and hypoxia in invasive breast carcinoma.
Carcinoma, Ductal
[Significance of carbonic anhydrase IX protein expression in molecular subtyping of breast cancers].
Carcinoma, Ductal
[Significance of carbonic anhydrase IX protein in fibrotic foci of mammary invasive ductal carcinomas].
Carcinoma, Embryonal
Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors.
Carcinoma, Hepatocellular
3'UTR polymorphisms of carbonic anhydrase IX determine the miR-34a targeting efficiency and prognosis of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Analyses of polypeptides in the liver of a novel mutant (LEC rats) to hereditary hepatitis and hepatoma by two-dimensional gel electrophoresis: identification of P29/6.8 as carbonic anhydrase III and triosephosphate isomerase.
Carcinoma, Hepatocellular
Association between the expression of carbonic anhydrase II and clinicopathological features of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Carbonic anhydrase 2 inhibits epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Carbonic anhydrase III promotes transformation and invasion capability in hepatoma cells through FAK signaling pathway.
Carcinoma, Hepatocellular
Carbonic anhydrase inhibitors based on sorafenib scaffold: Design, synthesis, crystallographic investigation and effects on primary breast cancer cells.
Carcinoma, Hepatocellular
Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis.
Carcinoma, Hepatocellular
Dual-Functional Liposomes with Carbonic Anhydrase IX Antibody and BR2 Peptide Modification Effectively Improve Intracellular Delivery of Cantharidin to Treat Orthotopic Hepatocellular Carcinoma Mice.
Carcinoma, Hepatocellular
Expression of carbonic anhydrase 9 is a novel prognostic marker in resectable hepatocellular carcinoma.
Carcinoma, Hepatocellular
Expression of carbonic anhydrase IX is associated with poor prognosis through regulation of the epithelial?mesenchymal transition in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Expression of Hypoxic Marker Carbonic Anhydrase IX Predicts Poor Prognosis in Resectable Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Expression of proteins associated with hypoxia and Wnt pathway activation is of prognostic significance in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Hypoxia and cytokines regulate carbonic anhydrase 9 expression in hepatocellular carcinoma cells in vitro.
Carcinoma, Hepatocellular
Increased Expression of the Matrix-Modifying Enzyme Lysyl Oxidase-Like 2 in Aggressive Hepatocellular Carcinoma with Poor Prognosis.
Carcinoma, Hepatocellular
Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis.
Carcinoma, Hepatocellular
Irradiation-induced localization of IL-12-expressing mesenchymal stem cells to enhance the curative effect in murine metastatic hepatoma.
Carcinoma, Hepatocellular
Prognostic value of carbonic anhydrase XII (CA XII) overexpression in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Quantitative Secretome Analysis Reveals Clinical Values of Carbonic Anhydrase II in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Synthesis, biological activity and multiscale molecular modeling studies of bis-coumarins as selective carbonic anhydrase IX and XII inhibitors with effective cytotoxicity against hepatocellular carcinoma.
Carcinoma, Hepatocellular
The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
The production of heparin cofactor II is not regulated by inflammatory cytokines in human hepatoma cells: comparison with plasminogen activator inhibitor type-1.
Carcinoma, Hepatocellular
[3H]acetazolamide binding to carbonic anhydrase in normal and transformed cells.
Carcinoma, Intraductal, Noninfiltrating
Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.
Carcinoma, Intraductal, Noninfiltrating
Expression of hypoxia-induced proteins in ductal carcinoma in situ and invasive cancer of the male breast.
Carcinoma, Intraductal, Noninfiltrating
Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast.
Carcinoma, Intraductal, Noninfiltrating
Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast.
Carcinoma, Lobular
Correlation of carbonic anhydrase IX expression with clinico-morphological parameters, hormonal receptor status and HER-2 expression in breast cancer.
Carcinoma, Medullary
Glycolysis-related protein expression in thyroid cancer.
Carcinoma, Non-Small-Cell Lung
A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.
Carcinoma, Non-Small-Cell Lung
Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Carbonic anhydrase 1 is a promising biomarker for early detection of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Carbonic anhydrase inhibitors--Part 94. 1,3,4-thiadiazole-2-sulfonamidederivatives as antitumor agents?
Carcinoma, Non-Small-Cell Lung
Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
Carbonic anhydrase IX expression correlates with FDG uptake by primary non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Carbonic anhydrase IX in early-stage non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Carbonic anhydrase-related protein VIII increases invasiveness of non-small cell lung adenocarcinoma.
Carcinoma, Non-Small-Cell Lung
Diverging prognostic impacts of hypoxic markers according to NSCLC histology.
Carcinoma, Non-Small-Cell Lung
Downregulation of carbonic anhydrase IV contributes to promotion of cell proliferation and is associated with poor prognosis in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Effect of carbonic anhydrase-related protein VIII expression on lung adenocarcinoma cell growth.
Carcinoma, Non-Small-Cell Lung
Expression of carbonic anhydrase-related protein CA-RP VIII in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Prognostic significance of carbonic anhydrase IX overexpression in stage III non-small cell lung cancer patients after neoadjuvant treatment.
Carcinoma, Non-Small-Cell Lung
Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Response of CAIX and CAXII to in vitro re-oxygenation and clinical significance of the combined expression in NSCLC patients.
Carcinoma, Non-Small-Cell Lung
The aberrant expression of cytosolic carbonic anhydrase and its clinical significance in human non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
Postoperative recurrence of epithelial ovarian cancer patients and chemoresistance related protein analyses.
Carcinoma, Ovarian Epithelial
Prognostic Relevance of the Expression of CA IX, GLUT-1, and VEGF in Ovarian Epithelial Cancers.
Carcinoma, Papillary
Expression of glycolysis-related proteins in solid papillary carcinoma of the breast according to basement membrane status.
Carcinoma, Renal Cell
'Image and treat': an individualized approach to urological tumors.
Carcinoma, Renal Cell
A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo.
Carcinoma, Renal Cell
A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX((R))) and interferon-alpha-2a in metastatic renal cell carcinoma patients.
Carcinoma, Renal Cell
A Novel Fully-Human Potency-Matched Dual Cytokine-Antibody Fusion Protein Targets Carbonic Anhydrase IX in Renal Cell Carcinomas.
Carcinoma, Renal Cell
A potential for tissue restrictive gene therapy in renal cell carcinoma using MN/CA IX promoter.
Carcinoma, Renal Cell
Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Acetazolamide-based [
Carcinoma, Renal Cell
Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
Carcinoma, Renal Cell
An Intrarenal Adrenocortical Carcinoma Arising in an Adrenal Rest.
Carcinoma, Renal Cell
Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice.
Carcinoma, Renal Cell
Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma.
Carcinoma, Renal Cell
Association of the Gross Appearance of Intratumoral Vascularity at MDCT With the Carbonic Anhydrase IX Score in Clear Cell Renal Cell Carcinoma.
Carcinoma, Renal Cell
CA9 Silencing Promotes Mitochondrial Biogenesis, Increases Putrescine Toxicity and Decreases Cell Motility to Suppress ccRCC Progression.
Carcinoma, Renal Cell
CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Carcinoma, Renal Cell
Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy.
Carcinoma, Renal Cell
Carbonic Anhydrase 4 serves as a Clinicopathological Biomarker for Outcomes and Immune Infiltration in Renal Cell Carcinoma, Lower Grade Glioma, Lung Adenocarcinoma and Uveal Melanoma.
Carcinoma, Renal Cell
Carbonic anhydrase 9 in clear cell renal cell carcinoma: A marker for diagnosis, prognosis and treatment.
Carcinoma, Renal Cell
Carbonic anhydrase expression in kidney and renal cancer: implications for diagnosis and treatment.
Carcinoma, Renal Cell
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
Carcinoma, Renal Cell
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
Carcinoma, Renal Cell
Carbonic anhydrase IX (CA9) expression in multiple renal epithelial tumour subtypes.
Carcinoma, Renal Cell
Carbonic anhydrase IX (CAIX) does not differentiate between benign and malignant mesothelium.
Carcinoma, Renal Cell
Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
Carcinoma, Renal Cell
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Carcinoma, Renal Cell
Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies.
Carcinoma, Renal Cell
Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma.
Carcinoma, Renal Cell
Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)?
Carcinoma, Renal Cell
Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Carbonic anhydrase IX as a specific biomarker for clear cell renal cell carcinoma: comparative study of Western blot and immunohistochemistry and implications for diagnosis.
Carcinoma, Renal Cell
Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy.
Carcinoma, Renal Cell
Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies.
Carcinoma, Renal Cell
Carbonic anhydrase IX expression in clear cell renal cell carcinomas negatively correlates with the proportion of the granular cell component.
Carcinoma, Renal Cell
Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma.
Carcinoma, Renal Cell
Carbonic anhydrase IX immunohistochemistry has potential to predict renal cell carcinoma outcomes: A systematic review and meta-analyses.
Carcinoma, Renal Cell
Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management.
Carcinoma, Renal Cell
Carbonic Anhydrase IX in Renal Cell Carcinoma: Implications for Prognosis, Diagnosis, and Therapy.
Carcinoma, Renal Cell
Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma.
Carcinoma, Renal Cell
Carbonic anhydrase IX is expressed in mesothelioma and metastatic clear cell renal cell carcinoma of the lung.
Carcinoma, Renal Cell
Carbonic Anhydrase IX is Not a Predictor of Outcomes in Non-Metastatic Clear Cell Renal Cell Carcinoma - A Digital Analysis of Tissue Microarray.
Carcinoma, Renal Cell
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Characterization of carbonic anhydrase IX interactome reveals proteins assisting its nuclear localization in hypoxic cells.
Carcinoma, Renal Cell
Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis.
Carcinoma, Renal Cell
Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers.
Carcinoma, Renal Cell
Clear Cell Renal Cell Carcinoma Metastatic to the Gynecologic Tract: A Clinicopathologic Analysis of 17 Cases.
Carcinoma, Renal Cell
Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients.
Carcinoma, Renal Cell
Combining DNA Vaccine and AIM2 in H1 Nanoparticles Exert Anti-Renal Carcinoma Effects via Enhancing Tumor-Specific Multi-functional CD8+ T-cell Responses.
Carcinoma, Renal Cell
Comparative evaluation of Affibody molecules for radionuclide imaging of in vivo expression of carbonic anhydrase IX.
Carcinoma, Renal Cell
Current status and future directions of molecular markers in renal cell carcinoma.
Carcinoma, Renal Cell
Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Diagnostic and prognostic molecular markers in renal cell carcinoma.
Carcinoma, Renal Cell
Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis.
Carcinoma, Renal Cell
Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.
Carcinoma, Renal Cell
Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation.
Carcinoma, Renal Cell
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
Carcinoma, Renal Cell
Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma.
Carcinoma, Renal Cell
Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2.
Carcinoma, Renal Cell
Establishment of patient-derived three-dimensional organoid culture in renal cell carcinoma.
Carcinoma, Renal Cell
Evaluation of morphologically unclassified renal cell carcinoma with electron microscopy and novel renal markers: implications for tumor reclassification.
Carcinoma, Renal Cell
Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110.
Carcinoma, Renal Cell
Exosomes expressing carbonic anhydrase 9 promote angiogenesis.
Carcinoma, Renal Cell
Expression and diagnostic implications of carbonic anhydrase IX in several tumours with predominantly clear cell morphology.
Carcinoma, Renal Cell
Expression of carbonic anhydrase IX in genitourinary and adrenal tumours.
Carcinoma, Renal Cell
Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors.
Carcinoma, Renal Cell
Fabrication of mAb G250-SPIO molecular magnetic resonance imaging nanoprobe for the specific detection of renal cell carcinoma in vitro.
Carcinoma, Renal Cell
Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with 111In-girentuximab.
Carcinoma, Renal Cell
Generation of anti-tumour immune response using dendritic cells pulsed with carbonic anhydrase IX-Acinetobacter baumannii outer membrane protein A fusion proteins against renal cell carcinoma.
Carcinoma, Renal Cell
Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9.
Carcinoma, Renal Cell
hERG1 and CA IX expression are associated with disease recurrence in surgically resected clear cell renal carcinoma.
Carcinoma, Renal Cell
High-Throughput Image Cytometry Detection Method for CAR-T Transduction, Cell Proliferation, and Cytotoxicity Assays.
Carcinoma, Renal Cell
HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Carcinoma, Renal Cell
Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
Carcinoma, Renal Cell
Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers.
Carcinoma, Renal Cell
Hypoxia-inducible expression of tumor-associated carbonic anhydrases.
Carcinoma, Renal Cell
Hypoxic marker CA IX and adhesion mediator ?-catenin are downregulated by lymphocytic choriomeningitis virus persistent infection.
Carcinoma, Renal Cell
Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor.
Carcinoma, Renal Cell
Immune responses to transgene and retroviral vector in patients treated with ex vivo engineered T cells.
Carcinoma, Renal Cell
Immunoaffinity Enrichment and Liquid Chromatography-Selected Reaction Monitoring Mass Spectrometry for Quantitation of Carbonic Anhydrase 12 in Cultured Renal Carcinoma Cells.
Carcinoma, Renal Cell
Immunohistochemical distinction of metastases of renal cell carcinoma to the adrenal from primary adrenal nodules, including oncocytic tumor.
Carcinoma, Renal Cell
Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma.
Carcinoma, Renal Cell
Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma.
Carcinoma, Renal Cell
Immunohistochemical expression of microvascular density and carbonic anhidrase IX in renal carcinoma. Relation to histological type and tumoral progression.
Carcinoma, Renal Cell
Immunohistochemical marker panel differentiates between the three most common subtypes of renal cell carcinoma independent from histomorphologic criteria.
Carcinoma, Renal Cell
Immunohistochemical Panel for Differentiating Renal Cell Carcinoma with Clear and Papillary Features.
Carcinoma, Renal Cell
Immunohistochemical panel for differentiating renal cell carcinoma with clear and papillary features.
Carcinoma, Renal Cell
ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.
Carcinoma, Renal Cell
Immunostimulatory Activity of Dendritic cells pulsed with carbonic anhydrase IX and Acinetobacter baumannii outer membrane protein A.
Carcinoma, Renal Cell
Indium-111-labeled Girentuximab ImmunoSPECT as a Diagnostic Tool in Clear Cell Renal Cell Carcinoma.
Carcinoma, Renal Cell
Inhibition of carbonic anhydrase IX (CA9) sensitizes renal cell carcinoma to ionizing radiation.
Carcinoma, Renal Cell
Intercalated cells as a probable source for the development of renal oncocytoma.
Carcinoma, Renal Cell
Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and (124)I-cG250 PET/CT.
Carcinoma, Renal Cell
LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen.
Carcinoma, Renal Cell
Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.
Carcinoma, Renal Cell
Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Molecular imaging of urogenital diseases.
Carcinoma, Renal Cell
Monoclonal antibody G250 targeting CA ?: Binding specificity, internalization and therapeutic effects in a non-renal cancer model.
Carcinoma, Renal Cell
Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
Carcinoma, Renal Cell
Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
Carcinoma, Renal Cell
Optimizing Lutetium 177-Anti-Carbonic Anhydrase IX Radioimmunotherapy in an Intraperitoneal Clear Cell Renal Cell Carcinoma Xenograft Model.
Carcinoma, Renal Cell
Pairwise comparison of (89)Zr- and (124)I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.
Carcinoma, Renal Cell
Pazopanib-associated posterior reversible encephalopathy syndrome with intracerebral haemorrhage.
Carcinoma, Renal Cell
PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.
Carcinoma, Renal Cell
Phase 1 Radioimmunotherapy Study with Lutetium 177-labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.
Carcinoma, Renal Cell
Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.
Carcinoma, Renal Cell
Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer.
Carcinoma, Renal Cell
Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion.
Carcinoma, Renal Cell
Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
Carcinoma, Renal Cell
Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma.
Carcinoma, Renal Cell
Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma.
Carcinoma, Renal Cell
Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.
Carcinoma, Renal Cell
Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.
Carcinoma, Renal Cell
Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials.
Carcinoma, Renal Cell
Radionuclide and fluorescence imaging of clear cell renal cell carcinoma using dual-labeled anti-Carbonic Anhydrase IX antibody G250.
Carcinoma, Renal Cell
Re: carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
Carcinoma, Renal Cell
Recent advances in preoperative imaging of renal tumors.
Carcinoma, Renal Cell
Redox state and carbonic anhydrase isozyme IX expression in human renal cell carcinoma: biochemical and morphological investigations.
Carcinoma, Renal Cell
Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor.
Carcinoma, Renal Cell
Renal cell carcinoma-associated G250 methylation and expression: in vivo and in vitro studies.
Carcinoma, Renal Cell
Renal cell carcinoma: new prognostic factors?
Carcinoma, Renal Cell
Role of carbonic anhydrase IX, ?-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: a tissue microarray immunohistochemical study.
Carcinoma, Renal Cell
Sarcomatoid Renal Cell Carcinoma With Unusual Metastasis to the Small Intestine Manifesting as Perforated Appendicitis.
Carcinoma, Renal Cell
Serum adenosine deaminase, catalase, and carbonic anhydrase activities in patients with renal cell carcinoma.
Carcinoma, Renal Cell
Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer.
Carcinoma, Renal Cell
Significant variation of immunohistochemical marker expression in paired primary and metastatic clear cell renal cell carcinomas.
Carcinoma, Renal Cell
Small renal masses: current concepts regarding the natural history and reflections on the American Urological Association guidelines.
Carcinoma, Renal Cell
Soluble carbonic anhydrase IX is not an independent prognostic factor in human renal cell carcinoma.
Carcinoma, Renal Cell
Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients.
Carcinoma, Renal Cell
Sortase-Mediated Site-Specific Modification of Interleukin-2 for the Generation of a Tumor-Targeting Acetazolamide-Cytokine Conjugate.
Carcinoma, Renal Cell
STRA13 expression and subcellular localisation in normal and tumour tissues: implications for use as a diagnostic and differentiation marker.
Carcinoma, Renal Cell
Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.
Carcinoma, Renal Cell
T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.
Carcinoma, Renal Cell
Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study.
Carcinoma, Renal Cell
Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.
Carcinoma, Renal Cell
The impact of immunohistochemical staining with ezrin-carbonic anhydrase IX and neuropilin-2 on prognosis in patients with metastatic renal cell cancer receiving tyrosine kinase inhibitors.
Carcinoma, Renal Cell
Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy.
Carcinoma, Renal Cell
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.
Carcinoma, Renal Cell
Tumor M2-Pyruvate Kinase, Matrix Carbonic Anhydrase IX, and Metalloproteinase 9 - Novel Prognostic Markers of Renal Cell Carcinoma.
Carcinoma, Renal Cell
Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study.
Carcinoma, Renal Cell
Useful immunohistochemical panel for differentiating clear cell papillary renal cell carcinoma from its mimics.
Carcinoma, Renal Cell
Utility of multiphasic multidetector computed tomography in discriminating between clear cell renal cell carcinomas with high and low carbonic anhydrase-IX expression.
Carcinoma, Renal Cell
Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma.
Carcinoma, Renal Cell
VHL-gene Deletion in Single Renal Tubular Epithelial Cells and Renal Tubular Cysts: Further Evidence for a Cyst-dependent Progression Pathway of Clear Cell Renal Carcinoma in von Hippel-Lindau Disease.
Carcinoma, Renal Cell
Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study.
Carcinoma, Renal Cell
Words of wisdom. Re: Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Stillebroer AB, Mulders PFA, Boerman DC, Oyen WJG, Oosterwijk. E Eur Urol. In press. DOI: 10.1016/j.eururo.2010.03.015.
Carcinoma, Renal Cell
Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology, immunohistochemistry, and FISH analysis.
Carcinoma, Renal Cell
[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma.
Carcinoma, Renal Cell
[Clinical significance for detection of circulating cancer cells in renal cell carcinoma]
Carcinoma, Renal Cell
[Detection of carbonic anhydrase IX gene expression in renal cell carcinoma with reverse transcription-PCR]
Carcinoma, Renal Cell
[Future perspectives for diagnostic imaging in urology: from anatomic and functional to molecular imaging.]
Carcinoma, Squamous Cell
A new PCR-based assay amplifies the E6-E7 genes of most mucosal human papillomaviruses (HPV).
Carcinoma, Squamous Cell
A pair of long intergenic non-coding RNA LINC00887 variants act antagonistically to control Carbonic Anhydrase IX transcription upon hypoxia in tongue squamous carcinoma progression.
Carcinoma, Squamous Cell
Association between carbonic anhydrase 9 expression and poor prognosis in sinonasal squamous cell carcinoma.
Carcinoma, Squamous Cell
Association of increased radiocurability of murine carcinomas with low constitutive expression of p21(WAF1/CIP1) protein.
Carcinoma, Squamous Cell
Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density.
Carcinoma, Squamous Cell
CAXII Is a sero-diagnostic marker for lung cancer.
Carcinoma, Squamous Cell
Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Correlation of carbonic anhydrase 9 (CA9) with pathological T-stage and prognosis in patients with oral tongue squamous cell carcinoma.
Carcinoma, Squamous Cell
Expression of TMPRSS4 in non-small cell lung cancer and its modulation by hypoxia.
Carcinoma, Squamous Cell
Hemoglobin level predicts outcome for vulvar cancer patients independent of GLUT-1 and CA-IX expression in tumor tissue.
Carcinoma, Squamous Cell
High stromal carbonic anhydrase IX expression is associated with nodal metastasis and decreased survival in patients with surgically-treated oral cavity squamous cell carcinoma.
Carcinoma, Squamous Cell
Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas.
Carcinoma, Squamous Cell
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Carcinoma, Squamous Cell
Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study.
Carcinoma, Squamous Cell
Microsatellite alterations in head and neck squamous cell carcinoma and relation to expression of pimonidazole, CA IX and GLUT-1.
Carcinoma, Squamous Cell
Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis.
Carcinoma, Squamous Cell
Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy.
Carcinoma, Squamous Cell
Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review.
Carcinoma, Squamous Cell
Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue.
Carcinoma, Squamous Cell
Prognostic value of carbonic anhydrase IX expression in penile squamous cell carcinoma: A pilot study.
Carcinoma, Squamous Cell
Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence.
Carcinoma, Squamous Cell
Single nucleotide polymorphisms and haplotypes of carbonic anhydrase 9 can predict invasive squamous cell carcinoma of uterine cervix.
Carcinoma, Squamous Cell
The prognostic value of immunohistochemical markers for oral tongue squamous cell carcinoma.
Carcinoma, Squamous Cell
The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy.
Carcinoma, Transitional Cell
Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder.
Carcinoma, Transitional Cell
Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract.
Carcinoma, Transitional Cell
The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder.
Cardiomegaly
Discovery of arjunolic acid as a novel non-zinc binding carbonic anhydrase II inhibitor.
Cardiomyopathies
Carbonic anhydrase II/sodium-proton exchanger 1 metabolon complex in cardiomyopathy of ob-/- type 2 diabetic mice.
Cardiovascular Diseases
The hypoxia-sensor carbonic anhydrase IX affects macrophage metabolism, but is not a suitable biomarker for human cardiovascular disease.
Cataract
A topical or oral carbonic anhydrase inhibitor to control ocular hypertension after cataract surgery.
Cataract
Oral versus topical carbonic anhydrase inhibitors in ocular hypertension after scleral tunnel cataract surgery.
Cataract
The effect of carbonic anhydrase inhibition on central corneal thickness after cataract extraction.
Cataract
Topical carbonic anhydrase inhibition increases ocular pulse amplitude in high tension primary open angle glaucoma.
Cataract
Transforming growth factor-beta 2 levels in aqueous humor of glaucomatous eyes.
Cataract
[Therapy of cystoid diffuse macular edema after uveitis and cataract surgery with the carbonic anhydrase inhibitor acetazolamide (Diamox)]
Central Nervous System Infections
Carbonic anhydrase II in the cerebrospinal fluid: its value as a disease marker.
Central Serous Chorioretinopathy
Efficacy of Topical Carbonic Anhydrase Inhibitors in Reducing Duration of Chronic Central Serous Chorioretinopathy.
Central Serous Chorioretinopathy
RECURRENT CENTRAL SEROUS CHORIORETINOPATHY ASSOCIATED WITH RETINITIS PIGMENTOSA TREATED WITH CARBONIC ANHYDRASE INHIBITORS.
Cerebellar Ataxia
Neurochondrin Antibody Serum Positivity in Three Cases of Autoimmune Cerebellar Ataxia.
Cerebellar Ataxia
Novel homozygous variant of carbonic anhydrase 8 gene expanding the phenotype of cerebellar ataxia, mental retardation, and disequilibrium syndrome subtype 3.
Cerebellar Ataxia
Phenotypical spectrum of cerebellar ataxia associated with a novel mutation in the CA8 gene, encoding carbonic anhydrase (CA) VIII.
Cerebral Hemorrhage
Inhibition of carbonic anhydrase reduces brain injury after intracerebral hemorrhage.
Cerebral Hemorrhage
Mechanism Study of the Protective Effects of Sodium Tanshinone IIA Sulfonate Against Atorvastatin-Induced Cerebral Hemorrhage in Zebrafish: Transcriptome Analysis.
Cerebral Infarction
[Juvenile cerebral infarction associated with heparin cofactor II abnormality. A case report]
Cerebrovascular Disorders
Acetazolamide improves cerebral hemodynamics in CADASIL.
Cerebrovascular Disorders
The influence of acetazolamide on cerebral low-flow regions in migraine--an interictal 99mTc-HMPAO SPECT study.
Cervical Intraepithelial Neoplasia
Comparison of human papillomavirus detection and typing by hybrid capture 2, linear array, DNA chip, and cycle sequencing in cervical swab samples.
Cervical Intraepithelial Neoplasia
Comparison of two signal-amplification DNA tests for high-risk HPV as an aid to colposcopy.
Cervical Intraepithelial Neoplasia
Role of human papillomavirus testing in reducing the number of surgical treatments for precancerous cervical lesions.
Cervical Intraepithelial Neoplasia
Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence.
Chagas Disease
A Class of Sulfonamides with Strong Inhibitory Action against the ?-Carbonic Anhydrase from Trypanosoma cruzi.
Chagas Disease
A structure-based approach towards the identification of novel antichagasic compounds: Trypanosoma cruzi carbonic anhydrase inhibitors.
Chagas Disease
Anion inhibition studies of the ?-carbonic anhydrase from the protozoan pathogen Trypanosoma cruzi, the causative agent of Chagas disease.
Chagas Disease
Are Carbonic Anhydrases Suitable Targets to Fight Protozoan Parasitic Diseases?
Chagas Disease
Cloning, Characterization, and Sulfonamide and Thiol Inhibition Studies of an ?-Carbonic Anhydrase from Trypanosoma cruzi, the Causative Agent of Chagas Disease.
Chagas Disease
Inhibition of carbonic anhydrase from Trypanosoma cruzi for the management of Chagas disease: an underexplored therapeutic opportunity.
Chagas Disease
N-Nitrosulfonamides as Carbonic Anhydrase Inhibitors: A Promising Chemotype for Targeting Chagas Disease and Leishmaniasis.
Chagas Disease
Nanoemulsions of sulfonamide carbonic anhydrase inhibitors strongly inhibit the growth of Trypanosoma cruzi.
Cherubism
Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts.
Cheyne-Stokes Respiration
[Influencing of Cheyne-Stokes respiration through carbonic anhydrase inhibitors]
Cholangiocarcinoma
CA9 overexpression is an independent favorable prognostic marker in intrahepatic cholangiocarcinoma.
Cholangiocarcinoma
Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma.
Cholangitis
Antibodies to carbonic anhydrase in patients with immune cholangiopathies.
Cholangitis
Autoimmune liver disease.
Cholangitis
Different susceptibility of mice to immune-mediated cholangitis induced by immunization with carbonic anhydrase II.
Cholangitis
Primary biliary cirrhosis with antibody against carbonic anhydrase II associates with distinct immunological backgrounds.
Cholangitis
The ability of anti-carbonic anhydrase II antibody to distinguish autoimmune cholangitis from primary biliary cirrhosis in Japanese patients.
Cholangitis
Ursodeoxycholic acid (UDCA) suppresses liver interleukin 2 mRNA in the cholangitis model.
Cholangitis, Sclerosing
Antibodies to carbonic anhydrase in patients with immune cholangiopathies.
Cholera
Anion inhibition profiles of ?-, ?- and ?-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
Cholera
Cholera toxin-stimulated bone resorption in cultured mouse calvarial bones not inhibited by calcitonin: a possible interaction at the stimulatory G protein.
Cholera
Novel Indole-Based Hydrazones as Potent Inhibitors of the ?-class Carbonic Anhydrase from Pathogenic Bacterium Vibrio cholerae.
Cholera
The effect of cholera toxin on choroid plexus carbonic anhydrase activity in vitro.
Chondroblastoma
Histochemistry of tartrate-resistant acid phosphatase and carbonic anhydrase isoenzyme II in osteoclast-like giant cells in bone tumours.
Chorea
Zonisamide ameliorates symptoms of secondary paroxysmal dystonia.
Choriocarcinoma
Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors.
Choroid Plexus Neoplasms
Immunohistochemical demonstration of human carbonic anhydrase isoenzyme II in brain tumours.
Choroidal Effusions
Determinants of Corneal Endothelial Cell Loss After Trabeculectomy With Mitomycin C.
Choroidal Effusions
Dorzolamide-induced choroidal detachment in a surgically untreated eye.
Choroideremia
TOPICAL DORZOLAMIDE FOR TREATMENT OF CYSTOID MACULAR EDEMA IN PATIENTS WITH CHOROIDEREMIA.
Colitis
Colonic epithelial functional phenotype varies with type and phase of experimental colitis.
Colitis
Epithelial proliferation, cell death, and gene expression in experimental colitis: alterations in carbonic anhydrase I, mucin MUC2, and trefoil factor 3 expression.
Colitis
Oral administration of carbonic anhydrase I ameliorates murine experimental colitis induced by Foxp3-CD4+CD25- T cells.
Colitis
Regulatory Dendritic Cells Pulsed with Carbonic Anhydrase I Protect Mice from Colitis Induced by CD4+CD25- T Cells.
Colitis
Uncoupling of Carbonic Anhydrase from Na-H exchanger-1 in Experimental Colitis: A Possible Mechanistic Link with Na-H Exchanger.
Colitis, Ulcerative
Carbonic anhydrase I reduction in colonic mucosa of patients with active ulcerative colitis.
Colitis, Ulcerative
Elevated serum anti-carbonic anhydrase II antibodies in patients with ulcerative colitis.
Colitis, Ulcerative
In vivo effects of curcumin on the paraoxonase, carbonic anhydrase, glucose-6-phosphate dehydrogenase and ?-glucosidase enzyme activities in dextran sulphate sodium-induced ulcerative colitis mice.
Colitis, Ulcerative
Increased serum anti-carbonic anhydrase II antibodies in patients with Graves' disease.
Colonic Neoplasms
Carbonic anhydrase IV inhibits colon cancer development by inhibiting the Wnt signalling pathway through targeting the WTAP-WT1-TBL1 axis.
Colonic Neoplasms
Carbonic anhydrase-related protein VIII promotes colon cancer cell growth.
Colonic Neoplasms
Development of certain new 2-substituted-quinazolin-4-yl-aminobenzenesulfonamide as potential antitumor agents.
Colonic Neoplasms
Differential proteomics mass spectrometry of melanosis coli.
Colonic Neoplasms
Discovery of New Sulfonamide Carbonic Anhydrase IX Inhibitors Incorporating Nitrogenous Bases.
Colonic Neoplasms
Discovery of novel artemisinin-sulfonamidehybrids as potential carbonicanhydraseIX inhibitors with improved antiproliferative activities.
Colonic Neoplasms
Expression of carbonic anhydrase I or II and correlation to clinical aspects of colorectal cancer.
Colonic Neoplasms
Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer.
Colonic Neoplasms
Genetic disruption of the pHi-regulating proteins Na+/H+ exchanger 1 (SLC9A1) and carbonic anhydrase 9 severely reduces growth of colon cancer cells.
Colonic Neoplasms
Immunohistochemical localization of sodium-potassium-stimulated adenosine triphosphatase and carbonic anhydrase in human colon and colonic neoplasms.
Colonic Neoplasms
PEG Linker Length Strongly Affects Tumor Cell Killing by PEGylated Carbonic Anhydrase Inhibitors in Hypoxic Carcinomas Expressing Carbonic Anhydrase IX.
Colonic Neoplasms
Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
Colonic Neoplasms
Synthesis of coumarin-sulfonamide derivatives and determination of their cytotoxicity, carbonic anhydrase inhibitory and molecular docking studies.
Colonic Neoplasms
Tumor-associated carbonic anhydrase isoform IX and XII inhibitory properties of certain isatin-bearing sulfonamides endowed with in vitro antitumor activity towards colon cancer.
Colorectal Neoplasms
A new approach to the validation of tissue microarrays.
Colorectal Neoplasms
A novel 111Indium-labeled dual carbonic anhydrase 9-targeted probe as a potential SPECT imaging radiotracer for detection of hypoxic colorectal cancer cells.
Colorectal Neoplasms
Binding of the Phage Display Derived Peptide CaIX-P1 on Human Colorectal Carcinoma Cells Correlates with the Expression of Carbonic Anhydrase IX.
Colorectal Neoplasms
Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma.
Colorectal Neoplasms
CA II, a potential biomarker by proteomic analysis, exerts significant inhibitory effect on the growth of colorectal cancer cells.
Colorectal Neoplasms
Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer.
Colorectal Neoplasms
Carbonic anhydrase enzymes II, VII, IX and XII in colorectal carcinomas.
Colorectal Neoplasms
Carbonic anhydrase IV inhibits cell proliferation in gastric cancer by regulating the cell cycle.
Colorectal Neoplasms
Carbonic anhydrase IV inhibits colon cancer development by inhibiting the Wnt signalling pathway through targeting the WTAP-WT1-TBL1 axis.
Colorectal Neoplasms
Carbonic anhydrase IX expression in prostate cancer.
Colorectal Neoplasms
Carbonic anhydrase IX is associated with early pulmonary spreading of primary colorectal carcinoma and tobacco smoking.
Colorectal Neoplasms
Carbonic anhydrase IX is highly expressed in hereditary nonpolyposis colorectal cancer.
Colorectal Neoplasms
Carbonic anhydrase-related protein VIII promotes colon cancer cell growth.
Colorectal Neoplasms
Cloning and chromosome assignment of the human CDX2 gene.
Colorectal Neoplasms
Cyclooxygenase-2/Carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cells.
Colorectal Neoplasms
Development of certain new 2-substituted-quinazolin-4-yl-aminobenzenesulfonamide as potential antitumor agents.
Colorectal Neoplasms
Differential expression of cytoplasmic carbonic anhydrases, CA I and II, and membrane-associated isozymes, CA IX and XII, in normal mucosa of large intestine and in colorectal tumors.
Colorectal Neoplasms
Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2.
Colorectal Neoplasms
Expression and association of carbonic anhydrase IX and cyclooxygenase-2 in colorectal cancer.
Colorectal Neoplasms
Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa.
Colorectal Neoplasms
Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors.
Colorectal Neoplasms
Expression of carbonic anhydrase I or II and correlation to clinical aspects of colorectal cancer.
Colorectal Neoplasms
Fecal protein markers of colorectal cancer.
Colorectal Neoplasms
Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours.
Colorectal Neoplasms
Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer.
Colorectal Neoplasms
Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation.
Colorectal Neoplasms
Impairment of Hypoxia-Induced CA IX by Beta-Blocker Propranolol-Impact on Progression and Metastatic Potential of Colorectal Cancer Cells.
Colorectal Neoplasms
Inhibition of cell proliferation, migration and colony formation of LS174T Cells by carbonic anhydrase inhibitor.
Colorectal Neoplasms
Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: in vivo identification from hypoxic tumor cells.
Colorectal Neoplasms
Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts.
Colorectal Neoplasms
Overexpression of carbonic anhydrase-related protein VIII in human colorectal cancer.
Colorectal Neoplasms
PET Imaging of Carbonic Anhydrase IX Expression of HT-29 Tumor Xenograft Mice with (68)Ga-Labeled Benzenesulfonamides.
Colorectal Neoplasms
Poorer outcome in stromal HIF-2 alpha- and CA9-positive colorectal adenocarcinomas is associated with wild-type TP53 but not with BNIP3 promoter hypermethylation or apoptosis.
Colorectal Neoplasms
Prognostic value of carbonic anhydrase VII expression in colorectal carcinoma.
Colorectal Neoplasms
Radiolabeling of the antibody IgG M75 for epitope of human carbonic anhydrase IX by 61Cu and 64Cu and its biological testing.
Colorectal Neoplasms
Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells.
Colorectal Neoplasms
Sulfonamide derivative targeting carbonic anhydrase IX as a nuclear imaging probe for colorectal cancer detection in vivo.
Colorectal Neoplasms
Synthesis of coumarin-sulfonamide derivatives and determination of their cytotoxicity, carbonic anhydrase inhibitory and molecular docking studies.
Colorectal Neoplasms
The cytotoxic, apoptotic and oxidative effects of carbonic anhydrase IX inhibitor on colorectal cancer cells.
Colorectal Neoplasms
The potential role of fecal carbonic anhydrase II in screening for colorectal cancer.
Colorectal Neoplasms
The significance of carbonic anhydrase expression in human colorectal cancer.
Colorectal Neoplasms
[Proteome study of colorectal cancer genesis and hepatic metastasis]
Colorectal Neoplasms, Hereditary Nonpolyposis
Carbonic anhydrase IX is highly expressed in hereditary nonpolyposis colorectal cancer.
Colorectal Neoplasms, Hereditary Nonpolyposis
Development of certain new 2-substituted-quinazolin-4-yl-aminobenzenesulfonamide as potential antitumor agents.
Cone-Rod Dystrophies
Mutant carbonic anhydrase 4 impairs pH regulation and causes retinal photoreceptor degeneration.
Congenital Abnormalities
Carbonic anhydrase distribution in rodent embryos and its relationship to acetazolamide teratogenesis.
Congenital Hypothyroidism
Carbonic anhydrase content in the brain of rats with thiouracil induced cretinism.
Connective Tissue Diseases
Antibodies to carbonic anhydrase in patients with connective tissue diseases: relationship with lung involvement.
Corneal Diseases
Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study.
Corneal Dystrophies, Hereditary
Use of carbonic anhydrase inhibitor acetazoleamide (diamox) for endothelial corneal dystrophy and diseased corneal grafts.
Corneal Edema
Retinoschisis associated with Kearns-Sayre syndrome.
Corneal Edema
[The role of Brinzolamide 1% ophtalmic suspension in corneal edema]
Corneal Ulcer
Suspected Spontaneous Aqueous Humor Misdirection Syndrome in a Boston Terrier.
Coronavirus Infections
A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection?
Cough
Effect of acetazolamide on cough induced by low-chloride-ion solutions in normal subjects: comparison with furosemide.
COVID-19
Is carbonic anhydrase inhibition useful as a complementary therapy of Covid-19 infection?
Craniopharyngioma
Expression of carbonic anhydrase IX in craniopharyngiomas.
Cryptorchidism
Malondialdehyde and CA II autoantibody levels are elevated in children with undescended testes.
Cystadenocarcinoma, Mucinous
Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours.
Cystadenocarcinoma, Serous
Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours.
Cystadenoma, Mucinous
Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours.
Cystadenoma, Papillary
Papillary cystadenoma of the epididymis and broad ligament: morphologic and immunohistochemical overlap with clear cell papillary renal cell carcinoma.
Cystic Fibrosis
Altered expression of Na(+)/K(+)-ATPase and other osmoregulatory genes in the gills of euryhaline animals in response to salinity transfer: A meta-analysis of 59 quantitative PCR studies over 10years.
Cystic Fibrosis
cAMP stimulation of HCO3- secretion across airway epithelia.
Cystic Fibrosis
Cigarette smoke-induced differential expression of the genes involved in exocrine function of the rat pancreas.
Cystic Fibrosis
Expression of carbonic anhydrase, cystic fibrosis transmembrane regulator (CFTR) and V-H(+)-ATPase in the lancelet Branchiostoma lanceolatum (Pallas, 1774).
Cystic Fibrosis
Expression of ion transport-associated proteins in human efferent and epididymal ducts.
Cystic Fibrosis
Expressional Changes of Water Transport-related Molecules in the Efferent Ductules and Initial Segment of Mouse Treated with Bisphenol A-Containing Drinking Water for Two Generations.
Cystic Fibrosis
Immortalization of bovine pancreatic duct epithelial cells.
Cystic Fibrosis
Immortalized bovine pancreatic duct cells become tumorigenic after transfection with mutant k-ras.
Cystic Fibrosis
Immunohistochemical analysis of the distribution of molecules involved in ionic and pH regulation in the lancelet Branchiostoma floridae (Hubbs, 1922).
Cystic Fibrosis
Immunohistochemical and electron microscopic characterization of brush cells of the rat cecum.
Cystic Fibrosis
Immunohistochemical localization of carbonic anhydrase I and II in eccrine sweat glands from control subjects and patients with cystic fibrosis.
Cystic Fibrosis
Immunolocalization of ion-transport proteins to branchial epithelium mitochondria-rich cells in the mudskipper (Periophthalmodon schlosseri).
Cystic Fibrosis
Implication of sulfonylurea derivatives as prospective inhibitors of human carbonic anhydrase II.
Cystic Fibrosis
In vitro validation of duct differentiation in developing embryonic mouse pancreas.
Cystic Fibrosis
In-vivo functional study on the involvement of CFTR, SLC26A6, NHE-1 and CA isoenzymes II and XII in uterine fluid pH, volume and electrolyte regulation in rats under different sex-steroid influence.
Cystic Fibrosis
Molecular Basis and Differentiation-Associated Alterations of Anion Secretion in Human Duodenal Enteroid Monolayers.
Cystic Fibrosis
Mouse pancreatic acinar/ductular tissue gives rise to epithelial cultures that are morphologically, biochemically, and functionally indistinguishable from interlobular duct cell cultures.
Cystic Fibrosis
New pancreas cancers cell lines that represent distinct stages of ductal differentiation.
Cystic Fibrosis
Physiological and molecular mechanisms of osmoregulatory plasticity in killifish after seawater transfer.
Cystic Fibrosis
Putative interaction of brush cells with bicarbonate secreting cells in the proximal corpus mucosa.
Cystic Fibrosis
Rapid screening of genetic polymorphisms using buccal cell DNA with detection by matrix-assisted laser desorption/ionization mass spectrometry.
Cystic Fibrosis
Regulatory mechanism underlying cyclic changes in mouse uterine bicarbonate secretion: role of estrogen.
Cystic Fibrosis
Tandem mass tag-based quantitative proteomic analysis of the liver reveals potential protein targets of Xiaochaihutang in CUMS model of depression.
Cysts
CA9 level in renal cyst fluid: a possible molecular diagnosis of malignant tumours.
Cysts
Cytopathologic features of clear cell papillary renal cell carcinoma: A recently described variant to be considered in the differential diagnosis of clear cell renal epithelial neoplasms.
Cysts
Expression of carbonic anhydrase IX in craniopharyngiomas.
Cysts
Iron regulatory protein 2 in ovarian endometrial cysts.
Cysts
Kidney intercalated cells and the transcription factor FOXi1 drive cystogenesis in tuberous sclerosis complex.
Cysts
Macular cysts in retinal dystrophy.
Cysts
Ophthalmic manifestations of Heimler syndrome due to PEX6 mutations.
Cysts
Pathologic spectrum of cysts in end-stage kidneys: possible precursors to renal neoplasia.
Cysts
Polycystic disease of the kidney. Evaluation and classification based on nephron segment and cell-type specific markers.
Cysts
Regression of macular edema with topical brinzolamide and nepafenac alone and identification of a novel gyrate atrophy mutation.
Cysts
Renal carbonic anhydrase activity in DBA/2FG-pcy/pcy mice with inherited polycystic kidney disease.
Cysts
Synchronous primary carcinoid tumor and primary adenocarcinoma arising within mature cystic teratoma of horseshoe kidney: a unique case report and review of the literature.
Cysts
The Acetazolamide Challenge: A Tool for Surgical Decision Making and Predicting Surgical Outcome in Patients with Arachnoid Cysts.
Cysts
The Prevalence of Macular Cysts in Patients with Clinical Cone-Rod Dystrophy Determined by Spectral-Domain Optical Coherence Tomography.
Cysts
THE USE OF CARBONIC ANHYDRASE INHIBITORS IN THE RETREATMENT OF CYSTIC MACULAR LESIONS IN RETINITIS PIGMENTOSA AND X-LINKED RETINOSCHISIS.
Cysts
Topical dorzolamide treatment of macular cysts in the enhanced S-cone syndrome patient.
Cysts
USE OF A CARBONIC ANHYDRASE INHIBITOR IN X-LINKED RETINOSCHISIS: Effect on Cystic-Appearing Macular Lesions and Visual Acuity.
Cysts
VHL-gene Deletion in Single Renal Tubular Epithelial Cells and Renal Tubular Cysts: Further Evidence for a Cyst-dependent Progression Pathway of Clear Cell Renal Carcinoma in von Hippel-Lindau Disease.
Cysts
X-linked juvenile retinoschisis in females and response to carbonic anhydrase inhibitors: case report and review of the literature.
Dandruff
A new procedure for the cloning, expression and purification of the ?-carbonic anhydrase from the pathogenic yeast Malassezia globosa, an anti-dandruff drug target.
Dandruff
Anion Inhibition Profile of the ?-Carbonic Anhydrase from the Opportunist Pathogenic Fungus Malassezia Restricta Involved in Dandruff and Seborrheic Dermatitis.
Dandruff
Anion inhibition studies of the dandruff-producing fungus Malassezia globosa ?-carbonic anhydrase MgCA.
Dandruff
Carbonic anhydrase activators: Activation of the ?-carbonic anhydrase from Malassezia globosa with amines and amino acids.
Dandruff
Cloning, Purification, and Characterization of a ?-Carbonic Anhydrase from Malassezia restricta, an Opportunistic Pathogen Involved in Dandruff and Seborrheic Dermatitis.
Dandruff
Phenols from Origanum dictamnus L. and Thymus vulgaris L. and their activity against Malassezia globosa carbonic anhydrase.
Deafness
New insights into the pathogenesis of renal tubular acidosis--from functional to molecular studies.
Deficiency Diseases
Induction of carbonic anhydrase in SaOS-2 cells, exposed to bicarbonate and consequences for calcium phosphate crystal formation.
Dehydration
13C saturation transfer effect of carbon dioxide-bicarbonate exchange catalyzed by carbonic anhydrase in vivo.
Dehydration
Acetazolamide inhibits the recovery from triethyl tin intoxication: putative role of carbonic anhydrase in dehydration of central myelin.
Dehydration
Activation of mammalian skeletal-muscle carbonic anhydrase III by arginine modification.
Dehydration
Active CO(2) Transport by the Green Alga Chlamydomonas reinhardtii.
Dehydration
Apparent diffusion limitations for CO(2) excretion in rainbow trout are relieved by injections of carbonic anhydrase.
Dehydration
Ascorbic Acid Induces the Increase of Secondary Metabolites, Antioxidant Activity, Growth, and Productivity of the Common Bean under Water Stress Conditions.
Dehydration
Bicarbonate uptake via an anion exchange protein is the main mechanism of inorganic carbon acquisition by the giant kelp Macrocystis pyrifera (Laminariales, Phaeophyceae) under variable pH
Dehydration
Bicarbonate uptake via an anion exchange protein is the main mechanism of inorganic carbon acquisition by the giant kelp Macrocystis pyrifera (Laminariales, Phaeophyceae) under variable pH.
Dehydration
Bromine catalysis for carbon dioxide hydration and dehydration and some observations concerning the mechanism of carbonic anhydrase.
Dehydration
Buffer enhancement of proton transfer in catalysis by human carbonic anhydrase III.
Dehydration
Buffering limits plasma HCO3- dehydration when red blood cell anion exchange is inhibited.
Dehydration
Bulky guanidinato and amidinato zinc complexes and their comparative stabilities.
Dehydration
Carbon isotope effect on dehydration of bicarbonate ion catalyzed by carbonic anhydrase.
Dehydration
Carbon-concentrating mechanism in a green alga, Chlamydomonas reinhardtii, revealed by transcriptome analyses.
Dehydration
Carbonic anhydrase activity in intact red blood cells measured with 18O exchange.
Dehydration
Carbonic anhydrase II and IV mRNA in rabbit nephron segments: stimulation during metabolic acidosis.
Dehydration
Carbonic anhydrase inhibitor in trout plasma.
Dehydration
CARBONIC ANHYDRASE INJECTION PROVIDES EVIDENCE FOR THE ROLE OF BLOOD ACID-BASE STATUS IN STIMULATING VENTILATION AFTER EXHAUSTIVE EXERCISE IN RAINBOW TROUT
Dehydration
Carbonic anhydrase IV is expressed in H(+)-secreting cells of rabbit kidney.
Dehydration
Carboxysomal carbonic anhydrases: Structure and role in microbial CO(2) fixation.
Dehydration
Catalysis and inhibition of human carbonic anhydrase IV.
Dehydration
Catalytic Mechanism of ?-Class Carbonic Anhydrases: CO2 Hydration and Proton Transfer.
Dehydration
Characterization of the carboxysomal carbonic anhydrase CsoSCA from Halothiobacillus neapolitanus.
Dehydration
Chemical rescue of proton transfer in catalysis by carbonic anhydrases in the beta- and gamma-class.
Dehydration
CO2 exchange characteristics during dark-light transitions in wild-type and mutant Chlamydomonas reinhardii cells.
Dehydration
Colonic microbiota alters host susceptibility to infectious colitis by modulating inflammation, redox status and ion transporter gene expression.
Dehydration
Differential modification of specificity in carbonic anhydrase catalysis.
Dehydration
Discovery and microassay of a nitrite-dependent carbonic anhydrase activity by stable-isotope dilution gas chromatography-mass spectrometry.
Dehydration
Disequilibrium pH and ammonia transport in isolated perfused cortical collecting ducts.
Dehydration
Effect of CO2-induced seawater acidification on growth, photosynthesis and inorganic carbon acquisition of the harmful bloom-forming marine microalga, Karenia mikimotoi.
Dehydration
Exertional rhabdomyolysis in carbonic anhydrase 12 deficiency.
Dehydration
Extracellular carbonic anhydrase and an acid-base disequilibrium in the blood of the dogfish Squalus acanthias
Dehydration
Flow-through sol-gel optical biosensor for the colorimetric determination of acetazolamide.
Dehydration
Gas transfer in dogfish: a unique model of CO2 excretion.
Dehydration
H 2 CO 3 as substrate for carbonic anhydrase in the dehydration of HCO 3 .
Dehydration
Hagfish (Myxine glutinosa) red cell membrane exhibits no bicarbonate permeability as detected by (18)O exchange.
Dehydration
HCO3- absorption in rabbit outer medullary collecting duct: role of luminal carbonic anhydrase.
Dehydration
Hydrogen Sulfide-Mediated Activation of O-Acetylserine (Thiol) Lyase and l/d-Cysteine Desulfhydrase Enhance Dehydration Tolerance in Eruca sativa Mill.
Dehydration
Identification and characterization of a carboxysomal ?-carbonic anhydrase from the cyanobacterium Nostoc sp. PCC 7120.
Dehydration
Immobilized carbonic anhydrase: preparation, characteristics and biotechnological applications.
Dehydration
Inactivation and adsorption of human carbonic anhydrase II by nanoparticles.
Dehydration
Influence of carbon dioxide kinetics on pulmonary carbon dioxide exchange.
Dehydration
Inhibition of Carbonic Anhydrase by Anions in the Carbon Dioxide-Bicarbonate System.
Dehydration
Inhibitory effects of nitrite on the reactions of bovine carbonic anhydrase II with CO2 and bicarbonate consistent with zinc-bound nitrite.
Dehydration
Isotope and pH effects on the dehydration of acetaldehyde hydrate by carbonic anhydrase.
Dehydration
Kinetic and crystallographic studies of the role of tyrosine 7 in the active site of human carbonic anhydrase II.
Dehydration
Kinetics of carbonic anhydrase catalysis in solvents of increased viscosity: a partially diffusion-controlled reaction.
Dehydration
Kinetics of inhibition by acetazolamide and sulfanilamide of bicarbonate dehydration catalyzed by bovine carbonic anhydrase.
Dehydration
Localization of carbonic anhydrase on pulmonary artery endothelial cells in culture.
Dehydration
Maturation of carbonic anhydrase IV expression in rabbit kidney.
Dehydration
Membrane Associated Carbonic Anhydrase IV (CA IV): A Personal and Historical Perspective.
Dehydration
Microalgal bacterial flocs treating paper mill effluent: A sunlight-based approach for removing carbon, nitrogen, phosphorus, and calcium.
Dehydration
Microalgal carbon-dioxide-concentrating mechanisms: Chlamydomonas inorganic carbon transporters.
Dehydration
Microsensor studies on Padina from a natural CO2 seep: implications of morphology on acclimation to low pH
Dehydration
Microsensor studies on Padina from a natural CO2 seep: implications of morphology on acclimation to low pH.
Dehydration
Modification of carbonic anhydrase activity by antisense and over-expression constructs in transgenic tobacco.
Dehydration
Molecular basis of ionic strength effects: interaction of enzyme and sulfate ion in CO2 hydration and HCO3- dehydration reactions catalyzed by carbonic anhydrase II.
Dehydration
Na+-H+ exchange and pH regulation in red blood cells: role of uncatalyzed H2CO3 dehydration.
Dehydration
Natural protein engineering: a uniquely salt-tolerant, but not halophilic, alpha-type carbonic anhydrase from algae proliferating in low- to hyper-saline environments.
Dehydration
On the lack of specificity of the cobalt-bicarbonate method for carbonic anhydrase.
Dehydration
Origin of viscosity effects in carbonic anhydrase catalysis. Kinetic studies with bulky buffers at limiting concentrations.
Dehydration
Origins of enhanced proton transport in the Y7F mutant of human carbonic anhydrase II.
Dehydration
PGE2 stimulates gastric chloride transport: possible key to cytoprotection.
Dehydration
Photosynthetic carbon acquisition in Sargassum henslowianum (Fucales, Phaeophyta), with special reference to the comparison between the vegetative and reproductive tissues.
Dehydration
Photosynthetic use of inorganic carbon in deep-water kelps from the Strait of Gibraltar.
Dehydration
Physiology and molecular biology of renal carbonic anhydrase.
Dehydration
Plant carbonic anhydrase. Properties and bicarbonate dehydration kinetics.
Dehydration
Possible CO2 concentrating mechanism in chloroplasts of C3 plants. Role of carbonic anhydrase.
Dehydration
Postnatal development of carbonic anhydrase IV expression in rabbit kidney.
Dehydration
Potential role for microbial ureolysis in the rapid formation of carbonate tufa mounds.
Dehydration
Potential role of endothelial carbonic anhydrase in dehydration of plasma bicarbonate.
Dehydration
Preferred orientations of His64 in human carbonic anhydrase II.
Dehydration
Production and X-ray crystallographic analysis of fully deuterated human carbonic anhydrase II.
Dehydration
Proton transfer in a Thr200His mutant of human carbonic anhydrase II.
Dehydration
Pyropia yezoensis genome reveals diverse mechanisms of carbon acquisition in the intertidal environment.
Dehydration
Rate of CO2 diffusion in the human red blood cell measured with pH-sensitive fluorescence.
Dehydration
Rate-equilibria relationships in intramolecular proton transfer in human carbonic anhydrase III.
Dehydration
Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors.
Dehydration
Regulation of photosynthesis and stomatal and mesophyll conductance under water stress and recovery in olive trees: correlation with gene expression of carbonic anhydrase and aquaporins.
Dehydration
Relationship of urinary and blood carbon dioxide tension during hypercapnia in the rat. Its significance in the evaluation of collecting duct hydrogen ion secretion.
Dehydration
Role of anions and carbonic anhydrase in epithelia.
Dehydration
Role of C4 carbon fixation in Ulva prolifera, the macroalga responsible for the world's largest green tides.
Dehydration
Speeding up proton transfer in a fast enzyme: kinetic and crystallographic studies on the effect of hydrophobic amino acid substitutions in the active site of human carbonic anhydrase II.
Dehydration
Structural and kinetic characterization of active-site histidine as a proton shuttle in catalysis by human carbonic anhydrase II.
Dehydration
Symbiosis-dependent gene expression in coral-dinoflagellate association: cloning and characterization of a P-type H+-ATPase gene.
Dehydration
Taste buds and nerve fibers in the rat larynx: an ultrastructural and immunohistochemical study.
Dehydration
The effects of exogenous extracellular carbonic anhydrase on CO2 excretion in rainbow trout (Oncorhynchus mykiss): role of plasma buffering capacity.
Dehydration
Thermodynamics of carbonic anhydrase catalysis. A comparison between human isoenzymes B and C.
Dehydration
Thylakoid lumen carbonic anhydrase (CAH3) mutation suppresses air-Dier phenotype of LCIB mutant in Chlamydomonas reinhardtii.
Dehydration
Type IV carbonic anhydrase is present in the gills of spiny dogfish (Squalus acanthias).
Dehydration
Ultrastructural localization of carbonic anhydrase in gastric parietal cells with the immunoglobulin-enzyme bridge method.
Dementia
Carbonic anhydrase II in the cerebrospinal fluid: its value as a disease marker.
Demyelinating Diseases
A single-step solid phase radioimmunoassay for quantifying human carbonic anhydrase I and II in cerebrospinal fluid.
Demyelinating Diseases
Atypical localization of the oligodendrocytic isoform (PI) of glutathione-S-transferase in astrocytes during cuprizone intoxication.
Demyelinating Diseases
Carbonic anhydrase and 2',3' cyclic nucleotide 3'-phosphohydrolase activity in normal human brain and in demyelinating diseases.
Demyelinating Diseases
Changes in glial cell markers in recent and old demyelinated lesions in central pontine myelinolysis.
Demyelinating Diseases
Class switching of carbonic anhydrase isoforms mediates remyelination in CA3 hippocampal neurons during chronic hypoxia.
Demyelinating Diseases
Decrease in oligodendrocyte carbonic anhydrase activity preceding myelin degeneration in cuprizone induced demyelination.
Demyelinating Diseases
Expression of carbonic anhydrase II mRNA and protein in oligodendrocytes during toxic demyelination in the young adult mouse.
Demyelinating Diseases
Perineuronal oligodendrocytes protect against neuronal apoptosis through the production of lipocalin-type prostaglandin D synthase in a genetic demyelinating model.
Dent Disease
A novel renal carbonic anhydrase type III plays a role in proximal tubule dysfunction.
Dental Calculus
Effect of Genetic Polymorphisms in CA6 Gene on the Expression and Catalytic Activity of Human Salivary Carbonic Anhydrase VI.
Dental Caries
Children with a Higher Activity of Carbonic Anhydrase VI in Saliva Are More Likely to Develop Dental Caries.
Dental Caries
Cloning, characterization and anion inhibition study of a ?-class carbonic anhydrase from the caries producing pathogen Streptococcus mutans.
Dental Caries
Effects of the carbonic anhydrase VI gene polymorphisms on dental caries: A meta-analysis.
Dental Caries
Engineered Carbonic Anhydrase VI-Mimic Enzyme Switched the Structure and Affinities of Inhibitors.
Dental Caries
Genetic polymorphisms in the carbonic anhydrase VI gene and dental caries susceptibility.
Dental Caries
Polymorphism in the CAVI gene, salivary properties and dental caries.
Dental Caries
Salivary protein polymorphisms and risk of dental caries: a systematic review.
Dental Caries
Sulfonamide inhibition study of the ?-class carbonic anhydrase from the caries producing pathogen Streptococcus mutans.
Dental Caries
[Carbonic anhydrase activity in human saliva and dental caries]
Dental Plaque
A role of salivary carbonic anhydrase VI in dental plaque.
Dental Plaque
Association of polymorphisms in the carbonic anhydrase 6 gene with salivary buffer capacity, dental plaque pH, and caries index in children aged 7-9 years.
Dentigerous Cyst
Immunohistochemical expression of GLUT-1, GLUT-3, and carbonic anhydrase IX in benign odontogenic lesions.
Dermatitis, Atopic
Importance of tryptophan nitration of carbonic anhydrase III for the morbidity of atopic dermatitis.
Dermatitis, Atopic
Increased expression of carbonic anhydrase II (CA II) in lesional skin of atopic dermatitis: regulation by Th2 cytokines.
Dermatitis, Atopic
Toll-like Receptor 3 Agonist, Polyinosinic-polycytidylic Acid, Upregulates Carbonic Anhydrase II in Human Keratinocytes.
Dermatitis, Seborrheic
Anion Inhibition Profile of the ?-Carbonic Anhydrase from the Opportunist Pathogenic Fungus Malassezia Restricta Involved in Dandruff and Seborrheic Dermatitis.
Dermatitis, Seborrheic
Cloning, Purification, and Characterization of a ?-Carbonic Anhydrase from Malassezia restricta, an Opportunistic Pathogen Involved in Dandruff and Seborrheic Dermatitis.
Dermatomyositis
A study of anti-carbonic anhydrase II antibodies in rheumatic autoimmune diseases.
Dermatomyositis
The role of carbonic anhydrase in the pathogenesis of vascular calcification in humans.
Diabetes Mellitus
Acetazolamide-insensitive carbonic anhydrase activities in liver and tonic skeletal muscle of adult male rats with streptozotocin-induced diabetes mellitus.
Diabetes Mellitus
Cholinesterases, ?-glycosidase, and carbonic anhydrase inhibition properties of 1H-pyrazolo[1,2-b]phthalazine-5,10-dione derivatives: Synthetic analogues for the treatment of Alzheimer's disease and diabetes mellitus.
Diabetes Mellitus
Decreased total carbonic anhydrase esterase activity and decreased levels of carbonic anhydrase 1 isozyme in erythrocytes of type II diabetic patients.
Diabetes Mellitus
Determination of carbonic anhydrase-III by enzyme-immunoassay in liver, muscle and serum of male rats with streptozotocin-induced diabetes mellitus.
Diabetes Mellitus
Erythrocyte carbonic anhydrase activity in smokers and in diabetic patients.
Diabetes Mellitus
Erythrocyte carbonic anhydrase: a major intracellular enzyme to regulate cellular sodium metabolism in chronic renal failure patients with diabetes and hypertension.
Diabetes Mellitus
Estimation and characterization of glycosylated carbonic anhydrase I in erythrocytes from patients with diabetes mellitus.
Diabetes Mellitus
No effects of atorvastatin (10mg/d or 80mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study.
Diabetes Mellitus
Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study.
Diabetes Mellitus
Study on the changes of carbonic anhydrase activity in insulin resistance and the effect of methylglyoxal.
Diabetes Mellitus
Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and ?-glycosidase inhibitors.
Diabetes Mellitus
The L-arginine/NO pathway, homoarginine, and nitrite-dependent renal carbonic anhydrase activity in young people with type 1 diabetes mellitus.
Diabetes Mellitus
The Role of Carbonic Anhydrase in Hepatic Glucose Production.
Diabetes Mellitus
[Changes in carbohydrate metabolism in diabetes mellitus under treatment with the carbonic anhydrase inhibitor 6063; preliminary report.]
Diabetes Mellitus, Experimental
Determination of carbonic anhydrase-III by enzyme-immunoassay in liver, muscle and serum of male rats with streptozotocin-induced diabetes mellitus.
Diabetes Mellitus, Type 1
High prevalence of autoantibodies against carbonic anhydrase II and lactoferrin in type 1 diabetes: concept of autoimmune exocrinopathy and endocrinopathy of the pancreas.
Diabetes Mellitus, Type 1
Increased serum anti-carbonic anhydrase II antibodies in patients with Graves' disease.
Diabetes Mellitus, Type 1
Prevalence of autoantibodies to carbonic anhydrase II and lactoferrin in patients with type 1 diabetes.
Diabetes Mellitus, Type 1
Regional cerebral blood flow and cerebrovascular reactivity in IDDM.
Diabetes Mellitus, Type 1
The L-arginine/NO pathway, homoarginine, and nitrite-dependent renal carbonic anhydrase activity in young people with type 1 diabetes mellitus.
Diabetes Mellitus, Type 1
The Relationship between Serum Carbonic Anhydrase I-II Autoantibody Levels and Diabetic Retinopathy in Type 1 Diabetes Patients.
Diabetes Mellitus, Type 2
Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ?50 kg/m2 Prior to Bariatric Surgery.
Diabetes Mellitus, Type 2
No effects of atorvastatin (10mg/d or 80mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study.
Diabetes Mellitus, Type 2
Oxygen-18 isotope of breath CO2 linking to carbonic anhydrase activity: A biomarker for type 2 diabetes.
Diabetes Mellitus, Type 2
Oxygen-18 isotope of breath CO2 linking to erythrocytes carbonic anhydrase activity: a biomarker for pre-diabetes and type 2 diabetes.
Diabetes Mellitus, Type 2
Targeting erythrocyte carbonic anhydrase and (18)O-isotope of breath CO2 for sorting out type 1 and type 2 diabetes.
Diabetes Mellitus, Type 2
The Role of Carbonic Anhydrase in Hepatic Glucose Production.
Diabetic Cardiomyopathies
Carbonic anhydrase activation is associated with worsened pathological remodeling in human ischemic diabetic cardiomyopathy.
Diabetic Nephropathies
Effect of carbonic anhydrase inhibitors on glomerular filtration rate in diabetic nephropathy.
Diabetic Retinopathy
Diabetic retinopathy is not associated with carbonic anhydrase gene polymorphisms.
Diabetic Retinopathy
Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation.
Diabetic Retinopathy
Inhibition of Apoptosis and Reduction of Intracellular pH Decrease in Retinal Neural Cell Cultures by a Blocker of Carbonic Anhydrase.
Diabetic Retinopathy
Müller's cell involvement in proliferative diabetic retinopathy.
Diabetic Retinopathy
Optic nerve oxygenation.
Diabetic Retinopathy
Proteomics as a research tool in clinical and experimental ophthalmology.
Diabetic Retinopathy
Targeting carbonic anhydrase to treat diabetic retinopathy: emerging evidences and encouraging results.
Diabetic Retinopathy
The Relationship between Serum Carbonic Anhydrase I-II Autoantibody Levels and Diabetic Retinopathy in Type 1 Diabetes Patients.
Diabetic Retinopathy
Utilization of the common functional groups in bioactive molecules: Exploring dual inhibitory potential and computational analysis of keto esters against ?-glucosidase and carbonic anhydrase-II enzymes.
Diabetic Retinopathy
Vascular endothelial growth factor gene polymorphisms and vitreous proteome changes in diabetic retinopathy.
Diphtheria
Naturally-occurring anti-thymocyte autoantibody which identifies a restricted CD4+CD8+CD3-/lo/int thymocyte subpopulation exhibits extensive polyspecificity.
Disseminated Intravascular Coagulation
Consumption of heparin cofactor II (dermatan sulfate cofactor) and antithrombin during coagulation.
Disseminated Intravascular Coagulation
Heparin cofactor II in adults and infants with thrombosis and DIC.
Disseminated Intravascular Coagulation
Preferential consumption of heparin cofactor II in disseminated intravascular coagulation associated with acute promyelocytic leukemia.
Down Syndrome
Increased levels of carbonic anhydrase II in the developing Down syndrome brain.
Down Syndrome
Plasma carbonic anhydrase II protein is elevated in Alzheimer's disease.
Down Syndrome
The levels of superoxide dismutase, catalase, and carbonic anhydrase in erythrocytes of patients with Down's syndrome.
Drug Resistant Epilepsy
Urolithiasis on the ketogenic diet with concurrent topiramate or zonisamide therapy.
Drug-Related Side Effects and Adverse Reactions
Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years.
Dry Eye Syndromes
A Divalent PAMAM-Based Matrix Metalloproteinase/Carbonic Anhydrase Inhibitor for the Treatment of Dry Eye Syndrome.
Dry Eye Syndromes
Association between Glaucoma Medication Usage and Dry Eye in Taiwan.
Dry Eye Syndromes
Clinical Correlations of Novel Autoantibodies in Patients with Dry Eye.
Dry Eye Syndromes
Prevalence of Novel Candidate Sjogren Syndrome Autoantibodies in the Dry Eye Assessment and Management (DREAM) Study.
Dry Eye Syndromes
Utility of Novel Autoantibodies in the Diagnosis of Sjögren's Syndrome Among Patients With Dry Eye.
Duodenal Ulcer
"Ulcosilvanil"--an inhibitor of carbonic anhydrase--associated with adrenergic beta-blockers in the treatment of duodenal ulcers.
Duodenal Ulcer
Anti-inflammatory and carbonic anhydrase restoring actions of yam powder (Dioscorea spp) contribute to the prevention of cysteamine-induced duodenal ulcer in a rat model.
Duodenal Ulcer
Effect of ZnSO4 upon gastric acid secretion and carbonic anhydrase.
Duodenal Ulcer
Effects of the synthetic PGE1 derivative misoprostol on basal, stimulated and nocturnal acid secretion in duodenal ulcer cases. Mechanism of action.
Duodenal Ulcer
In vitro inhibition of ?-carbonic anhydrase isozymes by some phenolic compounds.
Duodenal Ulcer
NO-releasing esters show carbonic anhydrase inhibitory action against human isoforms I and II.
Duodenal Ulcer
Red cell carbonic anhydrase activity in duodenal ulcer.
Duodenal Ulcer
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols and their derivatives including natural products: Vidalol B.
Duodenal Ulcer
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols including natural products.
Duodenal Ulcer
Synthesis and carbonic anhydrase inhibitory properties of novel cyclohexanonyl bromophenol derivatives.
Duodenal Ulcer
Synthesis and characterization of novel substituted thiophene derivatives and discovery of their carbonic anhydrase and acetylcholinesterase inhibition effects.
Duodenal Ulcer
Treatment of duodenal ulcers with ethoxzolamide, an inhibitor of gastric mucosa carbonic anhydrase.
Duodenal Ulcer
[Carbonic anhydrase inhibitors in the treatment of gastric and duodenal ulcers (author's transl)]
Duodenal Ulcer
[Treatment of duodenal ulcer with carbonic anhydrase inhibitors in combination with adrenergic beta blockaders]
Duodenogastric Reflux
Effect of bile salts on carbonic anhydrase from rat and human gastric mucosa.
Dysgeusia
Acetazolamide promotes decreased consumption of carbonated drinks and weight loss.
Dysgeusia
Efficacy of exogenous oral zinc in treatment of patients with carbonic anhydrase VI deficiency.
Dysgeusia
Recovery of a patient with a recurrent dysgeusia monitored by salivary variables and serum zinc content.
Dyspnea
Activity of carbon anhydrase in the blood; study of patients with dyspnea consequent to chronic cardiac and pulmonary disease.
Eczema
Molecular Diagnostics of Psoriasis, Atopic Dermatitis, Allergic Contact Dermatitis and Irritant Contact Dermatitis.
Eczema
[Activity of carbonic anhydrase in the blood and skin of patients with disseminated forms of eczema.]
Edema, Cardiac
[Diamox, a carbonic anhydrase inhibitor, in therapy of cardiac edema.]
Encephalomyelitis, Autoimmune, Experimental
Gliosis in the spinal cords of rats with experimental allergic encephalomyelitis: immunostaining of carbonic anhydrase and vimentin in reactive astrocytes.
Endemic Diseases
Sulfonamide inhibition profile of the ?-carbonic anhydrase identified in the genome of the pathogenic bacterium Burkholderia pseudomallei the etiological agent responsible of melioidosis.
Endocarditis
[Blood carbonic anhydrase and certain blood and urinary indicators in infective and rheumatic endocarditis.]
Endocarditis, Bacterial
[Clinical importance of determining the blood carbonic anhydrase activity in congenital heart defects complicated by bacterial endocarditis]
Endodermal Sinus Tumor
Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors.
Endolymphatic Hydrops
Activities of carbonic anhydrase in the cochleae of guinea pigs with early experimental endolymphatic hydrops.
Endolymphatic Hydrops
Changes in immunostaining of cochleas with experimentally induced endolymphatic hydrops.
Endolymphatic Hydrops
[Effect of furosemide on the carbonic anhydrase activity in vestibule]
Endometrial Neoplasms
Comparative assessment of lymph node micrometastasis in cervical, endometrial and vulvar cancer: insights on the real time qRT-PCR approach versus immunohistochemistry, employing dual molecular markers.
Endometrial Neoplasms
Correlation between Expression of Biological Markers and [F]Fluorodeoxyglucose Uptake in Endometrial Cancer.
Endometrial Neoplasms
Hypoxia contributes to development of recurrent endometrial carcinoma.
Endometrial Neoplasms
The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators.
Endometrial Neoplasms
The role of Hypoxia-inducible factor-1 ? , glucose transporter-1, (GLUT-1) and carbon anhydrase IX in endometrial cancer patients.
Endometriosis
Antibodies to carbonic anhydrase in endometriosis: prevalence, specificity, and relationship to clinical and laboratory parameters.
Endometriosis
Autoantibody responses to carbohydrate epitopes in endometriosis.
Endometriosis
Carbonic anhydrase antibody in sera from patients with endometriosis.
Endometriosis
CD44, TGM2 and EpCAM as novel plasma markers in endometrial cancer diagnosis.
Endometriosis
Dapsone hydroxylamine-mediated alterations in human red blood cells from endometriotic patients.
Endometriosis
Endometriosis: identification by carbonic anhydrase autoantibodies and clinical features.
Endometriosis
Increased oxidation-related glutathionylation and carbonic anhydrase activity in endometriosis.
Enteritis
Bacteria grown on natural gas prevent soybean meal-induced enteritis in Atlantic salmon.
Eosinophilia
Autoimmune pancreatitis as a new clinical entity. Three cases of autoimmune pancreatitis with effective steroid therapy.
Ependymoma
Primary glial tumor of the retina with features of myxopapillary ependymoma.
Ependymoma
Prognostic marker analysis in pediatric intracranial ependymomas.
Epilepsies, Partial
Carbonic anhydrase inhibitor sulthiame reduces intracellular pH and epileptiform activity of hippocampal CA3 neurons.
Epilepsies, Partial
Zonisamide: new drug. No advantage in refractory partial epilepsy.
Epilepsy
13C saturation transfer effect of carbon dioxide-bicarbonate exchange catalyzed by carbonic anhydrase in vivo.
Epilepsy
Acetazolamide in bipolar affective disorders.
Epilepsy
Acetazolamide in the treatment of seizures.
Epilepsy
An efficient method for the synthesis of novel derivatives 4-{5-[4-(4-amino-5-mercapto-4H-[1,2,4]triazol-3-yl)-phenyl]-3-trifluoromethyl-pyrazol-1-yl}-benzenesulfonamide and their anti-inflammatory potential.
Epilepsy
Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review.
Epilepsy
Aplastic anemia and agranulocytosis in patients using methazolamide for glaucoma.
Epilepsy
Carbonic anhydrase activators: activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines.
Epilepsy
Carbonic anhydrase enzymes: Likely targets for inhalational anesthetics.
Epilepsy
Carbonic anhydrase II in the cerebrospinal fluid: its value as a disease marker.
Epilepsy
Carbonic anhydrase inhibitors as anticonvulsant agents.
Epilepsy
Design and synthesis of novel 1,3-diaryltriazene-substituted sulfonamides as potent and selective carbonic anhydrase II inhibitors.
Epilepsy
Design, synthesis and biological evaluation of novel ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as potent carbonic anhydrase IX inhibitors.
Epilepsy
Determination of acetazolamide in human serum by enzymatic assay.
Epilepsy
Developments of small molecules as inhibitors for carbonic anhydrase isoforms.
Epilepsy
Diamox; a carbonic anhydrase inhibitor; its use in epilepsy.
Epilepsy
Discovery of new 2, 5-disubstituted 1,3-selenazoles as selective human carbonic anhydrase IX inhibitors with potent anti-tumor activity.
Epilepsy
Estimations of active and inactive carbonic anhydrase isozyme B in human red cells.
Epilepsy
Evaluating off-label uses of acetazolamide.
Epilepsy
Evaluation of selenide, diselenide and selenoheterocycle derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
Epilepsy
Exploring structure-activity relationship of S-substituted 2-mercaptoquinazolin-4(3H)-one including 4-ethylbenzenesulfonamides as human carbonic anhydrase inhibitors.
Epilepsy
First evaluation of organotellurium derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
Epilepsy
Heterocyclic compounds as carbonic anhydrase inhibitor.
Epilepsy
Implication of sulfonylurea derivatives as prospective inhibitors of human carbonic anhydrase II.
Epilepsy
Inhibition of carbonic anhydrase isoforms I, II, IV, VII and XII with carboxylates and sulfonamides incorporating phthalimide/phthalic anhydride scaffolds.
Epilepsy
Intrinsic Thermodynamics and Structure Correlation of Benzenesulfonamides with a Pyrimidine Moiety Binding to Carbonic Anhydrases I, II, VII, XII, and XIII.
Epilepsy
Intrinsic thermodynamics of sulfonamide inhibitor binding to human carbonic anhydrases I and II.
Epilepsy
Intrinsic thermodynamics of trifluoromethanesulfonamide and ethoxzolamide binding to human carbonic anhydrase VII.
Epilepsy
Investigation of inhibitory properties of some hydrazone compounds on hCA I, hCA II and AChE enzymes.
Epilepsy
Isoform-selective inhibitory profile of 2-imidazoline-substituted benzene sulfonamides against a panel of human carbonic anhydrases.
Epilepsy
Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders.
Epilepsy
Neutron structure of human carbonic anhydrase II in complex with methazolamide: mapping the solvent and hydrogen-bonding patterns of an effective clinical drug.
Epilepsy
Possible association between acetazolamide administration during pregnancy and multiple congenital malformations.
Epilepsy
Potential inhibitors of human carbonic anhydrase isozymes I and II: Design, synthesis and docking studies of new 1,3,4-thiadiazole derivatives.
Epilepsy
Probing the chemical interaction space governed by 4-aminosubstituted benzenesulfonamides and carbonic anhydrase isoforms.
Epilepsy
Purification, enzymatic activity and inhibitor discovery for recombinant human carbonic anhydrase XIV.
Epilepsy
Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors.
Epilepsy
Structural elucidation of the hormonal inhibition mechanism of the bile acid cholate on human carbonic anhydrase II.
Epilepsy
Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.
Epilepsy
Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and ?-glycosidase inhibitors.
Epilepsy
Synthesis and carbonic anhydrase inhibition of polycyclic imides incorporating N-benzenesulfonamide moieties.
Epilepsy
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols and their derivatives including natural products: Vidalol B.
Epilepsy
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols including natural products.
Epilepsy
Synthesis and carbonic anhydrase inhibitory properties of novel cyclohexanonyl bromophenol derivatives.
Epilepsy
Synthesis and characterization of novel substituted thiophene derivatives and discovery of their carbonic anhydrase and acetylcholinesterase inhibition effects.
Epilepsy
Synthesis and evaluation of pharmacological profile of 1-aryl-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamides.
Epilepsy
Synthesis of 1,2,4-triazole-5-on derivatives and determination of carbonic anhydrase II isoenzyme inhibition effects.
Epilepsy
Synthesis of novel acyl selenoureido benzensulfonamides as carbonic anhydrase I, II, VII and IX inhibitors.
Epilepsy
Synthesis of novel bis-sulfone derivatives and their inhibition properties on some metabolic enzymes including carbonic anhydrase, acetylcholinesterase, and butyrylcholinesterase.
Epilepsy
Synthesis of novel tris-chalcones and determination of their inhibition profiles against some metabolic enzymes.
Epilepsy
Synthesis, biological evaluation and in silico studies of novel N-substituted phthalazine sulfonamide compounds as potent carbonic anhydrase and acetylcholinesterase inhibitors.
Epilepsy
The effects of acetazolamide on arterial pressure variability during REM sleep in the rat.
Epilepsy
The green synthesis and molecular docking of novel N-substituted rhodanines as effective inhibitors for carbonic anhydrase and acetylcholinesterase enzymes.
Epilepsy
The structural comparison between membrane-associated human carbonic anhydrases provides insights into drug design of selective inhibitors.
Epilepsy
Topiramate, pseudotumor cerebri, weight-loss and glaucoma: an ophthalmologic perspective.
Epilepsy
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.
Epilepsy
[Carbonic anhydrase in the blood in epilepsy.]
Epilepsy
[Effect of carbonic anhydrase inhibitors on electroencephalograms in epilepsy in children.]
Epilepsy, Reflex
Neuron-glia relationships in human and experimental epilepsy: a biochemical point of view.
Epilepsy, Reflex
[Activity of blood and brain carbonic anhydrase in white rats resistant to sound and rats predisposed to audiogenic epilepsy]
Epiretinal Membrane
Hypothesis concerning carbonic anhydrase treatment of cystoid macular edema: example with epiretinal membrane.
Erectile Dysfunction
Organic impotence associated with carbonic anhydrase inhibitor therapy for glaucoma.
Erectile Dysfunction
Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV.
Esophageal Achalasia
Triosephosphate isomerase, carbonic anhydrase, and creatinine kinase-brain isoform are possible antigen targets in patients with achalasia.
Esophageal Neoplasms
Carbonic Anhydrase IX Overexpression is Associated with Diminished Prognosis in Esophageal Cancer and Correlates with Her-2 Expression.
Esophageal Neoplasms
Catalase, carbonic anhydrase and other biochemical parameters in esophageal cancers in Turkey.
Esophageal Neoplasms
Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.
Esophageal Neoplasms
Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer.
Esophageal Neoplasms
Stromal expression of carbonic anhydrase IX in esophageal cancer.
Esophageal Squamous Cell Carcinoma
Carbonic Anhydrase XII as an Independent Prognostic Factor in Advanced Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Modulation of Tumor Microenvironment to Enhance Radiotherapy Efficacy in Esophageal Squamous Cell Carcinoma by Inhibiting Carbonic Anhydrase IX.
Esophageal Squamous Cell Carcinoma
Prognostic impact of LY6K and CDCA1 expression for patients with esophageal squamous cell carcinoma.
Esophagitis
Carbonic Anhydrases II, IX, and XII in Reflux Esophagitis.
Esophagitis
Cell biology of laryngeal epithelial defenses in health and disease: preliminary studies.
Essential Hypertension
Renal circulatory effects of acetazolamide in patients with essential hypertension.
Essential Hypertension
[Study on mechanism for anti-hypertension efficacy of Eucommiae Cortex through assistant analysis systems for acting mechanisms of traditional Chinese medicine].
Essential Tremor
Double-blind controlled study of methazolamide in the treatment of essential tremor.
Essential Tremor
Medical treatment of essential tremor and Parkinson's disease.
Essential Tremor
New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide.
Essential Tremor
The effect of acetazolamide on essential tremor: an open-label trial.
Exanthema
Use of Acetazolamide in Sulfonamide-Allergic Patients With Neurologic Channelopathies.
Eye Diseases
Discovery of 4-sulfamoyl-phenyl-?-lactams as a new class of potent carbonic anhydrase isoforms I, II, IV and VII inhibitors: The first example of subnanomolar CA IV inhibitors.
Eye Diseases
Discovery of curcumin inspired sulfonamide derivatives as a new class of carbonic anhydrase isoforms I, II, IX, and XII inhibitors.
Eye Diseases
Intrinsic thermodynamics of high affinity inhibitor binding to recombinant human carbonic anhydrase IV.
Eye Diseases
Purification of carbonic anhydrase from dog erythrocytes and investigation of in vitro inhibition by various compounds.
Familial Primary Pulmonary Hypertension
Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells.
Fanconi Syndrome
Drug-induced acid-base disorders.
Fanconi Syndrome
Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies.
Fanconi Syndrome
[Carbonic anhydrase II deficiency and Fanconi syndrome]
Fatty Liver
Carbonic Anhydrase Protects Fatty Liver Grafts against Ischemic Reperfusion Damage.
Fatty Liver
Correction: Carbonic Anhydrase Protects Fatty Liver Grafts against Ischemic Reperfusion Damage.
Fibroadenoma
Carbonic anhydrase IX: A promising diagnostic and prognostic biomarker in breast carcinoma.
Fibrocystic Breast Disease
Carcinoma arising in microglandular adenosis of the breast: triple negative phenotype with variable morphology.
Fibrocystic Breast Disease
Salivary gland-type mammary carcinoma arising in microglandular adenosis: A case report and clinicopathological review of the literature.
Fibrosarcoma
A carbonic anhydrase inhibitor as a potential modulator of cancer therapies.
Fibrosarcoma
Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells.
Fibrosarcoma
Induction of carbonic anhydrase IX by hypoxia and chemical disruption of oxygen sensing in rat fibroblasts and cardiomyocytes.
Fibrosarcoma
PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines.
Fibrosarcoma
Suppression of carbonic anhydrase IX leads to aberrant focal adhesion and decreased invasion of tumor cells.
Gallstones
High-activity carbonic anhydrase isoenzyme (CA II) in human gallbladder epithelium.
Ganglioneuroma
Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas.
Gastritis
Carbonic Anhydrase Inhibitors: DNA Cloning and Inhibition Studies of the alpha-Carbonic Anhydrase from Helicobacter pylori, A New Target for Developing Sulfonamide and Sulfamate Gastric Drugs.
Gastritis
[Role of carbonic anhydrase in the mechanism of action of "Dilizhan" mineral water in chronic gastritis]
Gastroesophageal Reflux
Carbonic Anhydrases II, IX, and XII in Reflux Esophagitis.
Gastrointestinal Diseases
Salivary carbonic anhydrase protects gastroesophageal mucosa from acid injury.
Gastrointestinal Stromal Tumors
Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors.
Gastrointestinal Stromal Tumors
Overexpression of carbonic anhydrase II and Ki-67 proteins in prognosis of gastrointestinal stromal tumors.
Gastrointestinal Stromal Tumors
Overexpression of carbonic anhydrase-related protein XI promotes proliferation and invasion of gastrointestinal stromal tumors.
Gastrointestinal Stromal Tumors
Sarcomatoid Renal Cell Carcinoma With Unusual Metastasis to the Small Intestine Manifesting as Perforated Appendicitis.
Giant Cell Tumor of Bone
Detection of mRNA for carbonic anhydrase II in human osteoclast-like cells by in situ hybridization.
Giant Cell Tumor of Bone
Histochemistry of tartrate-resistant acid phosphatase and carbonic anhydrase isoenzyme II in osteoclast-like giant cells in bone tumours.
Giant Cell Tumor of Bone
Immunohistochemical demonstration of carbonic anhydrase in human kidney, bone and giant cell tumor of bone.
Giant Cell Tumor of Bone
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.
Giant Cell Tumor of Bone
Ultrastructural immunocytochemical localization of carbonic anhydrase in a benign giant cell tumor of bone.
Giant Cell Tumors
Detection of mRNA for carbonic anhydrase II in human osteoclast-like cells by in situ hybridization.
Giant Cell Tumors
Histochemistry of tartrate-resistant acid phosphatase and carbonic anhydrase isoenzyme II in osteoclast-like giant cells in bone tumours.
Giant Cell Tumors
Immunohistochemical demonstration of carbonic anhydrase in human kidney, bone and giant cell tumor of bone.
Giant Cell Tumors
Immunohistochemical localization of carbonic anhydrase isoenzymes I and II in human bone, cartilage and giant cell tumor.
Giant Cell Tumors
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.
Giant Cell Tumors
Ultrastructural immunocytochemical localization of carbonic anhydrase in a benign giant cell tumor of bone.
Glaucoma
13C saturation transfer effect of carbon dioxide-bicarbonate exchange catalyzed by carbonic anhydrase in vivo.
Glaucoma
4-Substituted benzenesulfonamides featuring cyclic imides moieties exhibit potent and isoform-selective carbonic anhydrase II/IX inhibition.
Glaucoma
A class of carbonic anhydrase IX/XII - selective carboxylate inhibitors.
Glaucoma
A clinical trial of MK-507, Trusopt, for raised intraocular pressure--the Australian experience.
Glaucoma
A long term study of low concentration guanethidine and adrenaline therapy in glaucoma.
Glaucoma
A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology.
Glaucoma
A new synthesis of difluoromethanesulfonamides--a novel pharmacophore for carbonic anhydrase inhibition.
Glaucoma
A review of the pharmacology of carbonic anhydrase inhibitors for the treatment of glaucoma in dogs and cats.
Glaucoma
A topical carbonic anhydrase inhibitor for glaucoma.
Glaucoma
Acetazolamide blood concentrations are excessive in the elderly: propensity for acidosis and relationship to renal function.
Glaucoma
Acetazolamide impairs fear memory consolidation in rodents.
Glaucoma
Acetazolamide-like carbonic anhydrase inhibitors with topical ocular hypotensive activity.
Glaucoma
Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.
Glaucoma
Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure.
Glaucoma
Adult cytomegalic inclusion retinitis.
Glaucoma
Advances in Bile Acid Medicinal Chemistry.
Glaucoma
Aminozolamide gel. A trial of a topical carbonic anhydrase inhibitor in ocular hypertension.
Glaucoma
Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers.
Glaucoma
An efficient method for the synthesis of novel derivatives 4-{5-[4-(4-amino-5-mercapto-4H-[1,2,4]triazol-3-yl)-phenyl]-3-trifluoromethyl-pyrazol-1-yl}-benzenesulfonamide and their anti-inflammatory potential.
Glaucoma
Analysis of human carbonic anhydrase II: docking reliability and receptor-based 3D-QSAR study.
Glaucoma
Antiglaucoma medications: a review of safety and tolerability issues related to their use.
Glaucoma
Aplastic anemia and agranulocytosis in patients using methazolamide for glaucoma.
Glaucoma
Argon laser trabecular surgery as an alternative to carbonic anhydrase therapy.
Glaucoma
Association between Glaucoma Medication Usage and Dry Eye in Taiwan.
Glaucoma
Asymmetric bioreduction of a ketosulfone to the corresponding trans-hydroxysulfone by the yeast Rhodotorula rubra MY 2169.
Glaucoma
Basic pharmacology of some glaucoma drugs with emphasis on new information and new developments.
Glaucoma
Blood dyscrasias in patients using methazolamide (neptazane) for glaucoma.
Glaucoma
Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study.
Glaucoma
Brinzolamide--a new topical carbonic anhydrase inhibitor for glaucoma.
Glaucoma
Calcium metabolism in acidotic patients induced by carbonic anhydrase inhibitors: responses to citrate.
Glaucoma
Canine glaucoma: medical and surgical treatment options.
Glaucoma
Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019.
Glaucoma
Carbonic anhydrase inhibition in glaucoma: hazard or benefit for the chronic lunger?
Glaucoma
Carbonic anhydrase inhibitor acetazoleamide (diamox); a new approach to the therapy of glaucoma.
Glaucoma
Carbonic anhydrase inhibitor side effects. Serum chemical analysis.
Glaucoma
Carbonic anhydrase inhibitors and osmotic agents in glaucoma. Carbonic anhydrase inhibitors.
Glaucoma
Carbonic anhydrase inhibitors as fourth drug in primary glaucomas: Is it worth it?
Glaucoma
Carbonic Anhydrase Inhibitors in Corneal Endothelial Transport.
Glaucoma
Carbonic anhydrase inhibitors induce elevations in human whole-blood zinc levels.
Glaucoma
Carbonic Anhydrase Inhibitors suppress platelet procoagulant responses and in vivo thrombosis.
Glaucoma
Carbonic anhydrase inhibitors with strong topical antiglaucoma properties incorporating a 4-(2-aminopyrimidin-4-yl-amino)-benzenesulfonamide scaffold.
Glaucoma
Carbonic anhydrase inhibitors: binding of an antiglaucoma glycosyl-sulfanilamide derivative to human isoform II and its consequences for the drug design of enzyme inhibitors incorporating sugar moieties.
Glaucoma
Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma.
Glaucoma
Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.
Glaucoma
Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with a topically acting antiglaucoma sulfonamide.
Glaucoma
Changes in glaucoma medication numbers after cataract and glaucoma surgery: A nationwide population-based study.
Glaucoma
Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation.
Glaucoma
Comparative cost evaluation of brand name and generic ophthalmology medications in Ontario.
Glaucoma
Comparative effects of intraocular pressure between systemic and topical carbonic anhydrase inhibitors: a clinical masked, cross-over study.
Glaucoma
Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America.
Glaucoma
Comparison of latanoprost/timolol with carbonic anhydrase inhibitor and dorzolamide/timolol with prostaglandin analog in the treatment of glaucoma.
Glaucoma
Complexes with biologically active ligands. Part 11. Synthesis and carbonic anhydrase inhibitory activity of metal complexes of 4,5-disubstituted-3-mercapto-1,2,4-triazole derivatives.
Glaucoma
Continued exploration and tail approach synthesis of benzenesulfonamides containing triazole and dual triazole moieties as carbonic anhydrase I, II, IV and IX inhibitors.
Glaucoma
Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by The United Kingdom General Practitioner Research Database.
Glaucoma
Costs and persistence of carbonic anhydrase inhibitor versus alpha-2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK-GPRD database.
Glaucoma
Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension.
Glaucoma
Cyclodextrin-based formulation of carbonic anhydrase inhibitors for ocular delivery - A review.
Glaucoma
Daily cost of ophthalmic solutions for treating glaucoma in Japan.
Glaucoma
Decreased libido--a side effect of carbonic anhydrase inhibitor.
Glaucoma
Design and synthesis of novel 1,3-diaryltriazene-substituted sulfonamides as potent and selective carbonic anhydrase II inhibitors.
Glaucoma
Design and synthesis of novel benzenesulfonamide containing 1,2,3-triazoles as potent human carbonic anhydrase isoforms I, II, IV and IX inhibitors.
Glaucoma
Design, synthesis and biological evaluation of novel ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as potent carbonic anhydrase IX inhibitors.
Glaucoma
Determinants of Corneal Endothelial Cell Loss After Trabeculectomy With Mitomycin C.
Glaucoma
Determination of acetazolamide in human serum by enzymatic assay.
Glaucoma
Determination of methazolamide concentrations in human biological fluids using high performance liquid chromatography.
Glaucoma
Development of 3-(4-aminosulphonyl)-phenyl-2-mercapto-3H-quinazolin-4-ones as inhibitors of carbonic anhydrase isoforms involved in tumorigenesis and glaucoma.
Glaucoma
Development of a Fingerprint-Based Scoring Function for the Prediction of the Binding Mode of Carbonic Anhydrase II Inhibitors.
Glaucoma
Development of inclusion complex of brinzolamide with hydroxypropyl-?-cyclodextrin
Glaucoma
Development of inclusion complex of brinzolamide with hydroxypropyl-?-cyclodextrin.
Glaucoma
Development of sulfonamides incorporating phenylacrylamido functionalities as carbonic anhydrase isoforms I, II, IX and XII inhibitors.
Glaucoma
Developments of small molecules as inhibitors for carbonic anhydrase isoforms.
Glaucoma
Discovery of 4-sulfamoyl-phenyl-?-lactams as a new class of potent carbonic anhydrase isoforms I, II, IV and VII inhibitors: The first example of subnanomolar CA IV inhibitors.
Glaucoma
Discovery of ?-Adrenergic Receptors Blocker-Carbonic Anhydrase Inhibitor Hybrids for Multitargeted Antiglaucoma Therapy.
Glaucoma
Discovery of New 1,1'-Biphenyl-4-sulfonamides as Selective Subnanomolar Human Carbonic Anhydrase II Inhibitors.
Glaucoma
Discovery of new 2, 5-disubstituted 1,3-selenazoles as selective human carbonic anhydrase IX inhibitors with potent anti-tumor activity.
Glaucoma
Discovery of Potent Dual-Tailed Benzenesulfonamide Inhibitors of Human Carbonic Anhydrases Implicated in Glaucoma and in Vivo Profiling of Their Intraocular Pressure-Lowering Action.
Glaucoma
Disturbance of CO2 elimination in the lungs by carbonic anhydrase inhibition.
Glaucoma
Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo.
Glaucoma
Docking of sulfonamides to carbonic anhydrase II and IV.
Glaucoma
Dorzolamide, a 40-year wait. From an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma.
Glaucoma
Dorzolamide, A Topical Carbonic Anhydrase Inhibitor: A Two-Week Dose-Response Study in Patients with Glaucoma or Ocular Hypertension.
Glaucoma
Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma.
Glaucoma
Dorzolamide-Induced Relaxation of Intraocular Porcine Ciliary Arteries In Vitro Depends on Nitric Oxide and The Vascular Endothelium.
Glaucoma
Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor.
Glaucoma
Dose-dependent pharmacokinetics of MK-417, a potent carbonic anhydrase inhibitor, in rabbits following single and multiple doses.
Glaucoma
Dose-dependent stereopharmacokinetics of 5,6-dihydro-4H-4(isobutylamino)thieno(2,3-B)thiopyran-2-sulfonamide-7,7 -dioxide , a potent carbonic anhydrase inhibitor, in rats.
Glaucoma
Effect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure.
Glaucoma
Effect of chronic carbonic anhydrase inhibitor therapy on bone mineral density in white women.
Glaucoma
Effect of dorzolamide/timolol combination on the visual field in glaucoma.
Glaucoma
Effect of topical dorzolamide on optic nerve head blood flow.
Glaucoma
Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase after Cataract Surgery in Eyes with Glaucoma.
Glaucoma
Effects of acetazolamide on choroidal blood flow.
Glaucoma
Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells.
Glaucoma
Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or ?-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis.
Glaucoma
Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.
Glaucoma
Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication.
Glaucoma
Emerging drugs for ocular hypertension.
Glaucoma
Evaluating off-label uses of acetazolamide.
Glaucoma
Evaluation of selenide, diselenide and selenoheterocycle derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
Glaucoma
Experience with COSOPT, the fixed combination of timolol and dorzolamide, gained in Swiss ophthalmologists' offices.
Glaucoma
Exploring structure-activity relationship of S-substituted 2-mercaptoquinazolin-4(3H)-one including 4-ethylbenzenesulfonamides as human carbonic anhydrase inhibitors.
Glaucoma
Expression of cell surface transmembrane carbonic anhydrase genes CA9 and CA12 in the human eye: overexpression of CA12 (CAXII) in glaucoma.
Glaucoma
Eye Conditions in Older Adults: Open-Angle Glaucoma.
Glaucoma
Fabrication of Transgelosomes for Enhancing the Ocular Delivery of Acetazolamide: Statistical Optimization, In Vitro Characterization, and In Vivo Study.
Glaucoma
First evaluation of organotellurium derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
Glaucoma
Gamma sterilization and in vivo evaluation of cationic nanostructured lipid carriers as potential ocular delivery systems for antiglaucoma drugs.
Glaucoma
Glaucoma and the applications of carbonic anhydrase inhibitors.
Glaucoma
Glaucoma Medication Preferences among Glaucoma Specialists in Mexico.
Glaucoma
Glaucoma medications, glaucoma therapy, and the evolving paradigm.
Glaucoma
Heterocyclic compounds as carbonic anhydrase inhibitor.
Glaucoma
High Correlation between Glaucoma Treatment with Topical Prostaglandin Analogs and BDNF Immunoreactivity in Human Retina.
Glaucoma
Hybrid dendrimer hydrogel/poly(lactic-co-glycolic Acid) nanoparticle platform: an advanced vehicle for topical delivery of antiglaucoma drugs and a likely solution to improving compliance and adherence in glaucoma management.
Glaucoma
Hydrophilic acrylic hydrogels with built-in or pendant cyclodextrins for delivery of anti-glaucoma drugs
Glaucoma
Hyperkalaemia induced by carbonic anhydrase inhibitor.
Glaucoma
Identification of isoenzyme C as the principal carbonic anhydrase in human ciliary processes.
Glaucoma
Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.
Glaucoma
Implication of sulfonylurea derivatives as prospective inhibitors of human carbonic anhydrase II.
Glaucoma
Increased oxidation-related glutathionylation and carbonic anhydrase activity in endometriosis.
Glaucoma
Influence of Anti-Glaucoma Drugs on Uptake of Extracellular Vesicles by Trabecular Meshwork Cells.
Glaucoma
Influence of dorzolamide on corneal thickness, endothelial cell count and corneal sensibility.
Glaucoma
Inhibition of bovine carbonic anhydrase by new sulfonamide compounds.
Glaucoma
Inhibition of carbonic anhydrase in the treatment of glaucoma.
Glaucoma
Inhibition of carbonic anhydrase isoforms I, II, IV, VII and XII with carboxylates and sulfonamides incorporating phthalimide/phthalic anhydride scaffolds.
Glaucoma
Intrinsic Thermodynamics and Structure Correlation of Benzenesulfonamides with a Pyrimidine Moiety Binding to Carbonic Anhydrases I, II, VII, XII, and XIII.
Glaucoma
Intrinsic thermodynamics of high affinity inhibitor binding to recombinant human carbonic anhydrase IV.
Glaucoma
Intrinsic thermodynamics of sulfonamide inhibitor binding to human carbonic anhydrases I and II.
Glaucoma
Investigation of inhibitory properties of some hydrazone compounds on hCA I, hCA II and AChE enzymes.
Glaucoma
Keratitis in six dogs after topical treatment with carbonic anhydrase inhibitors for glaucoma.
Glaucoma
Long-term Glaucoma Treatment with MK-507, Dorzolamide, a Topical Carbonic Anhydrase Inhibitor.
Glaucoma
Lowering of IOP by echothiophate iodide in pseudophakic eyes with glaucoma.
Glaucoma
Management of glaucoma: focus on pharmacological therapy.
Glaucoma
Medical therapy of pediatric glaucoma and glaucoma in pregnancy.
Glaucoma
Medical treatment of normal tension glaucoma.
Glaucoma
Medical versus surgical interventions for open angle glaucoma.
Glaucoma
Metabolic acidosis and anaemia associated with dorzolamide in a patient with impaired renal function.
Glaucoma
Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function.
Glaucoma
Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension.
Glaucoma
MicroPulse® transscleral laser therapy in the management of glaucoma patients.
Glaucoma
Mitochondrial proteomic profiling reveals increased carbonic anhydrase II in aging and neurodegeneration.
Glaucoma
MK-927: a topical carbonic anhydrase inhibitor. Dose response and duration of action.
Glaucoma
Multiple-dose efficacy comparison of the two topical carbonic anhydrase inhibitors sezolamide and MK-927.
Glaucoma
Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders.
Glaucoma
Neutron structure of human carbonic anhydrase II in complex with methazolamide: mapping the solvent and hydrogen-bonding patterns of an effective clinical drug.
Glaucoma
New developments in the drug treatment of glaucoma.
Glaucoma
New medical therapies in glaucoma management.
Glaucoma
Newer therapeutic vistas for antiglaucoma medicines.
Glaucoma
Nitric oxide donors and selective carbonic anhydrase inhibitors: a dual pharmacological approach for the treatment of glaucoma, cancer and osteoporosis.
Glaucoma
Novel Polymeric Nanoparticles Intended for Ophthalmic Administration of Acetazolamide.
Glaucoma
Novel therapies for glaucoma: a patent review 2007 - 2011.
Glaucoma
Ocular hypertension. II. A carbonic anhydrase inhibitor test for early detection of glaucoma.
Glaucoma
Ocular microemulsion of brinzolamide: Formulation, physicochemical characterization, and in vitro irritation studies based on EpiOcular eye irritation assay.
Glaucoma
Ocular pharmacology of methazolamide analogs: distribution in the eye and effects on pressure after topical application.
Glaucoma
Ocular pharmacology of sulfonamides: the cornea as barrier and depot.
Glaucoma
Ocular Surface Disease and Quality of Life in Patients With Glaucoma.
Glaucoma
Oculohypotensive effects of various acetozolamide nanopreparations for topical treatment of animal model-induced glaucoma and their impact on optic nerve.
Glaucoma
Oleuropein and Verbascoside - Their Inhibition Effects on Carbonic Anhydrase and Molecular Docking Studies.
Glaucoma
Optic nerve oxygenation.
Glaucoma
Organic impotence associated with carbonic anhydrase inhibitor therapy for glaucoma.
Glaucoma
Papillomacular retinoschisis associated with glaucoma: Response to topical carbonic anhydrase inhibitor.
Glaucoma
Permeability of human cornea and sclera to sulfonamide carbonic anhydrase inhibitors.
Glaucoma
Persisent ocular hypertension following intravitreal ranibizumab.
Glaucoma
Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom.
Glaucoma
Perspectives on the Classical Enzyme Carbonic Anhydrase and the Search for Inhibitors.
Glaucoma
Pharmacological advances in the treatment of glaucoma.
Glaucoma
Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors.
Glaucoma
Pharmacological therapy for glaucoma: a review.
Glaucoma
Poly(amidoamine) Dendrimers with Carbonic Anhydrase Inhibitory Activity and Antiglaucoma Action.
Glaucoma
Poly-(cyclo)dextrins as ethoxzolamide carriers in ophthalmic solutions and in contact lenses
Glaucoma
Poly-(cyclo)dextrins as ethoxzolamide carriers in ophthalmic solutions and in contact lenses.
Glaucoma
Possible association between acetazolamide administration during pregnancy and multiple congenital malformations.
Glaucoma
Potential inhibitors of human carbonic anhydrase isozymes I and II: Design, synthesis and docking studies of new 1,3,4-thiadiazole derivatives.
Glaucoma
Preclinical overview of brinzolamide.
Glaucoma
Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017.
Glaucoma
Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study.
Glaucoma
Probing the chemical interaction space governed by 4-aminosubstituted benzenesulfonamides and carbonic anhydrase isoforms.
Glaucoma
Problems With Large Joints: Knee Conditions.
Glaucoma
Prophylactic anti-glaucoma therapy in dogs with primary glaucoma: A practitioner survey of current medical protocols.
Glaucoma
Prostaglandin analogues in the treatment of glaucoma.
Glaucoma
Purification of carbonic anhydrase from dog erythrocytes and investigation of in vitro inhibition by various compounds.
Glaucoma
Quantitative structure activity relationship studies of sulfamide derivatives as carbonic anhydrase inhibitor: as antiglaucoma agents.
Glaucoma
Quinazolinones as Competitive Inhibitors of Carbonic Anhydrase-II (Human and Bovine): Synthesis, in-vitro, in-silico, Selectivity, and Kinetics Studies.
Glaucoma
Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors.
Glaucoma
Red blood cell (RBC) surface acetylcholinesterase showing a hemorheological pattern during glaucoma treatment.
Glaucoma
Regulation of retinal proteome by topical antiglaucomatous eye drops in an inherited glaucoma rat model.
Glaucoma
Relationship of patient age and tolerance to carbonic anhydrase inhibitors.
Glaucoma
Risk factors of shallow anterior chamber other than hypotony after Ahmed glaucoma valve implant.
Glaucoma
Secondary glaucoma in patients with juvenile rheumatoid arthritis-associated iridocyclitis.
Glaucoma
Severe mixed acidosis by combined therapy with acetazolamide and timolol eyedrops.
Glaucoma
Single and mixed poloxamine micelles as nanocarriers for solubilization and sustained release of ethoxzolamide for topical glaucoma therapy.
Glaucoma
Structural analysis of inhibitor binding to human carbonic anhydrase II.
Glaucoma
Structural aspects of isozyme selectivity in the binding of inhibitors to carbonic anhydrases II and IV.
Glaucoma
Structural elucidation of the hormonal inhibition mechanism of the bile acid cholate on human carbonic anhydrase II.
Glaucoma
Structure-activity relationship of human carbonic anhydrase-II inhibitors: Detailed insight for future development as anti-glaucoma agents.
Glaucoma
Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor.
Glaucoma
Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits.
Glaucoma
Sulfamates of methyl triterpenoates are effective and competitive inhibitors of carbonic anhydrase II.
Glaucoma
Sulfonamide drugs: structure, antibacterial property, toxicity, and biophysical interactions.
Glaucoma
Sulfonamides and secretion of aqueous humor.
Glaucoma
Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: effect on the quality of life of glaucoma patients with drug-related side effects.
Glaucoma
Syntesis of thio- and seleno-acetamides bearing benzenesulfonamide as potent inhibitors of human carbonic anhydrase II and XII.
Glaucoma
Synthesis 4-[2-(2-mercapto-4-oxo-4H-quinazolin-3-yl)-ethyl]-benzenesulfonamides with subnanomolar carbonic anhydrase II and XII inhibitory properties.
Glaucoma
Synthesis and biological evaluation of benzenesulphonamide-bearing 1,4,5-trisubstituted-1,2,3-triazoles possessing human carbonic anhydrase I, II, IV, and IX inhibitory activity.
Glaucoma
Synthesis and biological evaluation of cyclic imides incorporating benzenesulfonamide moieties as carbonic anhydrase I, II, IV and IX inhibitors.
Glaucoma
Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and ?-glycosidase inhibitors.
Glaucoma
Synthesis and carbonic anhydrase inhibition of polycyclic imides incorporating N-benzenesulfonamide moieties.
Glaucoma
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols and their derivatives including natural products: Vidalol B.
Glaucoma
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols including natural products.
Glaucoma
Synthesis and carbonic anhydrase inhibitory properties of novel cyclohexanonyl bromophenol derivatives.
Glaucoma
Synthesis and characterization of novel substituted thiophene derivatives and discovery of their carbonic anhydrase and acetylcholinesterase inhibition effects.
Glaucoma
Synthesis of 1,2,4-triazole-5-on derivatives and determination of carbonic anhydrase II isoenzyme inhibition effects.
Glaucoma
Synthesis of a new series of 3-functionalised-1-phenyl-1,2,3-triazole sulfamoylbenzamides as carbonic anhydrase I, II, IV and IX inhibitors.
Glaucoma
Synthesis of benzamide derivatives with thiourea-substituted benzenesulfonamides as carbonic anhydrase inhibitors.
Glaucoma
Synthesis of novel acyl selenoureido benzensulfonamides as carbonic anhydrase I, II, VII and IX inhibitors.
Glaucoma
Synthesis of novel bis-sulfone derivatives and their inhibition properties on some metabolic enzymes including carbonic anhydrase, acetylcholinesterase, and butyrylcholinesterase.
Glaucoma
Synthesis of novel sulfonamides under mild conditions with effective inhibitory activity against the carbonic anhydrase isoforms I and II.
Glaucoma
Synthesis of novel tris-chalcones and determination of their inhibition profiles against some metabolic enzymes.
Glaucoma
Synthesis of sulfanilamide derivatives and investigation of in vitro inhibitory activities and antimicrobial and physical properties.
Glaucoma
Synthesis, biological evaluation and in silico studies of novel N-substituted phthalazine sulfonamide compounds as potent carbonic anhydrase and acetylcholinesterase inhibitors.
Glaucoma
Systemic carbonic anhydrase inhibitors have been used to reduce intraocular pressure in glaucoma patients unresponsive to other anti glaucomatous medical treatments.
Glaucoma
Systemic side effects of glaucoma medications.
Glaucoma
The additive effect of topical dorzolamide and systemic acetazolamide in pediatric glaucoma.
Glaucoma
The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents.
Glaucoma
The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents.
Glaucoma
The Effect of Long-term Antiglaucomatous Drug Administration on Central Corneal Thickness.
Glaucoma
The effectiveness and safety of dorzolamide 2% in addition to multiple topical antiglaucoma medications.
Glaucoma
The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group.
Glaucoma
The ocular hypotensive effect of the topical carbonic anhydrase inhibitor L-671,152 in glaucomatous monkeys.
Glaucoma
The rates of movement of Na+, Cl-, and HCO-3 from plasma to posterior chamber: effect of acetazolamide and relation to the treatment of glaucoma.
Glaucoma
The safety and efficacy of glaucoma medication in the pediatric population.
Glaucoma
The study of ocular hypotensive effect of 6-hydroxyethoxy-2-benzothiazole sulfonamide: a topical carbonic anhydrase inhibitor.
Glaucoma
The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion.
Glaucoma
The use of non-steroidal anti-inflammatory drugs in paediatric rheumatic diseases.
Glaucoma
Thienothiopyran-2-sulfonamides: novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma.
Glaucoma
Timolol activates the enzyme activities of human carbonic anhydrase I and II.
Glaucoma
Topical carbonic anhydrase inhibition increases ocular pulse amplitude in high tension primary open angle glaucoma.
Glaucoma
Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Glaucoma
Topical carbonic anhydrase inhibitors and visual function in glaucoma and ocular hypertension.
Glaucoma
Topical carbonic anhydrase inhibitors in the treatment of glaucoma.
Glaucoma
Topical carbonic anhydrase inhibitors.
Glaucoma
Topical carbonic anhydrase inhibitors: a new perspective in glaucoma therapy.
Glaucoma
Topical carbonic anhydrase inhibitors: potential adjuvants to glaucoma therapy in the future.
Glaucoma
Topical drug delivery to the eye: dorzolamide.
Glaucoma
Topical ocular hypotensive activity and ocular penetration of dichlorphenamide sodium in rabbits.
Glaucoma
Topical therapies for glaucoma: what family physicians need to know.
Glaucoma
Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma.
Glaucoma
Topically active carbonic anhydrase inhibitors for glaucoma.
Glaucoma
Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin.
Glaucoma
Transient renal tubular acidosis in a neonate following transplacental acetazolamide.
Glaucoma
Treatment of glaucoma among elderly patients in Sofia.
Glaucoma
Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595.
Glaucoma
Treatment of glaucoma in children with Sturge-Weber syndrome.
Glaucoma
Trends in licence approvals for ophthalmic medicines in the United Kingdom.
Glaucoma
Two flavonoid-based compounds from Murraya paniculata as novel human carbonic anhydrase isozyme II inhibitors detected by a resazurin yeast-based assay.
Glaucoma
Ultratrace analysis of drugs in biological fluids using affinity probe capillary electrophoresis: analysis of dorzolamide with fluorescently labeled carbonic anhydrase.
Glaucoma
Update and critical appraisal of combined timolol and carbonic anhydrase inhibitors and the effect on ocular blood flow in glaucoma patients.
Glaucoma
Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues.
Glaucoma
Update on the management of glaucoma.
Glaucoma
Update on topical carbonic anhydrase inhibitors.
Glaucoma
Use of a new carbonic anhydrase inhibitor (cardrase) in glaucoma.
Glaucoma
Variable involvement of the perivascular retinal tissue in carbonic anhydrase inhibitor induced relaxation of porcine retinal arterioles in vitro.
Glaucoma
Xanthates and trithiocarbonates strongly inhibit carbonic anhydrases and show antiglaucoma effects in vivo.
Glaucoma
[Changes in corneal thickness in glaucoma].
Glaucoma
[Clinical experiences with timolol eye drops]
Glaucoma
[Clinical tests on the use of ethoxzolamide in glaucoma therapy (author's transl)]
Glaucoma
[Corneal descompensation in patients with endothelial compromise treated with topical dorzolamide]
Glaucoma
[Decrease in intraocular pressure following administration of the local carbonic anhydrase inhibitor (MK-927)--comparison of the effect with pilocarpine]
Glaucoma
[Diuretics; their characteristics and future development]
Glaucoma
[Early adherence to anti-glaucoma therapy: An observational study].
Glaucoma
[Effect of methazolamide on the intraocular pressure of patients with open-angle glaucoma (author's transl)]
Glaucoma
[Effects of carbonic anhydrase inhibitors on pseudophakic corneal edema].
Glaucoma
[Experiences with timolol in treatment of glaucoma (author's transl)]
Glaucoma
[Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost]
Glaucoma
[Innovative glaucoma therapy. Glaucoma therapy with topical carbonic anhydrase inhibitors]
Glaucoma
[Mode of action, clinical profile and relevance of carbonic anhydrase inhibitors in glaucoma therapy].
Glaucoma
[New carbonic anhydrase inhibitors in the treatment of glaucoma.]
Glaucoma
[Ocular hemodynamics and visual field in glaucoma treated with dorzolamide]
Glaucoma
[Ocular pulse amplitude, intraocular pressure and beta blocker/carbonic anhydrase inhibition in combined therapy of primary open-angle glaucoma]
Glaucoma
[ON UROLITHIASIS FOLLOWING LONG-TERM ADMINISTRATION OF CARBONIC ANHYDRASE INHIBITORS IN THE THERAPY OF GLAUCOMA.]
Glaucoma
[Pharmacology aspects of glaucoma]
Glaucoma
[Renal lithiasis, a logical complication of long-term treatment of glaucoma with a carbonic anhydrase inhibitor]
Glaucoma
[Sport and Glaucoma].
Glaucoma
[The background of therapeutic use of carbonic anhydrase inhibitors in glaucoma.]
Glaucoma
[Tolerance to fixed combinations]
Glaucoma
[Topical carbonic anhydrase inhibitors for glaucoma]
Glaucoma
[Topical carbonic anhydrase inhibitors in the treatment of glaucoma]
Glaucoma
[Treatment of glaucoma with carbonic anhydrase inhibitors in eyewash: medium term retrospective experience with dorzolamide]
Glaucoma
[Treatment of glaucoma].
Glaucoma
[Trusopt, a local carboanhydrase inhibitor, in the treatment of glaucoma in children (preliminary report)]
Glaucoma
[Trusopt--a new form of drug for treating glaucoma]
Glaucoma, Angle-Closure
The effect of prophylactic topical carbonic anhydrase inhibitors in canine primary closed-angle glaucoma.
Glaucoma, Angle-Closure
Timolol therapy in secondary angle-closure glaucoma post penetrating keratoplasty.
Glaucoma, Angle-Closure
[Clinical experiences with timolol eye drops]
Glaucoma, Open-Angle
A long term study of low concentration guanethidine and adrenaline therapy in glaucoma.
Glaucoma, Open-Angle
Acetazolamide Intoxication in an Elderly Patient with Diabetes and Chronic Renal Failure after Cataract Surgery.
Glaucoma, Open-Angle
Acetazolamide-induced cerebral and ocular vasodilation in humans is independent of nitric oxide.
Glaucoma, Open-Angle
Argon laser trabecular surgery as an alternative to carbonic anhydrase therapy.
Glaucoma, Open-Angle
Brinzolamide/Brimonidine: A Review of Its Use in Patients with Open-Angle Glaucoma or Ocular Hypertension.
Glaucoma, Open-Angle
Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.
Glaucoma, Open-Angle
Clinical use of a topical carbonic anhydrase inhibitor in patients affected by chronic simple glaucoma.
Glaucoma, Open-Angle
Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma.
Glaucoma, Open-Angle
Dilatation of Retinal Arterioles Induced by Topical Dorzolamide for One Week Is Impaired in Patients with Type 1 Diabetes and Mild Retinopathy.
Glaucoma, Open-Angle
Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor.
Glaucoma, Open-Angle
Effect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure.
Glaucoma, Open-Angle
Effect of dorzolamide/timolol combination on the visual field in glaucoma.
Glaucoma, Open-Angle
Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase after Cataract Surgery in Eyes with Glaucoma.
Glaucoma, Open-Angle
Intraocular pressure effects of carbonic anhydrase inhibitors in primary open-angle glaucoma.
Glaucoma, Open-Angle
Intraocular pressure reduction with travoprost/timolol fixed combination, with and without adjunctive brinzolamide, in glaucoma.
Glaucoma, Open-Angle
Medical versus surgical interventions for open angle glaucoma.
Glaucoma, Open-Angle
MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors.
Glaucoma, Open-Angle
MK-927: a topical carbonic anhydrase inhibitor. Dose response and duration of action.
Glaucoma, Open-Angle
Multiple-dose efficacy comparison of the two topical carbonic anhydrase inhibitors sezolamide and MK-927.
Glaucoma, Open-Angle
New topical drugs for open-angle glaucoma.
Glaucoma, Open-Angle
Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma.
Glaucoma, Open-Angle
Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom.
Glaucoma, Open-Angle
Rational use of the fixed combination of dorzolamide - timolol in the management of raised intraocular pressure and glaucoma.
Glaucoma, Open-Angle
Red blood cell (RBC) surface acetylcholinesterase showing a hemorheological pattern during glaucoma treatment.
Glaucoma, Open-Angle
The efficacy of dorzolamide, a topical carbonic anhydrase inhibitor, in combination with timolol in the treatment of patients with open-angle glaucoma and ocular hypertension.
Glaucoma, Open-Angle
Timolol activates the enzyme activities of human carbonic anhydrase I and II.
Glaucoma, Open-Angle
Topical carbonic anhydrase inhibition increases ocular pulse amplitude in high tension primary open angle glaucoma.
Glaucoma, Open-Angle
Topically active carbonic anhydrase inhibitors. 4. [(Hydroxyalkyl)sulfonyl]benzene and [(hydroxyalkyl)sulfonyl]thiophenesulfonamides.
Glaucoma, Open-Angle
[Decrease in intraocular pressure following administration of the local carbonic anhydrase inhibitor (MK-927)--comparison of the effect with pilocarpine]
Glaucoma, Open-Angle
[Ocular pulse amplitude and local carbonic anhydrase inhibition]
Glaucoma, Open-Angle
[Ocular pulse amplitude, intraocular pressure and beta blocker/carbonic anhydrase inhibition in combined therapy of primary open-angle glaucoma]
Glioblastoma
Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo.
Glioblastoma
Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy.
Glioblastoma
Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme.
Glioblastoma
Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma.
Glioblastoma
Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma.
Glioblastoma
Cardiac glycosides suppress the maintenance of stemness and malignancy via inhibiting HIF-1? in human glioma stem cells.
Glioblastoma
Differential expression of HIF-1 in glioblastoma multiforme and anaplastic astrocytoma.
Glioblastoma
Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo.
Glioblastoma
Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia.
Glioblastoma
Fenofibrate inhibits hypoxia-inducible factor-1 alpha and carbonic anhydrase expression through activation of AMP-activated protein kinase/HO-1/Sirt1 pathway in glioblastoma cells.
Glioblastoma
Function of carbonic anhydrase IX in glioblastoma multiforme.
Glioblastoma
Glioblastomas with copy number gains in EGFR and RNF139 show increased expressions of carbonic anhydrase genes transformed by ENO1.
Glioblastoma
Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma.
Glioblastoma
Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas.
Glioblastoma
Inhibition of carbonic anhydrase IX in glioblastoma multiforme.
Glioblastoma
Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma.
Glioblastoma
Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PET In Vivo.
Glioblastoma
Myoglobin variants are expressed in human glioblastoma cells?hypoxia effect?
Glioblastoma
Rapid detection of the hypoxia-regulated CA-IX and NDRG1 gene expression in different glioblastoma cells in vitro.
Glioblastoma
Targeting Hypoxia Downstream Signaling Protein, CAIX, for CAR-T Cell Therapy against Glioblastoma.
Glioblastoma
The Carbonic Anhydrase Inhibitor E7070 Sensitizes Glioblastoma Cells to Radio- and Chemotherapy and Reduces Tumor Growth.
Glioblastoma
Topiramate induces acute intracellular acidification in glioblastoma.
Glioblastoma
[3H]acetazolamide binding to carbonic anhydrase in normal and transformed cells.
Glioma
"Paradoxical" findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab.
Glioma
Adipocyte proteome and secretome influence inflammatory and hormone pathways in glioma.
Glioma
Biochemical and Structural Insights into Carbonic Anhydrase XII/Fab6A10 Complex.
Glioma
Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.
Glioma
Carbonic Anhydrase 4 serves as a Clinicopathological Biomarker for Outcomes and Immune Infiltration in Renal Cell Carcinoma, Lower Grade Glioma, Lung Adenocarcinoma and Uveal Melanoma.
Glioma
Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells.
Glioma
Comparative Transcriptomic Analysis of Temozolomide Resistant Primary GBM Stem-Like Cells and Recurrent GBM Identifies Up-Regulation of the Carbonic Anhydrase CA2 Gene as Resistance Factor.
Glioma
Distinct patterns of hypoxic expression of carbonic anhydrase IX (CA IX) in human malignant glioma cell lines.
Glioma
Enzymatic and morphological properties of primary rat brain astrocyte cultures, and enzyme development in vivo.
Glioma
Fully Automated Production and Characterization of 64 Cu and Proof-of-Principle Small-Animal PET Imaging Using 64 Cu-Labelled CA XII Targeting 6A10 Fab.
Glioma
Hypoxia-related molecules HIF-1?, CA9, and osteopontin : predictors of survival in patients with high-grade glioma.
Glioma
Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers.
Glioma
Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007.
Glioma
siRNA-mediated knockdown against CDCA1 and KNTC2, both frequently overexpressed in colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis.
Glioma
Targeting CAIX with [64Cu]XYIMSR-06 small molecular radio-tracer enables noninvasive PET imaging of malignant glioma in U87 MG tumor cell xenograft mice.
Glioma
Trace elements, heavy metals and other biochemical parameters in malignant glioma patients.
Glioma
[3H]acetazolamide binding to carbonic anhydrase in normal and transformed cells.
Glomerulonephritis
Gene therapy for renal diseases.
Glomerulonephritis
Herpes simplex virus as a model vector system for gene therapy in renal disease.
Glycogen Storage Disease Type IIb
Cystoid macular edema in a patient with Danon disease.
Granuloma
Sarcoidosis patient: an unexpected reaction to carbonic anhydrase enzyme inhibitor.
Graves Disease
Erythrocyte carbonic anhydrase-I concentrations in patients with Graves' disease and subacute thyroiditis reflect integrated thyroid hormone levels over the previous few months.
Graves Disease
Increased serum anti-carbonic anhydrase II antibodies in patients with Graves' disease.
Gyrate Atrophy
Carbonic anhydrase inhibitor with topical NSAID therapy to manage cystoid macular edema in a case of gyrate atrophy.
Head and Neck Neoplasms
Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial.
Head and Neck Neoplasms
High serum carbonic anhydrase IX predicts shorter survival in head and neck cancer.
Head and Neck Neoplasms
High stromal carbonic anhydrase IX expression is associated with nodal metastasis and decreased survival in patients with surgically-treated oral cavity squamous cell carcinoma.
Head and Neck Neoplasms
Imaging carbonic anhydrase IX as a method for monitoring hypoxia-related radioresistance in preclinical head and neck cancer models.
Head and Neck Neoplasms
[Relation between carbonic anhydrase IX serum level, hypoxia and radiation resistance of head and neck cancers].
Heart Defects, Congenital
Carbonic anhydrase in congenital heart disease.
Heart Defects, Congenital
[Blood carbonic anhydrase activity in young children with different forms of congenital heart defects]
Heart Defects, Congenital
[Clinical importance of determining the blood carbonic anhydrase activity in congenital heart defects complicated by bacterial endocarditis]
Heart Diseases
The effects of cardiac drugs on human erythrocyte carbonic anhydrase I and II isozymes.
Heart Failure
Acetazolamide protects against posthypoxic unstable breathing in the C57BL/6J mouse.
Heart Failure
Carbonic anhydrases III and IV autoantibodies in rheumatoid arthritis, systemic lupus erythematosus, diabetes, hypertensive renal disease, and heart failure.
Heart Failure
Discovery of arjunolic acid as a novel non-zinc binding carbonic anhydrase II inhibitor.
Heart Failure
Diuretic therapy in fluid-overloaded and heart failure patients.
Heart Failure
Diuretic treatment of the patient with diabetes and heart failure. Role of SGLT2 inhibitors and similarities with carbonic anhydrase inhibitors.
Heart Failure
Effect of Acetazolamide on Chemosensitivity, Cheyne-Stokes Respiration, and Response to Effort in Patients With Heart Failure.
Heart Failure
Oral administration of a potent carbonic anhydrase inhibitor (Diamox). II. Its use as a diuretic in patients with severe congestive heart failure.
Heart Failure
Oral administration of a potent carbonic anhydrase inhibitor (diamox). III. Its use as a diuretic in patients with severe congestive heart failure due to cor pulmonale.
Heart Failure
Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial.
Heart Failure
The effect of intravenously administered 6063, the carbonic anhydrase inhibitor, 2-acetylamino-1, 3, 4-thiadiazole-5-sulfonamide, on fluid and electrolytes in normal subjects and patients with congestive heart failure.
Heart Failure
The use of carbonic anhydrase inhibitor (diamox) in congestive heart failure.
Heart Failure
The use of diamox, a carbonic anhydrase inhibitor, as an oral diuretic in patients with congestive heart failure.
Heart Failure
Transgenic Expression of Carbonic Anhydrase III in Cardiac Muscle Demonstrates A Mechanism to Tolerate Acidosis.
Heart Failure
[Effect of carbonic anhydrase inhibitor (diamox A) and of mercurial diuretics on electrolyte and water elimination in congestive heart failure.]
HELLP Syndrome
Circulating parameters of oxidative stress and hypoxia in normal pregnancy and HELLP syndrome.
Hemangioblastoma
Expression of HIF-1 regulated proteins vascular endothelial growth factor, carbonic anhydrase IX and hypoxia inducible gene 2 in hemangioblastomas.
Hemangioblastoma
Expression of hypoxia-inducible carbonic anhydrases in brain tumors.
Hemangioblastoma
Soft-tissue Hemangioblastoma of the Retroperitoneum: A Case Study and Review of the Literature.
Hemangioblastoma
Specific immunohistochemical pattern of carbonic anhydrase IX is helpful for the diagnosis of CNS hemangioblastoma.
Hemangioma
Carbonic anhydrase is abundant in fenestrated capillaries of cherry hemangioma.
Hematologic Neoplasms
The expression of carbonic anhydrase II in hematological malignancies.
Hemorrhagic Fever, Crimean
Carbonic anhydrase I-II autoantibodies and oxidative status in long-term follow-up of patients with Crimean-Congo haemorrhagic fever.
Hepatic Encephalopathy
Production of impending hepatic coma by a carbonic anhydrase inhibitor, diamox.
Hepatitis
Analyses of polypeptides in the liver of a novel mutant (LEC rats) to hereditary hepatitis and hepatoma by two-dimensional gel electrophoresis: identification of P29/6.8 as carbonic anhydrase III and triosephosphate isomerase.
Hepatitis
Identification of the zinc-binding protein specifically present in male rat liver as carbonic anhydrase III.
Hepatitis
Serum antibody to carbonic anhydrase II in patients with chronic viral hepatitis: a review of its prevalence in liver diseases.
Hepatitis
Sexual dimorphism in LEC rat liver: suppression of carbonic anhydrase III by copper accumulation during hepatocarcinogenesis.
Hepatitis A
Serum antibody to carbonic anhydrase II in patients with chronic viral hepatitis: a review of its prevalence in liver diseases.
Hepatitis, Autoimmune
Antibodies to carbonic anhydrase in patients with immune cholangiopathies.
Hepatitis, Autoimmune
Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status.
Hepatitis, Autoimmune
The ability of anti-carbonic anhydrase II antibody to distinguish autoimmune cholangitis from primary biliary cirrhosis in Japanese patients.
Hepatolenticular Degeneration
Identification of the zinc-binding protein specifically present in male rat liver as carbonic anhydrase III.
Herpes Zoster
Carbonic anhydrase isoenzymes II and I are present in the zona glomerulosa cells of the human adrenal gland.
Herpes Zoster
Carbonic anhydrases in the human adrenal gland and its disorders: Immunohistochemical and biochemical studies of the enzymes.
Histiocytoma, Malignant Fibrous
Histochemistry of tartrate-resistant acid phosphatase and carbonic anhydrase isoenzyme II in osteoclast-like giant cells in bone tumours.
Hodgkin Disease
Hypoxia related carbonic anhydrase IX expression is associated with unfavourable response to first-line therapy in classical Hodgkin's lymphoma.
Hodgkin Disease
Quantitative Analysis of Carbonic Anhydrase IX Uncovers Hypoxia-Related Functional Differences in Classical Hodgkin Lymphoma Subtypes.
Huntington Disease
The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain.
Hydrocephalus
Acetazolamide Attenuates Thrombin-Induced Hydrocephalus.
Hydrocephalus
Acetazolamide treatment of progressive hydrocephalus secondary to intraventricular hemorrhage in a preterm infant.
Hydrocephalus
Carbonic anhydrase inhibitors in chronic infantile hydrocephalus.
Hydrocephalus
Risk Factors for Intraoperative Hypocapnia in Pediatric Neurosurgical Patients: A Retrospective Cohort Study.
Hyperaldosteronism
A novel low-activity form of carbonic anhydrase I in erythrocytes of patients with primary aldosteronism. Evidence for the presence of a mixed disulfide with glutathione.
Hyperaldosteronism
Inactive form of carbonic anhydrase I in erythrocytes from primary aldosteronism.
Hyperalgesia
Acetazolamide, a carbonic anhydrase inhibitor, reverses inflammation-induced thermal hyperalgesia in rats.
Hyperalgesia
Oxaliplatin-induced neuropathy occurs through impairment of haemoglobin proton buffering and is reversed by carbonic anhydrase inhibitors.
Hyperalgesia
Trigeminal antihyperalgesic effect of intranasal carbon dioxide.
Hypercalcemia
Drug-induced acid-base disorders.
Hypercalcemia
Treatment of humoral hypercalcemia of malignancy in rats with inhibitors of carbonic anhydrase.
Hyperemia
New glaucoma medications in the geriatric population: efficacy and safety.
Hypergammaglobulinemia
Autoimmune chronic pancreatitis.
Hypergammaglobulinemia
Autoimmune pancreatitis as a new clinical entity. Three cases of autoimmune pancreatitis with effective steroid therapy.
Hypergammaglobulinemia
Autoimmune pancreatitis, pancreatic mass, and lower gastrointestinal bleed.
Hyperglycemia
PDX1 in Ducts Is Not Required for Postnatal Formation of ?-Cells but Is Necessary for Their Subsequent Maturation.
Hyperinsulinism
Carbonic anhydrase III in obese Zucker rats.
Hyperkalemia
DSR-71167, a novel mineralocorticoid receptor antagonist with carbonic anhydrase inhibitory activity, separates urinary sodium excretion and serum potassium elevation in rats.
Hyperkalemia
The treatment of hyperpotassemia: some observations on the use of a carbonic anhydrase inhibitor as a therapeutic aid.
Hyperkalemia
Use of diuretics in chronic renal failure.
Hyperlactatemia
Mitochondrial carbonic anhydrase VA deficiency in three Indian infants manifesting early metabolic crisis.
Hyperlipidemias
Use of diuretics in chronic renal failure.
Hyperphosphatemia
The role of vitamin D in chorioallantoic membrane calcium transport.
Hypersensitivity
Evaluation of Adverse Events in Self-Reported Sulfa-Allergic Patients Using Topical Carbonic Anhydrase Inhibitors.
Hypersensitivity
Octreotide: The IIH therapy beyond weight loss, carbonic anhydrase inhibitors, lumbar punctures and surgical/interventional treatments.
Hypersensitivity
Use of Acetazolamide in Sulfonamide-Allergic Patients With Neurologic Channelopathies.
Hypersensitivity
[Activity of blood carbonic anhydrase in various allergies.]
Hypertension
A Rare Case of Synchronous Esophageal and Pancreatic Malignancy.
Hypertension
A Taste-intensity Visual Analog Scale: An Improved Zinc Taste-test Protocol.
Hypertension
Acetazolamide Reduces Blood Pressure and Sleep-Disordered Breathing in Patients With Hypertension and Obstructive Sleep Apnea: A Randomized Controlled Trial.
Hypertension
Aminozolamide gel. A trial of a topical carbonic anhydrase inhibitor in ocular hypertension.
Hypertension
Aplastic anemia and agranulocytosis in patients using methazolamide for glaucoma.
Hypertension
Carbonic anhydrase I and II autoantibody levels in primary hypertension: our preliminary results.
Hypertension
Carbonic anhydrase, obstructive sleep apnea and hypertension: Effects of intervention.
Hypertension
Changes in carbonic anhydrase may be the initial step of altered metabolism in hypertension.
Hypertension
Erythrocyte carbonic anhydrase: a major intracellular enzyme to regulate cellular sodium metabolism in chronic renal failure patients with diabetes and hypertension.
Hypertension
Hypotensive effect of calcium channel blockers is parallel with carbonic anhydrase I inhibition.
Hypertension
Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells.
Hypertension
Increased oxidation-related glutathionylation and carbonic anhydrase activity in endometriosis.
Hypertension
Independent associations between arterial bicarbonate, apnea severity and hypertension in obstructive sleep apnea.
Hypertension
Lagenaria siceraria and it's bioactive constituents in carbonic anhydrase inhibition: A bioactivity guided LC-MS/MS approach.
Hypertension
Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study.
Hypertension
Risk factors of shallow anterior chamber other than hypotony after Ahmed glaucoma valve implant.
Hypertension
[Study on mechanism for anti-hypertension efficacy of Eucommiae Cortex through assistant analysis systems for acting mechanisms of traditional Chinese medicine].
Hypertension, Pulmonary
CA Dreamin': Carbonic Anhydrase Inhibitors, Macrophages and Pulmonary Hypertension.
Hypertension, Pulmonary
Carbonic Anhydrase Inhibition Ameliorates Inflammation and Experimental Pulmonary Hypertension.
Hypertension, Pulmonary
Carbonic anhydrase inhibition improves pulmonary artery reactivity and nitric oxide-mediated relaxation in sugen-hypoxia model of pulmonary hypertension.
Hypertension, Pulmonary
[Mountain sickness].
Hyperthyroidism
Carbonic anhydrase isoenzyme B in erythrocytes of hyperthyroid, pregnant and oestrogen-treated subjects.
Hyperthyroidism
Carbonic anhydrase isozymes of red blood cells in surgically treated hyperthyroidism.
Hyperthyroidism
Carbonic anhydrase of the blood in hyperthyroidism.
Hyperthyroidism
Changes in red cell carbonic anhydrase B and serum iodothyronines in hyperthyroid subjects following 131-I treatment.
Hyperthyroidism
Clinical utility of red blood cell carbonic anhydrase I and zinc concentrations in patients with thyroid diseases.
Hyperthyroidism
Effect of thyroid hormone on the levels of erythrocyte carbonic anhydrase isozymes and 2,3-diphosphoglycerate in rabbits.
Hyperthyroidism
Effects of thyroid hormone on carbonic anhydrase I concentration in human erythroid burst-forming unit-derived cells.
Hyperthyroidism
Effects of thyroid hormone on carbonic anhydrase I gene expression in human erythroid cells.
Hyperthyroidism
Effects of thyroid hormone on carbonic anhydrase I levels in human erythroid (YN-1) cells.
Hyperthyroidism
Erythrocyte carbonic anhydrase I concentration in patients receiving thyroxine.
Hyperthyroidism
Erythrocyte carbonic anhydrase-I concentrations in patients with Graves' disease and subacute thyroiditis reflect integrated thyroid hormone levels over the previous few months.
Hyperthyroidism
Estimations of active and inactive carbonic anhydrase isozyme B in human red cells.
Hyperthyroidism
Investigation of red blood cell carbonic anhydrase, glucose 6-phosphate dehydrogenase, hexokinase enzyme activities, and zinc concentration in patients with hyperthyroid diseases.
Hyperthyroidism
Regulation of carbonic anhydrase III by thyroid hormone: opposite modulation in slow- and fast-twitch skeletal muscle.
Hyperthyroidism
[Erythrocytic carbonic anhydrase in hyperthyroidism]
Hyperventilation
Acetazolamide, metabolic acidosis, and intraocular pressure.
Hyperventilation
Dorzolamide hydrochloride and visual function in normal eyes.
Hyperventilation
Drug-induced acid-base disorders.
Hyperventilation
Elevated erythrocyte carbonic anhydrase activity is a novel clinical marker in hyperventilation syndrome.
Hyperventilation
Topiramate-induced metabolic acidosis: report of two cases.
Hyperventilation
Ventilatory response to carbonic anhydrase inhibition in cats: effects of acetazolamide in intact vs peripherally chemodenervated animals.
Hyphema
Reversal of retinal and optic disc ischemia in a patient with sickle cell trait and glaucoma secondary to traumatic hyphema.
Hypocalcemia
Acidosis inhibits the hypocalcemic effect of acetazolamide.
Hypocalcemia
The role of vitamin D in chorioallantoic membrane calcium transport.
Hypoglycemia
Mitochondrial carbonic anhydrase VA deficiency in three Indian infants manifesting early metabolic crisis.
Hypoglycemia
Sulfonamide drugs: structure, antibacterial property, toxicity, and biophysical interactions.
Hypoglycemia
Two cases of carbonic anhydrase VA deficiency-An ultrarare metabolic decompensation syndrome presenting with hyperammonemia, lactic acidosis, ketonuria, and good clinical outcome.
Hypohidrosis
Clear cell injury associated with reduced expression of carbonic anhydrase II in eccrine glands consistently occurs in patients with acquired idiopathic generalized anhidrosis.
Hypohidrosis
Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management.
Hypokalemia
Distal renal tubular acidosis and the potassium enigma.
Hypokalemia
Diuretic complications.
Hypokalemia
Hypokalemia and suspected renal tubular acidosis associated with topical carbonic anhydrase inhibitor therapy in a cat.
Hypokalemia
Renal bicarbonate reabsorption in the rat. I. Effects of hypokalemia and carbonic anhydrase.
Hypokalemic Periodic Paralysis
Acetazolamide prevents vacuolar myopathy in skeletal muscle of K(+) -depleted rats.
Hypokalemic Periodic Paralysis
Channelopathies.
Hypokalemic Periodic Paralysis
Treatment of "permanent" muscle weakness in familial Hypokalemic Periodic Paralysis.
Hypokalemic Periodic Paralysis
Treatment of hypokalemic periodic paralysis with topiramate.
Hypokalemic Periodic Paralysis
Treatment of neuromuscular channelopathies: current concepts and future prospects.
Hyponatremia
Autosomal recessive hyponatremia due to isolated salt wasting in sweat associated with a mutation in the active site of Carbonic Anhydrase 12.
Hyponatremia
Natural History and Clinical Manifestations of Hyponatremia and Hyperchlorhidrosis due to Carbonic Anhydrase XII Deficiency.
Hypophosphatemia, Familial
Carbonic anhydrase, cyclic AMP, and the phosphaturia of parathyroid hormone.
Hypotension
Cardiorespiratory effects induced by acetazolamide on the ventromedullary surface of the cat.
Hypotension
The effect of metabolic alkalosis, hypotension and inhibitors of carbonic anhydrase on fluid secretion by rat testes.
Hypotension
[Anaesthesia and intraocular pressure (author's transl)]
Hypothyroidism
Effects of hyper- and hypothyroidism on carbonic anhydrase, Mg2(+)-dependent ATPase and Mg2(+)-dependent, HCO3(-)-stimulated ATPase activities of rat duodenal mucosa and kidney cortex.
Hypothyroidism
Quantitation of red cell carbonic anhydrase B. A diagnostic test for hyper and hypothyroidism.
Hypothyroidism
[Quantity of carbonic anhydrase in hypothyroidism (author's transl)]
Infections
Biochemical and structural characterisation of a protozoan beta-carbonic anhydrase from Trichomonas vaginalis.
Infections
Carbonic anhydrase 2 deficiency leads to increased pyelonephritis susceptibility.
Infections
Carbonic anhydrase enzymes regulate mast cell-mediated inflammation.
Infections
Carbonic anhydrase II in the cerebrospinal fluid: its value as a disease marker.
Infections
Carbonic Anhydrase IX and Hypoxia Promote Rat Pulmonary Endothelial Cell Survival During Infection.
Infections
Carbonic anhydrase, acetazolamide and Helicobacter pylori infection.
Infections
CD4+ T cell proliferative responses to PPD and CFP-10 associate with recent M. tuberculosis infection.
Infections
Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States).
Infections
Colonic microbiota alters host susceptibility to infectious colitis by modulating inflammation, redox status and ion transporter gene expression.
Infections
Comparative proteome analysis of splenic lymphocytes in senescence-accelerated mice.
Infections
Comparative study between the Hybrid Capture II test and PCR based assay for the detection of human papillomavirus DNA in oral submucous fibrosis and oral squamous cell carcinoma.
Infections
Cyclooxygenase-2/Carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cells.
Infections
Decreased expression of GRIM-19 and its association with high-risk HPV infection in cervical squamous intraepithelial neoplasias and cancer.
Infections
Detection of persistent high risk human papillomavirus infections with hybrid capture II and SPF10/LiPA.
Infections
Differential expression of resistance to powdery mildew at the early stage of development in wheat line N0308.
Infections
Distinct neural stem cell tropism, early immune activation, and choroid plexus pathology following coxsackievirus infection in the neonatal central nervous system.
Infections
Effect of the carbonic anhydrase inhibitor, acetazolamide, on Helicobacter pylori infection in vivo: a pilot study.
Infections
Evaluation of the digene hybrid capture II CT-ID test for detection of Chlamydia trachomatis in endocervical specimens.
Infections
HPV test by Hybrid Capture II for the diagnosis of HR-HPV persistent infection.
Infections
Hybrid capture-II and LCR-E7 PCR assays for HPV typing in cervical cytologic samples.
Infections
Hypoxic marker CA IX and adhesion mediator ?-catenin are downregulated by lymphocytic choriomeningitis virus persistent infection.
Infections
Increased oxidation-related glutathionylation and carbonic anhydrase activity in endometriosis.
Infections
Lymphocyte depletion in ileal Peyer's patch follicles in lambs infected with Eimeria ovinoidalis.
Infections
Molecular characterization of a carbon dioxide-dependent Escherichia coli small-colony variant isolated from blood cultures.
Infections
New Gene Variants Associated with the Risk of Chronic HBV Infection.
Infections
Newcastle disease virus degrades HIF-1? through proteasomal pathways independent of VHL and p53.
Infections
Nuclear carbonic anhydrase 6B associates with PRMT5 to epigenetically promote IL-12 expression in innate response.
Infections
Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade.
Infections
Prevalence of human papillomavirus infection in the genital tract determined by hybrid capture assay.
Infections
Quantitative Proteomics Analysis of Plasmodium vivax Induced Alterations in Human Serum during the Acute and Convalescent Phases of Infection.
Infections
Serum Carbonic Anhydrase 1 is a Biomarker for Diagnosis of Human Schistosoma mansoni Infection.
Infections
The effects of bronchodilator drugs and antibiotics used for respiratory infection on human erythrocyte carbonic anhydrase I and II isozymes.
Infections
The pivotal role of carbonic anhydrase in malaria infection.
Infertility
Alternation of cytosolic carbonic anhydrase isoenzymes during deciduomatal development in pregnant mice.
Infertility
Endometriosis: identification by carbonic anhydrase autoantibodies and clinical features.
Infertility, Male
Ectopic expression of mitochondrial gamma carbonic anhydrase 2 causes male sterility by anther indehiscence.
Inflammatory Bowel Diseases
Carbonic Anhydrate I Epitope Peptide Improves Inflammation in a Murine Model of Inflammatory Bowel Disease.
Inflammatory Bowel Diseases
Elevated serum anti-carbonic anhydrase II antibodies in patients with ulcerative colitis.
Influenza, Human
QSAR models based on quantum topological molecular similarity.
Influenza, Human
Quantum topological QSAR models based on the MOLMAP approach.
Insulin Resistance
Study on the changes of carbonic anhydrase activity in insulin resistance and the effect of methylglyoxal.
Intellectual Disability
Brain calcification in Kallman's syndrome. Computed tomographic appearance.
Intellectual Disability
Carbonic anhydrase gating of attention: memory therapy and enhancement.
Intellectual Disability
Carbonic anhydrase II (CA II) deficiency in Maghrebian patients: evidence for founder effect and genomic recombination at the CA II locus.
Intellectual Disability
Carbonic anhydrase II deficiency: report of a novel mutation.
Intellectual Disability
Carbonic anhydrase II in the developing and adult human brain.
Intellectual Disability
Clinical and molecular heterogeneity in carbonic anhydrase II deficiency and prenatal diagnosis in an Italian family.
Intellectual Disability
Five- and Six-Membered Nitrogen-Containing Compounds as Selective Carbonic Anhydrase Activators.
Intellectual Disability
Genetic diseases of acid-base transporters.
Intellectual Disability
Indazole, Pyrazole, and Oxazole Derivatives Targeting Nitric Oxide Synthases and Carbonic Anhydrases.
Intellectual Disability
Molecular basis of human carbonic anhydrase II deficiency.
Intellectual Disability
Molecular basis of proximal renal tubular acidosis.
Intellectual Disability
Novel homozygous variant of carbonic anhydrase 8 gene expanding the phenotype of cerebellar ataxia, mental retardation, and disequilibrium syndrome subtype 3.
Intellectual Disability
Osteopetrosis, renal tubular acidosis without urinary concentration abnormality, cerebral calcification and severe mental retardation in three Turkish brothers.
Intellectual Disability
Plasma carbonic anhydrase II protein is elevated in Alzheimer's disease.
Intellectual Disability
[Syndrome associating: osteopetrosis, tubular acidosis, mental retardation and cerebral calcifications due to carbonic anhydrase II deficiency. Apropos of 3 cases in the siblings]
Intracranial Hypertension
Topiramate-responsive headache due to idiopathic intracranial hypertension in Behçet syndrome.
Iridocyclitis
The use of non-steroidal anti-inflammatory drugs in paediatric rheumatic diseases.
Iron Deficiencies
Differential expression of carbonic anhydrase isoenzymes in various types of anemia.
Keratitis
Keratitis in six dogs after topical treatment with carbonic anhydrase inhibitors for glaucoma.
Ketosis
Two cases of carbonic anhydrase VA deficiency-An ultrarare metabolic decompensation syndrome presenting with hyperammonemia, lactic acidosis, ketonuria, and good clinical outcome.
Kidney Calculi
Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet.
Kidney Calculi
The role of carbonic anhydrase in the pathogenesis of vascular calcification in humans.
Kidney Calculi
Topiramate-Induced Refractory Hypokalemia.
Kidney Diseases
The excretion of carbonic anhydrase isozymes CA I and CA II in the urine of apparently healthy subjects and in patients with kidney disease.
Kidney Diseases
Urinary carbonic anhydrase VI as a biomarker for kidney disease in pigs.
Kidney Diseases
[Carbonic anhydrase activity of the kidneys in various kidney diseases, experimental and in humans.]
Kidney Diseases
[Carbonic anhydrase inhibition in kidney diseases.]
Kidney Failure, Chronic
Anti-carbonic anhydrase II antibodies in end-stage renal disease patients.
Kidney Failure, Chronic
Carbonic anhydrase B concentration of erythrocytes in chronic renal failure.
Kidney Failure, Chronic
Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile.
Kidney Failure, Chronic
Erythrocyte carbonic anhydrase: a major intracellular enzyme to regulate cellular sodium metabolism in chronic renal failure patients with diabetes and hypertension.
Kidney Failure, Chronic
Isotope-specific breath analysis to track the end-stage renal disease during hemodialysis.
Kidney Failure, Chronic
Severe metabolic acidosis and disturbances of calcium metabolism induced by acetazolamide in patients on haemodialysis.
Kidney Failure, Chronic
The use of myoglobin/carbonic anhydrase III ratio as a marker for myocardial damage in patients with renal failure.
Kidney Failure, Chronic
[Erythrocyte carbonic anhydrase in subjects on periodic hemodialysis]
Kidney Neoplasms
Acetazolamide serves as selective delivery vehicle for dipeptide-linked drugs to renal cell carcinoma.
Kidney Neoplasms
Addressable Peptide Self-Assembly on the Cancer Cell Membrane for Sensitizing Chemotherapy of Renal Cell Carcinoma.
Kidney Neoplasms
Biomarker discovery in urogenital cancer.
Kidney Neoplasms
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
Kidney Neoplasms
Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factor-Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer.
Kidney Neoplasms
Carbonic anhydrase expression in kidney and renal cancer: implications for diagnosis and treatment.
Kidney Neoplasms
Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro.
Kidney Neoplasms
Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)?
Kidney Neoplasms
Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy.
Kidney Neoplasms
Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade.
Kidney Neoplasms
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
Kidney Neoplasms
Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma.
Kidney Neoplasms
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Kidney Neoplasms
Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo.
Kidney Neoplasms
Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: a novel vaccine for renal cell carcinoma.
Kidney Neoplasms
In vivo molecular prediction of carbonic anhydrase IX-G250MN expression on immunotherapy outcome in renal cancer.
Kidney Neoplasms
Kidney cancer: Carbonic anhydrase IX in resected clear cell RCC.
Kidney Neoplasms
Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer.
Kidney Neoplasms
Molecular and immunologic markers of kidney cancer-potential applications in predictive, preventive and personalized medicine.
Kidney Neoplasms
Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene.
Kidney Neoplasms
Re: Grant D. Stewart, Fiach C. O'Mahony, Alexander Laird, et al. Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factor-Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.007.
Kidney Neoplasms
Role of CAIX Expression in Conventional Renal Cell Carcinomas as a Diagnostic Marker and its Prognostic Importance.
Kidney Neoplasms
Role of carbonic anhydrase IX, ?-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: a tissue microarray immunohistochemical study.
Kidney Neoplasms
The role of carbonic anhydrase IX overexpression in kidney cancer.
Kidney Neoplasms
[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma.
Laryngopharyngeal Reflux
Biomarkers and laryngopharyngeal reflux.
Laryngopharyngeal Reflux
Expression of CAIII and Hsp70 Is Increased the Mucous Membrane of the Posterior Commissure in Laryngopharyngeal Reflux Disease.
Laryngopharyngeal Reflux
Laryngeal epithelial defenses against laryngopharyngeal reflux: investigations of E-cadherin, carbonic anhydrase isoenzyme III, and pepsin.
Laryngopharyngeal Reflux
Pepsin and carbonic anhydrase isoenzyme III as diagnostic markers for laryngopharyngeal reflux disease.
Leiomyoma
Carbonic anhydrase isozymes II, IX, and XII in uterine tumors.
Leiomyoma
Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia.
Leiomyoma
Proteomic identification of plasma biomarkers in uterine leiomyoma.
Leiomyosarcoma
Carbonic anhydrase isozymes II, IX, and XII in uterine tumors.
Leishmaniasis
Are Carbonic Anhydrases Suitable Targets to Fight Protozoan Parasitic Diseases?
Leishmaniasis
Cloning, Characterization, and Inhibition Studies of a ?-Carbonic Anhydrase from Leishmania donovani chagasi , the Protozoan Parasite Responsible for Leishmaniasis.
Leishmaniasis
Discovery of new organoselenium compounds as antileishmanial agents.
Leishmaniasis
N-Nitrosulfonamides as Carbonic Anhydrase Inhibitors: A Promising Chemotype for Targeting Chagas Disease and Leishmaniasis.
Leukemia
Carbonic anhydrase: a marker for the erythroid phenotype in acute nonlymphocytic leukemia.
Leukemia
Clinical and molecular features of papillary thyroid cancer in adolescents and young adults.
Leukemia
Erythrocyte catalase and carbonic anhydrase activities in acute leukemias.
Leukemia
Implication of sulfonylurea derivatives as prospective inhibitors of human carbonic anhydrase II.
Leukemia
Preferential consumption of heparin cofactor II in disseminated intravascular coagulation associated with acute promyelocytic leukemia.
Leukemia
Stimulation of human colonic epithelial cells by leukemia inhibitory factor is dependent on collagen-embedded fibroblasts in organotypic culture.
Leukemia
Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and ?-glycosidase inhibitors.
Leukemia
Synthesis of novel bis-sulfone derivatives and their inhibition properties on some metabolic enzymes including carbonic anhydrase, acetylcholinesterase, and butyrylcholinesterase.
Leukemia, Erythroblastic, Acute
A case of juvenile erythroleukemia with uncoordinated expression of fetal red cell markers.
Leukemia, Erythroblastic, Acute
Carbonic anhydrase is aberrantly and constitutively expressed in both human and murine erythroleukemia cells.
Leukemia, Erythroblastic, Acute
Erythroid cell differentiation.
Leukemia, Erythroblastic, Acute
Increased carbonic anhydrase activity in Friend erythroleukemia cells during DMSO-stimulated erythroid differentiation and its inhibition by BrdU.
Leukemia, Erythroblastic, Acute
Induction of carbonic anhydrase I isozyme precedes the globin synthesis during erythropoiesis in K562 cells.
Leukemia, Erythroblastic, Acute
The carbonic anhydrase I locus contains a c-Myb target promoter and modulates differentiation of murine erythroleukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytosolic carbonic anhydrase activity in chronic myeloid disorders with different clinical phenotype.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Erythroid cell differentiation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Myelomonocytic leukemia with Philadelphia-positive and Philadelphia-negative cell lines in early childhood (author's transl)]
Leukemia, Myeloid, Acute
Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
Carbonic anhydrase: a marker for the erythroid phenotype in acute nonlymphocytic leukemia.
Leukemia, Myelomonocytic, Juvenile
[Juvenile chronic myelogenous leukemia in a seven-year-old boy with normal red cell carbonic anhydrase activity--a case report (author's transl)]
Leukemia, Promyelocytic, Acute
Arsenolipids.
Leukemia, Promyelocytic, Acute
Preferential consumption of heparin cofactor II in disseminated intravascular coagulation associated with acute promyelocytic leukemia.
Leukodystrophy, Globoid Cell
Carbonic anhydrase and 2',3' cyclic nucleotide 3'-phosphohydrolase activity in normal human brain and in demyelinating diseases.
Leukoencephalopathies
Identification of membrane-bound carbonic anhydrase in white matter coated vesicles: the fate of carbonic anhydrase and other white matter coated vesicle proteins in triethyl tin-induced leukoencephalopathy.
Leukopenia
Evaluation of carbonic anhydrase isozymes in disorders involving osteopetrosis and/or renal tubular acidosis.
Leukopenia
Heparin cofactor II as a predictor of thrombotic microangiopathy after bone marrow transplantation.
Leukoplakia
Different expression patterns of carbonic anhydrase IX in oral lichen planus and leukoplakia.
Leukoplakia
The use of CA-IX as a diagnostic method for oral leukoplakia.
Leukoplakia, Oral
Different expression patterns of carbonic anhydrase IX in oral lichen planus and leukoplakia.
Leukoplakia, Oral
The use of CA-IX as a diagnostic method for oral leukoplakia.
Leydig Cell Tumor
Treatment of humoral hypercalcemia of malignancy in rats with inhibitors of carbonic anhydrase.
Lichen Planus, Oral
Different expression patterns of carbonic anhydrase IX in oral lichen planus and leukoplakia.
Liver Cirrhosis
Heparin cofactor II: a simple assay method and results of its clinical application.
Liver Cirrhosis
The Role of Beta-7 Integrin and Carbonic Anhydrase IX in Predicting the Occurrence of de Novo Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients.
Liver Cirrhosis, Alcoholic
Plasma heparin cofactor II in alcoholic liver disease.
Liver Cirrhosis, Biliary
Antibodies to carbonic anhydrase in patients with immune cholangiopathies.
Liver Cirrhosis, Biliary
Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status.
Liver Cirrhosis, Biliary
Are antibodies to carbonic anhydrase II specific for anti-mitochondrial antibody-negative primary biliary cirrhosis?
Liver Cirrhosis, Biliary
Autoimmune liver disease.
Liver Cirrhosis, Biliary
Increased serum anti-carbonic anhydrase II antibodies in patients with Graves' disease.
Liver Cirrhosis, Biliary
Lack of serum antibodies to membrane bound carbonic anhydrase IV in patients with primary biliary cirrhosis.
Liver Cirrhosis, Biliary
Primary biliary cirrhosis with antibody against carbonic anhydrase II associates with distinct immunological backgrounds.
Liver Cirrhosis, Biliary
Relation between zinc status and hepatic functional reserve in patients with liver disease.
Liver Cirrhosis, Biliary
The ability of anti-carbonic anhydrase II antibody to distinguish autoimmune cholangitis from primary biliary cirrhosis in Japanese patients.
Liver Diseases
Antibodies to carbonic anhydrase in patients with immune cholangiopathies.
Liver Diseases
Detection of autoantibody against carbonic anhydrase II in various liver diseases by enzyme-linked immunosorbent assay using appropriate conditions.
Liver Diseases
Hereditary heparin cofactor II deficiency and the risk of development of thrombosis.
Liver Diseases
Preferential consumption of heparin cofactor II in disseminated intravascular coagulation associated with acute promyelocytic leukemia.
Liver Diseases
Relation between zinc status and hepatic functional reserve in patients with liver disease.
Liver Diseases
Serum antibody to carbonic anhydrase II in patients with chronic viral hepatitis: a review of its prevalence in liver diseases.
Liver Diseases
The Role of Beta-7 Integrin and Carbonic Anhydrase IX in Predicting the Occurrence of de Novo Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients.
Liver Diseases, Alcoholic
Expression of testosterone-dependent enzyme, carbonic anhydrase III, and oxidative stress in experimental alcoholic liver disease.
Liver Diseases, Alcoholic
Relation between zinc status and hepatic functional reserve in patients with liver disease.
Liver Failure
Plasma heparin cofactor II in alcoholic liver disease.
Liver Neoplasms
Carbonic anhydrase III promotes transformation and invasion capability in hepatoma cells through FAK signaling pathway.
Liver Neoplasms
Expression of liver cancer associated gene HCCA3.
Liver Neoplasms
Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis.
Low Tension Glaucoma
Effect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure.
Lung Diseases
Activity of carbon anhydrase in the blood; study of patients with dyspnea consequent to chronic cardiac and pulmonary disease.
Lung Diseases
Carbonic anhydrase inhibition in glaucoma: hazard or benefit for the chronic lunger?
Lung Diseases
Carbonic anhydrase isoenzyme B in erythrocytes of subjects with pulmonary diseases.
Lung Diseases
DICHLORPHENAMIDE, A POTENT CARBONIC ANHYDRASE INHIBITOR. EFFECT ON ALVEOLAR VENTILATION, VENTILATION-PERFUSION RELATIONSHIPS AND DIFFUSION IN PATIENTS WITH CHRONIC LUNG DISEASE.
Lung Diseases
Is carbonic anhydrase inhibition useful as a complementary therapy of Covid-19 infection?
Lung Diseases
[Determination of carbonic anhydrase in the blood in chronic pulmonary diseases.]
Lung Diseases
[Inhibition of renal carbonic anhydrase as a respiratory stimulant-- an obsolete indication?]
Lung Diseases, Obstructive
Estimations of active and inactive carbonic anhydrase isozyme B in human red cells.
Lung Injury
Carbonic anhydrase inhibitor attenuates ischemia-reperfusion induced acute lung injury.
Lung Neoplasms
A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.
Lung Neoplasms
Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis.
Lung Neoplasms
Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer.
Lung Neoplasms
Association of Carbonic Anhydrase 9 Polymorphism and the Epithelial Growth Factor Receptor Mutations in Lung Adenocarcinoma Patients.
Lung Neoplasms
Biochemical and Structural Insights into Carbonic Anhydrase XII/Fab6A10 Complex.
Lung Neoplasms
Carbonic anhydrase 1 is a promising biomarker for early detection of non-small cell lung cancer.
Lung Neoplasms
Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration.
Lung Neoplasms
Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy.
Lung Neoplasms
Carbonic anhydrase inhibitors--Part 94. 1,3,4-thiadiazole-2-sulfonamidederivatives as antitumor agents?
Lung Neoplasms
Carbonic anhydrase IX expression correlates with FDG uptake by primary non-small cell lung cancer.
Lung Neoplasms
Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer.
Lung Neoplasms
Carbonic anhydrase IX in early-stage non-small cell lung cancer.
Lung Neoplasms
Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells in vitro.
Lung Neoplasms
Carbonic anhydrase-related protein VIII increases invasiveness of non-small cell lung adenocarcinoma.
Lung Neoplasms
CAXII Is a sero-diagnostic marker for lung cancer.
Lung Neoplasms
Clinical Impact and Reliability of Carbonic Anhydrase XII in the Differentiation of Malignant and Tuberculous Pleural Effusions.
Lung Neoplasms
Diverging prognostic impacts of hypoxic markers according to NSCLC histology.
Lung Neoplasms
Downregulation of carbonic anhydrase IV contributes to promotion of cell proliferation and is associated with poor prognosis in non-small cell lung cancer.
Lung Neoplasms
Drug Repurposing as an Antitumor Agent: Disulfiram-Mediated Carbonic Anhydrase 12 and Anion Exchanger 2 Modulation to Inhibit Cancer Cell Migration.
Lung Neoplasms
Effect of carbonic anhydrase-related protein VIII expression on lung adenocarcinoma cell growth.
Lung Neoplasms
Erythrocyte catalase and carbonic anhydrase activities in lung cancer.
Lung Neoplasms
Expression of carbonic anhydrase-related protein CA-RP VIII in non-small cell lung cancer.
Lung Neoplasms
Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer.
Lung Neoplasms
High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer.
Lung Neoplasms
Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression.
Lung Neoplasms
Inhibition of carbonic anhydrase II by sulfonamide derivatives.
Lung Neoplasms
Inhibitory Monoclonal Antibodies and Their Recombinant Derivatives Targeting Surface-Exposed Carbonic Anhydrase XII on Cancer Cells.
Lung Neoplasms
Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I-II Non-Small-Cell Lung Cancer.
Lung Neoplasms
Multimodal evaluation of hypoxia in brain metastases of lung cancer and interest of hypoxia image-guided radiotherapy.
Lung Neoplasms
Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer.
Lung Neoplasms
Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis.
Lung Neoplasms
Prognostic significance of carbonic anhydrase IX overexpression in stage III non-small cell lung cancer patients after neoadjuvant treatment.
Lung Neoplasms
Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma.
Lung Neoplasms
Pulmonary delivery of triptolide-loaded liposomes decorated with anti-carbonic anhydrase IX antibody for lung cancer therapy.
Lung Neoplasms
Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer.
Lung Neoplasms
Response of CAIX and CAXII to in vitro re-oxygenation and clinical significance of the combined expression in NSCLC patients.
Lung Neoplasms
siRNA-mediated knockdown against CDCA1 and KNTC2, both frequently overexpressed in colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis.
Lung Neoplasms
The aberrant expression of cytosolic carbonic anhydrase and its clinical significance in human non-small cell lung cancer.
Lung Neoplasms
[Value of Detection of CAIX in the Pleural Effusion and Its Sediment in the Diagnosis of Lung Cancer].
Lupus Erythematosus, Systemic
A novel autoantibody reactive with carbonic anhydrase in sera from patients with systemic lupus erythematosus and Sjögren's syndrome.
Lupus Erythematosus, Systemic
A study of anti-carbonic anhydrase II antibodies in rheumatic autoimmune diseases.
Lupus Erythematosus, Systemic
Antibodies to carbonic anhydrase in systemic lupus erythematosus and other rheumatic diseases.
Lupus Erythematosus, Systemic
Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status.
Lupus Erythematosus, Systemic
Carbonic anhydrases III and IV autoantibodies in rheumatoid arthritis, systemic lupus erythematosus, diabetes, hypertensive renal disease, and heart failure.
Lymphadenitis
Immunohistochemical observations on carbonic anhydrase I and II in human salivary glands and submandibular obstructive adenitis.
Lymphatic Metastasis
Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer.
Lymphatic Metastasis
Downregulation of carbonic anhydrase IV contributes to promotion of cell proliferation and is associated with poor prognosis in non-small cell lung cancer.
Lymphatic Metastasis
Expression of carbonic anhydrases I/II and the correlation to clinical aspects of oral squamous cell carcinoma analyzed using tissue microarray.
Lymphatic Metastasis
Expression of hypoxia-associated proteins in sporadic medullary thyroid cancer is associated with desmoplastic stroma reaction and lymph node metastasis and may indicate somatic mutations in the VHL gene.
Lymphatic Metastasis
Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases.
Lymphatic Metastasis
Prognostic value of carbonic anhydrase IX expression in penile squamous cell carcinoma: A pilot study.
Lymphatic Metastasis
Role of hypoxia-inducible factor-1?, carbonic anhydrase-IX, glucose transporter-1 and vascular endothelial growth factor associated with lymph node metastasis and recurrence in patients with locally advanced cervical cancer.
Lymphatic Metastasis
The Expression of Carbonic Anhydrase (CA) IX/ XII and Lymph Node Metastasis in Early Breast Cancer.
Lymphatic Metastasis
Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer.
Lymphatic Metastasis
Tumor-associated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis.
Lymphatic Metastasis
[Expression and clinical pathological implications of carbonic anhydrase 9 and P glycoprotein in laryngeal squamous cell carcinoma].
Lymphocytic Choriomeningitis
Hypoxic marker CA IX and adhesion mediator ?-catenin are downregulated by lymphocytic choriomeningitis virus persistent infection.
Lymphocytic Choriomeningitis
Lymphocytic choriomeningitis virus mx strain does not induce the expression of tumor-associated carbonic anhydrase IX in persistently infected HeLa cells.
Lymphoma
An Intrarenal Adrenocortical Carcinoma Arising in an Adrenal Rest.
Lymphoma
Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models.
Lymphoma
Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma.
Lymphoma
Pharmacological inhibition of carbonic anhydrase XII interferes with cell proliferation and induces cell apoptosis in T-cell lymphomas.
Lymphoma, B-Cell
Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models.
Lymphoma, B-Cell
Carbonic Anhydrase Inhibitor Acetazolamide Enhances CHOP Treatment Response and Stimulates Effector T-Cell Infiltration in A20/BalbC Murine B-Cell Lymphoma.
Lymphoma, B-Cell
Cytokeratin and protein expression patterns in squamous cell carcinoma of the oral cavity provide evidence for two distinct pathogenetic pathways.
Lymphoma, Non-Hodgkin
Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
Sjögren's syndrome--study of autoantigens and autoantibodies.
Lymphoma, T-Cell
Pharmacological inhibition of carbonic anhydrase XII interferes with cell proliferation and induces cell apoptosis in T-cell lymphomas.
Machado-Joseph Disease
Protective roles of carbonic anhydrase 8 in Machado-Joseph Disease.
Macular Degeneration
Oral acetazolamide as a medical adjuvant to retinal surgery in optic disc pit maculopathy in a pediatric patient.
Macular Degeneration
Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study.
Macular Edema
Bilateral intravitreal dexamethasone implant for retinitis pigmentosa-related macular edema.
Macular Edema
Carbonic anhydrase inhibitor with topical NSAID therapy to manage cystoid macular edema in a case of gyrate atrophy.
Macular Edema
Carbonic anhydrase inhibitors in patients with X-linked retinoschisis: effects on macular morphology and function.
Macular Edema
Carbonic anhydrase XIV is enriched in specific membrane domains of retinal pigment epithelium, Muller cells, and astrocytes.
Macular Edema
Coats-like Exudative Vitreoretinopathy in Retinitis Pigmentosa: Ocular Manifestations and Treatment Outcomes.
Macular Edema
Efficacy and prognostic factors of response to carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa.
Macular Edema
Efficacy of carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa: A meta-analysis.
Macular Edema
Efficacy of dorzolamide hydrochloride in the management of chronic cystoid macular edema in patients with retinitis pigmentosa.
Macular Edema
Efficacy of topical brinzolamide in children with retinal dystrophies.
Macular Edema
Graft failure: III. Glaucoma escalation after penetrating keratoplasty.
Macular Edema
Hypothesis concerning carbonic anhydrase treatment of cystoid macular edema: example with epiretinal membrane.
Macular Edema
Inhibition of membrane-bound carbonic anhydrase decreases subretinal pH and volume.
Macular Edema
Intravitreal dexamethasone implant for recalcitrant cystoid macular edema secondary to retinitis pigmentosa: a pilot study.
Macular Edema
Macular cysts in retinal dystrophy.
Macular Edema
Membrane-bound carbonic anhydrase in human retinal pigment epithelium.
Macular Edema
Regression of macular edema with topical brinzolamide and nepafenac alone and identification of a novel gyrate atrophy mutation.
Macular Edema
Resolution of cystoid macular edema with topical carbonic anhydrase inhibitor in a patient with retinal dystrophy associated with Cohen syndrome.
Macular Edema
Short-term outcomes of subtenon triamcinolone acetonide injections in patients with retinitis pigmentosa-associated cystoid macular edema unresponsive to carbonic anhydrase inhibitors.
Macular Edema
Simplex Crumbs Homologue 1 Maculopathy Masquerading as Juvenile X-Linked Retinoschisis in Male Patients.
Macular Edema
Strong topical steroid, NSAID, and carbonic anhydrase inhibitor cocktail for treatment of cystoid macular edema.
Macular Edema
STRUCTURAL AND FUNCTIONAL MONITORING OF EXTRAMACULAR CYSTOID SPACES IN A CASE OF X-LINKED RETINOSCHISIS TREATED WITH ACETAZOLAMIDE.
Macular Edema
The Relationship between Serum Carbonic Anhydrase I-II Autoantibody Levels and Diabetic Retinopathy in Type 1 Diabetes Patients.
Macular Edema
The role of carbonic anhydrase inhibitors in the management of macular edema.
Macular Edema
Topical Aqueous Suppression and Closure of Idiopathic Full-Thickness Macular Holes.
Macular Edema
Topical carbonic anhydrase inhibitors in macular edema associated with Alström syndrome.
Macular Edema
TOPICAL DORZOLAMIDE FOR CYSTOID MACULAR EDEMA IN BIETTI CRYSTALLINE RETINAL DYSTROPHY.
Macular Edema
Topical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal.
Macular Edema
TOPICAL DORZOLAMIDE FOR TREATMENT OF CYSTOID MACULAR EDEMA IN PATIENTS WITH CHOROIDEREMIA.
Macular Edema
Topical steroidal and nonsteroidal antiinflammatory drugs for the treatment of cystoid macular edema in retinitis pigmentosa.
Macular Edema
Treatment of chronic macular edema with acetazolamide.
Macular Edema
Vascular endothelial growth factor gene polymorphisms and vitreous proteome changes in diabetic retinopathy.
Macular Edema
Vitreoretinal toxicity of acetazolamide following intravitreal administration in the rabbit eye.
Macular Edema
[Efficacy of dorzolamide in reducing retinal thickness after photocoagulation in diabetic macular oedema].
Macular Edema
[Therapy of cystoid diffuse macular edema after uveitis and cataract surgery with the carbonic anhydrase inhibitor acetazolamide (Diamox)]
Malaria
Anion inhibition studies of a beta carbonic anhydrase from the malaria mosquito Anopheles gambiae.
Malaria
Are Carbonic Anhydrases Suitable Targets to Fight Protozoan Parasitic Diseases?
Malaria
Carbonic anhydrase inhibitors: inhibition of Plasmodium falciparum carbonic anhydrase with aromatic/heterocyclic sulfonamides-in vitro and in vivo studies.
Malaria
Carbonic anhydrases and anion transport in mosquito midgut pH regulation.
Malaria
Discovery of a new family of carbonic anhydrases in the malaria pathogen Plasmodium falciparum--the ?-carbonic anhydrases.
Malaria
Inhibition survey with phenolic compounds against the ?- and ?-class carbonic anhydrases from the marine diatom thalassiosira weissflogii and protozoan Plasmodium falciparum.
Malaria
Malaria parasite carbonic anhydrase: inhibition of aromatic/heterocyclic sulfonamides and its therapeutic potential.
Malaria
Mild Plasmodium falciparum Malaria following an Episode of Severe Malaria Is Associated with Induction of the Interferon Pathway in Malawian Children.
Malaria
Plasmodium falciparum carbonic anhydrase is a possible target for malaria chemotherapy.
Malaria
Quantitative Proteomics Analysis of Plasmodium vivax Induced Alterations in Human Serum during the Acute and Convalescent Phases of Infection.
Malaria
Sulfonamide inhibition studies of the ?-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.
Malaria
The ?-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
Malaria
The alpha-carbonic anhydrase from the malaria parasite and its inhibition.
Malaria
The first activation studies of the ?-carbonic anhydrase from the malaria parasite Plasmodium falciparum with amines and amino acids.
Malaria
The pivotal role of carbonic anhydrase in malaria infection.
Malaria, Cerebral
Mild Plasmodium falciparum Malaria following an Episode of Severe Malaria Is Associated with Induction of the Interferon Pathway in Malawian Children.
Malaria, Cerebral
Synthesis and human/bacterial carbonic anhydrase inhibition with a series of sulfonamides incorporating phthalimido moieties.
Malnutrition
Effects of abnormal thyroid state and undernutrition on carbonic anhydrase and oligodendroglia development in the rat cerebellum.
Malnutrition
Heparin cofactor II deficiency in the elderly: comparison with antithrombin III.
Malnutrition
[Studies on acid-balance and the concentration of carbonic dioxide, oxygen and carbonic anhydrase in the blood of patients with malnutrition. 3. Variation of carbonic anhydrase content in blood]
Malnutrition
[Studies on the acid-balance and the concentration of carbonic dioxide, oxygen and carbonic anhydrase in the blood of patients with malnutrition. II. Effect of various endocrine organ preparations on CO2 and O2 content in blood]
Malnutrition
[Studies on the acid-base balance and the concentration of carbonic dioxide, oxygen and carbonic anhydrase in the blood of patients with malnutrition. I. Observation on the acid-base balance in the blood]
Mammary Analogue Secretory Carcinoma
Carbonic anhydrase VI: a novel marker for salivary serous acinar differentiation and its application to discriminate acinic cell carcinoma from mammary analogue secretory carcinoma of the salivary gland.
Mastocytosis
Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type-2 inflammation: a patent evaluation (WO2017/058370).
Measles
Microwave antigen retrieval for immunocytochemistry on formalin-fixed, paraffin-embedded post-mortem CNS tissue.
Medulloblastoma
The choroid plexus carcinomas of childhood: histopathology, immunocytochemistry and clinicopathological correlations.
Medulloblastoma
The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis.
Meibomian Gland Dysfunction
The Carbonic Anhydrase Inhibitor Dorzolamide Stimulates the Differentiation of Human Meibomian Gland Epithelial Cells.
Melanoma
An Intrarenal Adrenocortical Carcinoma Arising in an Adrenal Rest.
Melanoma
Carbonic Anhydrase 4 serves as a Clinicopathological Biomarker for Outcomes and Immune Infiltration in Renal Cell Carcinoma, Lower Grade Glioma, Lung Adenocarcinoma and Uveal Melanoma.
Melanoma
Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy.
Melanoma
Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy.
Melanoma
Carbonic anhydrase inhibitors--Part 94. 1,3,4-thiadiazole-2-sulfonamidederivatives as antitumor agents?
Melanoma
Carbonic Anhydrase-Related Protein VIII antibodies and paraneoplastic cerebellar degeneration.
Melanoma
Cell division cycle-associated protein 1 as a new melanoma-associated antigen.
Melanoma
Combining DNA Vaccine and AIM2 in H1 Nanoparticles Exert Anti-Renal Carcinoma Effects via Enhancing Tumor-Specific Multi-functional CD8+ T-cell Responses.
Melanoma
Inhibition of Melanoma Cell Migration and Invasion Targeting the Hypoxic Tumor Associated CAXII.
Melanoma
Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells.
Melanoma
Melanoma tumors exhibit a variable but distinct metabolic signature.
Melanoma
Plasma Proteomics of Renal Function: A Trans-ethnic Meta-analysis and Mendelian Randomization Study.
Melanoma
Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically.
Melanoma
The acidic tumor microenvironment drives a stem-like phenotype in melanoma cells.
Melanoma
The Carbonic Anhydrase IX inhibitor SLC-0111 as emerging agent against the mesenchymal stem cell-derived pro-survival effects on melanoma cells.
Melanoma
Umbelliferone decreases intracellular pH and sensitizes melanoma cell line A375 to dacarbazin. Comparison with acetazolamide.
Melioidosis
Anion inhibition profiles of the ?-carbonic anhydrase from the pathogenic bacterium Burkholderia pseudomallei responsible of melioidosis and highly drug resistant to common antibiotics.
Melioidosis
Comparison of the amine/amino acid activation profiles of the ?- and ?-carbonic anhydrases from the pathogenic bacterium Burkholderia pseudomallei.
Melioidosis
Comparison of the anion inhibition profiles of the ?- and ?-carbonic anhydrases from the pathogenic bacterium Burkholderia pseudomallei.
Melioidosis
Comparison of the Sulfonamide Inhibition Profiles of the ?- and ?-Carbonic Anhydrases from the Pathogenic Bacterium Burkholderia pseudomallei.
Melioidosis
Sulfonamide inhibition profile of the ?-carbonic anhydrase identified in the genome of the pathogenic bacterium Burkholderia pseudomallei the etiological agent responsible of melioidosis.
Meningioma
Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.
Meningioma
Carbonic anhydrases in meningiomas: association of endothelial carbonic anhydrase II with aggressive tumor features.
Meningioma
Distinct Expression Patterns of Carbonic Anhydrase IX in Clear Cell, Microcystic, and Angiomatous Meningiomas.
Meningioma
Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas.
Meningomyelocele
Relationship of antioxidant enzyme activities with myelomeningocele.
MERRF Syndrome
Promoter analysis and transcriptional regulation of human carbonic anhydrase VIII gene in a MERRF disease cell model.
Mesothelioma
Carbonic anhydrase IX in malignant pleural mesotheliomas: A potential target for anti-cancer therapy.
Mesothelioma
Carbonic anhydrase IX is expressed in mesothelioma and metastatic clear cell renal cell carcinoma of the lung.
Mesothelioma
In vitro and in vivo BNCT investigations using a carborane containing sulfonamide targeting CAIX epitopes on malignant pleural mesothelioma and breast cancer cells.
Mesothelioma
Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma.
Mesothelioma, Malignant
Carbonic anhydrase 9 confers resistance to ferroptosis/apoptosis in malignant mesothelioma under hypoxia.
Mesothelioma, Malignant
Carbonic anhydrase IX in malignant pleural mesotheliomas: A potential target for anti-cancer therapy.
Mesothelioma, Malignant
Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
Mesothelioma, Malignant
Role of carbonic anhydrases in ferroptosis-resistance.
Metabolic Diseases
Erythrocyte carbonic anhydrase: a major intracellular enzyme to regulate cellular sodium metabolism in chronic renal failure patients with diabetes and hypertension.
Metabolic Syndrome
Design and development of 5-(4H)-oxazolones as potential inhibitors of human carbonic anhydrase VA: towards therapeutic management of diabetes and obesity.
Metabolic Syndrome
The Role of Beta-7 Integrin and Carbonic Anhydrase IX in Predicting the Occurrence of de Novo Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients.
Microphthalmos
Carbonic anhydrase II and H+ -ATPase in osteoclasts of four osteopetrotic mutations in the rat.
Migraine Disorders
Efficacy of zonisamide in migraineurs with nonresponse to topiramate.
Migraine Disorders
Topiramate, pseudotumor cerebri, weight-loss and glaucoma: an ophthalmologic perspective.
Monoclonal Gammopathy of Undetermined Significance
Microvessel density, endothelial-cell proliferation and carbonic anhydrase IX expression in haematological malignancies, bone-marrow metastases and monoclonal gammopathy of undetermined significance.
Mouth Neoplasms
Carbonic Anhydrase III Promotes Cell Migration and Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma.
Mouth Neoplasms
Expression of carbonic anhydrases I/II and the correlation to clinical aspects of oral squamous cell carcinoma analyzed using tissue microarray.
Mouth Neoplasms
Lipocalin 2 prevents oral cancer metastasis through carbonic anhydrase IX inhibition and is associated with favourable prognosis.
Mucopolysaccharidosis III
Characterization of a Case of Pigmentary Retinopathy in Sanfilippo Syndrome Type IIIA Associated with Compound Heterozygous Mutations in the SGSH Gene.
Multiple Endocrine Neoplasia
Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression.
Multiple Endocrine Neoplasia Type 1
Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression.
Multiple Myeloma
Microvessel density, endothelial-cell proliferation and carbonic anhydrase IX expression in haematological malignancies, bone-marrow metastases and monoclonal gammopathy of undetermined significance.
Multiple Sclerosis
A single-step solid phase radioimmunoassay for quantifying human carbonic anhydrase I and II in cerebrospinal fluid.
Multiple Sclerosis
Carbonic anhydrase II in the cerebrospinal fluid: its value as a disease marker.
Muscle Weakness
Treatment of "permanent" muscle weakness in familial Hypokalemic Periodic Paralysis.
Muscle Weakness
Treatment of hypokalemic periodic paralysis with topiramate.
Muscular Atrophy
Effect of immobilization on carbonic anhydrase III and myoglobin content in human leg muscle.
Muscular Atrophy
[Carbonic anhydrase III and mRNA expression levels in quadriceps femoris muscle of chronic obstructive pulmonary disease patients].
Muscular Atrophy, Spinal
Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: relationship with creatine kinase.
Muscular Diseases
Carbonic anhydrase III in neuromuscular disorders.
Muscular Diseases
Carbonic Anhydrase III Is Expressed in Mouse Skeletal Muscles Independent of Fiber Type-Specific Myofilament Protein Isoforms and Plays a Role in Fatigue Resistance.
Muscular Diseases
Detection of the phosphatase activity of carbonic anhydrase III on a nitrocellulose membrane following 2D gel electrophoresis.
Muscular Diseases
Human muscle carbonic anhydrase III (CA-III). Purification, immunohistochemical localization in the human skeletal muscle and its clinical application to the neuromuscular disease.
Muscular Diseases
Plasma biomarker identification in S-adenosylhomocysteine hydrolase deficiency.
Muscular Disorders, Atrophic
Effect of immobilization on carbonic anhydrase III and myoglobin content in human leg muscle.
Muscular Disorders, Atrophic
Role of carbonic anhydrase in bone: partial inhibition of disuse atrophy of bone by parenteral acetazolamide.
Muscular Dystrophies
Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies.
Muscular Dystrophies
Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: relationship with creatine kinase.
Muscular Dystrophies
Distribution of immunoreactive carbonic anhydrase III in various human tissues determined by a sensitive enzyme immunoassay method.
Muscular Dystrophies
Early postnatal muscle contractile activity regulates the carbonic anhydrase phenotype of proprioceptive neurons in young and mature mice: evidence for a critical period in development.
Muscular Dystrophies
Evaluation of the therapeutic potential of carbonic anhydrase inhibitors in two animal models of dystrophin deficient muscular dystrophy.
Muscular Dystrophies
Human muscle carbonic anhydrase III (CA-III). Purification, immunohistochemical localization in the human skeletal muscle and its clinical application to the neuromuscular disease.
Muscular Dystrophies
Muscle-specific carbonic anhydrase III is a more sensitive marker of muscle damage than creatine kinase in neuromuscular disorders.
Muscular Dystrophies
Serum carbonic anhydrase III in neuromuscular disorders and in healthy persons after a long-distance run.
Muscular Dystrophies
Serum carbonic anhydrase III in progressive muscular dystrophy.
Muscular Dystrophies
[Serum carbonic anhydrase III in patients with muscular dystrophy]
Muscular Dystrophy, Duchenne
Carbonic anhydrase III in Duchenne muscular dystrophy.
Muscular Dystrophy, Duchenne
Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: relationship with creatine kinase.
Muscular Dystrophy, Duchenne
Development of a highly sensitive enzyme-immunoassay for serum carbonic anhydrase-III.
Muscular Dystrophy, Duchenne
Evaluation of carrier detection of Duchenne muscular dystrophy using carbonic anhydrase III and creatine kinase.
Muscular Dystrophy, Duchenne
Fetal plasma carbonic anhydrase III in prenatal diagnosis of Duchenne muscular dystrophy.
Muscular Dystrophy, Duchenne
Radioimmunoassay of human muscle carbonic anhydrase III in dystrophic states.
Muscular Dystrophy, Duchenne
Serum carbonic anhydrase III in progressive muscular dystrophy.
Myalgia
Warm underwater water-jet massage improves recovery from intense physical exercise.
Myasthenia Gravis
Carbonic anhydrase III is insufficient in muscles of myasthenia gravis patients.
Myasthenia Gravis
Detection of the phosphatase activity of carbonic anhydrase III on a nitrocellulose membrane following 2D gel electrophoresis.
Myasthenia Gravis
Serum carbonic anhydrase III in neuromuscular disorders and in healthy persons after a long-distance run.
Myasthenia Gravis
Suppression of CHRN endocytosis by carbonic anhydrase CAR3 in the pathogenesis of myasthenia gravis.
Mycoses
Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type-2 inflammation: a patent evaluation (WO2017/058370).
Mycosis Fungoides
Catalase, carbonic anhydrase and xanthine oxidase activities in patients with mycosis fungoides.
Mydriasis
Pseudophakic pupillary-block glaucoma.
Myocardial Infarction
Carbonic anhydrase inhibitors reduce cardiac dysfunction after sustained coronary artery ligation in rats.
Myocardial Infarction
Carbonic anhydrase IX and hypoxia-inducible factor 1 attenuate cardiac dysfunction after myocardial infarction.
Myocardial Infarction
Characteristics of myoglobin, carbonic anhydrase III and the myoglobin/carbonic anhydrase III ratio in trauma, exercise, and myocardial infarction patients.
Myocardial Infarction
Distribution of immunoreactive carbonic anhydrase III in various human tissues determined by a sensitive enzyme immunoassay method.
Myocardial Infarction
Human muscle carbonic anhydrase III (CA-III). Purification, immunohistochemical localization in the human skeletal muscle and its clinical application to the neuromuscular disease.
Myocardial Infarction
Improved specificity of myoglobin plus carbonic anhydrase assay versus that of creatine kinase-MB for early diagnosis of acute myocardial infarction.
Myocardial Infarction
Myoglobin/carbonic anhydrase III ratio: highly specific and sensitive early indicator for myocardial damage in acute myocardial infarction.
Myocardial Infarction
Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study.
Myocardial Infarction
Serum carbonic anhydrase III and myoglobin concentrations in acute myocardial infarction.
Myocardial Infarction
Serum myoglobin/carbonic anhydrase III ratio as a marker of reperfusion after myocardial infarction.
Myocardial Infarction
Serum myoglobin/carbonic anhydrase III ratio in the diagnosis of perioperative myocardial infarction during coronary bypass surgery.
Myopia
Hypotony following trabeculectomy.
Myopia
Inhibition of carbonic anhydrase in the lens does not induce myopia in cynomolgus monkeys.
Myopia
Late Acute Myopia Syndrome Induced by Combination of Sulfonamide Drugs.
Myopia
Transient myopia during treatment with carbonic anhydrase inhibitors.
Myositis
Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis.
Myotonia
Acetazolamide acts directly on the human skeletal muscle chloride channel.
Myotonia
Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders.
Myotonic Dystrophy
Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: relationship with creatine kinase.
Myotonic Dystrophy
Human muscle carbonic anhydrase III (CA-III). Purification, immunohistochemical localization in the human skeletal muscle and its clinical application to the neuromuscular disease.
Myotonic Dystrophy
Serum carbonic anhydrase III in myotonic dystrophy.
Nasal Polyps
Down-regulation of carbonic anhydrase isoenzymes in nasal polyps.
Nasal Polyps
Effects of pepsin A on heat shock protein 70 response in laryngopharyngeal reflux patients with chronic rhinosinusitis.
Nasal Polyps
[HIF-1alpha and CA IX expression in nasal polyps and study on their correlation].
Nasopharyngeal Carcinoma
Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival.
Nasopharyngeal Carcinoma
Expression of HIF-1? and CAIX in nasopharyngeal carcinoma and their correlation with patients' prognosis.
Nasopharyngeal Carcinoma
Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Oncogenic roles of carbonic anhydrase IX in human nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Silencing of hypoxia-inducible tumor suppressor lysyl oxidase gene by promoter methylation activates carbonic anhydrase IX in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
SWATH-based proteomics identified carbonic anhydrase 2 as a potential diagnosis biomarker for nasopharyngeal carcinoma.
Neoplasm Metastasis
6-Substituted sulfocoumarins are selective carbonic anhdydrase IX and XII inhibitors with significant cytotoxicity against colorectal cancer cells.
Neoplasm Metastasis
An inhibitory antibody targeting carbonic anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo.
Neoplasm Metastasis
Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer.
Neoplasm Metastasis
Attachment of carbohydrates to methoxyaryl moieties leads to highly selective inhibitors of the cancer associated carbonic anhydrase isoforms IX and XII.
Neoplasm Metastasis
Biophysical Characterization of Cancer-Related Carbonic Anhydrase IX.
Neoplasm Metastasis
Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia.
Neoplasm Metastasis
Cancer Drug Development of Carbonic Anhydrase Inhibitors beyond the Active Site.
Neoplasm Metastasis
Carbonic anhydrase 13 suppresses bone metastasis in breast cancer.
Neoplasm Metastasis
Carbonic anhydrase 2 inhibits epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma.
Neoplasm Metastasis
Carbonic anhydrase IX (CA9) modulates tumor-associated cell migration and invasion.
Neoplasm Metastasis
Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials.
Neoplasm Metastasis
Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma.
Neoplasm Metastasis
Carbonic Anhydrase IX as an Imaging and Therapeutic Target for Tumors and Metastases.
Neoplasm Metastasis
Carbonic anhydrase IX correlates with survival and is a potential therapeutic target for neuroblastoma.
Neoplasm Metastasis
Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain.
Neoplasm Metastasis
Carbonic anhydrase IX is associated with early pulmonary spreading of primary colorectal carcinoma and tobacco smoking.
Neoplasm Metastasis
Carbonic anhydrase XII promotes invasion and migration ability of MDA-MB-231 breast cancer cells through the p38 MAPK signaling pathway.
Neoplasm Metastasis
Carving out its niche: A role for carbonic anhydrase IX in pre-metastatic niche development.
Neoplasm Metastasis
Cellular and radiobiological effects of carbonic anhydrase IX in human breast cancer cells.
Neoplasm Metastasis
Clear cell renal cell carcinoma bone metastasis: What should be considered in prognostic evaluation.
Neoplasm Metastasis
Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Neoplasm Metastasis
Design of a Carbonic Anhydrase IX Active-Site Mimic To Screen Inhibitors for Possible Anticancer Properties (dagger) (double dagger).
Neoplasm Metastasis
Designing carbonic anhydrase inhibitors for the treatment of breast cancer.
Neoplasm Metastasis
Downregulation of carbonic anhydrase IV contributes to promotion of cell proliferation and is associated with poor prognosis in non-small cell lung cancer.
Neoplasm Metastasis
Efficient Expression and Crystallization System of Cancer-Associated Carbonic Anhydrase Isoform IX.
Neoplasm Metastasis
Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients.
Neoplasm Metastasis
Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models.
Neoplasm Metastasis
Expression of carbonic anhydrase I or II and correlation to clinical aspects of colorectal cancer.
Neoplasm Metastasis
Expression of carbonic anhydrase IX in human pancreatic cancer.
Neoplasm Metastasis
Expression of carbonic anhydrases I/II and the correlation to clinical aspects of oral squamous cell carcinoma analyzed using tissue microarray.
Neoplasm Metastasis
Expression of hypoxia-associated proteins in sporadic medullary thyroid cancer is associated with desmoplastic stroma reaction and lymph node metastasis and may indicate somatic mutations in the VHL gene.
Neoplasm Metastasis
Expression of liver cancer associated gene HCCA3.
Neoplasm Metastasis
Fluorescent sulfonamide carbonic anhydrase inhibitors incorporating 1,2,3-triazole moieties: Kinetic and X-ray crystallographic studies.
Neoplasm Metastasis
Gastric Adenocarcinoma Biomarker Expression Profiles and their Prognostic Value.
Neoplasm Metastasis
Genetic polymorphism and carbonic anhydrase 9 expression can predict nodal metastatic prostate cancer risk in patients with prostate-specific antigen levels ?10 ng/ml at initial biopsy.
Neoplasm Metastasis
Glycosidic carbonic anhydrase IX inhibitors: A sweet approach against cancer.
Neoplasm Metastasis
Harnessing Induced Essentiality: Targeting Carbonic Anhydrase IX and Angiogenesis Reduces Lung Metastasis of Triple Negative Breast Cancer Xenografts.
Neoplasm Metastasis
Hemoglobin level predicts outcome for vulvar cancer patients independent of GLUT-1 and CA-IX expression in tumor tissue.
Neoplasm Metastasis
Heterocoumarins Are Selective Carbonic Anhydrase IX and XII Inhibitors with Cytotoxic Effects against Cancer Cells Lines.
Neoplasm Metastasis
High stromal carbonic anhydrase IX expression is associated with nodal metastasis and decreased survival in patients with surgically-treated oral cavity squamous cell carcinoma.
Neoplasm Metastasis
Histopathological Determinants of Tumor Resistance: a Special Look to The Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers.
Neoplasm Metastasis
Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer.
Neoplasm Metastasis
Identification of non-classical hCA XII inhibitors using combination of computational approaches for drug design and discovery.
Neoplasm Metastasis
Immunotargeting of human cervical carcinoma xenograft expressing CA IX tumor-associated antigen by 125I-labeled M75 monoclonal antibody.
Neoplasm Metastasis
Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression.
Neoplasm Metastasis
Inhibition of carbonic anhydrase IX as a novel anticancer mechanism.
Neoplasm Metastasis
Inhibition of Carbonic Anhydrase IX by Ureidosulfonamide Inhibitor U104 Reduces Prostate Cancer Cell Growth, But Does Not Modulate Daunorubicin or Cisplatin Cytotoxicity.
Neoplasm Metastasis
Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: Three for the price of one.
Neoplasm Metastasis
Inhibition of V-ATPases and Carbonic Anhydrases as Interference Strategy with Tumor Acidification Processes.
Neoplasm Metastasis
Inhibitors of CA IX Enzyme Based on Polyhedral Boron Compounds.
Neoplasm Metastasis
Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: in vivo identification from hypoxic tumor cells.
Neoplasm Metastasis
LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen.
Neoplasm Metastasis
Lipocalin 2 prevents oral cancer metastasis through carbonic anhydrase IX inhibition and is associated with favourable prognosis.
Neoplasm Metastasis
Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas.
Neoplasm Metastasis
Metastatic instability of murine tumor metastases: dependence on tumor type.
Neoplasm Metastasis
Microvessel density, endothelial-cell proliferation and carbonic anhydrase IX expression in haematological malignancies, bone-marrow metastases and monoclonal gammopathy of undetermined significance.
Neoplasm Metastasis
Modulation of Tumor Microenvironment to Enhance Radiotherapy Efficacy in Esophageal Squamous Cell Carcinoma by Inhibiting Carbonic Anhydrase IX.
Neoplasm Metastasis
N-?-Glycosyl sulfamides are selective inhibitors of the cancer associated carbonic anhydrase isoforms IX and XII.
Neoplasm Metastasis
Oncogenic roles of carbonic anhydrase IX in human nasopharyngeal carcinoma.
Neoplasm Metastasis
Organic Photodynamic Nanoinhibitor for Synergistic Cancer Therapy.
Neoplasm Metastasis
Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases.
Neoplasm Metastasis
Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX.
Neoplasm Metastasis
PET Imaging of Carbonic Anhydrase IX Expression of HT-29 Tumor Xenograft Mice with (68)Ga-Labeled Benzenesulfonamides.
Neoplasm Metastasis
PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.
Neoplasm Metastasis
Predicting Isoform-Selective Carbonic Anhydrase Inhibitors via Machine Learning and Rationalizing Structural Features Important for Selectivity.
Neoplasm Metastasis
Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry.
Neoplasm Metastasis
Prognostic Significance of Osteopontin and Carbonic Anhydrase 9 in Human Brain Tumors: A Meta-Analysis.
Neoplasm Metastasis
Prognostic value of carbonic anhydrase IX expression in penile squamous cell carcinoma: A pilot study.
Neoplasm Metastasis
Quantitative assessment of specific carbonic anhydrase inhibitors effect on hypoxic cells using electrical impedance assays.
Neoplasm Metastasis
Reproducibility and biological basis of in vivo T(2) * magnetic resonance imaging of liver metastasis of colorectal cancer.
Neoplasm Metastasis
Role of hypoxia-inducible factor-1?, carbonic anhydrase-IX, glucose transporter-1 and vascular endothelial growth factor associated with lymph node metastasis and recurrence in patients with locally advanced cervical cancer.
Neoplasm Metastasis
Roles of Carbonic Anhydrase IX in Development of Pancreatic Cancer.
Neoplasm Metastasis
Selective carbonic anhydrase IX inhibitors based on coumarin scaffold as promising antimetastatic agents: WO2012070024.
Neoplasm Metastasis
SLC-0111 enaminone analogs, 3/4-(3-aryl-3-oxopropenyl) aminobenzenesulfonamides, as novel selective subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform IX.
Neoplasm Metastasis
Structural comparison of protiated, H/D-exchanged and deuterated human carbonic anhydrase IX.
Neoplasm Metastasis
Structural investigations on coumarins leading to chromeno[4,3-c]pyrazol-4-ones and pyrano[4,3-c]pyrazol-4-ones: New scaffolds for the design of the tumor-associated carbonic anhydrase isoforms IX and XII.
Neoplasm Metastasis
Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.
Neoplasm Metastasis
Synthesis, biological evaluation and in silico modelling studies of 1,3,5-trisubstituted pyrazoles carrying benzenesulfonamide as potential anticancer agents and selective cancer-associated hCA IX isoenzyme inhibitors.
Neoplasm Metastasis
Targeting CAIX with [64Cu]XYIMSR-06 small molecular radio-tracer enables noninvasive PET imaging of malignant glioma in U87 MG tumor cell xenograft mice.
Neoplasm Metastasis
Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: A new concept of dual targeting drugs.
Neoplasm Metastasis
Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.
Neoplasm Metastasis
Targeting Hypoxic Tumors with Hybrid Nanobullets for Oxygen-Independent Synergistic Photothermal and Thermodynamic Therapy.
Neoplasm Metastasis
Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors.
Neoplasm Metastasis
TFAP2C regulates carbonic anhydrase XII in human breast cancer.
Neoplasm Metastasis
TGF-beta upregulates tumor-associated carbonic anhydrase IX gene expression in Hep3B cells.
Neoplasm Metastasis
The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
Neoplasm Metastasis
The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer.
Neoplasm Metastasis
The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.
Neoplasm Metastasis
The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma.
Neoplasm Metastasis
The Expression of Carbonic Anhydrase (CA) IX/ XII and Lymph Node Metastasis in Early Breast Cancer.
Neoplasm Metastasis
The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON.
Neoplasm Metastasis
The roles of carbonic anhydrases IX and XII in cancer cell adhesion, migration, invasion and metastasis.
Neoplasm Metastasis
TSGA10 Over Expression Decreases Metastasic and Metabolic Activity by Inhibiting HIF-1 in Breast Cancer Cells.
Neoplasm Metastasis
Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer.
Neoplasm Metastasis
Tumor-associated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis.
Neoplasm Metastasis
Ureido-Substituted Benzenesulfonamides Potently Inhibit Carbonic Anhydrase IX and Show Antimetastatic Activity in a Model of Breast Cancer Metastasis.
Neoplasm Metastasis
Using neutron crystallography to elucidate the basis of selective inhibition of carbonic anhydrase by saccharin and a derivative.
Neoplasm Metastasis
[Expression and clinical pathological implications of carbonic anhydrase 9 and P glycoprotein in laryngeal squamous cell carcinoma].
Neoplasm Metastasis
[Proteome study of colorectal cancer genesis and hepatic metastasis]
Neoplasm Metastasis
[The clinical significance of E-cadherin and alpha-catenin expression in human gastric cancer]
Neoplasm Micrometastasis
Comparative assessment of lymph node micrometastasis in cervical, endometrial and vulvar cancer: insights on the real time qRT-PCR approach versus immunohistochemistry, employing dual molecular markers.
Neoplasm, Residual
[Relation between carbonic anhydrase IX serum level, hypoxia and radiation resistance of head and neck cancers].
Neoplasms
"Paradoxical" findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab.
Neoplasms
"Seriously Sweet": Acesulfame K Exhibits Selective Inhibition Using Alternative Binding Modes in Carbonic Anhydrase Isoforms.
Neoplasms
1-Naphthol basic dye (1-NBD). An alternative to diaminobenzidine (DAB) in immunoperoxidase techniques.
Neoplasms
18F-FAZA PET/CT in pretreatment assessment of hypoxic status in high-grade glioma: correlation with hypoxia immunohistochemical biomarkers.
Neoplasms
18F-FDG uptake in well-differentiated neuroendocrine tumors correlates with both Ki-67 and VHL pathway inactivation.
Neoplasms
3,17-disubstituted 2-alkylestra-1,3,5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anticancer activity.
Neoplasms
3,17?-Bis-sulfamoyloxy-2-methoxyestra-1,3,5(10)-triene and Nonsteroidal Sulfamate Derivatives Inhibit Carbonic Anhydrase IX: Structure-Activity Optimization for Isoform Selectivity.
Neoplasms
4-Functionalized 1,3-diarylpyrazoles bearing 6-aminosulfonylbenzothiazole moiety as potent inhibitors of carbonic anhydrase isoforms hCA I, II, IX and XII.
Neoplasms
4-Functionalized 1,3-diarylpyrazoles bearing benzenesulfonamide moiety as selective potent inhibitors of the tumor associated carbonic anhydrase isoforms IX and XII.
Neoplasms
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
Neoplasms
4-Hydroxy-7-oxo-5-heptenoic acid lactone is a potent inducer of brain cancer cell invasiveness that may contribute to the failure of anti-angiogenic therapies.
Neoplasms
5-Substituted-benzylsulfanyl-thiophene-2-sulfonamides with effective carbonic anhydrase inhibitory activity: Solution and crystallographic investigations.
Neoplasms
6-Substituted sulfocoumarins are selective carbonic anhdydrase IX and XII inhibitors with significant cytotoxicity against colorectal cancer cells.
Neoplasms
7-Acylamino-3H-1,2-benzoxathiepine 2,2-dioxides as new isoform-selective carbonic anhydrase IX and XII inhibitors.
Neoplasms
A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo.
Neoplasms
A carbonic anhydrase inhibitor as a potential modulator of cancer therapies.
Neoplasms
A combined theoretical and spectroscopic study of 4,6-di-O-acetyl-2,3-dideoxy-D-erythro-hex-2-enopyranosyl sulfamide: a novel glycosyl carbonic anhydrase IX inhibitor.
Neoplasms
A comparative study of the binding modes of SLC-0111 and its analogues in the hCA II and hCA IX active sites using QM/MM, molecular docking, MM-GBSA and MD approaches.
Neoplasms
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.
Neoplasms
A Multifunctional Graphene Oxide Platform for Targeting Cancer.
Neoplasms
A multivariate approach for the determination of isoelectric point of human carbonic anhydrase isoforms by capillary isoelectric focusing.
Neoplasms
A new peptide ligand for targeting human carbonic anhydrase IX, identified through the phage display technology.
Neoplasms
A Nonsense Mitochondrial DNA Mutation Associates with Dysfunction of HIF1? in a Von Hippel-Lindau Renal Oncocytoma.
Neoplasms
A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
Neoplasms
A Novel Fully-Human Potency-Matched Dual Cytokine-Antibody Fusion Protein Targets Carbonic Anhydrase IX in Renal Cell Carcinomas.
Neoplasms
A Novel Inhibitor of Carbonic Anhydrases Prevents Hypoxia-Induced TNBC Cell Plasticity.
Neoplasms
A novel VHH nanobody against the active site (the CA domain) of tumor-associated, carbonic anhydrase isoform IX and its usefulness for cancer diagnosis
Neoplasms
A novel VHH nanobody against the active site (the CA domain) of tumor-associated, carbonic anhydrase isoform IX and its usefulness for cancer diagnosis.
Neoplasms
A pair of long intergenic non-coding RNA LINC00887 variants act antagonistically to control Carbonic Anhydrase IX transcription upon hypoxia in tongue squamous carcinoma progression.
Neoplasms
A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors.
Neoplasms
A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.
Neoplasms
A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer.
Neoplasms
A prodrug approach toward cancer-related carbonic anhydrase inhibition.
Neoplasms
A Rare Case of Renal Cell Carcinoma With Leiomyomatous Stroma and Concomitant Ruptured Adrenal Aneurysm.
Neoplasms
A Rare Case of Synchronous Esophageal and Pancreatic Malignancy.
Neoplasms
A Rare Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of MED15-TFE3 Fusion.
Neoplasms
A Review on Anti-Tumor Mechanisms of Coumarins.
Neoplasms
A Small-Molecule Drug Conjugate for the Treatment of Carbonic Anhydrase IX Expressing Tumors.
Neoplasms
A study of pancreatic secretory and intracellular enzymes in pancreatic cancer tissue, other gastrointestinal cancers, normal pancreas and serum.
Neoplasms
A sucrose-binding site provides a lead towards an isoform-specific inhibitor of the cancer-associated enzyme carbonic anhydrase IX.
Neoplasms
A surface proton antenna in carbonic anhydrase II supports lactate transport in cancer cells.
Neoplasms
A systematic quantitative approach to rational drug design and discovery of novel human carbonic anhydrase IX inhibitors.
Neoplasms
A Versatile Carbonic Anhydrase IX Targeting Ligand-Functionalized Porous Silicon Nanoplatform for Dual Hypoxia Cancer Therapy and Imaging.
Neoplasms
Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma.
Neoplasms
Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions.
Neoplasms
Acetazolamide-based [
Neoplasms
Acetazolamide-Loaded pH-Responsive Nanoparticles Alleviating Tumor Acidosis to Enhance Chemotherapy Effects.
Neoplasms
Acinar-ductal-carcinoma sequence in transforming growth factor-alpha transgenic mice.
Neoplasms
Activation of carbonic anhydrase IX by alternatively spliced tissue factor under late-stage tumor conditions.
Neoplasms
Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo.
Neoplasms
Adenoviral targeting of gene expression to tumors.
Neoplasms
Adiponectin Attenuates the Inflammation in Atopic Dermatitis-Like Reconstructed Human Epidermis.
Neoplasms
Adult-onset renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: 3 case reports and review of literature.
Neoplasms
Affinity Selections of DNA-Encoded Chemical Libraries on Carbonic Anhydrase IX-Expressing Tumor Cells Reveal a Dependence on Ligand Valence.
Neoplasms
Agents described in the Molecular Imaging and Contrast Agent Database for imaging carbonic anhydrase IX expression.
Neoplasms
Albumin/sulfonamide stabilized iron porphyrin metal organic framework nanocomposites: targeting tumor hypoxia by carbonic anhydrase IX inhibition and T1-T2 dual mode MRI guided photodynamic/photothermal therapy.
Neoplasms
ALK-rearranged renal cell carcinoma with a novel PLEKHA7-ALK translocation and metanephric adenoma-like morphology.
Neoplasms
Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype.
Neoplasms
Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer.
Neoplasms
Amine coupling versus biotin capture for the assessment of sulfonamide as ligands of hCA isoforms.
Neoplasms
An efficient method for the synthesis of novel derivatives 4-{5-[4-(4-amino-5-mercapto-4H-[1,2,4]triazol-3-yl)-phenyl]-3-trifluoromethyl-pyrazol-1-yl}-benzenesulfonamide and their anti-inflammatory potential.
Neoplasms
An evaluation of cytosolic erythrocyte carbonic anhydrase and catalase in carcinoma patients: an elevation of carbonic anhydrase activity.
Neoplasms
An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers.
Neoplasms
An Immunohistochemical Study of the Expression of the Hypoxia Markers Glut-1 and Ca-IX in Canine Sarcomas.
Neoplasms
An inhibitory antibody targeting carbonic anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo.
Neoplasms
An Intrarenal Adrenocortical Carcinoma Arising in an Adrenal Rest.
Neoplasms
An update on anticancer drug development and delivery targeting carbonic anhydrase IX.
Neoplasms
Analysis of evolution of carbonic anhydrases IV and XV reveals a rich history of gene duplications and a new group of isozymes.
Neoplasms
Analysis of human carbonic anhydrase II: docking reliability and receptor-based 3D-QSAR study.
Neoplasms
Analysis of Modification of Liver Proteome in Diabetic Rats by 2D Electrophoresis and MALDI-TOF-MS.
Neoplasms
Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer.
Neoplasms
Anti-breast cancer action of carbonic anhydrase IX inhibitor 4-[4-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-benzylidene-hydrazinocarbonyl]-benzenesulfonamide (BSM-0004): in vitro and in vivo studies.
Neoplasms
Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response.
Neoplasms
Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX.
Neoplasms
Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice.
Neoplasms
Antibody-specific detection of CAIX in breast and prostate cancers.
Neoplasms
Anticancer carbonic anhydrase inhibitors: a patent review (2008 - 2013).
Neoplasms
Anticancer Effect of Biodegradable Magnesium on Hepatobiliary Carcinoma: An In Vitro and In Vivo Study.
Neoplasms
Antitumor and antimetastatic activity of the differentiating agent N-methylformamide in murine tumor systems.
Neoplasms
Antitumor efficacy of a monoclonal antibody that inhibits the activity of cancer-associated carbonic anhydrase XII.
Neoplasms
Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients.
Neoplasms
Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy.
Neoplasms
Application of carbonic anhydrase inhibitors to increase the penetration of doxorubicin and its liposomal formulation into 2D and 3D triple negative breast cancer cell cultures.
Neoplasms
Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models.
Neoplasms
Assessment of hypoxic subvolumes in laryngeal cancer with (18)F-fluoroazomycinarabinoside ((18)F-FAZA)-PET/CT scanning and immunohistochemistry.
Neoplasms
Assessment of the antiproliferative and apoptotic roles of sulfonamide carbonic anhydrase IX inhibitors in HeLa cancer cell line.
Neoplasms
Assessment of tumor hypoxia for prediction of response to therapy and cancer prognosis.
Neoplasms
Assessment of tumor response to radiation and vascular targeting therapy in mice using quantitative ultrasound spectroscopy.
Neoplasms
Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer.
Neoplasms
Association between the expression of carbonic anhydrase II and clinicopathological features of hepatocellular carcinoma.
Neoplasms
Attachment of carbohydrates to methoxyaryl moieties leads to highly selective inhibitors of the cancer associated carbonic anhydrase isoforms IX and XII.
Neoplasms
Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy.
Neoplasms
Autoimmune phenomena and spontaneous tumour regression. The role of carbonic anhydrase I.
Neoplasms
Autoimmunity against carbonic anhydrase II affects retinal cell functions in autoimmune retinopathy.
Neoplasms
Benzenesulfonamide bearing 1,2,4-triazole scaffolds as potent inhibitors of tumor associated carbonic anhydrase isoforms hCA IX and hCA XII.
Neoplasms
Benzenesulfonamide bearing imidazothiadiazole and thiazolotriazole scaffolds as potent tumor associated human carbonic anhydrase IX and XII inhibitors.
Neoplasms
Benzimidazole derivatives as potent and isoform selective tumor-associated carbonic anhydrase IX/XII inhibitors.
Neoplasms
Benzoxepinones: A new isoform-selective class of tumor associated carbonic anhydrase inhibitors.
Neoplasms
Betulin Sulfonamides as Carbonic Anhydrase Inhibitors and Anticancer Agents in Breast Cancer Cells.
Neoplasms
Bile Acid Conjugated DNA Chimera that Conditionally Inhibits Carbonic Anhydrase-II in the Presence of MicroRNA-21.
Neoplasms
Biochemical and Structural Insights into Carbonic Anhydrase XII/Fab6A10 Complex.
Neoplasms
Biochemical, biophysical and molecular dynamics studies on the proteoglycan-like domain of carbonic anhydrase IX.
Neoplasms
Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma.
Neoplasms
Biologic instability of pancreatic cancer xenografts in the nude mouse.
Neoplasms
Biological evaluation of p-toluene sulphonylhydrazone as carbonic anhydrase IX inhibitors: An approach to fight hypoxia-induced tumors.
Neoplasms
Biomarkers in clear cell renal cell carcinoma.
Neoplasms
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
Neoplasms
Biophysical Characterization of Cancer-Related Carbonic Anhydrase IX.
Neoplasms
Brachytherapy for oral tongue cancer: an analysis of treatment results with various biological markers.
Neoplasms
Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia.
Neoplasms
CA II, a potential biomarker by proteomic analysis, exerts significant inhibitory effect on the growth of colorectal cancer cells.
Neoplasms
CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
Neoplasms
CA IX stratification based on cancer treatment: a patent evaluation of US2016/0002350.
Neoplasms
CA9 Silencing Promotes Mitochondrial Biogenesis, Increases Putrescine Toxicity and Decreases Cell Motility to Suppress ccRCC Progression.
Neoplasms
Caged [(18)F]FDG Glycosylamines for Imaging Acidic Tumor Microenvironments Using Positron Emission Tomography.
Neoplasms
CAIX aptamer-functionalized targeted nanobubbles for ultrasound molecular imaging of various tumors.
Neoplasms
CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells.
Neoplasms
CAIX-Mediated Control of LIN28/let-7 Axis Contributes to Metabolic Adaptation of Breast Cancer Cells to Hypoxia.
Neoplasms
CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models.
Neoplasms
Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study.
Neoplasms
Can sparsely and heterogeneously expressed proteins be detected using tissue microarrays? A simulation study of the hypoxia marker carbonic anhydrase IX (CA IX) in human soft tissue sarcoma.
Neoplasms
Cancer Drug Development of Carbonic Anhydrase Inhibitors beyond the Active Site.
Neoplasms
Cancer initiating-cells are enriched in the CA9 positive fraction of primary cervix cancer xenografts.
Neoplasms
Cancer-associated splicing variants of the CDCA1 and MSMB genes expressed in cancer cell lines and surgically resected gastric cancer tissues.
Neoplasms
Carbamoylphosphonates Control Tumor Cell Proliferation and Dissemination by Simultaneously Inhibiting Carbonic Anhydrase IX and Matrix Metalloproteinase-2. Toward Nontoxic Chemotherapy Targeting Tumor Microenvironment (1).
Neoplasms
Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy.
Neoplasms
Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix.
Neoplasms
Carbonic anhydrase 13 suppresses bone metastasis in breast cancer.
Neoplasms
Carbonic anhydrase 2 (CAII) supports tumor blood endothelial cell survival under lactic acidosis in the tumor microenvironment.
Neoplasms
Carbonic anhydrase 2 inhibits epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma.
Neoplasms
Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration.
Neoplasms
Carbonic anhydrase 9 (CA9) expression in tumor cells enhances sensitivity to tirapazamine.
Neoplasms
Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer.
Neoplasms
Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival.
Neoplasms
Carbonic anhydrase 9 expression is associated with poor prognosis, tumor proliferation, and radiosensitivity of thymic carcinomas.
Neoplasms
Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer.
Neoplasms
Carbonic anhydrase activators: activation of the human tumor-associated isozymes IX and XII with amino acids and amines.
Neoplasms
Carbonic Anhydrase Activity Monitored In Vivo by Hyperpolarized 13C-Magnetic Resonance Spectroscopy Demonstrates Its Importance for pH Regulation in Tumors.
Neoplasms
Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.
Neoplasms
Carbonic Anhydrase Glycoinhibitors belonging to the Aminoxysulfonamide Series.
Neoplasms
Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy.
Neoplasms
Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy.
Neoplasms
Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors.
Neoplasms
Carbonic anhydrase II: a novel biomarker for pseudomyxoma peritonei.
Neoplasms
Carbonic anhydrase III is a new target of HIF1? in prostate cancer model.
Neoplasms
Carbonic Anhydrase III Promotes Cell Migration and Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma.
Neoplasms
Carbonic anhydrase in human pancreas: hypotheses for the pathophysiological roles of CA isozymes.
Neoplasms
Carbonic Anhydrase Inhibition and the Management of Hypoxic Tumors.
Neoplasms
Carbonic anhydrase inhibition as a cancer therapy: a review of patent literature, 2007 - 2009.
Neoplasms
Carbonic anhydrase inhibitor coated gold nanoparticles selectively inhibit the tumor-associated isoform IX over the cytosolic isozymes I and II.
Neoplasms
Carbonic anhydrase inhibitors and the management of cancer.
Neoplasms
Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).
Neoplasms
Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors.
Neoplasms
Carbonic Anhydrase Inhibitors Targeting Metabolism and Tumor Microenvironment.
Neoplasms
Carbonic anhydrase inhibitors--Part 94. 1,3,4-thiadiazole-2-sulfonamidederivatives as antitumor agents?
Neoplasms
Carbonic anhydrase inhibitors. Biphenylsulfonamides with inhibitory action towards the transmembrane, tumor-associated isozymes IX possess cytotoxic activity against human colon, lung and breast cancer cell lines.
Neoplasms
Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
Neoplasms
Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors.
Neoplasms
Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes.
Neoplasms
Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V and IX with complex fluorides, chlorides and cyanides.
Neoplasms
Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors.
Neoplasms
Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
Neoplasms
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates.
Neoplasms
Carbonic anhydrase inhibitors. Selective inhibition of human tumor-associated isozymes IX and XII and cytosolic isozymes I and II with some substituted-2-mercapto-benzenesulfonamides.
Neoplasms
Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with boron-containing sulfonamides, sulfamides, and sulfamates: toward agents for boron neutron capture therapy of hypoxic tumors.
Neoplasms
Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.
Neoplasms
Carbonic anhydrase inhibitors: a review on the progress of patent literature (2011-2016).
Neoplasms
Carbonic anhydrase inhibitors: aromatic sulfonamides and disulfonamides act as efficient tumor growth inhibitors.
Neoplasms
Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
Neoplasms
Carbonic anhydrase inhibitors: design of membrane-impermeant copper(II) complexes of DTPA-, DOTA-, and TETA-tailed sulfonamides targeting the tumor-associated transmembrane isoform IX.
Neoplasms
Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes.
Neoplasms
Carbonic Anhydrase Inhibitors: DNA Cloning and Inhibition Studies of the alpha-Carbonic Anhydrase from Helicobacter pylori, A New Target for Developing Sulfonamide and Sulfamate Gastric Drugs.
Neoplasms
Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
Neoplasms
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides.
Neoplasms
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides.
Neoplasms
Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozymes IX and XII with polyfluorinated aromatic/heterocyclic sulfonamides.
Neoplasms
Carbonic anhydrase inhibitors: inhibition of transmembrane, tumor-associated isozyme IX, and cytosolic isozymes I and II with aliphatic sulfamates.
Neoplasms
Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.
Neoplasms
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.
Neoplasms
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates.
Neoplasms
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
Neoplasms
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
Neoplasms
Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX.
Neoplasms
Carbonic anhydrase inhibitors: Transepithelial transport of thioureido sulfonamide inhibitors of the cancer-associated isozyme IX is dependent on efflux transporters.
Neoplasms
Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX.
Neoplasms
Carbonic anhydrase inhibitors; fluorinated phenyl sulfamates show strong inhibitory activity and selectivity for the inhibition of the tumor-associated isozymes IX and XII over the cytosolic ones I and II.
Neoplasms
Carbonic anhydrase isozymes II, IX, and XII in uterine tumors.
Neoplasms
Carbonic anhydrase isozymes IX and XII in gastric tumors.
Neoplasms
Carbonic anhydrase IX (CA IX) mediates tumor cell interactions with microenvironment.
Neoplasms
Carbonic anhydrase IX (CA9) expression in multiple renal epithelial tumour subtypes.
Neoplasms
Carbonic anhydrase IX (CA9) modulates tumor-associated cell migration and invasion.
Neoplasms
Carbonic Anhydrase IX (CAIX) as a Mediator of Hypoxia-Induced Stress Response in Cancer Cells.
Neoplasms
Carbonic Anhydrase IX (CAIX), Cancer, and Radiation Responsiveness.
Neoplasms
Carbonic anhydrase IX and acid transport in cancer.
Neoplasms
Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States.
Neoplasms
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Neoplasms
Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials.
Neoplasms
Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma.
Neoplasms
Carbonic anhydrase IX as a novel candidate in liquid biopsy.
Neoplasms
Carbonic anhydrase IX as a specific biomarker for clear cell renal cell carcinoma: comparative study of Western blot and immunohistochemistry and implications for diagnosis.
Neoplasms
Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs.
Neoplasms
Carbonic anhydrase IX as a target for metastatic disease.
Neoplasms
Carbonic Anhydrase IX as an Anticancer therapy Target: Preclinical Evaluation of Internalizing Monoclonal Antibody Directed to Catalytic Domain.
Neoplasms
Carbonic Anhydrase IX as an Imaging and Therapeutic Target for Tumors and Metastases.
Neoplasms
Carbonic anhydrase IX correlates with survival and is a potential therapeutic target for neuroblastoma.
Neoplasms
Carbonic anhydrase IX enhances tumor cell proliferation and tumor progression in osteosarcoma.
Neoplasms
Carbonic anhydrase IX expression and outcome after radiotherapy for muscle-invasive bladder cancer.
Neoplasms
Carbonic anhydrase IX expression and tumor oxygenation status do not correlate at the microregional level in locally advanced cancers of the uterine cervix.
Neoplasms
Carbonic anhydrase IX expression correlates with FDG uptake by primary non-small cell lung cancer.
Neoplasms
Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies.
Neoplasms
Carbonic anhydrase IX expression in prostate cancer.
Neoplasms
Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade.
Neoplasms
Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma.
Neoplasms
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
Neoplasms
Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer.
Neoplasms
Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas.
Neoplasms
Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells.
Neoplasms
Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant.
Neoplasms
Carbonic anhydrase IX in early-stage non-small cell lung cancer.
Neoplasms
Carbonic anhydrase IX in malignant pleural mesotheliomas: A potential target for anti-cancer therapy.
Neoplasms
Carbonic anhydrase IX in oligodendroglial brain tumors.
Neoplasms
Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer.
Neoplasms
Carbonic anhydrase IX induction defines a heterogeneous cancer cell response to hypoxia and mediates stem cell-like properties and sensitivity to HDAC inhibition.
Neoplasms
Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis.
Neoplasms
Carbonic anhydrase IX inhibition is an effective strategy for osteosarcoma treatment.
Neoplasms
Carbonic anhydrase IX inhibitors in cancer therapy: an update.
Neoplasms
Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain.
Neoplasms
Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma.
Neoplasms
Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer.
Neoplasms
Carbonic anhydrase IX is a pH-stat that sets an acidic tumour extracellular pH in vivo.
Neoplasms
Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme.
Neoplasms
Carbonic anhydrase IX is associated with early pulmonary spreading of primary colorectal carcinoma and tobacco smoking.
Neoplasms
Carbonic anhydrase IX is expressed in mesothelioma and metastatic clear cell renal cell carcinoma of the lung.
Neoplasms
Carbonic anhydrase IX is highly expressed in hereditary nonpolyposis colorectal cancer.
Neoplasms
Carbonic Anhydrase IX is Not a Predictor of Outcomes in Non-Metastatic Clear Cell Renal Cell Carcinoma - A Digital Analysis of Tissue Microarray.
Neoplasms
Carbonic Anhydrase IX Overexpression is Associated with Diminished Prognosis in Esophageal Cancer and Correlates with Her-2 Expression.
Neoplasms
Carbonic anhydrase IX overexpression regulates the migration and progression in oral squamous cell carcinoma.
Neoplasms
Carbonic Anhydrase IX Promotes Human Cervical Cancer Cell Motility by Regulating PFKFB4 Expression.
Neoplasms
Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy.
Neoplasms
Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin.
Neoplasms
Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas.
Neoplasms
Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors.
Neoplasms
Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder.
Neoplasms
Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density.
Neoplasms
Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts.
Neoplasms
Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells in vitro.
Neoplasms
Carbonic Anhydrase IX-Mouse versus Human.
Neoplasms
Carbonic Anhydrase IX-Targeted Near-Infrared Dye for Fluorescence Imaging of Hypoxic Tumors.
Neoplasms
Carbonic anhydrase IX: A hypoxia-controlled "catalyst" of cell migration.
Neoplasms
Carbonic anhydrase IX: a new druggable target for the design of antitumor agents.
Neoplasms
Carbonic anhydrase IX: A promising diagnostic and prognostic biomarker in breast carcinoma.
Neoplasms
Carbonic anhydrase IX: a regulator of pH and participant in carcinogenesis.
Neoplasms
Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target.
Neoplasms
Carbonic Anhydrase IX: Regulation and Role in Cancer.
Neoplasms
Carbonic anhydrase IX: role in diagnosis prognosis and cancer therapy. Introduction.
Neoplasms
Carbonic anhydrase related protein expression in astrocytomas and oligodendroglial tumors.
Neoplasms
Carbonic Anhydrase Related Protein VIII and its Role in Neurodegeneration and Cancer.
Neoplasms
Carbonic anhydrase type IX expression in lobular endocervical glandular hyperplasia and gastric-type adenocarcinoma of the uterine cervix.
Neoplasms
Carbonic Anhydrase XII as an Independent Prognostic Factor in Advanced Esophageal Squamous Cell Carcinoma.
Neoplasms
Carbonic anhydrase XII expression is associated with histologic grade of cervical cancer and superior radiotherapy outcome.
Neoplasms
Carbonic anhydrase XII expression is linked to suppression of Sonic hedgehog ligand expression in triple negative breast cancer cells.
Neoplasms
Carbonic anhydrase XII functions in health and disease.
Neoplasms
Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells.
Neoplasms
Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma.
Neoplasms
Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells.
Neoplasms
Carbonic anhydrase XII promotes invasion and migration ability of MDA-MB-231 breast cancer cells through the p38 MAPK signaling pathway.
Neoplasms
Carbonic Anhydrases and Metabolism.
Neoplasms
Carbonic anhydrases as disease markers.
Neoplasms
Carbonic anhydrases in meningiomas: association of endothelial carbonic anhydrase II with aggressive tumor features.
Neoplasms
Carnosine inhibits carbonic anhydrase IX-mediated extracellular acidosis and suppresses growth of HeLa tumor xenografts.
Neoplasms
Catalase, carbonic anhydrase and xanthine oxidase activities in patients with mycosis fungoides.
Neoplasms
Catalysis and pH control by membrane-associated carbonic anhydrase IX in MDA-MB-231 breast cancer cells.
Neoplasms
Catalytic activity of human carbonic anhydrase isoform IX is displayed both extra- and intracellularly.
Neoplasms
Cell division cycle associated 1 as a novel prognostic biomarker and therapeutic target for oral cancer.
Neoplasms
CellectSeq: In silico discovery of antibodies targeting integral membrane proteins combining in situ selections and next-generation sequencing.
Neoplasms
Cellular and radiobiological effects of carbonic anhydrase IX in human breast cancer cells.
Neoplasms
Changes in protein expression after neoadjuvant use of aromatase inhibitors in primary breast cancer: a proteomic approach to search for potential biomarkers to predict response or resistance.
Neoplasms
Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells.
Neoplasms
Characterization of carbonic anhydrase IX interactome reveals proteins assisting its nuclear localization in hypoxic cells.
Neoplasms
Characterization of CD147, CA9, and CD70 as Tumor-Specific Markers on Extracellular Vesicles in Clear Cell Renal Cell Carcinoma.
Neoplasms
Characterization of human carbonic anhydrase XII stability and inhibitor binding.
Neoplasms
Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis.
Neoplasms
Chemokine-Dependent pH Elevation at the Cell Front Sustains Polarity in Directionally Migrating Zebrafish Germ Cells.
Neoplasms
Chemopreventive agents modulate the protein expression profile of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo[a]pyrene-induced lung tumors in A/J mice.
Neoplasms
Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
Neoplasms
Chromene-Containing Aromatic Sulfonamides with Carbonic Anhydrase Inhibitory Properties.
Neoplasms
Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity.
Neoplasms
Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile.
Neoplasms
Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins.
Neoplasms
Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions.
Neoplasms
Clinical Molecular Imaging with Radiotracers: Current Status.
Neoplasms
Clinical Report on the First Prototype of a Photoacoustic Tomography System with Dual Illumination for Breast Cancer Imaging.
Neoplasms
Clinical value of significance of Hypoxia Inducible Factor-1?, Glucose Transporter-1 and Carbonic Anhydrase IX in rectal cancer after preoperative chemoradiotherapy.
Neoplasms
Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
Neoplasms
Clinicopathological characteristics associated with necrosis in pulmonary metastases from colorectal cancer.
Neoplasms
Cobalt Bis(dicarbollide) Alkylsulfonamides: Potent and Highly Selective Inhibitors of Tumor Specific Carbonic Anhydrase IX.
Neoplasms
Coexistent loss of INI1 and BRG1 expression in a rhabdoid renal cell carcinoma (RCC): implications for a possible role of SWI/SNF complex in the pathogenesis of RCC.
Neoplasms
Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival.
Neoplasms
COILED COIL PEPTIDES AS UNIVERSAL LINKERS FOR THE ATTACHMENT OF RECOMBINANT PROTEINS TO POLYMER THERAPEUTICS.
Neoplasms
Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma.
Neoplasms
Combined 3-O-acetylbetulin treatment and carbonic anhydrase IX inhibition results in additive effects on human breast cancer cells.
Neoplasms
Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells.
Neoplasms
Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients.
Neoplasms
Combining carbonic anhydrase and thioredoxin reductase inhibitory motifs within a single molecule dramatically increases its cytotoxicity.
Neoplasms
Comparative assessment of lymph node micrometastasis in cervical, endometrial and vulvar cancer: insights on the real time qRT-PCR approach versus immunohistochemistry, employing dual molecular markers.
Neoplasms
Comparative evaluation of Affibody molecules for radionuclide imaging of in vivo expression of carbonic anhydrase IX.
Neoplasms
Comparative Transcriptomic Analysis of Temozolomide Resistant Primary GBM Stem-Like Cells and Recurrent GBM Identifies Up-Regulation of the Carbonic Anhydrase CA2 Gene as Resistance Factor.
Neoplasms
Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines.
Neoplasms
Comparison of human papillomavirus detection and typing by hybrid capture 2, linear array, DNA chip, and cycle sequencing in cervical swab samples.
Neoplasms
Comparison of hypoxia transcriptome in vitro with in vivo gene expression in human bladder cancer.
Neoplasms
Comparison of two signal-amplification DNA tests for high-risk HPV as an aid to colposcopy.
Neoplasms
Comprehensive Analysis of CDCAs Methylation and Immune Infiltrates in Hepatocellular Carcinoma.
Neoplasms
Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes.
Neoplasms
Construction of ultrasonic nanobubbles carrying CAIX polypeptides to target carcinoma cells derived from various organs.
Neoplasms
Continued exploration and tail approach synthesis of benzenesulfonamides containing triazole and dual triazole moieties as carbonic anhydrase I, II, IV and IX inhibitors.
Neoplasms
Continued exploration of 1,2,4-oxadiazole periphery for carbonic anhydrase-targeting primary arene sulfonamides: Discovery of subnanomolar inhibitors of membrane-bound hCA IX isoform that selectively kill cancer cells in hypoxic environment.
Neoplasms
Coordinated Regulation of Metabolic Transporters and Migration/Invasion by Carbonic Anhydrase IX.
Neoplasms
Correction to Quercetin-Modified Metal-Organic Frameworks for Dual Sensitization of Radiotherapy in Tumor Tissues by Inhibiting the Carbonic Anhydrase IX.
Neoplasms
Correlation between carbonic anhydrase IX (CA-9), XII (CA-12) and hypoxia inducible factor-2? (HIF-2?) in breast cancer.
Neoplasms
Correlation between maximum standardized uptake values on FDG-PET and microenvironmental factors in patients with clinical stage IA radiologic pure-solid lung adenocarcinoma.
Neoplasms
Correlation of a priori DCE-MRI and (1)H-MRS data with molecular markers in neck nodal metastases: Initial analysis.
Neoplasms
Correlation of carbonic anhydrase IX expression with clinico-morphological parameters, hormonal receptor status and HER-2 expression in breast cancer.
Neoplasms
Corrigendum to "Investigation of 3-sulfamoyl coumarins against cancer-related IX and XII isoforms of human carbonic anhydrase as well as cancer cells leads to the discovery of 2-oxo-2H-benzo[h]chromene-3-sulfonamide - A new caspase-activating proapoptotic agent" [J. Med. Chem. 222 (2021) 113589].
Neoplasms
Coumarin-Thiourea Hybrids Show Potent Carbonic Anhydrase IX and XIII Inhibitory Action.
Neoplasms
Coumarins and other fused bicyclic heterocycles with selective tumor-associated carbonic anhydrase isoforms inhibitory activity.
Neoplasms
Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma.
Neoplasms
CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing.
Neoplasms
Crucial role of carbonic anhydrase IX in tumorigenicity of xenotransplanted adult T-cell leukemia-derived cells.
Neoplasms
Cryptophane Nanoscale Assemblies Expand 129Xe NMR Biosensing.
Neoplasms
Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX.
Neoplasms
Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells.
Neoplasms
Current status and future directions of molecular markers in renal cell carcinoma.
Neoplasms
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Neoplasms
CuZnSOD and MnSOD inhibit metabolic stress-induced necrosis and multicellular tumour spheroid growth.
Neoplasms
Cyclic Secondary Sulfonamides: Unusually Good Inhibitors of Cancer-Related Carbonic Anhydrase Enzymes.
Neoplasms
Cyclic tertiary sulfamates: selective inhibition of the tumor-associated carbonic anhydrases IX and XII by N- and O-substituted acesulfame derivatives.
Neoplasms
Cystic clear cell papillary renal cell carcinoma: is it related to multilocular clear cell cystic neoplasm of low malignant potential?
Neoplasms
Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer.
Neoplasms
Cytosolic carbonic anhydrase activity in chronic myeloid disorders with different clinical phenotype.
Neoplasms
Darwinian dynamics of intratumoral heterogeneity: not solely random mutations but also variable environmental selection forces.
Neoplasms
Design and development of 5-(4H)-oxazolones as potential inhibitors of human carbonic anhydrase VA: towards therapeutic management of diabetes and obesity.
Neoplasms
Design and synthesis of a novel class of carbonic anhydrase-IX inhibitor 1-(3-(phenyl/4-fluorophenyl)-7-imino-3H-[1,2,3]triazolo[4,5d]pyrimidin 6(7H)yl)urea.
Neoplasms
Design and synthesis of novel 1,3-diaryltriazene-substituted sulfonamides as potent and selective carbonic anhydrase II inhibitors.
Neoplasms
Design and synthesis of novel benzenesulfonamide containing 1,2,3-triazoles as potent human carbonic anhydrase isoforms I, II, IV and IX inhibitors.
Neoplasms
Design of a Carbonic Anhydrase IX Active-Site Mimic To Screen Inhibitors for Possible Anticancer Properties (dagger) (double dagger).
Neoplasms
Design of zinc binding functions for carbonic anhydrase inhibitors.
Neoplasms
Design, synthesis & biological evaluation of ferulic acid-based small molecule inhibitors against tumor-associated carbonic anhydrase IX.
Neoplasms
Design, synthesis and biological evaluation of coumarin-3-carboxamides as selective carbonic anhydrase IX and XII inhibitors.
Neoplasms
Design, synthesis and biological evaluation of novel ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as potent carbonic anhydrase IX inhibitors.
Neoplasms
Design, synthesis and evaluation of (18)F-labeled cationic carbonic anhydrase IX inhibitors for PET imaging.
Neoplasms
Design, synthesis and molecular docking of novel N,N-dimethylbenzenesulfonamide derivatives as potential antiproliferative agents.
Neoplasms
Designing carbonic anhydrase inhibitors for the treatment of breast cancer.
Neoplasms
Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole.
Neoplasms
Detecting extracellular carbonic anhydrase activity using membrane inlet mass spectrometry.
Neoplasms
Detection of carbonic anhydrase 9-expressing tumor cells in the lymph nodes of vulvar carcinoma patients by RT-PCR.
Neoplasms
Detection of carbonic anhydrase IX protein in the diagnosis of malignant pleural effusion by enzyme-linked immunosorbent assay and immunocytochemistry.
Neoplasms
Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors.
Neoplasms
Detection of mRNA for carbonic anhydrase II in human osteoclast-like cells by in situ hybridization.
Neoplasms
Development and biological evaluation of ??mTc-sulfonamide derivatives for in vivo visualization of CA IX as surrogate tumor hypoxia markers.
Neoplasms
Development and characterization of new monoclonal antibodies against human recombinant CA XII.
Neoplasms
Development and initial clinical testing of a multi-plexed circulating tumor cell assay in patients with clear cell renal cell carcinoma.
Neoplasms
Development of a 68 Ga-labelled PET tracer for carbonic anhydrase IX-overexpressed tumors using the artificial sweetener saccharin.
Neoplasms
Development of a Fingerprint-Based Scoring Function for the Prediction of the Binding Mode of Carbonic Anhydrase II Inhibitors.
Neoplasms
Development of a Small Molecule Tubulysin B Conjugate for Treatment of Carbonic Anhydrase IX Receptor Expressing Cancers.
Neoplasms
Development of sulfonamides incorporating phenylacrylamido functionalities as carbonic anhydrase isoforms I, II, IX and XII inhibitors.
Neoplasms
Development of the 99mTc-Hydroxamamide Complex as a Probe Targeting Carbonic Anhydrase IX.
Neoplasms
Dexamethasone downregulates expression of carbonic anhydrase IX via HIF-1? and NF-?B-dependent mechanisms.
Neoplasms
Diagnostic Challenges of Kidney Cancer: A Systematic Review of the Role of Positron Emission Tomography-Computerized Tomography.
Neoplasms
Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.
Neoplasms
Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer.
Neoplasms
Different expression patterns of carbonic anhydrase IX in oral lichen planus and leukoplakia.
Neoplasms
Differential expression and function of CAIX and CAXII in breast cancer: A comparison between tumorgraft models and cells.
Neoplasms
Differential expression of cytoplasmic carbonic anhydrases, CA I and II, and membrane-associated isozymes, CA IX and XII, in normal mucosa of large intestine and in colorectal tumors.
Neoplasms
Differential in vitro inhibition effects of some antibiotics on tumor associated carbonic anhydrase isozymes of hCA-IX and hCA-XII.
Neoplasms
Differential in vitro inhibitory effects of anticancer drugs on tumor-associated carbonic anhydrase isozymes CA IX and CA XII.
Neoplasms
Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer.
Neoplasms
Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients.
Neoplasms
Differentially expressed genes in a flock of Chinese local-breed chickens infected with a subgroup J avian leukosis virus using suppression subtractive hybridization.
Neoplasms
Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia.
Neoplasms
Direct and straightforward access to substituted alkyl selenols as novel carbonic anhydrase inhibitors.
Neoplasms
Direct Introduction of an Alkylsulfonamido Group on C-sites of Isomeric Carboranes; the Influence of Stereochemistry on Inhibitory Activity Against Cancer-associated Carbonic Anhydrase IX Isoenzyme.
Neoplasms
Disclosing the Interaction of Carbonic Anhydrase IX with Cullin-Associated NEDD8-Dissociated Protein 1 by Molecular Modeling and Integrated Binding Measurements.
Neoplasms
Discovering novel carbonic anhydrase type IX (CA IX) inhibitors from seven million compounds using virtual screening and in vitro analysis.
Neoplasms
Discovery and characterization of novel selective inhibitors of carbonic anhydrase IX.
Neoplasms
Discovery of 4-Hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 Analogues for the Treatment of Hypoxic Tumors Overexpressing Carbonic Anhydrase IX.
Neoplasms
Discovery of new 2, 5-disubstituted 1,3-selenazoles as selective human carbonic anhydrase IX inhibitors with potent anti-tumor activity.
Neoplasms
Discovery of new ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as carbonic anhydrase I, II, IX and XII inhibitors.
Neoplasms
Discovery of novel artemisinin-sulfonamidehybrids as potential carbonicanhydraseIX inhibitors with improved antiproliferative activities.
Neoplasms
Discovery of novel isatin-based sulfonamides with potent and selective inhibition of the tumor-associated carbonic anhydrase isoforms IX and XII.
Neoplasms
Discovery of potent nucleotide pyrophosphatase/phosphodiesterase3 (NPP3) inhibitors with ancillary carbonic anhydrase inhibition for cancer (immuno)therapy.
Neoplasms
Disrupting Hypoxia-Induced Bicarbonate Transport Acidifies Tumor Cells and Suppresses Tumor Growth.
Neoplasms
Disruption of pH Dynamics Suppresses Proliferation and Potentiates Doxorubicin Cytotoxicity in Breast Cancer Cells.
Neoplasms
Dissecting the Inhibition Mechanism of Cytosolic versus Transmembrane Carbonic Anhydrases by ESR.
Neoplasms
Distinct patterns of hypoxic expression of carbonic anhydrase IX (CA IX) in human malignant glioma cell lines.
Neoplasms
Distinct Tumor Microenvironment at Tumor Edge as a Result of Astrocyte Activation Is Associated With Therapeutic Resistance for Brain Tumor.
Neoplasms
Distinctive renal cell tumor simulating atrophic kidney with 2 types of microcalcifications. Report of 3 cases.
Neoplasms
Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo.
Neoplasms
DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX.
Neoplasms
DNA-linked Inhibitor Antibody Assay (DIANA) for sensitive and selective enzyme detection and inhibitor screening.
Neoplasms
Down-regulation of metabolic proteins in hepatocellular carcinoma with portal vein thrombosis.
Neoplasms
Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes.
Neoplasms
Downregulation of BCL-2 induces downregulation of carbonic anhydrase IX, vascular endothelial growth factor, and pAkt and induces radiation sensitization.
Neoplasms
Downregulation of carbonic anhydrase IV contributes to promotion of cell proliferation and is associated with poor prognosis in non-small cell lung cancer.
Neoplasms
Downregulation of EGFR in hypoxic, diffusion-limited areas of squamous cell carcinomas of the head and neck.
Neoplasms
Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII.
Neoplasms
Drug Repurposing as an Antitumor Agent: Disulfiram-Mediated Carbonic Anhydrase 12 and Anion Exchanger 2 Modulation to Inhibit Cancer Cell Migration.
Neoplasms
Dual carbonic anhydrase--cyclooxygenase-2 inhibitors.
Neoplasms
Dual carbonic anhydrase/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors.
Neoplasms
Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer.
Neoplasms
Dual Human Carbonic Anhydrase/Cyclooxygenase-2 Inhibitors: A Promising Approach for Cancer Treatment.
Neoplasms
Dual P-Glycoprotein and CA XII Inhibitors: A New Strategy to Reverse the P-gp Mediated Multidrug Resistance (MDR) in Cancer Cells.
Neoplasms
Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation.
Neoplasms
Dual-Functional Liposomes with Carbonic Anhydrase IX Antibody and BR2 Peptide Modification Effectively Improve Intracellular Delivery of Cantharidin to Treat Orthotopic Hepatocellular Carcinoma Mice.
Neoplasms
Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide.
Neoplasms
Dual-tail approach to discovery of novel carbonic anhydrase IX inhibitors by simultaneously matching the hydrophobic and hydrophilic halves of the active site.
Neoplasms
Dynamic contrast-enhanced magnetic resonance imaging is a poor measure of rectal cancer angiogenesis.
Neoplasms
Dysregulated pH in Tumor Microenvironment Checkmates Cancer Therapy.
Neoplasms
Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17.
Neoplasms
Effect of an Imidazole-Containing Schiff Base of an Aromatic Sulfonamide on the Cytotoxic Efficacy of N,N-Coordinated Half-Sandwich Ruthenium(II) p-Cymene Complexes.
Neoplasms
Effect of Carbonic Anhydrase IX inhibitors on human endothelial cell survival.
Neoplasms
Effect of carbonic anhydrase-related protein VIII expression on lung adenocarcinoma cell growth.
Neoplasms
Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX.
Neoplasms
Effect of low-dose irradiation on induction of an apoptotic adaptive response in the murine system.
Neoplasms
Effect of pazopanib on tumor microenvironment and liposome delivery.
Neoplasms
Effect of Treatment Sequencing on the Tumor Response to Combined Treatment With Ultrasound-Stimulated Microbubbles and Radiotherapy.
Neoplasms
Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma.
Neoplasms
Efficacy of a Three Drug-Based Therapy for Neuroblastoma in Mice.
Neoplasms
Efficient Expression and Crystallization System of Cancer-Associated Carbonic Anhydrase Isoform IX.
Neoplasms
Elucidation of stable intermediates in urea-induced unfolding pathway of human carbonic anhydrase IX.
Neoplasms
Emerging drugs for renal cell carcinoma.
Neoplasms
Encapsulation of anti-carbonic anhydrase IX antibody in hydrogel microspheres for tumor targeting.
Neoplasms
Endogenous Hypoxia Markers in Locally Advanced Cancers of the Uterine Cervix: Reality or Wishful Thinking?
Neoplasms
Endogenous hypoxia markers: case not proven!
Neoplasms
Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
Neoplasms
Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Neoplasms
Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients.
Neoplasms
Enhanced response to C225 of A431 tumor xenografts growing in irradiated tumor bed.
Neoplasms
Enhanced sensitivity to hydrogen peroxide-induced apoptosis in Evi1 transformed Rat1 fibroblasts due to repression of carbonic anhydrase III.
Neoplasms
Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2.
Neoplasms
Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma.
Neoplasms
Eosinophilic Solid and Cystic Renal Cell Carcinoma With Melanin Pigment-Expanding the Morphological Spectrum.
Neoplasms
Erythrocyte catalase and carbonic anhydrase activities in lung cancer.
Neoplasms
Establishment of hypoxia induction in an in vivo animal replacement model for experimental evaluation of pancreatic cancer.
Neoplasms
Esterase activity of carbonic anhydrases serves as surrogate for selecting antibodies blocking hydratase activity.
Neoplasms
Estimation of thermodynamic stability of human carbonic anhydrase IX from urea-induced denaturation and MD simulation studies.
Neoplasms
Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer.
Neoplasms
Evaluation of 99mTc-sulfonamide and sulfocoumarin derivatives for imaging carbonic anhydrase IX expression.
Neoplasms
Evaluation of a Carbonic Anhydrase IX-Targeted Near-Infrared Dye for Fluorescence-Guided Surgery of Hypoxic Tumors.
Neoplasms
Evaluation of a novel real-time fluorescent polymerase chain reaction assay for high-risk human papilloma virus DNA genotypes in cytological cervical screening.
Neoplasms
Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.
Neoplasms
Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma.
Neoplasms
Evaluation of Nonpeptidic Ligand Conjugates for SPECT Imaging of Hypoxic and Carbonic Anhydrase IX-Expressing Cancers.
Neoplasms
Evaluation of Nonpeptidic Ligand Conjugates for the Treatment of Hypoxic and Carbonic Anhydrase IX-Expressing Cancers.
Neoplasms
Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110.
Neoplasms
Evaluation of selenide, diselenide and selenoheterocycle derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
Neoplasms
Evaluation of the anticancer potential of a sulphonamide carbonic anhydrase IX inhibitor on cervical cancer cells.
Neoplasms
Exosomes expressing carbonic anhydrase 9 promote angiogenesis.
Neoplasms
Expanding the anticancer potential of 1,2,3-triazoles via simultaneously targeting Cyclooxygenase-2, 15-lipoxygenase and tumor-associated carbonic anhydrases.
Neoplasms
Experimental Approaches to Identify Selective Picomolar Inhibitors for Carbonic Anhydrase IX.
Neoplasms
Experimental Carbonic Anhydrase Inhibitors for the Treatment of Hypoxic Tumors.
Neoplasms
Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.
Neoplasms
Exploring structure-activity relationship of S-substituted 2-mercaptoquinazolin-4(3H)-one including 4-ethylbenzenesulfonamides as human carbonic anhydrase inhibitors.
Neoplasms
Expression and Activity of Carbonic Anhydrase IX Is Associated With Metabolic Dysfunction in MDA-MB-231 Breast Cancer Cells.
Neoplasms
Expression and diagnostic implications of carbonic anhydrase IX in several tumours with predominantly clear cell morphology.
Neoplasms
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas.
Neoplasms
Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa.
Neoplasms
Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors.
Neoplasms
Expression of CA IX in dysplasia adjacent to surgical resection margins of oral squamous cell carcinoma.
Neoplasms
Expression of CA-IX is associated with advanced stage tumors and poor survival in oral squamous cell carcinoma patients.
Neoplasms
Expression of cancer-related carbonic anhydrases IX and XII in normal skin and skin neoplasms.
Neoplasms
Expression of carbonic anhydrase 9 at the invasion front of gastric cancers.
Neoplasms
Expression of carbonic anhydrase 9 is a novel prognostic marker in resectable hepatocellular carcinoma.
Neoplasms
Expression of Carbonic Anhydrase IX (CA IX), a Hypoxia-Related Protein, Rather Than Vascular-Endothelial Growth Factor (VEGF), a Pro-Angiogenic Factor, Correlates With an Extremely Poor Prognosis in Esophageal and Gastric Adenocarcinomas.
Neoplasms
Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
Neoplasms
Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis.
Neoplasms
Expression of carbonic anhydrase IX in craniopharyngiomas.
Neoplasms
Expression of carbonic anhydrase IX in genitourinary and adrenal tumours.
Neoplasms
Expression of carbonic anhydrase IX in human pancreatic cancer.
Neoplasms
Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma.
Neoplasms
Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer.
Neoplasms
Expression of carbonic anhydrases I/II and the correlation to clinical aspects of oral squamous cell carcinoma analyzed using tissue microarray.
Neoplasms
Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer.
Neoplasms
Expression of hypoxia-induced proteins in ductal carcinoma in situ and invasive cancer of the male breast.
Neoplasms
Expression of hypoxia-inducible carbonic anhydrases in brain tumors.
Neoplasms
Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer.
Neoplasms
Expression of hypoxia-inducible factor 1 alpha and its downstream targets in fibroepithelial tumors of the breast.
Neoplasms
Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas.
Neoplasms
Expression of hypoxia-inducible, membrane-bound carbonic anhydrase isozyme XII in mouse tissues.
Neoplasms
Expression of hypoxic marker CA IX is regulated by site-specific DNA methylation and is associated with the histology of gastric cancer.
Neoplasms
Expression of Hypoxic Marker Carbonic Anhydrase IX Predicts Poor Prognosis in Resectable Hepatocellular Carcinoma.
Neoplasms
Expression of liver cancer associated gene HCCA3.
Neoplasms
Expression of Myoglobin in Normal and Cancer Brain Tissues: Correlation With Hypoxia Markers.
Neoplasms
Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma.
Neoplasms
Expression of proteins associated with hypoxia and Wnt pathway activation is of prognostic significance in hepatocellular carcinoma.
Neoplasms
Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas.
Neoplasms
Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast.
Neoplasms
Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.
Neoplasms
Expression of the interleukin-4 receptor alpha in human conjunctival epithelial cells.
Neoplasms
Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors.
Neoplasms
Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours.
Neoplasms
Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours.
Neoplasms
Expression of transmembrane carbonic anhydrases, CAIX and CAXII, in human development.
Neoplasms
Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours.
Neoplasms
Expression of von Hippel-Lindau tumor suppressor and tumor-associated carbonic anhydrases IX and XII in normal and neoplastic colorectal mucosa.
Neoplasms
Expression Pattern of Carbonic Anhydrase IX in Medullary Thyroid Carcinoma Supports a Role for RET-Mediated Activation of the HIF Pathway.
Neoplasms
Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo.
Neoplasms
Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia.
Neoplasms
Extraskeletal Myxoid Chondrosarcoma of the Vulva With PLAG1 Gene Activation: Molecular Genetic Characterization of 2 Cases.
Neoplasms
Familial occurrence of polymorphous oligodendroglioma.
Neoplasms
Feasibility and constraints of particle targeting using the antigen-antibody interaction.
Neoplasms
Fenofibrate inhibits hypoxia-inducible factor-1 alpha and carbonic anhydrase expression through activation of AMP-activated protein kinase/HO-1/Sirt1 pathway in glioblastoma cells.
Neoplasms
Ferrier sulfamidoglycosylation of glycals catalyzed by nitrosonium tetrafluoroborate: towards new carbonic anhydrase glycoinhibitors.
Neoplasms
Fibrotic focus and hypoxia in male breast cancer.
Neoplasms
First evaluation of organotellurium derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
Neoplasms
Fluorescence- and spin-labeled carbonic anhydrase inhibitors.
Neoplasms
Fluorescent sulfonamide carbonic anhydrase inhibitors incorporating 1,2,3-triazole moieties: Kinetic and X-ray crystallographic studies.
Neoplasms
Fluorinated benzenesulfonamide anticancer inhibitors of carbonic anhydrase IX exhibit lower toxic effects on zebrafish embryonic development than ethoxzolamide.
Neoplasms
Fluorine-18 click radiosynthesis and microPET/CT evaluation of a small peptide-a potential PET probe for carbonic anhydrase IX.
Neoplasms
Functionalized hydrogel microparticles prepared by microfluidics and their interaction with tumour marker carbonic anhydrase IX.
Neoplasms
G250: a carbonic anhydrase IX monoclonal antibody.
Neoplasms
Galectin-1: a link between tumor hypoxia and tumor immune privilege.
Neoplasms
Gallbladder metastasis of renal cell carcinoma presenting as a hypervascular polypoid lesion: case report of two cases with immunohistochemical analysis.
Neoplasms
Gastric Adenocarcinoma Biomarker Expression Profiles and their Prognostic Value.
Neoplasms
Gastric pit cell hyperplasia and glandular atrophy in carbonic anhydrase IX knockout mice: studies on two strains C57/BL6 and BALB/C.
Neoplasms
GdmCl-induced unfolding studies of human carbonic anhydrase IX: a combined spectroscopic and MD simulation approach.
Neoplasms
Gene expression in the mammary gland tissue of female Fischer 344 and Lewis rats after magnetic field exposure (50 Hz, 100 ?T) for 2 weeks.
Neoplasms
Generation and characterization of the first inhibitory antibody targeting tumour-associated carbonic anhydrase XII.
Neoplasms
Genetic polymorphism and carbonic anhydrase 9 expression can predict nodal metastatic prostate cancer risk in patients with prostate-specific antigen levels ?10 ng/ml at initial biopsy.
Neoplasms
Genetic profile and immunohistochemical study of clear cell renal carcinoma: Pathological-anatomical correlation and prognosis.
Neoplasms
Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma.
Neoplasms
Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors.
Neoplasms
Glucose Uptake and Intracellular pH in a Mouse Model of Ductal Carcinoma In situ (DCIS) Suggests Metabolic Heterogeneity.
Neoplasms
Glycolysis-related protein expression in thyroid cancer.
Neoplasms
Glycomimetic Based Approach toward Selective Carbonic Anhydrase Inhibitors.
Neoplasms
Glycosidic carbonic anhydrase IX inhibitors: A sweet approach against cancer.
Neoplasms
Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors.
Neoplasms
Handling drug-target selectivity: A study on ureido containing Carbonic Anhydrase inhibitors.
Neoplasms
Harnessing Induced Essentiality: Targeting Carbonic Anhydrase IX and Angiogenesis Reduces Lung Metastasis of Triple Negative Breast Cancer Xenografts.
Neoplasms
Hemoglobin level predicts outcome for vulvar cancer patients independent of GLUT-1 and CA-IX expression in tumor tissue.
Neoplasms
HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors.
Neoplasms
Heterocoumarins Are Selective Carbonic Anhydrase IX and XII Inhibitors with Cytotoxic Effects against Cancer Cells Lines.
Neoplasms
HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
Neoplasms
HIF-mediated hypoxic response is missing in severely hypoxic uterine leiomyomas.
Neoplasms
High Expression of Solute Carrier Family 2 Member 1 (SLC2A1) in Cancer Cells Is an Independent Unfavorable Prognostic Factor in Pediatric Malignant Peripheral Nerve Sheath Tumor.
Neoplasms
High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC.
Neoplasms
High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer.
Neoplasms
High monocarboxylate transporter 4 protein expression in stromal cells predicts adverse survival in gastric cancer.
Neoplasms
High serum carbonic anhydrase IX predicts shorter survival in head and neck cancer.
Neoplasms
High Stromal Carbonic Anhydrase IX Expression Is Associated with Decreased Survival in p16-Negative Head-and-Neck Tumors.
Neoplasms
Hippocampal and Cerebellar Changes in Acute Restraint Stress and the Impact of Pretreatment with Ceftriaxone.
Neoplasms
Histochemistry of tartrate-resistant acid phosphatase and carbonic anhydrase isoenzyme II in osteoclast-like giant cells in bone tumours.
Neoplasms
Histopathological Determinants of Tumor Resistance: a Special Look to The Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers.
Neoplasms
HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Neoplasms
Homology modeling and receptor-based 3D-QSAR study of carbonic anhydrase IX.
Neoplasms
How and Why Are Cancers Acidic? Carbonic Anhydrase IX and the Homeostatic Control of Tumour Extracellular pH.
Neoplasms
Hsp27 and its expression pattern in diffusely infiltrating astrocytomas.
Neoplasms
Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers.
Neoplasms
Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours.
Neoplasms
Humanized Monoclonal Antibody Blocking Carbonic Anhydrase 12 Enzymatic Activity Leads to Reduced Tumor Growth In Vitro.
Neoplasms
Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions.
Neoplasms
Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH.
Neoplasms
Hypoxia and energetic tumour metabolism.
Neoplasms
Hypoxia biomarkers in squamous cell carcinoma of the uterine cervix.
Neoplasms
Hypoxia contributes to development of recurrent endometrial carcinoma.
Neoplasms
Hypoxia in human colorectal adenocarcinoma: Comparison between extrinsic and potential intrinsic hypoxia markers.
Neoplasms
Hypoxia in larynx carcinomas assessed by pimonidazole binding and the value of CA-IX and vascularity as surrogate markers of hypoxia.
Neoplasms
Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer.
Neoplasms
Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma.
Neoplasms
Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target.
Neoplasms
Hypoxia inducible factor (HIF1alpha and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy.
Neoplasms
Hypoxia-Activated Prodrug Derivatives of Carbonic Anhydrase Inhibitors in Benzenesulfonamide Series: Synthesis and Biological Evaluation.
Neoplasms
Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer.
Neoplasms
Hypoxia-Associated Marker CA IX Does Not Predict the Response of Locally Advanced Rectal Cancers to Neoadjuvant Chemoradiotherapy.
Neoplasms
Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use.
Neoplasms
Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer.
Neoplasms
Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH.
Neoplasms
Hypoxia-inducible carbonic anhydrase IX expression is insufficient to alleviate intracellular metabolic acidosis in the muscle of zebrafish, Danio rerio.
Neoplasms
Hypoxia-inducible expression of the mouse carbonic anhydrase IX demonstrated by new monoclonal antibodies.
Neoplasms
Hypoxia-inducible expression of tumor-associated carbonic anhydrases.
Neoplasms
Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix.
Neoplasms
Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways.
Neoplasms
Hypoxia-inducible factors in OSCC.
Neoplasms
Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer.
Neoplasms
Hypoxia-related molecules HIF-1?, CA9, and osteopontin : predictors of survival in patients with high-grade glioma.
Neoplasms
Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
Neoplasms
Hypoxia-targeted gold nanorods for cancer photothermal therapy.
Neoplasms
Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates.
Neoplasms
Hypoxic regulation of cytoglobin and neuroglobin expression in human normal and tumor tissues.
Neoplasms
Identification and characterization of Birt-Hogg-Dubé associated renal carcinoma.
Neoplasms
Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas.
Neoplasms
Identification of carbonic anhydrase I immunodominant epitopes recognized by specific autoantibodies which indicate an improved prognosis in patients with malignancy after autologous stem cell transplantation.
Neoplasms
Identification of Carbonic Anhydrase IX as a Novel Target for Endoscopic Molecular Imaging of Human Bladder Cancer.
Neoplasms
Identification of CDCA1-derived long peptides bearing both CD4+ and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer patients.
Neoplasms
Identification of non-classical hCA XII inhibitors using combination of computational approaches for drug design and discovery.
Neoplasms
Identification of potential tumour-associated carbonic anhydrase isozyme IX inhibitors: atom-based 3D-QSAR modelling, pharmacophore-based virtual screening and molecular docking studies.
Neoplasms
Identification of proteins that regulate radiation-induced apoptosis in murine tumors with wild type p53.
Neoplasms
Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging.
Neoplasms
Identifying potential selective fluorescent probes for cancer-associated protein carbonic anhydrase IX using a computational approach.
Neoplasms
Identifying the stromal cell type that contributes to tumor aggressiveness associated with carbonic anhydrase IX.
Neoplasms
IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients.
Neoplasms
Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model.
Neoplasms
Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Neoplasms
Immunohistochemical demonstration of carbonic anhydrase in human kidney, bone and giant cell tumor of bone.
Neoplasms
Immunohistochemical demonstration of human carbonic anhydrase isoenzyme II in brain tumours.
Neoplasms
Immunohistochemical demonstration of the carbonic anhydrase isoenzymes I and II in pancreatic tumours.
Neoplasms
Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters.
Neoplasms
Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.
Neoplasms
Immunohistochemical localization of carbonic anhydrase isoenzymes I and II in human bone, cartilage and giant cell tumor.
Neoplasms
Immunohistochemical localization of transport mediators in Wilms' tumor: comparison with fetal and mature human kidney.
Neoplasms
Immunohistochemical Panel for Differentiating Renal Cell Carcinoma with Clear and Papillary Features.
Neoplasms
Immunohistochemical panel for differentiating renal cell carcinoma with clear and papillary features.
Neoplasms
Immunohistochemical reevaluation of carbonic anhydrase IX (CA IX) expression in tumors and normal tissues.
Neoplasms
Immunohistochemical study of carbonic anhydrase in mixed tumours and adenomas of sweat and sebaceous glands.
Neoplasms
Immunohistochemical study of carbonic anhydrase in mixed tumours from major salivary glands and skin.
Neoplasms
Immunohistochemical study of carbonic anhydrase in normal salivary gland and salivary gland tumor.
Neoplasms
Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity.
Neoplasms
Immunohistochemistry-based hypoxia-immune prognostic classifier for head-and-neck cancer patients undergoing chemoradiation - Post-hoc analysis from a prospective imaging trial.
Neoplasms
Impact of Acetazolamide, a Carbonic Anhydrase Inhibitor, on the Development of Intestinal Polyps in Min Mice.
Neoplasms
Impacts of CA9 gene polymorphisms and environmental factors on oral-cancer susceptibility and clinicopathologic characteristics in Taiwan.
Neoplasms
Impacts of CA9 gene polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic characteristics in Taiwan.
Neoplasms
Impairment of carbonic anhydrase IX ectodomain cleavage reinforces tumorigenic and metastatic phenotype of cancer cells.
Neoplasms
Impairment of Hypoxia-Induced CA IX by Beta-Blocker Propranolol-Impact on Progression and Metastatic Potential of Colorectal Cancer Cells.
Neoplasms
In Search of Advanced Tumor Diagnostics and Treatment: Achievements and Perspectives of Carbonic Anhydrase IX Targeted Delivery.
Neoplasms
In vitro and in vivo BNCT investigations using a carborane containing sulfonamide targeting CAIX epitopes on malignant pleural mesothelioma and breast cancer cells.
Neoplasms
In vivo imaging and quantification of carbonic anhydrase IX expression as an endogenous biomarker of tumor hypoxia.
Neoplasms
In Vivo Loss of Function Screening Reveals Carbonic Anhydrase IX as a Key Modulator of Tumor Initiating Potential in Primary Pancreatic Tumors.
Neoplasms
In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives.
Neoplasms
In-Vitro Anticancer Evaluation and Docking Study of Novel benzo[g] quinazoline-sulfonamide Derivatives.
Neoplasms
Inclusion of a 5-fluorouracil moiety in nitrogenous bases derivatives as human carbonic anhydrase IX and XII inhibitors produced a targeted action against MDA-MB-231 and T47D breast cancer cells.
Neoplasms
Increased expression of carbonic anhydrase IX in oral submucous fibrosis and oral squamous cell carcinoma.
Neoplasms
Increased expression of stemness markers and altered tumor stroma in hepatocellular carcinoma under TACE-induced hypoxia: A biopsy and resection matched study.
Neoplasms
Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX.
Neoplasms
Indisulam: an anticancer sulfonamide in clinical development.
Neoplasms
Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells.
Neoplasms
Induction of carbonic anhydrase IX by hypoxia and chemical disruption of oxygen sensing in rat fibroblasts and cardiomyocytes.
Neoplasms
Influence of hypoxia-dependent factors on the progression of neuroblastoma.
Neoplasms
Influence of Paclitaxel and Doxorubicin Therapy of ßIII-Tubulin, Carbonic Anhydrase IX, and Survivin in Chemically Induced Breast Cancer in Female Rat.
Neoplasms
Influence of tumor transplantation methods on tumor growth rate and metastatic potential of solitary tumors derived from metastases.
Neoplasms
Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro.
Neoplasms
Inhibition of carbonic anhydrase IX as a novel anticancer mechanism.
Neoplasms
Inhibition of Carbonic Anhydrase IX by Ureidosulfonamide Inhibitor U104 Reduces Prostate Cancer Cell Growth, But Does Not Modulate Daunorubicin or Cisplatin Cytotoxicity.
Neoplasms
Inhibition of carbonic anhydrase IX in glioblastoma multiforme.
Neoplasms
Inhibition of Carbonic Anhydrase IX Promotes Apoptosis through Intracellular pH Level Alterations in Cervical Cancer Cells.
Neoplasms
Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: Three for the price of one.
Neoplasms
Inhibition of carbonic anhydrase IX: a new strategy against cancer.
Neoplasms
Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma.
Neoplasms
Inhibition of Carbonic Anhydrase Using SLC-149: Support for a Noncatalytic Function of CAIX in Breast Cancer.
Neoplasms
Inhibition of Melanoma Cell Migration and Invasion Targeting the Hypoxic Tumor Associated CAXII.
Neoplasms
Inhibition of smoothened in breast cancer cells reduces CAXII expression and cell migration.
Neoplasms
Inhibition of tumor-associated human carbonic anhydrase isozymes IX and XII by a new class of substituted-phenylacetamido aromatic sulfonamides.
Neoplasms
Inhibition of V-ATPases and Carbonic Anhydrases as Interference Strategy with Tumor Acidification Processes.
Neoplasms
Inhibition on angiotensin-converting enzyme exerts beneficial effects on trabecular bone in orchidectomized mice.
Neoplasms
Inhibitors of CA IX Enzyme Based on Polyhedral Boron Compounds.
Neoplasms
Inhibitory activity against carbonic anhydrase IX and XII as a candidate selection criterion in the development of new anticancer agents.
Neoplasms
Inhibitory Monoclonal Antibodies and Their Recombinant Derivatives Targeting Surface-Exposed Carbonic Anhydrase XII on Cancer Cells.
Neoplasms
Insights towards sulfonamide drug specificity in ?-carbonic anhydrases.
Neoplasms
Interaction of HIF-1? and Notch3 Is Required for the Expression of Carbonic Anhydrase 9 in Breast Carcinoma Cells.
Neoplasms
Interactions between hypoxia and epidermal growth factor receptor in non-small-cell lung cancer.
Neoplasms
Interfering with pH regulation in tumours as a therapeutic strategy.
Neoplasms
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.
Neoplasms
Interplay of Carbonic Anhydrase IX With Amino Acid and Acid/Base Transporters in the Hypoxic Tumor Microenvironment.
Neoplasms
Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
Neoplasms
Intracellular carbonic anhydrase activity sensitizes cancer cell pH signaling to dynamic changes in CO2 partial pressure.
Neoplasms
Intratumoral oxygenation of invasive squamous cell carcimoma of the vulva is not correlated with regional lymph node metastasis.
Neoplasms
Intrinsic binding of 4-substituted-2,3,5,6-tetrafluorobenezenesulfonamides to native and recombinant human carbonic anhydrase VI.
Neoplasms
Intrinsic Thermodynamics and Structure Correlation of Benzenesulfonamides with a Pyrimidine Moiety Binding to Carbonic Anhydrases I, II, VII, XII, and XIII.
Neoplasms
Intrinsic thermodynamics of inhibitor binding to human carbonic anhydrase IX.
Neoplasms
Intrinsic thermodynamics of sulfonamide inhibitor binding to human carbonic anhydrases I and II.
Neoplasms
Intrinsically disordered features of carbonic anhydrase IX proteoglycan-like domain.
Neoplasms
Investigation of 3-sulfamoyl coumarins against cancer-related IX and XII isoforms of human carbonic anhydrase as well as cancer cells leads to the discovery of 2-oxo-2H-benzo[h]chromene-3-sulfonamide - A new caspase-activating proapoptotic agent.
Neoplasms
Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and (124)I-cG250 PET/CT.
Neoplasms
Investigation of inhibitory properties of some hydrazone compounds on hCA I, hCA II and AChE enzymes.
Neoplasms
Investigation of possible endogenous hypoxia markers in colorectal cancer.
Neoplasms
Involvement of histone deacetylation in MORC2-mediated down-regulation of carbonic anhydrase IX.
Neoplasms
Is carbonic anhydrase IX a validated target for molecular imaging of cancer and hypoxia?
Neoplasms
Ischemia dysregulates DNA methyltransferases and p16(INK4a) methylation in human colorectal cancer cells.
Neoplasms
Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: in vivo identification from hypoxic tumor cells.
Neoplasms
Kinetically labile ruthenium(II) complexes of terpyridines and saccharin: effect of substituents on photoactivity, solvation kinetics, and photocytotoxicity.
Neoplasms
LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen.
Neoplasms
Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.
Neoplasms
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Neoplasms
Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study.
Neoplasms
Lactate stimulates CA IX expression in normoxic cancer cells.
Neoplasms
Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells.
Neoplasms
Large (>3.8 cm) clear cell renal cell carcinomas are morphologically and immunohistochemically heterogeneous.
Neoplasms
LDH-A influences hypoxia-inducible factor 1? (HIF1 ?) and is critical for growth of HT29 colon carcinoma cells in vivo.
Neoplasms
Lead Development of Thiazolylsulfonamides with Carbonic Anhydrase Inhibitory Action.
Neoplasms
Lipoyl-Homotaurine Derivative (ADM_12) Reverts Oxaliplatin-Induced Neuropathy and Reduces Cancer Cells Malignancy by Inhibiting Carbonic Anhydrase IX (CAIX).
Neoplasms
Low CA II expression is associated with tumor aggressiveness and poor prognosis in gastric cancer patients.
Neoplasms
Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas.
Neoplasms
Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3'-kinase.
Neoplasms
Lymphocytic choriomeningitis virus mx strain does not induce the expression of tumor-associated carbonic anhydrase IX in persistently infected HeLa cells.
Neoplasms
Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1?/VEGF signaling pathway in human bladder cancer cells.
Neoplasms
Mapping Selective Inhibition of the Cancer-Related Carbonic Anhydrase IX Using Structure-Activity Relationships of Glucosyl-Based Sulfamates.
Neoplasms
MCM2 and Carbonic Anhydrase 9 Are Novel Potential Targets for Neuroblastoma Pharmacological Treatment.
Neoplasms
Measuring carbonic anhydrase IX as a hypoxia biomarker: differences in concentrations in serum and plasma using a commercial enzyme-linked immunosorbent assay due to influences of metal ions.
Neoplasms
Mesenchymal stem cell transplantation attenuates growth of chemotherapy treated oral squamous cell carcinoma in an animal model.
Neoplasms
Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma.
Neoplasms
Metallacarborane Sulfamides: Unconventional, Specific, and Highly Selective Inhibitors of Carbonic Anhydrase IX.
Neoplasms
Metastatic instability of murine tumor metastases: dependence on tumor type.
Neoplasms
Methanethiol Binding Strengths and Deprotonation Energies in Zn(II)-Imidazole Complexes from M05-2X and MP2 Theories: Coordination Number and Geometry Influences Relevant to Zinc Enzymes.
Neoplasms
Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines.
Neoplasms
Metronidazole-coumarin conjugates and 3-cyano-7-hydroxy-coumarin act as isoform-selective carbonic anhydrase inhibitors.
Neoplasms
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.
Neoplasms
Microfluidic Encapsulation of Prickly Zinc-Doped Copper Oxide Nanoparticles with VD1142 Modified Spermine Acetalated Dextran for Efficient Cancer Therapy.
Neoplasms
Microsecond Simulation of the Proteoglycan-like Region of Carbonic Anhydrase IX and Design of Chemical Inhibitors Targeting pH Homeostasis in Cancer Cells.
Neoplasms
Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression.
Neoplasms
Microvessel density, endothelial-cell proliferation and carbonic anhydrase IX expression in haematological malignancies, bone-marrow metastases and monoclonal gammopathy of undetermined significance.
Neoplasms
Mitochondrial proteomic profiling reveals increased carbonic anhydrase II in aging and neurodegeneration.
Neoplasms
Modeling of pH regulation in tumor cells: Direct interaction between proton-coupled lactate transporters and cancer-associated carbonic anhydrase.
Neoplasms
Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer.
Neoplasms
Modulation of cell surface density of carbonic anhydrase IX by shedding of the ectodomain and endocytosis.
Neoplasms
Modulation of the Pharmacokinetics of a Radioligand Targeting Carbonic Anhydrase-IX with Albumin-Binding Moieties.
Neoplasms
Modulation of Tumor Microenvironment to Enhance Radiotherapy Efficacy in Esophageal Squamous Cell Carcinoma by Inhibiting Carbonic Anhydrase IX.
Neoplasms
Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
Neoplasms
Molecular imaging of urogenital diseases.
Neoplasms
Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.
Neoplasms
Molecular targeting of bioconjugated graphene oxide nanocarriers revealed at a cellular level using label-free Raman imaging.
Neoplasms
Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts.
Neoplasms
Molecular-genetic analysis is essential for accurate classification of renal carcinoma resembling Xp11.2 translocation carcinoma.
Neoplasms
Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model.
Neoplasms
Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach.
Neoplasms
Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX.
Neoplasms
Monoclonal antibody G250 targeting CA ?: Binding specificity, internalization and therapeutic effects in a non-renal cancer model.
Neoplasms
Multimodal evaluation of hypoxia in brain metastases of lung cancer and interest of hypoxia image-guided radiotherapy.
Neoplasms
Multiple and bilateral kidney tumors with clear cells of three different histotypes: A case report with clinicopathologic and molecular study.
Neoplasms
Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders.
Neoplasms
Myoglobin variants are expressed in human glioblastoma cells?hypoxia effect?
Neoplasms
N-?-Glycosyl sulfamides are selective inhibitors of the cancer associated carbonic anhydrase isoforms IX and XII.
Neoplasms
N-Acylbenzenesulfonamide Dihydro-1,3,4-oxadiazole Hybrids: Seeking Selectivity toward Carbonic Anhydrase Isoforms.
Neoplasms
Natural product polyamines that inhibit human carbonic anhydrases.
Neoplasms
Near-infrared fluorescence activation probes based on disassembly-induced emission cyanine dye.
Neoplasms
Near-Infrared Fluorescence Imaging of Carbonic Anhydrase IX in Athymic Mice Bearing HT-29 Tumor Xenografts.
Neoplasms
Neoplastic transformation of propagable cultured rat pancreatic duct epithelial cells by azaserine and streptozotocin.
Neoplasms
Neuroendocrine regulation of carbonic anhydrase expression in the gills of the euryhaline green crab, Carcinus maenas.
Neoplasms
New coumarin/sulfocoumarin linked phenylacrylamides as selective transmembrane carbonic anhydrase inhibitors: Synthesis and in-vitro biological evaluation.
Neoplasms
New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation.
Neoplasms
New Monoclonal Antibodies for a Selective Detection of Membrane-Associated and Soluble Forms of Carbonic Anhydrase IX in Human Cell Lines and Biological Samples.
Neoplasms
New power of self-assembling carbonic anhydrase inhibitor: Short peptide-constructed nanofibers inspire hypoxic cancer therapy.
Neoplasms
New selective carbonic anhydrase IX inhibitors: Synthesis and pharmacological evaluation of diarylpyrazole-benzenesulfonamides.
Neoplasms
Next revolution in molecular theranostics: personalized medicine for urologic cancers.
Neoplasms
Nitric oxide donors and selective carbonic anhydrase inhibitors: a dual pharmacological approach for the treatment of glaucoma, cancer and osteoporosis.
Neoplasms
Nitroimidazole-based inhibitors DTP338 and DTP348 are safe for zebrafish embryos and efficiently inhibit the activity of human CA IX in Xenopus oocytes.
Neoplasms
Novel 2-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)-1-(1,3,5-triazin-2-ylamino)guanidine derivatives: Inhibition of human carbonic anhydrase cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII, anticancer activity, and molecular modeling studies.
Neoplasms
Novel antibody to a carbonic anhydrase: patent evaluation of WO2011138279A1.
Neoplasms
Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer.
Neoplasms
Novel fluorinated carbonic anhydrase IX inhibitors reduce hypoxia-induced acidification and clonogenic survival of cancer cells.
Neoplasms
Novel insights on saccharin- and acesulfame-based carbonic anhydrase inhibitors: design, synthesis, modelling investigations and biological activity evaluation.
Neoplasms
Novel predictive biomarkers for cervical cancer prognosis.
Neoplasms
Novel sulfonamide bearing coumarin scaffolds as selective inhibitors of tumor associated carbonic anhydrase isoforms IX and XII.
Neoplasms
Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer.
Neoplasms
Oleuropein and Verbascoside - Their Inhibition Effects on Carbonic Anhydrase and Molecular Docking Studies.
Neoplasms
Oncogenic roles of carbonic anhydrase IX in human nasopharyngeal carcinoma.
Neoplasms
Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
Neoplasms
Optimization of a novel peptide ligand targeting human carbonic anhydrase IX.
Neoplasms
Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters.
Neoplasms
Organic Photodynamic Nanoinhibitor for Synergistic Cancer Therapy.
Neoplasms
Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment.
Neoplasms
Overcoming the Limits of Hypoxia in Photodynamic Therapy: A Carbonic Anhydrase IX-Targeted Approach.
Neoplasms
Overexpressed CA12 has prognostic value in pancreatic cancer and promotes tumor cell apoptosis via NF-?B signaling.
Neoplasms
Overexpression of CA1 mRNA and the CA I Protein in Tumor Cells Does Not Change the Gene Expression of the ECM Proteins.
Neoplasms
Overexpression of carbonic anhydrase and HIF-1? in Wilms tumours.
Neoplasms
Overexpression of carbonic anhydrase II and Ki-67 proteins in prognosis of gastrointestinal stromal tumors.
Neoplasms
Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases.
Neoplasms
Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer.
Neoplasms
Overexpression of carbonic anhydrase IX induces cell motility by activating matrix metalloproteinase-9 in human oral squamous cell carcinoma cells.
Neoplasms
Overexpression of Carbonic Anhydrase IX is a Dismal Prognostic Marker in Breast Carcinoma in Egyptian Patients.
Neoplasms
Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis.
Neoplasms
Overexpression of carbonic anhydrase-related protein XI promotes proliferation and invasion of gastrointestinal stromal tumors.
Neoplasms
Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy.
Neoplasms
Overlap of epitopes recognized by anti-carbonic anhydrase I IgG in patients with malignancy-related aplastic anemia-like syndrome and in patients with aplastic anemia.
Neoplasms
Overlapping Immunohistochemical Features of Adenocarcinoma of the Nonpigmented Ciliary Body Epithelium and Renal Cell Carcinoma.
Neoplasms
Oxaliplatin-induced neuropathy occurs through impairment of haemoglobin proton buffering and is reversed by carbonic anhydrase inhibitors.
Neoplasms
Oxygen and glucose consumption in gastrointestinal adenocarcinomas: Correlation with markers of hypoxia, acidity and anaerobic glycolysis.
Neoplasms
Oxygen Deprivation Modulates EGFR and PD-L1 in Squamous Cell Carcinomas of the Head and Neck.
Neoplasms
P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors.
Neoplasms
P53 tumour suppressor modulates transcription of the TATA-less gene coding for the tumour-associated carbonic anhydrase MN/CA IX in MaTu cells.
Neoplasms
p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres.
Neoplasms
Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression.
Neoplasms
Papillary cystadenoma of the epididymis and broad ligament: morphologic and immunohistochemical overlap with clear cell papillary renal cell carcinoma.
Neoplasms
Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX.
Neoplasms
Pdcd4 inhibits growth of tumor cells by suppression of carbonic anhydrase type II.
Neoplasms
PEG Linker Length Strongly Affects Tumor Cell Killing by PEGylated Carbonic Anhydrase Inhibitors in Hypoxic Carcinomas Expressing Carbonic Anhydrase IX.
Neoplasms
PEGylated Bis-Sulfonamide Carbonic Anhydrase Inhibitors Can Efficiently Control the Growth of Several Carbonic Anhydrase IX-Expressing Carcinomas.
Neoplasms
Personalized Treatment Response Assessment for Rare Childhood Tumors Using Microcalorimetry-Exemplified by Use of Carbonic Anhydrase IX and Aquaporin 1 Inhibitors.
Neoplasms
Perspectives on the Classical Enzyme Carbonic Anhydrase and the Search for Inhibitors.
Neoplasms
PET imaging and pharmacological therapy targeting carbonic anhydrase-IX high-expressing tumors using US2 platform based on bivalent ureidosulfonamide.
Neoplasms
PET Imaging of Carbonic Anhydrase IX Expression of HT-29 Tumor Xenograft Mice with (68)Ga-Labeled Benzenesulfonamides.
Neoplasms
PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
Neoplasms
PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.
Neoplasms
pH control mechanisms of tumor survival and growth.
Neoplasms
pH-Sensitive Multiligand Gold Nanoplatform Targeting Carbonic Anhydrase IX Enhances the Delivery of Doxorubicin to Hypoxic Tumor Spheroids and Overcomes the Hypoxia-Induced Chemoresistance.
Neoplasms
Pharmacological Inhibition of CA-IX Impairs Tumor Cell Proliferation, Migration and Invasiveness.
Neoplasms
Pharmacological inhibition of carbonic anhydrase XII interferes with cell proliferation and induces cell apoptosis in T-cell lymphomas.
Neoplasms
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS.
Neoplasms
Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer.
Neoplasms
Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors.
Neoplasms
Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer.
Neoplasms
Picomolar inhibitors of carbonic anhydrase: Importance of inhibition and binding assays.
Neoplasms
Plasma Osteopontin Is a Useful Diagnostic Biomarker for Advanced Non-Small Cell Lung Cancer.
Neoplasms
Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma.
Neoplasms
Plasmatic exosomes from prostate cancer patients show increased carbonic anhydrase IX expression and activity and low pH.
Neoplasms
Podoplanin-positive cancer associated fibroblast could have prognostic value independent of cancer cell phenotype in stage I lung squamous cell carcinoma: Utility of combining analysis of both cancer cell phenotype and cancer associated fibroblast phenotype.
Neoplasms
Polypharmacology of sulfonamides: pazopanib, a multitargeted receptor tyrosine kinase inhibitor in clinical use, potently inhibits several mammalian carbonic anhydrases.
Neoplasms
Poor outcome in hypoxic endometrial carcinoma is related to vascular density.
Neoplasms
Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype.
Neoplasms
Post-translational modifications in tumor-associated carbonic anhydrases.
Neoplasms
Potential anticancer activities of Rhus coriaria (sumac) extract against human cancer cell lines.
Neoplasms
Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
Neoplasms
Potential inhibitors of human carbonic anhydrase isozymes I and II: Design, synthesis and docking studies of new 1,3,4-thiadiazole derivatives.
Neoplasms
PPAR? and RXR Ligands Disrupt the Inflammatory Cross-talk in the Hypoxic Breast Cancer Stem Cells Niche.
Neoplasms
Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis.
Neoplasms
Preclinical Evaluation of Ureidosulfamate Carbonic Anhydrase IX/XII Inhibitors in the Treatment of Cancers.
Neoplasms
Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer.
Neoplasms
Prediction of activity and selectivity profiles of human Carbonic Anhydrase inhibitors using machine learning classification models.
Neoplasms
Predictors of tumor response after preoperative chemoradiotherapy for rectal adenocarcinomas.
Neoplasms
Preliminary biological evaluation of ¹²?I-labeled anti-carbonic anhydrase IX monoclonal antibody in the mice bearing HT-29 tumors.
Neoplasms
Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma.
Neoplasms
Primary endocervical gastric-type adenocarcinoma: a clinicopathologic and immunohistochemical analysis of 23 cases.
Neoplasms
Primary glial tumor of the retina with features of myxopapillary ependymoma.
Neoplasms
Probing the chemical interaction space governed by 4-aminosubstituted benzenesulfonamides and carbonic anhydrase isoforms.
Neoplasms
Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [111 In]In-XYIMSR-01 for phase I regulatory approval.
Neoplasms
Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry.
Neoplasms
Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma.
Neoplasms
Prognostic impact of LY6K and CDCA1 expression for patients with esophageal squamous cell carcinoma.
Neoplasms
Prognostic impact of the tumor immune microenvironment in pulmonary pleomorphic carcinoma.
Neoplasms
Prognostic impacts of hypoxic markers in soft tissue sarcoma.
Neoplasms
Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells.
Neoplasms
Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study.
Neoplasms
Prognostic Relevance of the Expression of CA IX, GLUT-1, and VEGF in Ovarian Epithelial Cancers.
Neoplasms
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.
Neoplasms
Prognostic Significance of Carbonic Anhydrase IX (CA-IX), Endoglin (CD105) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in Breast Cancer Patients.
Neoplasms
Prognostic significance of carbonic anhydrase IX expression by cancer-associated fibroblasts in lung adenocarcinoma.
Neoplasms
Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis.
Neoplasms
Prognostic Significance of Osteopontin and Carbonic Anhydrase 9 in Human Brain Tumors: A Meta-Analysis.
Neoplasms
Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Neoplasms
Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer - A survival model with external validation.
Neoplasms
Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue.
Neoplasms
Prognostic value of carbonic anhydrase IX expression in penile squamous cell carcinoma: A pilot study.
Neoplasms
Prognostic value of carbonic anhydrase XII (CA XII) overexpression in hepatocellular carcinoma.
Neoplasms
Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors.
Neoplasms
Prognostic value of serum carbonic anhydrase IX in testicular germ cell tumor patients.
Neoplasms
Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy.
Neoplasms
Prophylactic irradiation of para-aortic lymph nodes for patients with locally advanced cervical cancers with and without high CA9 expression (KROG 07-01): A randomized, open-label, multicenter, phase 2 trial.
Neoplasms
Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
Neoplasms
Prostate cancer cells and exosomes in acidic condition show increased carbonic anhydrase IX expression and activity.
Neoplasms
Protein profile changes in the human breast cancer cell line MCF-7 in response to SEL1L gene induction.
Neoplasms
Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers.
Neoplasms
Proteus mirabilis inhibits cancer growth and pulmonary metastasis in a mouse breast cancer model.
Neoplasms
Proton Transport in Cancer Cells: The Role of Carbonic Anhydrases.
Neoplasms
Protons make tumor cells move like clockwork.
Neoplasms
Purification and kinetic analysis of recombinant CA XII, a membrane carbonic anhydrase overexpressed in certain cancers.
Neoplasms
Purification, enzymatic activity and inhibitor discovery for recombinant human carbonic anhydrase XIV.
Neoplasms
Pyrazolylbenzo[d]imidazoles as new potent and selective inhibitors of carbonic anhydrase isoforms hCA IX and XII.
Neoplasms
Pyridazinone-substituted benzenesulfonamides display potent inhibition of membrane-bound human carbonic anhydrase IX and promising antiproliferative activity against cancer cell lines.
Neoplasms
Pyruvate dehydrogenase kinase 1 and carbonic anhydrase IX targeting in hypoxic tumors.
Neoplasms
Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer.
Neoplasms
Quantitative Analysis of Carbonic Anhydrase IX Uncovers Hypoxia-Related Functional Differences in Classical Hodgkin Lymphoma Subtypes.
Neoplasms
Quantitative assessment of specific carbonic anhydrase inhibitors effect on hypoxic cells using electrical impedance assays.
Neoplasms
Quercetin-Modified Metal-Organic Frameworks for Dual Sensitization of Radiotherapy in Tumor Tissues by Inhibiting the Carbonic Anhydrase IX.
Neoplasms
Quinoline-sulfamoyl carbamates/sulfamide derivatives: Synthesis, cytotoxicity, carbonic anhydrase activity, and molecular modelling studies.
Neoplasms
Radiolabeling of the antibody IgG M75 for epitope of human carbonic anhydrase IX by 61Cu and 64Cu and its biological testing.
Neoplasms
Radiosynthesis of three [11C]ureido-substituted benzenesulfonamides as PET probes for carbonic anhydrase IX in tumors.
Neoplasms
Radiotracers for positron emission tomography (PET) targeting tumour-associated carbonic anhydrase isoforms.
Neoplasms
Rapid detection of the hypoxia-regulated CA-IX and NDRG1 gene expression in different glioblastoma cells in vitro.
Neoplasms
Re: Grant D. Stewart, Fiach C. O'Mahony, Alexander Laird, et al. Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factor-Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.007.
Neoplasms
Recent advances in autoimmune pancreatitis: concept, diagnosis, and pathogenesis.
Neoplasms
Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors.
Neoplasms
Recent developments in targeting carbonic anhydrase IX for cancer therapeutics.
Neoplasms
Recent Developments on Thiourea Based Anticancer Chemotherapeutics.
Neoplasms
Recombinant human epidermal growth factor (rhEGF) protects radiation-induced intestine injury in murine system.
Neoplasms
Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers.
Neoplasms
Redox state and carbonic anhydrase isozyme IX expression in human renal cell carcinoma: biochemical and morphological investigations.
Neoplasms
Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor.
Neoplasms
Regulation of intracellular pH in neuronal and glial tumour cells, studied by multinuclear NMR spectroscopy.
Neoplasms
Regulation of tumor pH and the role of carbonic anhydrase 9.
Neoplasms
Relationship between Hypoxia and Carcinoembryonic Antigen and Upregulated Carcinoembryonic Antigen is Associated with Poor Prognosis in Breast Cancer Patients.
Neoplasms
Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer.
Neoplasms
Renal cell carcinoma in tuberous sclerosis complex.
Neoplasms
Renal cell carcinoma with rhabdoid and sarcomatoid features presented as a metastatic thigh mass with an unusual immunohistochemical profile.
Neoplasms
RENCA/carbonic anhydrase-IX: a murine model of a carbonic anhydrase-IX-expressing renal cell carcinoma.
Neoplasms
Reoxygenation and Repopulation of Tumor Cells after Ablative Hypofractionated Radiotherapy (SBRT and SRS) in Murine Tumors.
Neoplasms
Reproducibility and biological basis of in vivo T(2) * magnetic resonance imaging of liver metastasis of colorectal cancer.
Neoplasms
Reproducibility of functional volume and activity concentration in (18)F-FDG PET/CT of liver metastases in colorectal cancer.
Neoplasms
Response of CAIX and CAXII to in vitro re-oxygenation and clinical significance of the combined expression in NSCLC patients.
Neoplasms
Restoring physiological levels of ascorbate slows tumor growth and moderates HIF-1 pathway activity in Gulo(-/-) mice.
Neoplasms
Retinoblastoma in a dog.
Neoplasms
Retinoids: effects on growth, differentiation, and nuclear receptor expression in human pancreatic carcinoma cell lines.
Neoplasms
Revealing membrane alteration in cellsoverexpressing CA IX and EGFR by Surface-Enhanced Raman Scattering.
Neoplasms
RNAi-mediated knockdown of CAIX enhances the radiosensitivity of nasopharyngeal carcinoma cell line, CNE-2.
Neoplasms
Role of CAIX Expression in Conventional Renal Cell Carcinomas as a Diagnostic Marker and its Prognostic Importance.
Neoplasms
Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion.
Neoplasms
Role of carbonic anhydrase IX, ?-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: a tissue microarray immunohistochemical study.
Neoplasms
Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: proposal of a unified hypothesis.
Neoplasms
Role of human papillomavirus testing in reducing the number of surgical treatments for precancerous cervical lesions.
Neoplasms
Role of hypoxia-inducible factor-1?, carbonic anhydrase-IX, glucose transporter-1 and vascular endothelial growth factor associated with lymph node metastasis and recurrence in patients with locally advanced cervical cancer.
Neoplasms
Role of the HBx oncoprotein in carbonic anhydrase 9 induction.
Neoplasms
Role of zinc in catalytic activity of carbonic anhydrase IX.
Neoplasms
Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence.
Neoplasms
Roles of Carbonic Anhydrase IX in Development of Pancreatic Cancer.
Neoplasms
RT-PCR detection of fibronectin EDA+ and EDB+ mRNA isoforms: molecular markers for hepatocellular carcinoma.
Neoplasms
Ruthenium(II) complexes of saccharin with dipyridoquinoxaline and dipyridophenazine: Structures, biological interactions and photoinduced DNA damage activity.
Neoplasms
Saccharin: A lead compound for structure-based drug design of carbonic anhydrase IX inhibitors.
Neoplasms
Salen and tetrahydrosalen derivatives act as effective inhibitors of the tumor-associated carbonic anhydrase XII--a new scaffold for designing isoform-selective inhibitors.
Neoplasms
Sarcomatoid Renal Cell Carcinoma With Unusual Metastasis to the Small Intestine Manifesting as Perforated Appendicitis.
Neoplasms
Sclerosing Sertoli cell tumor without expression of typical sex cord stromal tumor markers: case report and literature review.
Neoplasms
Selective carbonic anhydrase IX inhibitors based on coumarin scaffold as promising antimetastatic agents: WO2012070024.
Neoplasms
Selective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cells.
Neoplasms
Selective inhibition of carbonic anhydrase IX over carbonic anhydrase XII in breast cancer cells using benzene sulfonamides: Disconnect between activity and growth inhibition.
Neoplasms
Selective inhibition of carbonic anhydrase-IX by sulphonamide derivatives induces pH and reactive oxygen species-mediated apoptosis in cervical cancer HeLa cells.
Neoplasms
Selective inhibition of human carbonic anhydrase IX in Xenopus oocytes and MDA-MB-231 breast cancer cells.
Neoplasms
Sense-and-Release Logic-Gated Molecular Network Responding to Dimeric Cell Surface Proteins.
Neoplasms
Sera of patients with spontaneous tumour regression and elevated anti-CA I autoantibodies change the gene expression of ECM proteins.
Neoplasms
Serum adenosine deaminase, catalase, and carbonic anhydrase activities in patients with renal cell carcinoma.
Neoplasms
Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer.
Neoplasms
Serum carbonic anhydrase IX and its prognostic relevance in vulvar cancer.
Neoplasms
Sexual dimorphism in LEC rat liver: suppression of carbonic anhydrase III by copper accumulation during hepatocarcinogenesis.
Neoplasms
Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas.
Neoplasms
Silencing of carbonic anhydrase I enhances the malignant potential of exosomes secreted by prostatic tumour cells.
Neoplasms
Silencing of hypoxia-inducible tumor suppressor lysyl oxidase gene by promoter methylation activates carbonic anhydrase IX in nasopharyngeal carcinoma.
Neoplasms
Similarities and Differences between Clear Cell Tubulo-Papillary and Conventional Clear Cell Renal Cell Carcinoma: A Comparative Phenotypical and Mutational Analysis.
Neoplasms
Single nucleotide polymorphisms and haplotypes of carbonic anhydrase 9 can predict invasive squamous cell carcinoma of uterine cervix.
Neoplasms
Sinonasal renal cell-like adenocarcinomas: robust carbonic anhydrase expression.
Neoplasms
siRNA-mediated knockdown against CDCA1 and KNTC2, both frequently overexpressed in colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis.
Neoplasms
SLC-0111 enaminone analogs, 3/4-(3-aryl-3-oxopropenyl) aminobenzenesulfonamides, as novel selective subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform IX.
Neoplasms
Small renal masses: current concepts regarding the natural history and reflections on the American Urological Association guidelines.
Neoplasms
Soft-tissue Hemangioblastoma of the Retroperitoneum: A Case Study and Review of the Literature.
Neoplasms
Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients.
Neoplasms
Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation.
Neoplasms
Splicing variants of carbonic anhydrase IX in bladder cancer and urine sediments.
Neoplasms
Spontaneous peripheral T-cell responses toward the tumor-associated antigen cyclin D1 in patients with clear cell renal cell carcinoma.
Neoplasms
Src induces expression of carbonic anhydrase IX via hypoxia-inducible factor 1.
Neoplasms
Stromal expression of carbonic anhydrase IX in esophageal cancer.
Neoplasms
Structural Basis for the Interaction Between Carbonic Anhydrase and 1,2,3,4-tetrahydroisoquinolin-2-ylsulfonamides.
Neoplasms
Structural comparison of protiated, H/D-exchanged and deuterated human carbonic anhydrase IX.
Neoplasms
Structural elucidation of the hormonal inhibition mechanism of the bile acid cholate on human carbonic anhydrase II.
Neoplasms
Structural insights into carbonic anhydrase IX isoform specificity of carbohydrate-based sulfamates.
Neoplasms
Structural investigations on coumarins leading to chromeno[4,3-c]pyrazol-4-ones and pyrano[4,3-c]pyrazol-4-ones: New scaffolds for the design of the tumor-associated carbonic anhydrase isoforms IX and XII.
Neoplasms
Structure of the carbonic anhydrase VI (CA6) gene: evidence for two distinct groups within the alpha-CA gene family.
Neoplasms
Structure-based drug discovery of carbonic anhydrase inhibitors.
Neoplasms
Structures of human carbonic anhydrase II/inhibitor complexes reveal a second binding site for steroidal and nonsteroidal inhibitors.
Neoplasms
Substituted benzene sulfonamides incorporating 1,3,5-triazinyl moieties potently inhibit human carbonic anhydrases II, IX and XII.
Neoplasms
Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC.
Neoplasms
Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells.
Neoplasms
Sulfamates and their therapeutic potential.
Neoplasms
Sulfocoumarins, specific carbonic anhydrase IX and XII inhibitors, interact with cancer multidrug resistant phenotype through pH regulation and reverse P-glycoprotein mediated resistance.
Neoplasms
Sulfonamide bearing pyrazolylpyrazolines as potent inhibitors of carbonic anhydrase isoforms I, II, IX and XII.
Neoplasms
Sulfonamido carboranes as highly selective inhibitors of cancer-specific carbonic anhydrase IX.
Neoplasms
Suppression of carbonic anhydrase IX leads to aberrant focal adhesion and decreased invasion of tumor cells.
Neoplasms
Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
Neoplasms
Surface-Enhanced Raman Scattering Nanoparticles for Multiplexed Imaging of Bladder Cancer Tissue Permeability and Molecular Phenotype.
Neoplasms
Sweet Binders: Carbonic Anhydrase IX in Complex with Sucralose.
Neoplasms
Synchronous clear cell renal cell carcinoma and multilocular cystic renal cell neoplasia of low malignant potential: A clinico-pathologic and molecular study.
Neoplasms
Syntesis of thio- and seleno-acetamides bearing benzenesulfonamide as potent inhibitors of human carbonic anhydrase II and XII.
Neoplasms
Synthesis 4-[2-(2-mercapto-4-oxo-4H-quinazolin-3-yl)-ethyl]-benzenesulfonamides with subnanomolar carbonic anhydrase II and XII inhibitory properties.
Neoplasms
Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia.
Neoplasms
Synthesis and biological evaluation of benzenesulphonamide-bearing 1,4,5-trisubstituted-1,2,3-triazoles possessing human carbonic anhydrase I, II, IV, and IX inhibitory activity.
Neoplasms
Synthesis and biological evaluation of coumarin-1,3,4-oxadiazole hybrids as selective carbonic anhydrase IX and XII inhibitors.
Neoplasms
Synthesis and biological evaluation of cyclic imides incorporating benzenesulfonamide moieties as carbonic anhydrase I, II, IV and IX inhibitors.
Neoplasms
Synthesis and biological evaluation of novel 4,7-disubstituted coumarins as selective tumor-associated carbonic anhydrase IX and XII inhibitors.
Neoplasms
Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.
Neoplasms
Synthesis and carbonic anhydrase inhibition of polycyclic imides incorporating N-benzenesulfonamide moieties.
Neoplasms
Synthesis and carbonic anhydrase inhibitory effects of new N-glycosylsulfonamides incorporating the phenol moiety.
Neoplasms
Synthesis and evaluation of (18)F-labeled carbonic anhydrase IX inhibitors for imaging with positron emission tomography.
Neoplasms
Synthesis and evaluation of (18)F-labeled tertiary benzenesulfonamides for imaging carbonic anhydrase IX expression in tumours with positron emission tomography.
Neoplasms
Synthesis and evaluation of 68Ga-labeled imidazothiadiazole sulfonamide derivatives for PET imaging of carbonic anhydrase-IX.
Neoplasms
Synthesis and evaluation of indium-111-labeled imidazothiadiazole sulfonamide derivative for single photon emission computed tomography imaging targeting carbonic anhydrase-IX.
Neoplasms
Synthesis and evaluation of near-infrared fluorescent sulfonamide derivatives for imaging of hypoxia-induced carbonic anhydrase IX expression in tumors.
Neoplasms
Synthesis and evaluation of novel technetium-99m-hydroxamamide complex based on imidazothiadiazole sulfonamide targeting carbonic anhydrase-IX for tumor imaging.
Neoplasms
Synthesis and exploration of 2-morpholino-4-phenylthiazol-5-yl acrylamide derivatives for their effects against carbonic anhydrase I, II, IX and XII isoforms as a non-sulfonamide class of inhibitors.
Neoplasms
Synthesis and in vitro anticancer evaluation of some novel hexahydroquinoline derivatives having a benzenesulfonamide moiety.
Neoplasms
Synthesis and in Vivo Biological Evaluation of (68)Ga-Labeled Carbonic Anhydrase IX Targeting Small Molecules for Positron Emission Tomography.
Neoplasms
Synthesis and radiolabeling of (64)Cu-labeled 2-nitroimidazole derivative (64)Cu-BMS2P2 for hypoxia imaging.
Neoplasms
Synthesis and SAR of novel Re/99mTc-labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia.
Neoplasms
Synthesis of 1,2,4-triazole-5-on derivatives and determination of carbonic anhydrase II isoenzyme inhibition effects.
Neoplasms
Synthesis of 2-[11C]methoxy-3,17?-O,O-bis(sulfamoyl)estradiol as a new potential PET agent for imaging of steroid sulfatase (STS) in cancers.
Neoplasms
Synthesis of 4-(thiazol-2-ylamino)-benzenesulfonamides with carbonic anhydrase I, II and IX inhibitory activity and cytotoxic effects against breast cancer cell lines.
Neoplasms
Synthesis of a new series of 3-functionalised-1-phenyl-1,2,3-triazole sulfamoylbenzamides as carbonic anhydrase I, II, IV and IX inhibitors.
Neoplasms
Synthesis of an acridine orange sulfonamide derivative with potent carbonic anhydrase IX inhibitory action.
Neoplasms
Synthesis of bulky-tailed sulfonamides incorporating pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-1(5H)-yl) moieties and evaluation of their carbonic anhydrases I, II, IV and IX inhibitory effects.
Neoplasms
Synthesis of coumarin-sulfonamide derivatives and determination of their cytotoxicity, carbonic anhydrase inhibitory and molecular docking studies.
Neoplasms
Synthesis of glycoconjugate carbonic anhydrase inhibitors by ruthenium-catalysed azide-alkyne 1,3-dipolar cycloaddition.
Neoplasms
Synthesis of N'-phenyl-N-hydroxyureas and investigation of their inhibitory activities on human carbonic anhydrases.
Neoplasms
Synthesis of new 3-(2-mercapto-4-oxo-4H-quinazolin-3-yl)-benzenesulfonamides with strong inhibition properties against the tumor associated carbonic anhydrases IX and XII.
Neoplasms
Synthesis of novel acyl selenoureido benzensulfonamides as carbonic anhydrase I, II, VII and IX inhibitors.
Neoplasms
Synthesis of saccharin-glycoconjugates targeting carbonic anhydrase using a one-pot cyclization/deprotection strategy.
Neoplasms
Synthesis of sulfonamide conjugates of Cu(ii), Ga(iii), In(iii), Re(v) and Zn(ii) complexes: carbonic anhydrase inhibition studies and cellular imaging investigations.
Neoplasms
Synthesis, biological evaluation and in silico modelling studies of 1,3,5-trisubstituted pyrazoles carrying benzenesulfonamide as potential anticancer agents and selective cancer-associated hCA IX isoenzyme inhibitors.
Neoplasms
Synthesis, carbonic anhydrase inhibition and cytotoxic activity of novel chromone-based sulfonamide derivatives.
Neoplasms
Synthesis, characterization, in vitro cytotoxicity and antimicrobial investigation and evaluation of physicochemical properties of novel 4-(2-methylacetamide)benzenesulfonamide derivatives.
Neoplasms
Synthesis, cytotoxicity and carbonic anhydrase inhibitory activities of new pyrazolines.
Neoplasms
Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.
Neoplasms
Targeted agents for the treatment of advanced renal cell carcinoma.
Neoplasms
Targeted and redox-responsive drug delivery systems based on carbonic anhydrase IX-decorated mesoporous silica nanoparticles for cancer therapy.
Neoplasms
Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.
Neoplasms
Targeting Carbonic Anhydrase IX Activity and Expression.
Neoplasms
Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: A new concept of dual targeting drugs.
Neoplasms
Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.
Neoplasms
Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors.
Neoplasms
Targeting carbonic anhydrase IX with small organic ligands.
Neoplasms
Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors.
Neoplasms
Targeting Hypoxic Tumors with Hybrid Nanobullets for Oxygen-Independent Synergistic Photothermal and Thermodynamic Therapy.
Neoplasms
Targeting ion transport in cancer.
Neoplasms
Targeting of adenovirus to human renal cell carcinoma cells.
Neoplasms
Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250.
Neoplasms
Targeting of carbonic anhydrase IX-positive cancer cells by glycine-coated superparamagnetic nanoparticles.
Neoplasms
Targeting Tumor Associated Carbonic Anhydrases IX and XII: Highly Isozyme Selective Coumarin and Psoralen Inhibitors.
Neoplasms
Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors.
Neoplasms
Targeting tumor-associated carbonic anhydrase IX in cancer therapy.
Neoplasms
Tellurides bearing benzensulfonamide as carbonic anhydrase inhibitors with potent antitumor activity.
Neoplasms
TGF-beta upregulates tumor-associated carbonic anhydrase IX gene expression in Hep3B cells.
Neoplasms
The acidic tumor microenvironment drives a stem-like phenotype in melanoma cells.
Neoplasms
The antibiotic furagin and its derivatives are isoform-selective human carbonic anhydrase inhibitors.
Neoplasms
The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
Neoplasms
The Anticancer Activity for the Bumetanide-Based Analogs via Targeting the Tumor-Associated Membrane-Bound Human Carbonic Anhydrase-IX Enzyme.
Neoplasms
The apoptosis repressor with a CARD domain (ARC) gene is a direct hypoxia-inducible factor 1 target gene and promotes survival and proliferation of VHL-deficient renal cancer cells.
Neoplasms
The basal-like breast carcinoma phenotype is regulated by SLUG gene expression.
Neoplasms
The Carbonic Anhydrase Inhibitor E7070 Sensitizes Glioblastoma Cells to Radio- and Chemotherapy and Reduces Tumor Growth.
Neoplasms
The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy.
Neoplasms
The chemistry, physiology and pathology of pH in cancer.
Neoplasms
The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer.
Neoplasms
The control of acidity in tumor cells: a biophysical model.
Neoplasms
The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.
Neoplasms
The cytotoxic, apoptotic and oxidative effects of carbonic anhydrase IX inhibitor on colorectal cancer cells.
Neoplasms
The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma.
Neoplasms
The effect of carbonic anhydrase IX on focal contacts during cell spreading and migration.
Neoplasms
The effects of CA IX catalysis products within tumor microenvironment.
Neoplasms
The effects of some tumor markers on human erythrocyte (HCA-I and HCA-II), bovine erythrocyte (BCA) and bovine lung (CA-IV) carbonic anhydrase enzyme activities in vitro.
Neoplasms
The expression of carbonic anhydrase II in hematological malignancies.
Neoplasms
The expression of carbonic anhydrase in canine mammary gland and mammary gland tumor.
Neoplasms
The expressions of carbonic anhydrase 9 and vascular endothelial growth factor in astrocytic tumors predict a poor prognosis.
Neoplasms
The histological growth pattern of colorectal cancer liver metastases has prognostic value.
Neoplasms
The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.
Neoplasms
The human chromophobe cell renal carcinoma: its probable relation to intercalated cells of the collecting duct.
Neoplasms
The hypoxia-controlled FBXL14 ubiquitin ligase targets SNAIL1 for proteasome degradation.
Neoplasms
The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer.
Neoplasms
The hypoxia-regulated transcription factor DEC1 (Stra13, SHARP-2) and its expression in human tissues and tumours.
Neoplasms
The Hypoxic Response Expression as a Survival Biomarkers in Treatment-Naive Advanced Breast Cancer.
Neoplasms
The impact of immunohistochemical staining with ezrin-carbonic anhydrase IX and neuropilin-2 on prognosis in patients with metastatic renal cell cancer receiving tyrosine kinase inhibitors.
Neoplasms
The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion.
Neoplasms
The Ketogenic Diet Alters the Hypoxic Response and Affects Expression of Proteins Associated with Angiogenesis, Invasive Potential and Vascular Permeability in a Mouse Glioma Model.
Neoplasms
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy.
Neoplasms
The Na(+) /HCO3 (-) Co-Transporter SLC4A4 Plays a Role in Growth and Migration of Colon and Breast Cancer Cells.
Neoplasms
The novel CA IX inhibition antibody chKM4927 shows anti-tumor efficacy in vivo.
Neoplasms
The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivo.
Neoplasms
The potential role of fecal carbonic anhydrase II in screening for colorectal cancer.
Neoplasms
The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis.
Neoplasms
The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON.
Neoplasms
The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy.
Neoplasms
The proteoglycan region of the tumor-associated carbonic anhydrase isoform IX acts as anintrinsic buffer optimizing CO2 hydration at acidic pH values characteristic of solid tumors.
Neoplasms
The proteoglycan-like domain of carbonic anhydrase IX mediates non-catalytic facilitation of lactate transport in cancer cells.
Neoplasms
The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas.
Neoplasms
The relevance of RT-PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes.
Neoplasms
The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths.
Neoplasms
The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond.
Neoplasms
The role of carbonic anhydrase IX in hypoxia control in OSCC.
Neoplasms
The role of carbonic anhydrase IX overexpression in kidney cancer.
Neoplasms
The roles of carbonic anhydrase in metabolism, cell growth and cancer in animals.
Neoplasms
The roles of carbonic anhydrases IX and XII in cancer cell adhesion, migration, invasion and metastasis.
Neoplasms
The structural basis for the selectivity of sulfonamido dicarbaboranes toward cancer-associated carbonic anhydrase IX.
Neoplasms
The Structure of Carbonic Anhydrase IX Is Adapted for Low-pH Catalysis.
Neoplasms
The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis.
Neoplasms
The Utility of Serum CA9 for Prognostication in Prostate Cancer.
Neoplasms
The VHL-dependent regulation of microRNAs in renal cancer.
Neoplasms
The Warburg Effect, Lactate, and Nearly a Century of Trying to Cure Cancer.
Neoplasms
Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9.
Neoplasms
Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung.
Neoplasms
Tissue Expression of Carbonic Anhydrase IX Correlates to More Aggressive Phenotype of Basal Cell Carcinoma.
Neoplasms
Toll-like receptors 2, 4 and 9 and hypoxia markers HIF-1alpha and CAIX in pancreatic intraepithelial neoplasia.
Neoplasms
Topiramate exhibits anti-tumorigenic and metastatic effects in ovarian cancer cells.
Neoplasms
Toward a hierarchical virtual screening and toxicity risk analysis for identifying novel CA XII inhibitors.
Neoplasms
Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia.
Neoplasms
Transcriptional regulation of carbonic anhydrase II by retinoic acid in the human pancreatic tumor cell line DANG.
Neoplasms
Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker for biliary tumours.
Neoplasms
Treatment of humoral hypercalcemia of malignancy in rats with inhibitors of carbonic anhydrase.
Neoplasms
Treatment selection for patients with metastatic renal cell carcinoma.
Neoplasms
Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy.
Neoplasms
Trimeric Radiofluorinated Sulfonamide Derivatives to Achieve In Vivo Selectivity for Carbonic Anhydrase IX-Targeted PET Imaging.
Neoplasms
Tubulocystic renal cell carcinoma is an entity that is immunohistochemically and genetically distinct from papillary renal cell carcinoma.
Neoplasms
Tumor antigen glycosaminoglycan modification regulates antibody-drug conjugate delivery and cytotoxicity.
Neoplasms
Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer.
Neoplasms
Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages.
Neoplasms
Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck.
Neoplasms
Tumor M2-Pyruvate Kinase, Matrix Carbonic Anhydrase IX, and Metalloproteinase 9 - Novel Prognostic Markers of Renal Cell Carcinoma.
Neoplasms
Tumor microenvironmental changes induced by the sulfamate carbonic anhydrase IX inhibitor S4 in a laryngeal tumor model.
Neoplasms
Tumor necrosis factor-alpha induces the expression of carbonic anhydrase II in pancreatic adenocarcinoma cells.
Neoplasms
Tumor-associated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis.
Neoplasms
Tumor-associated carbonic anhydrases and their clinical significance.
Neoplasms
Tumor-associated carbonic anhydrases are linked to metastases in primary cervical cancer.
Neoplasms
Tumour expressions of hypoxic markers predict the response to neo-adjuvant chemotherapy in children with inoperable rhabdomyosarcoma.
Neoplasms
Type 1 Sodium Calcium Exchanger Forms a Complex with Carbonic Anhydrase IX and Via Reverse Mode Activity Contributes to pH Control in Hypoxic Tumors.
Neoplasms
Ultrastructural immunocytochemical localization of carbonic anhydrase in a benign giant cell tumor of bone.
Neoplasms
Umbelliferone decreases intracellular pH and sensitizes melanoma cell line A375 to dacarbazin. Comparison with acetazolamide.
Neoplasms
Unconventional amino acids in medicinal chemistry: First report on taurine merged within carbonic anhydrase inhibitors.
Neoplasms
Understanding the importance of smart drugs in renal cell carcinoma.
Neoplasms
Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology.
Neoplasms
Update on carbonic anhydrase inhibitors: a patent review (2008 - 2011).
Neoplasms
Updates on Receptors Targeted by Heterocyclic Scaffolds: New Horizon in Anticancer Drug Development.
Neoplasms
Use of multiple biological markers in radiotherapy-treated head and neck cancer.
Neoplasms
Useful immunohistochemical panel for differentiating clear cell papillary renal cell carcinoma from its mimics.
Neoplasms
Using neutron crystallography to elucidate the basis of selective inhibition of carbonic anhydrase by saccharin and a derivative.
Neoplasms
Utility of multiphasic multidetector computed tomography in discriminating between clear cell renal cell carcinomas with high and low carbonic anhydrase-IX expression.
Neoplasms
Versatile protein recognition by the encoded display of multiple chemical elements on a constant macrocyclic scaffold.
Neoplasms
Whole cigarette smoke condensates induce ferroptosis in human bronchial epithelial cells.
Neoplasms
Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
Neoplasms
Xanthates and trithiocarbonates strongly inhibit carbonic anhydrases and show antiglaucoma effects in vivo.
Neoplasms
[(Cp-R)M(CO)(3) ] (M=Re or (99m) Tc) Arylsulfonamide, Arylsulfamide, and Arylsulfamate Conjugates for Selective Targeting of Human Carbonic Anhydrase IX.
Neoplasms
[Activity of blood carbonic anhydrase in cancer of various localizations.]
Neoplasms
[Carbonic anhydrase activity and acid-base equilibrium of the blood in patients with tumors and inflammatory diseases of the lungs]
Neoplasms
[Clinicopathologic features of mammary microglandular adenosis with carcinoma: a study of 5 cases].
Neoplasms
[Clinicopathological significance of the expression of carbonic anhydrase II in human pancreatic invasive ductal cancer].
Neoplasms
[Expression of carbonic anhydrase IX in NSCLC and its relationship with VEGF and Ki67 expression]
Neoplasms
[Expression of carbonic anhydrase IX in the breast carcinomas].
Neoplasms
[Expression of carbonic anhydrase IX, PAX2 and PAX8 and their association with clinicopathologic characteristics in renal epithelial tumors].
Neoplasms
[Predictive Biomarkers for Bevacizumab in Anti-tumor Therapy].
Neoplasms
[Progress in the study of carbonic anhydrase inhibitors as potential anticancer drugs].
Neoplasms
[Proteome study of colorectal cancer genesis and hepatic metastasis]
Neoplasms
[Proteomic analysis of morphine rabbit myocardium with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry]
Neoplasms
[Relation between carbonic anhydrase IX serum level, hypoxia and radiation resistance of head and neck cancers].
Neoplasms
[Significance of carbonic anhydrase IX protein in fibrotic foci of mammary invasive ductal carcinomas].
Neoplasms
[Significance of detection of serum carbonic anhydrase IX in the diagnosis of lung cancer].
Neoplasms
[The clinical significance of E-cadherin and alpha-catenin expression in human gastric cancer]
Neoplasms
[The role of carbonic anhydrase IX in the progression of malignant tumors - a potential therapeutic target?]
Neoplasms
[Value of Detection of CAIX in the Pleural Effusion and Its Sediment in the Diagnosis of Lung Cancer].
Neoplasms, Germ Cell and Embryonal
Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors.
Neoplasms, Germ Cell and Embryonal
Prognostic value of serum carbonic anhydrase IX in testicular germ cell tumor patients.
Neoplasms, Glandular and Epithelial
Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.
Neoplasms, Squamous Cell
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS.
Neoplastic Cells, Circulating
Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients.
Neoplastic Cells, Circulating
Development and initial clinical testing of a multi-plexed circulating tumor cell assay in patients with clear cell renal cell carcinoma.
Neoplastic Cells, Circulating
Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
Neoplastic Cells, Circulating
The relevance of RT-PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes.
Nephritis
Carbonic anhydrase inhibition. VIII. Lack of renal response to acetazolamide and to meralluride in a dog with chronic nephritis.
Nephritis, Interstitial
Acute Tubulointerstitial Nephritis With an Autoantibody Response Against Carbonic Anhydrase II.
Nephritis, Interstitial
Anti-carbonic anhydrase II antibody in autoimmune pancreatitis and tubulointerstitial nephritis.
Nephrocalcinosis
Nephrocalcinosis and urolithiasis in carbonic anhydrase II deficiency syndrome.
Nephrolithiasis
Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders.
Nephrolithiasis
Exacerbation of nephrolithiasis by a carbonic anhydrase inhibitor.
Nephrolithiasis
Possible Drug-Associated Sialolithiasis From the Bicarbonate Anhydrase Inhibitor Topiramate: A Case Report and Literature Review.
Nephrolithiasis
Reduced red blood cell carbonic anhydrase activity in a patient with nephrolithiasis.
Nephrolithiasis
[Nephrolithiasis and topiramate.]
Nephrolithiasis
[Urinary lithiasis of medical origin]
Nephrotic Syndrome
Plasma and urinary heparin cofactor II levels in patients with nephrotic syndrome.
Nervous System Diseases
A single-step solid phase radioimmunoassay for quantifying human carbonic anhydrase I and II in cerebrospinal fluid.
Nervous System Diseases
Acetazolamide therapy for symptomatic plateau waves in patients with brain tumors. Report of three cases.
Nervous System Diseases
Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: relationship with creatine kinase.
Nervous System Diseases
In vitro inhibition of ?-carbonic anhydrase isozymes by some phenolic compounds.
Nervous System Diseases
NO-releasing esters show carbonic anhydrase inhibitory action against human isoforms I and II.
Nervous System Diseases
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols and their derivatives including natural products: Vidalol B.
Nervous System Diseases
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols including natural products.
Nervous System Diseases
Synthesis and carbonic anhydrase inhibitory properties of novel cyclohexanonyl bromophenol derivatives.
Nervous System Diseases
Synthesis and characterization of novel substituted thiophene derivatives and discovery of their carbonic anhydrase and acetylcholinesterase inhibition effects.
Neuralgia
A class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects.
Neuralgia
Acetazolamide attenuates chemical-stimulated but not thermal-stimulated acute pain in mice.
Neuralgia
Analgesic and Antiallodynic Effects of 4-Fluoro-N-(4-Sulfamoylbenzyl) Benzene Sulfonamide in a Murine Model of Pain.
Neuralgia
Biochemical profiling of anti-HIV prodrug Elsulfavirine (Elpida®) and its active form VM1500A against a panel of twelve human carbonic anhydrase isoforms.
Neuralgia
Carbonic anhydrase inhibition and the management of neuropathic pain.
Neuralgia
Chalcogenides-incorporating carbonic anhydrase inhibitors concomitantly reverted oxaliplatin-induced neuropathy and enhanced antiproliferative action.
Neuralgia
Crystal structure of the C183S/C217S mutant of human CA VII in complex with acetazolamide.
Neuralgia
Design, synthesis and X-ray crystallography of selenides bearing benzenesulfonamide moiety with neuropathic pain modulating effects.
Neuralgia
Dual Carbonic Anhydrase IX/XII Inhibitors and Carbon Monoxide Releasing Molecules Modulate LPS-Mediated Inflammation in Mouse Macrophages.
Neuralgia
Effects of New NSAID-CAI Hybrid Compounds in Inflammation and Lung Fibrosis.
Neuralgia
N-aryl-N'-ureido-O-sulfamates: Potent and selective inhibitors of the human Carbonic Anhydrase VII isoform with neuropathic pain relieving properties.
Neuralgia
Pharmacological Modulation of Rate-Dependent Depression of the Spinal H-Reflex Predicts Therapeutic Efficacy against Painful Diabetic Neuropathy.
Neuralgia
Phenyl(thio)phosphon(amid)ate Benzenesulfonamides as Potent and Selective Inhibitors of Human Carbonic Anhydrases II and VII Counteract Allodynia in a Mouse Model of Oxaliplatin-Induced Neuropathy.
Neuralgia
Spirocyclic sulfonamides with carbonic anhydrase inhibitory and anti-neuropathic pain activity.
Neuroblastoma
Carbonic anhydrase IX correlates with survival and is a potential therapeutic target for neuroblastoma.
Neuroblastoma
Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas.
Neuroblastoma
Chelation of cellular calcium modulates hypoxia-inducible gene expression through activation of hypoxia-inducible factor-1alpha.
Neuroblastoma
Enzymatic and morphological properties of primary rat brain astrocyte cultures, and enzyme development in vivo.
Neuroblastoma
MCM2 and Carbonic Anhydrase 9 Are Novel Potential Targets for Neuroblastoma Pharmacological Treatment.
Neuroblastoma
Protective roles of carbonic anhydrase 8 in Machado-Joseph Disease.
Neuroectodermal Tumors, Primitive
The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis.
Neuroendocrine Tumors
Carbonic Anhydrase II Mediates Malignant Behavior of Pulmonary Neuroendocrine Tumors.
Neurofibromatoses
[Protein expression profiles in a rat cirrhotic model induced by thioacetamide.]
Neurofibromatosis 2
[Protein expression profiles in a rat cirrhotic model induced by thioacetamide.]
Neuroma
Myelinated sensory and alpha motor axon regeneration in peripheral nerve neuromas.
Neuromuscular Diseases
Acetazolamide acts directly on the human skeletal muscle chloride channel.
Neuromuscular Diseases
Carbonic anhydrase-III immunohistochemical localization in human skeletal muscle.
Neuromuscular Diseases
Heterocyclic compounds as carbonic anhydrase inhibitor.
Neuromuscular Diseases
Human muscle carbonic anhydrase III (CA-III). Purification, immunohistochemical localization in the human skeletal muscle and its clinical application to the neuromuscular disease.
Neuromuscular Diseases
Muscle-specific carbonic anhydrase III is a more sensitive marker of muscle damage than creatine kinase in neuromuscular disorders.
Neuromuscular Diseases
Serum carbonic anhydrase III and myoglobin concentrations in acute myocardial infarction.
Neurosyphilis
Distribution of carbonic anhydrase in the pallium in 19 cases of paretic neurosyphilis.
Nevus
Cell division cycle-associated protein 1 as a new melanoma-associated antigen.
Night Blindness
Resolution of cystoid macular edema with topical carbonic anhydrase inhibitor in a patient with retinal dystrophy associated with Cohen syndrome.
Non-alcoholic Fatty Liver Disease
Squalene Epoxidase Induces Nonalcoholic Steatohepatitis Via Binding to Carbonic Anhydrase III and is a Therapeutic Target.
Non-alcoholic Fatty Liver Disease
The Role of Beta-7 Integrin and Carbonic Anhydrase IX in Predicting the Occurrence of de Novo Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients.
non-specific serine/threonine protein kinase deficiency
Kinome siRNA screen identifies SMG-1 as a negative regulator of HIF-1alpha in hypoxia.
Nystagmus, Pathologic
[Treatment options for nystagmus].
Obesity
Active Components of Essential Oils as Anti-Obesity Potential Drugs Investigated by in Silico Techniques.
Obesity
Analysis of human carbonic anhydrase II: docking reliability and receptor-based 3D-QSAR study.
Obesity
Antiobesity carbonic anhydrase inhibitors.
Obesity
Carbonic anhydrase III (Car3) is not required for fatty acid synthesis and does not protect against high-fat diet induced obesity in mice.
Obesity
Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity.
Obesity
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
Obesity
Design and development of 5-(4H)-oxazolones as potential inhibitors of human carbonic anhydrase VA: towards therapeutic management of diabetes and obesity.
Obesity
Design and synthesis of novel 1,3-diaryltriazene-substituted sulfonamides as potent and selective carbonic anhydrase II inhibitors.
Obesity
Design of zinc binding functions for carbonic anhydrase inhibitors.
Obesity
Design, synthesis and biological evaluation of novel ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as potent carbonic anhydrase IX inhibitors.
Obesity
Developments of small molecules as inhibitors for carbonic anhydrase isoforms.
Obesity
Effects of leptin and insulin on CA III expression in rat adipose tissue.
Obesity
Expression of CA III in rodent models of obesity.
Obesity
Heterocyclic compounds as carbonic anhydrase inhibitor.
Obesity
Increased oxidation-related glutathionylation and carbonic anhydrase activity in endometriosis.
Obesity
Intraocular pressure in genetically distinct mice: an update and strain survey.
Obesity
Intrinsic Thermodynamics and Structure Correlation of Benzenesulfonamides with a Pyrimidine Moiety Binding to Carbonic Anhydrases I, II, VII, XII, and XIII.
Obesity
Investigation of inhibitory properties of some hydrazone compounds on hCA I, hCA II and AChE enzymes.
Obesity
Lagenaria siceraria and it's bioactive constituents in carbonic anhydrase inhibition: A bioactivity guided LC-MS/MS approach.
Obesity
Metronidazole-coumarin conjugates and 3-cyano-7-hydroxy-coumarin act as isoform-selective carbonic anhydrase inhibitors.
Obesity
Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders.
Obesity
N-Sulfamoylphenyl- and N-sulfamoylphenyl-N-thiazolyl-?-alanines and their derivatives as inhibitors of human carbonic anhydrases.
Obesity
Potential inhibitors of human carbonic anhydrase isozymes I and II: Design, synthesis and docking studies of new 1,3,4-thiadiazole derivatives.
Obesity
Probing the chemical interaction space governed by 4-aminosubstituted benzenesulfonamides and carbonic anhydrase isoforms.
Obesity
Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors.
Obesity
Synthesis of 1,2,4-triazole-5-on derivatives and determination of carbonic anhydrase II isoenzyme inhibition effects.
Obesity
The effect of carbonic anhydrase inhibition on leptin secretion by rat adipose tissue.
Obesity
The green synthesis and molecular docking of novel N-substituted rhodanines as effective inhibitors for carbonic anhydrase and acetylcholinesterase enzymes.
Obesity
Understanding the role and mechanism of carbonic anhydrase V in obesity and its therapeutic implications.
Obstetric Labor, Premature
[Zinc and carbonic anhydrase content in women with term and premature labor]
Ocular Hypertension
1,3-Oxazole-based selective picomolar inhibitors of cytosolic human carbonic anhydrase II alleviate ocular hypertension in rabbits: Potency is supported by X-ray crystallography of two leads.
Ocular Hypertension
3-substituted thieno[2,3-b][1,4]thiazine-6-sulfonamides. A novel class of topically active carbonic anhydrase inhibitors.
Ocular Hypertension
A topical or oral carbonic anhydrase inhibitor to control ocular hypertension after cataract surgery.
Ocular Hypertension
Aminozolamide gel. A trial of a topical carbonic anhydrase inhibitor in ocular hypertension.
Ocular Hypertension
Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers.
Ocular Hypertension
Brinzolamide/Brimonidine: A Review of Its Use in Patients with Open-Angle Glaucoma or Ocular Hypertension.
Ocular Hypertension
Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.
Ocular Hypertension
Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America.
Ocular Hypertension
Costs and persistence of carbonic anhydrase inhibitor versus alpha-2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK-GPRD database.
Ocular Hypertension
Dorzolamide, A Topical Carbonic Anhydrase Inhibitor: A Two-Week Dose-Response Study in Patients with Glaucoma or Ocular Hypertension.
Ocular Hypertension
Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor.
Ocular Hypertension
Effects of adrenergics, adrenolytics, cholinergics and carbonic anhydrase inhibitors on ibopamine-induced ocular hypertension in POAG.
Ocular Hypertension
Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or ?-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis.
Ocular Hypertension
Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.
Ocular Hypertension
Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication.
Ocular Hypertension
Intraocular pressure reduction with travoprost/timolol fixed combination, with and without adjunctive brinzolamide, in glaucoma.
Ocular Hypertension
MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors.
Ocular Hypertension
MK-927: a topical carbonic anhydrase inhibitor. Dose response and duration of action.
Ocular Hypertension
Multiple-dose efficacy comparison of the two topical carbonic anhydrase inhibitors sezolamide and MK-927.
Ocular Hypertension
Ocular hypertension. II. A carbonic anhydrase inhibitor test for early detection of glaucoma.
Ocular Hypertension
Oral versus topical carbonic anhydrase inhibitors in ocular hypertension after scleral tunnel cataract surgery.
Ocular Hypertension
Rational use of the fixed combination of dorzolamide - timolol in the management of raised intraocular pressure and glaucoma.
Ocular Hypertension
The Effect of Long-term Antiglaucomatous Drug Administration on Central Corneal Thickness.
Ocular Hypertension
The efficacy of dorzolamide, a topical carbonic anhydrase inhibitor, in combination with timolol in the treatment of patients with open-angle glaucoma and ocular hypertension.
Ocular Hypertension
The mechanisms by which latanoprost free acid inhibits human carbonic anhydrase I and II.
Ocular Hypertension
Topical carbonic anhydrase inhibitors and visual function in glaucoma and ocular hypertension.
Ocular Hypertension
Topically active carbonic anhydrase inhibitors. 3. Benzofuran- and indole-2-sulfonamides.
Ocular Hypertension
Topically active carbonic anhydrase inhibitors. 4. [(Hydroxyalkyl)sulfonyl]benzene and [(hydroxyalkyl)sulfonyl]thiophenesulfonamides.
Ocular Hypertension
Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595.
Ocular Hypertension
[Decrease in intraocular pressure following administration of the local carbonic anhydrase inhibitor (MK-927)--comparison of the effect with pilocarpine]
Ocular Hypertension
[Early postoperative intraocular pressure after phacoemulsification: Normal patients versus glaucoma patients].
Ocular Hypotension
Acetazolamide, metabolic acidosis, and intraocular pressure.
Ocular Hypotension
Ocular hypotensive effects of carbonic anhydrase inhibitors in normotensive and glaucomatous Beagles.
Odontogenic Cysts
Immunohistochemical expression of GLUT-1, GLUT-3, and carbonic anhydrase IX in benign odontogenic lesions.
Olfaction Disorders
cAMP and cGMP in human parotid saliva: relationships to taste and smell dysfunction, gender, and age.
Olfaction Disorders
Carbonic anhydrase I, II, and VI, blood plasma, erythrocyte and saliva zinc and copper increase after repetitive transcranial magnetic stimulation.
Olfaction Disorders
Decreased parotid saliva gustin/carbonic anhydrase VI secretion: an enzyme disorder manifested by gustatory and olfactory dysfunction.
Oligodendroglioma
Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy.
Oligodendroglioma
Carbonic anhydrase IX in oligodendroglial brain tumors.
Oligodendroglioma
High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q-codeletion and Favorable Prognosis in Oligodendroglioma.
Oligodendroglioma
Immunohistochemical characterization of oligodendrogliomas: an analysis of multiple markers.
Oligodendroglioma
Immunohistochemical demonstration of human carbonic anhydrase isoenzyme II in brain tumours.
Oliguria
[Renal carbonic anhydrase and oliguria of the burned dog.]
Oliguria
[Research on burns. Aminothiadiazolsulfamide, renal carbonic anhydrase and oliguria of the burned dog.]
Optic Nerve Diseases
The Effect of a Decrease in Intraocular Pressure on Optic Nerve Function in Patients with Optic Nerve Drusen.
Oral Submucous Fibrosis
Increased expression of carbonic anhydrase IX in oral submucous fibrosis and oral squamous cell carcinoma.
Osteoarthritis
A proteomic study of protein variation between osteopenic and age-matched control bone tissue.
Osteoblastoma
Histochemistry of tartrate-resistant acid phosphatase and carbonic anhydrase isoenzyme II in osteoclast-like giant cells in bone tumours.
Osteolysis
Osteocytes respond to particles of clinically-relevant conventional and cross-linked polyethylene and metal alloys by up-regulation of resorptive and inflammatory pathways.
Osteopetrosis
A Case of Carbonic Anhydrase Type 2 Deficiency Syndrome with Autistic Disorder.
Osteopetrosis
A novel homozygous nonsense mutation in the CA2 gene (c.368G>A, p.W123X) linked to carbonic anhydrase II deficiency syndrome in a Chinese family.
Osteopetrosis
A splice junction mutation in intron 2 of the carbonic anhydrase II gene of osteopetrosis patients from Arabic countries.
Osteopetrosis
Autosomal dominant osteopetrosis associated with renal tubular acidosis is due to a CLCN7 mutation.
Osteopetrosis
Bone marrow transplantation corrects osteopetrosis in the carbonic anhydrase II deficiency syndrome.
Osteopetrosis
Carbonic anhydrase II (CA II) deficiency in Maghrebian patients: evidence for founder effect and genomic recombination at the CA II locus.
Osteopetrosis
Carbonic anhydrase II and H+ -ATPase in osteoclasts of four osteopetrotic mutations in the rat.
Osteopetrosis
Carbonic anhydrase II deficiency a novel mutation.
Osteopetrosis
Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.
Osteopetrosis
Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.
Osteopetrosis
Carbonic Anhydrase II Deficiency in a Saudi Woman.
Osteopetrosis
Carbonic anhydrase II deficiency syndrome (osteopetrosis with renal tubular acidosis and brain calcification): novel mutations in CA2 identified by direct sequencing expand the opportunity for genotype-phenotype correlation.
Osteopetrosis
Carbonic anhydrase II deficiency syndrome: recessive osteopetrosis with renal tubular acidosis and cerebral calcification.
Osteopetrosis
Carbonic anhydrase II deficiency.
Osteopetrosis
Carbonic anhydrase II deficiency: a rare autosomal recessive disorder of osteopetrosis, renal tubular acidosis, and cerebral calcification.
Osteopetrosis
Carbonic Anhydrase II Deficiency: A Rare Case of Severe Obstructive Sleep Apnea.
Osteopetrosis
Carbonic anhydrase II deficiency: diagnosis and carrier detection using differential enzyme inhibition and inactivation.
Osteopetrosis
Carbonic anhydrase II deficiency: report of a novel mutation.
Osteopetrosis
Carbonic anhydrase II in the developing and adult human brain.
Osteopetrosis
Carbonic anhydrase isozymes IV and II in urinary membranes from carbonic anhydrase II-deficient patients.
Osteopetrosis
Carbonic anhydrase isozymes of osteoclasts and erythrocytes of osteopetrotic microphthalmic mice.
Osteopetrosis
Case report 668. Carbonic anhydrase II deficiency syndrome (osteopetrosis associated with renal tubular acidosis and cerebral calcification).
Osteopetrosis
Case report 718. Osteopetrosis with carbonic anhydrase II deficiency.
Osteopetrosis
Cerebral calcification, osteopetrosis and renal tubular acidosis: is it carbonic anhydrase-II deficiency?
Osteopetrosis
Clinical and molecular findings in a family with the carbonic anhydrase II deficiency syndrome.
Osteopetrosis
Clinical and molecular heterogeneity in carbonic anhydrase II deficiency and prenatal diagnosis in an Italian family.
Osteopetrosis
Clinical quiz. Osteopetrosis with carbonic anhydrase II deficiency.
Osteopetrosis
Correction of renal tubular acidosis in carbonic anhydrase II-deficient mice with gene therapy.
Osteopetrosis
Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders.
Osteopetrosis
Evaluation of carbonic anhydrase isozymes in disorders involving osteopetrosis and/or renal tubular acidosis.
Osteopetrosis
Genetic causes and mechanisms of distal renal tubular acidosis.
Osteopetrosis
Genetic diseases of acid-base transporters.
Osteopetrosis
Human osteopetrosis and other sclerosing disorders: recent genetic developments.
Osteopetrosis
Identification of a novel mutation in an Indian patient with CAII deficiency syndrome.
Osteopetrosis
Intracranial calcification in children with osteopetrosis caused by carbonic anhydrase II deficiency.
Osteopetrosis
Marble brain disease in two Saudi Arabian siblings.
Osteopetrosis
Molecular basis of human carbonic anhydrase II deficiency.
Osteopetrosis
Molecular basis of proximal renal tubular acidosis.
Osteopetrosis
Molecular Modelling and Dynamics of CA2 Missense Mutations Causative to Carbonic Anhydrase 2 Deficiency Syndrome.
Osteopetrosis
N-ethyl-N-nitrosourea-induced null mutation at the mouse Car-2 locus: an animal model for human carbonic anhydrase II deficiency syndrome.
Osteopetrosis
New insights into the pathogenesis of renal tubular acidosis--from functional to molecular studies.
Osteopetrosis
Osteoclast biology: lessons from mammalian mutations.
Osteopetrosis
Paralysis Episodes in Carbonic Anhydrase II Deficiency.
Osteopetrosis
Phenotypic Characteristics of Bone in Carbonic Anhydrase II-Deficient Mice.
Osteopetrosis
Polymorphic gene for human carbonic anhydrase II: a molecular disease marker located on chromosome 8.
Osteopetrosis
Proteomic Profiling of the First Human Dental Pulp Mesenchymal Stem/Stromal Cells from Carbonic Anhydrase II Deficiency Osteopetrosis Patients.
Osteopetrosis
Recent developments in the understanding of the pathophysiology of osteopetrosis.
Osteopetrosis
Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency.
Osteopetrosis
Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency: pathogenesis of impaired acidification.
Osteopetrosis
Renal Tubular Acidosis, Osteopetrosis, and Cerebral Calcification: A Rare Syndrome Caused by Carbonic Anhydrase II Deficiency.
Osteopetrosis
Targeted disruption of the Cl-/HCO3- exchanger Ae2 results in osteopetrosis in mice.
Osteopetrosis
The determination of osteopetrotic phenotypes by selective inactivation of red cell carbonic anhydrase isoenzymes.
Osteopetrosis
The neurology of carbonic anhydrase type II deficiency syndrome.
Osteopetrosis
The role of carbonic anhydrase in autosomal dominant osteopetrosis.
Osteopetrosis
Two novel CAII mutations causing carbonic anhydrase II deficiency syndrome in two unrelated Chinese families.
Osteopetrosis
[Carbonic anhydrase II deficiency: osteopetrosis, renal tubular acidosis and intracranial calcifications. Review of the literature and 3 cases]
Osteopetrosis
[Osteopetrosis and renal acidosis: a new case of this rare syndrome]
Osteopetrosis
[Osteopetrosis with carbonic anhydrase II deficiency: report of 24 cases]
Osteopetrosis
[Recessive osteopetrosis. Identification of a form of medium severity]
Osteopetrosis
[Syndrome associating: osteopetrosis, tubular acidosis, mental retardation and cerebral calcifications due to carbonic anhydrase II deficiency. Apropos of 3 cases in the siblings]
Osteoporosis
Development of a Fingerprint-Based Scoring Function for the Prediction of the Binding Mode of Carbonic Anhydrase II Inhibitors.
Osteoporosis
Effect of chronic carbonic anhydrase inhibitor therapy on bone mineral density in white women.
Osteoporosis
Enzymatically synthesized inorganic polymers as morphogenetically active bone scaffolds: application in regenerative medicine.
Osteoporosis
In vitro inhibition of ?-carbonic anhydrase isozymes by some phenolic compounds.
Osteoporosis
Nitric oxide donors and selective carbonic anhydrase inhibitors: a dual pharmacological approach for the treatment of glaucoma, cancer and osteoporosis.
Osteoporosis
NO-releasing esters show carbonic anhydrase inhibitory action against human isoforms I and II.
Osteoporosis
Nucleotide variations in genes encoding carbonic anhydrase 8 and 10 associated with femoral bone mineral density in Japanese female with osteoporosis.
Osteoporosis
Structural elucidation of the hormonal inhibition mechanism of the bile acid cholate on human carbonic anhydrase II.
Osteoporosis
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols and their derivatives including natural products: Vidalol B.
Osteoporosis
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols including natural products.
Osteoporosis
Synthesis and carbonic anhydrase inhibitory properties of novel cyclohexanonyl bromophenol derivatives.
Osteoporosis
Synthesis and characterization of novel substituted thiophene derivatives and discovery of their carbonic anhydrase and acetylcholinesterase inhibition effects.
Osteoporosis
[Recent progress in molecular biology of inherited tubular transport abnormalities]
Osteoporosis, Postmenopausal
17 beta-estradiol suppresses gene expression of tartrate-resistant acid phosphatase and carbonic anhydrase II in ovariectomized rats.
Osteosarcoma
Carbonic anhydrase IX enhances tumor cell proliferation and tumor progression in osteosarcoma.
Osteosarcoma
Carbonic anhydrase IX inhibition is an effective strategy for osteosarcoma treatment.
Osteosarcoma
Detection of mRNA for carbonic anhydrase II in human osteoclast-like cells by in situ hybridization.
Osteosarcoma
Histochemistry of tartrate-resistant acid phosphatase and carbonic anhydrase isoenzyme II in osteoclast-like giant cells in bone tumours.
Osteosarcoma
Hypoxia promotes osteosarcoma cell proliferation and migration through enhancing platelet-derived growth factor-BB/platelet-derived growth factor receptor-? axis.
Osteosarcoma
Oncogenic roles of carbonic anhydrase 8 in human osteosarcoma cells.
Otosclerosis
Spiral ligament and stria vascularis changes in cochlear otosclerosis: effect on hearing level.
Ototoxicity
Use of diuretics in chronic renal failure.
Ovarian Neoplasms
DNA hypomethylation-mediated overexpression of carbonic anhydrase 9 induces an aggressive phenotype in ovarian cancer cells.
Ovarian Neoplasms
Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours.
Ovarian Neoplasms
Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer.
Ovarian Neoplasms
Serum carbonic anhydrase IX during first-line therapy of ovarian cancer.
Ovarian Neoplasms
siRNA-mediated knockdown against CDCA1 and KNTC2, both frequently overexpressed in colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis.
Pancreatic Fistula
Pharmacological inhibition of digestive secretions in the management of pancreaticoduodenal fistulas.
Pancreatic Neoplasms
A Rare Case of Synchronous Esophageal and Pancreatic Malignancy.
Pancreatic Neoplasms
Autoimmune pancreatitis: An underdiagnosed autoimmune disease with clinical, imaging and serological features.
Pancreatic Neoplasms
Cell lineage markers in human pancreatic cancer.
Pancreatic Neoplasms
Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions.
Pancreatic Neoplasms
Combining carbonic anhydrase and thioredoxin reductase inhibitory motifs within a single molecule dramatically increases its cytotoxicity.
Pancreatic Neoplasms
Differentiation of autoimmune pancreatitis from pancreas cancer: utility of anti-amylase and anti-carbonic anhydrase II autoantibodies.
Pancreatic Neoplasms
Expression of carbonic anhydrase IX in human pancreatic cancer.
Pancreatic Neoplasms
In vivo and in vitro characterization of human fibroblasts recruited selectively into human cancer stroma.
Pancreatic Neoplasms
Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells.
Pancreatic Neoplasms
Lipoyl-Homotaurine Derivative (ADM_12) Reverts Oxaliplatin-Induced Neuropathy and Reduces Cancer Cells Malignancy by Inhibiting Carbonic Anhydrase IX (CAIX).
Pancreatic Neoplasms
Potential for differential diagnosis of autoimmune pancreatitis and pancreatic cancer using carbonic anhydrase II antibody.
Pancreatic Neoplasms
Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
Pancreatic Neoplasms
Roles of Carbonic Anhydrase IX in Development of Pancreatic Cancer.
Pancreatic Neoplasms
Utility of serum IgG, IgG4 and carbonic anhydrase II antibodies in distinguishing autoimmune pancreatitis from pancreatic cancer and chronic pancreatitis.
Pancreatic Neoplasms
Value of anti-plasminogen binding peptide, anti-carbonic anhydrase II, immunoglobulin G4, and other serological markers for the differentiation of autoimmune pancreatitis and pancreatic cancer.
Pancreatitis
Carbonic anhydrase in human pancreas: hypotheses for the pathophysiological roles of CA isozymes.
Pancreatitis
Experimental immune-mediated pancreatitis in neonatally thymectomized mice immunized with carbonic anhydrase II and lactoferrin.
Pancreatitis
Inhibition of human pancreatic secretion by diamox (carbonic anhydrase inhibitor; therapeutic implications in pancreatitis.
Pancreatitis
Use of carbonic anhydrase inhibitor in the treatment of pancreatitis.
Pancreatitis
Use of diuretics in chronic renal failure.
Pancreatitis, Chronic
Antibodies to carbonic anhydrase and IgG4 levels in idiopathic chronic pancreatitis: relevance for diagnosis of autoimmune pancreatitis.
Pancreatitis, Chronic
Carbonic anhydrase and primary chronic pancreatitis.
Pancreatitis, Chronic
Carbonic anhydrase in human pancreas: hypotheses for the pathophysiological roles of CA isozymes.
Pancreatitis, Chronic
Diminished cellular immune response to carbonic anhydrase II in patients with Sjögren's syndrome and idiopathic chronic pancreatitis.
Pancreatitis, Chronic
Elevated serum levels of antibodies to carbonic anhydrase I and II in patients with chronic pancreatitis.
Pancreatitis, Chronic
Low-avidity antibodies to carbonic anhydrase-I and -II in autoimmune chronic pancreatitis.
Pancreatitis, Chronic
Serum antibodies to carbonic anhydrase I and II in patients with idiopathic chronic pancreatitis and Sjögren's syndrome.
Pancreatitis, Chronic
Serum antibodies to carbonic anhydrase IV in patients with autoimmune pancreatitis.
Pancreatitis, Chronic
Utility of serum IgG, IgG4 and carbonic anhydrase II antibodies in distinguishing autoimmune pancreatitis from pancreatic cancer and chronic pancreatitis.
Papilloma
Association between high-risk human papillomavirus DNA load and precursor lesions of cervical cancer in Mexican women.
Papilloma
Association of gene expression with sequential proliferation, differentiation and tumor formation in murine skin.
Papillomavirus Infections
Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States).
Papillomavirus Infections
Detection of human papillomavirus DNA by the hybrid capture assay.
Papillomavirus Infections
Establishment of an efficient multiplex real-time PCR assay for human papillomavirus genotyping in cervical cytology specimens: comparison with hybrid capture II.
Papillomavirus Infections
Hybrid capture-II and LCR-E7 PCR assays for HPV typing in cervical cytologic samples.
Papillomavirus Infections
Presence of human papillomavirus infection determined by hybrid capture assay in cervical lesions in a Venezuelan population.
Papillomavirus Infections
Prevalence of human papillomavirus infection in the genital tract determined by hybrid capture assay.
Papillomavirus Infections
Retrospective analysis of cervical cancer and precancerous lesions in patients with atypical squamous cells of undetermined significance in China.
Paralysis
Acetazolamide prevents vacuolar myopathy in skeletal muscle of K(+) -depleted rats.
Paralysis
Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders.
Paralysis
Carbonic anhydrase inhibitors ameliorate the symptoms of hypokalaemic periodic paralysis in rats by opening the muscular Ca2+-activated-K+ channels.
Paralysis
Channelopathies.
Paralysis
Dichlorphenamide: A Review in Primary Periodic Paralyses.
Paralysis
Episodic Muscle Disorders.
Paralysis
Muscle channelopathies: does the predicted channel gating pore offer new treatment options for hypokalaemic periodic paralysis?
Paralysis
Open-Label, Dose-Escalation, Phase 1 Study of Safety and Single and Multiple-Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers.
Paralysis
Paralysis Episodes in Carbonic Anhydrase II Deficiency.
Paralysis
Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis.
Paralysis
Treatment of "permanent" muscle weakness in familial Hypokalemic Periodic Paralysis.
Paralysis
Treatment of hypokalemic periodic paralysis with topiramate.
Paralysis
Treatment of neuromuscular channelopathies: current concepts and future prospects.
Paralysis
Use of Acetazolamide in Sulfonamide-Allergic Patients With Neurologic Channelopathies.
Paralysis
[Treatment of familial hypokalemic paralysis with carbon dioxide anhydrase inhibitors]
Paraneoplastic Cerebellar Degeneration
Carbonic Anhydrase-Related Protein VIII antibodies and paraneoplastic cerebellar degeneration.
Paraneoplastic Cerebellar Degeneration
Carbonic anhydrase-related protein VIII: autoantigen in paraneoplastic cerebellar degeneration.
Paraneoplastic Cerebellar Degeneration
Paraneoplastic cerebellar degeneration in a patient with breast cancer associated with carbonic anhydrase-related protein VIII autoantibodies.
Paraneoplastic Syndromes, Ocular
Autoimmunity against carbonic anhydrase II affects retinal cell functions in autoimmune retinopathy.
Paraneoplastic Syndromes, Ocular
Unique epitopes for carbonic anhydrase II autoantibodies related to autoimmune retinopathy and cancer-associated retinopathy.
Paraproteinemias
Microvessel density, endothelial-cell proliferation and carbonic anhydrase IX expression in haematological malignancies, bone-marrow metastases and monoclonal gammopathy of undetermined significance.
Parasitic Diseases
Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type-2 inflammation: a patent evaluation (WO2017/058370).
Paresthesia
Efficacy of zonisamide in migraineurs with nonresponse to topiramate.
Penile Neoplasms
Prognostic value of carbonic anhydrase IX expression in penile squamous cell carcinoma: A pilot study.
Peptic Ulcer
Effect of the carbonic anhydrase inhibitor, acetazolamide, on Helicobacter pylori infection in vivo: a pilot study.
Peptic Ulcer
Expression and localization of alpha- and beta-carbonic anhydrase in Helicobacter pylori.
Peptic Ulcer
Inhibition of gastric mucosa carbonic anhydrase by pirenzepine in patients with gastroduodenal ulcers.
Peptic Ulcer
The history and rationale of using carbonic anhydrase inhibitors in the treatment of peptic ulcers. In memoriam Ioan Pu?ca? (1932-2015).
Peptic Ulcer
Treatment of gastroduodenal ulcers with carbonic anhydrase inhibitors.
Peptic Ulcer
[Carbonic anhydrase inhibitors in the treatment of gastroduodenal ulcer]
Periodontal Diseases
Effect of Genetic Polymorphisms in CA6 Gene on the Expression and Catalytic Activity of Human Salivary Carbonic Anhydrase VI.
Periodontitis
Sulfonamide inhibition studies of the ?-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis.
Peripheral Nerve Injuries
Differential effects of distal and proximal nerve lesions on carbonic anhydrase activity in rat primary sensory neurons, ventral and dorsal root axons.
Peripheral Nerve Injuries
Differential expression of carbonic anhydrase isozymes in microglial cell types.
Persistent Infection
Detection of persistent high risk human papillomavirus infections with hybrid capture II and SPF10/LiPA.
Persistent Infection
Hypoxic marker CA IX and adhesion mediator ?-catenin are downregulated by lymphocytic choriomeningitis virus persistent infection.
Pheochromocytoma
Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paraganglioma-a retrospective and prospective study.
Pheochromocytoma
Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas.
Phlebitis
[Autoimmune pancreatitis: inflammatory pseudotumor, multifocal fibrosclerosis, portal hypertension, and long-term outcome]
Phyllodes Tumor
The expression of metabolism-related proteins in phyllodes tumors.
Pick Disease of the Brain
Neurochemical enzyme changes in Alzheimer's and Pick's disease.
Pilomatrixoma
Calcifying epithelioma of Malherbe with ossification. Special reference to lectin binding and immunohistochemistry of ossified sites.
Pituitary Neoplasms
Comparison of two isozymes of carbonic anhydrase in the rat anterior pituitary gland and pituitary tumors.
Pleural Effusion
Clinical Impact and Reliability of Carbonic Anhydrase XII in the Differentiation of Malignant and Tuberculous Pleural Effusions.
Pleural Effusion, Malignant
Detection of carbonic anhydrase IX protein in the diagnosis of malignant pleural effusion by enzyme-linked immunosorbent assay and immunocytochemistry.
Pneumococcal Infections
Selected trace elements and esterase activity of carbonic anhydrase levels in lambs with pneumonia.
Pneumonia
Carbonic Anhydrase IX and Hypoxia Promote Rat Pulmonary Endothelial Cell Survival During Infection.
Pneumonia
Selected trace elements and esterase activity of carbonic anhydrase levels in lambs with pneumonia.
Pneumonia
[Blood carbonic anhydrase and erythrocyte zinc in cases of acute pneumonia in children]
Pneumonia
[Clinical value of determining carbonic anhydrase activity and zinc in children with acute pneumonia]
Pneumonia
[Zinc metabolism and carbonic activity anhydrase in patients with acute pneumonia]
Polycystic Kidney Diseases
Molecular mechanisms underlying the reception and transmission of sour taste information.
Polycystic Kidney Diseases
Renal carbonic anhydrase activity in DBA/2FG-pcy/pcy mice with inherited polycystic kidney disease.
Polycythemia Vera
Blood carbonic anhydrase activity in anemia, with a note on polycythemia vera.
Polycythemia Vera
Cytosolic carbonic anhydrase activity in chronic myeloid disorders with different clinical phenotype.
Polymyositis
Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: relationship with creatine kinase.
Polymyositis
Development of a highly sensitive enzyme-immunoassay for serum carbonic anhydrase-III.
Polymyositis
Human muscle carbonic anhydrase III (CA-III). Purification, immunohistochemical localization in the human skeletal muscle and its clinical application to the neuromuscular disease.
Polymyositis
Serum carbonic anhydrase III in neuromuscular disorders and in healthy persons after a long-distance run.
Pre-Eclampsia
Carbonic anhydrase inhibitors; their effect on water and electrolyte metabolism in toxemia of pregnancy.
Pre-Eclampsia
Effects of carbonic anhydrase inhibitors in toxemia of pregnancy.
Pre-Eclampsia
Renal dysfunction and podocyturia in pre-eclampsia may be explained by increased urinary VEGF.
Pre-Eclampsia
Serum Anti-Carbonic Anhydrase II Antibodies and Oxidant-Antioxidant Balance in Pre-eclampsia.
Pre-Eclampsia
Spontaneous pregnancy-induced hypertension and intrauterine growth restriction in rats.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Pharmacological inhibition of carbonic anhydrase XII interferes with cell proliferation and induces cell apoptosis in T-cell lymphomas.
Primary Myelofibrosis
Cytosolic carbonic anhydrase activity in chronic myeloid disorders with different clinical phenotype.
Prostatic Diseases
Carbonic anhydrase IX expression in prostate cancer.
Prostatic Neoplasms
Carbonic anhydrase I as a new plasma biomarker for prostate cancer.
Prostatic Neoplasms
Carbonic anhydrase III is a new target of HIF1? in prostate cancer model.
Prostatic Neoplasms
Carbonic anhydrase IX expression in prostate cancer.
Prostatic Neoplasms
Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells.
Prostatic Neoplasms
Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer.
Prostatic Neoplasms
Detecting extracellular carbonic anhydrase activity using membrane inlet mass spectrometry.
Prostatic Neoplasms
Genetic polymorphism and carbonic anhydrase 9 expression can predict nodal metastatic prostate cancer risk in patients with prostate-specific antigen levels ?10 ng/ml at initial biopsy.
Prostatic Neoplasms
Hypoxia and Prostate Cancer Aggressiveness: A Tale With Many Endings.
Prostatic Neoplasms
Inhibition of Carbonic Anhydrase IX by Ureidosulfonamide Inhibitor U104 Reduces Prostate Cancer Cell Growth, But Does Not Modulate Daunorubicin or Cisplatin Cytotoxicity.
Prostatic Neoplasms
pH low insertion peptide mediated cell division cycle-associated protein 1 -siRNA transportation for prostatic cancer therapy targeted to the tumor microenvironment.
Prostatic Neoplasms
Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer.
Prostatic Neoplasms
Plasmatic exosomes from prostate cancer patients show increased carbonic anhydrase IX expression and activity and low pH.
Prostatic Neoplasms
Prostate cancer cells and exosomes in acidic condition show increased carbonic anhydrase IX expression and activity.
Prostatic Neoplasms
Small Molecules for Immunomodulation in Cancer.
Prostatic Neoplasms
Understanding the pharmacological properties of a metabolic PET tracer in prostate cancer.
Prostatic Neoplasms
[Future perspectives for diagnostic imaging in urology: from anatomic and functional to molecular imaging.]
Prostatitis
Serum quantitative proteomic analysis reveals potential zinc-associated biomarkers for nonbacterial prostatitis.
Protein S Deficiency
Heparin cofactor II in adults and infants with thrombosis and DIC.
Pseudomyxoma Peritonei
Carbonic anhydrase II: a novel biomarker for pseudomyxoma peritonei.
Pseudotumor Cerebri
Acetazolamide Mitigates Intracranial Pressure Spikes Without Affecting Functional Outcome After Experimental Hemorrhagic Stroke.
Pseudotumor Cerebri
Possible association between acetazolamide administration during pregnancy and multiple congenital malformations.
Pseudotumor Cerebri
Topiramate, pseudotumor cerebri, weight-loss and glaucoma: an ophthalmologic perspective.
Psoriasis
Molecular Diagnostics of Psoriasis, Atopic Dermatitis, Allergic Contact Dermatitis and Irritant Contact Dermatitis.
Psoriasis
Pustular psoriasis precipitated by acetazolamide.
Psoriasis
[Blood carbonic anhydrase activity in patients with psoriasis]
Pterygium
Overexpression of carbonic anhydrase 1 in pterygium.
Pulmonary Disease, Chronic Obstructive
Acetazolamide and breathing. Does a clinical dose alter peripheral and central CO(2) sensitivity?
Pulmonary Disease, Chronic Obstructive
Acetazolamide Use in Severe Chronic Obstructive Pulmonary Disease. Pros and Cons.
Pulmonary Disease, Chronic Obstructive
Carbon dioxide elimination after acetazolamide in patients with chronic obstructive pulmonary disease and metabolic alkalosis.
Pulmonary Disease, Chronic Obstructive
Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Carbonic anhydrase isoenzyme B in erythrocytes of subjects with chronic acidosis.
Pulmonary Disease, Chronic Obstructive
Carbonic anhydrase isoenzyme B in erythrocytes of subjects with chronic obstructive lung disease.
Pulmonary Disease, Chronic Obstructive
Effect of low-dose acetazolamide on the ventilatory CO2 response during hypoxia in the anaesthetized cat.
Pulmonary Disease, Chronic Obstructive
Estimations of active and inactive carbonic anhydrase isozyme B in human red cells.
Pulmonary Disease, Chronic Obstructive
Expression and carbonylation of creatine kinase in the quadriceps femoris muscles of patients with chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Human erythrocyte carbonic anhydrase B and C in chronic obstructive lung disease.
Pulmonary Disease, Chronic Obstructive
Low-dose acetazolamide does affect respiratory muscle function in spontaneously breathing anesthetized rabbits.
Pulmonary Disease, Chronic Obstructive
Oxidized proteins and superoxide anion production in the diaphragm of severe COPD patients.
Pulmonary Disease, Chronic Obstructive
Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study.
Pulmonary Disease, Chronic Obstructive
Severe mixed acidosis by combined therapy with acetazolamide and timolol eyedrops.
Pulmonary Disease, Chronic Obstructive
[Acetazolamide in hypercapnic chronic obstructive lung disease--a renaissance?]
Pulmonary Disease, Chronic Obstructive
[Carbonic anhydrase III and mRNA expression levels in quadriceps femoris muscle of chronic obstructive pulmonary disease patients].
Pulmonary Embolism
Carbonic Anhydrase IX in the Prediction of Right Ventricular Dysfunction in Patients With Hemodynamically Stable Acute Pulmonary Embolism.
Pulmonary Emphysema
The effects of carbonic anhydrase inhibitor on arterial blood gases in chronic pulmonary emphysema: a preliminary report.
Pulmonary Emphysema
[Blood carbonic anhydrase activity in anthracosis (anthracosilicosis) and pulmonary emphysema]
Pulmonary Fibrosis
Investigation of the effects of alpha-tocopherol on the levels of Fe, Cu, Zn, Mn, and carbonic anhydrase in rats with bleomycin-induced pulmonary fibrosis.
Pulmonary Heart Disease
Oral administration of a potent carbonic anhydrase inhibitor (diamox). III. Its use as a diuretic in patients with severe congestive heart failure due to cor pulmonale.
Pulmonary Heart Disease
Sensitivity of respiratory center to carbon dioxide in emphysema and cor pulmonale: effects of carbonic anhydrase inhibition.
Pulmonary Heart Disease
[Acid-base equilibrium in arterial blood and cerebrospinal fluid in heart insufficiency and cor pulmonale and its control by carbonic anhydrase inhibition.]
Purpura
[Intervention of carbonic anhydrase in the mechanism of perforation of the lamellibranchs valves by Purpura (Thais) lapillus L. (Gastropoda Prosobrancha Muricida) ]
Pyelonephritis
Carbonic anhydrase 2 deficiency leads to increased pyelonephritis susceptibility.
Pyelonephritis
Developmental loss, but not pharmacological suppression, of renal carbonic anhydrase 2 results in pyelonephritis susceptibility.
pyruvate carboxylase deficiency
Mitochondrial Carbonic Anhydrase VA Deficiency Resulting from CA5A Alterations Presents with Hyperammonemia in Early Childhood.
Pyruvate Carboxylase Deficiency Disease
Mitochondrial Carbonic Anhydrase VA Deficiency Resulting from CA5A Alterations Presents with Hyperammonemia in Early Childhood.
Rectal Neoplasms
Carbonic anhydrase IX, hypoxia-inducible factor-1?, ezrin and glucose transporter-1 as predictors of disease outcome in rectal cancer: multivariate Cox survival models following data reduction by principal component analysis of the clinicopathological predictors.
Rectal Neoplasms
Clinical value of significance of Hypoxia Inducible Factor-1?, Glucose Transporter-1 and Carbonic Anhydrase IX in rectal cancer after preoperative chemoradiotherapy.
Rectal Neoplasms
Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer.
Rectal Neoplasms
Expression of carbonic anhydrase I or II and correlation to clinical aspects of colorectal cancer.
Rectal Neoplasms
Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer.
Rectal Neoplasms
Expression of carbonic anhydrase IX suggests poor response to therapy in rectal cancer.
Rectal Neoplasms
Hypoxia-Associated Marker CA IX Does Not Predict the Response of Locally Advanced Rectal Cancers to Neoadjuvant Chemoradiotherapy.
Rectal Neoplasms
Main Effects and Interactions of Carbonic Anhydrase IX, Hypoxia-inducible Factor-1?, Ezrin and Glucose Transporter-1 in Multivariate Analysis for Disease Outcome in Rectal Cancer.
Rectal Neoplasms
Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study.
Reflex, Abnormal
Spinal carbonic anhydrase contributes to nociceptive reflex enhancement by midazolam, pentobarbital, and propofol.
Refractive Errors
Ocular side effects of selected systemic drugs.
Refractive Errors
Predictors of success in selective laser trabeculoplasty for primary open angle glaucoma in Chinese.
Refractive Errors
Risk factors of shallow anterior chamber other than hypotony after Ahmed glaucoma valve implant.
Renal Insufficiency
Carbonic anhydrase isoenzyme B in erythrocytes of anemic and non-anemic uremic subjects.
Renal Insufficiency
Carbonic anhydrase isoenzyme B in erythrocytes of subjects with chronic acidosis.
Renal Insufficiency
Gene therapy for renal diseases.
Renal Insufficiency
Hypercarbia and acidosis associated with carbonic anhydrase inhibition: a hazard of topical mafenide acetate use in renal failure.
Renal Insufficiency
The use of myoglobin/carbonic anhydrase III ratio as a marker for myocardial damage in patients with renal failure.
Renal Insufficiency, Chronic
Carbonic anhydrase I and II levels in erythrocytes of chronic renal disease patients.
Renal Insufficiency, Chronic
Erythrocyte zinc and carbonic anhydrase levels in nondialyzed chronic kidney disease patients.
Renal Insufficiency, Chronic
Metabolic acidosis and anaemia associated with dorzolamide in a patient with impaired renal function.
Reperfusion Injury
Carbonic Anhydrase Protects Fatty Liver Grafts against Ischemic Reperfusion Damage.
Reperfusion Injury
Cardioprotection of benzolamide in a regional ischemia model: Role of eNOS/NO.
Reperfusion Injury
Correction: Carbonic Anhydrase Protects Fatty Liver Grafts against Ischemic Reperfusion Damage.
Reperfusion Injury
Role of carbonic anhydrase in acute recovery following renal ischemia reperfusion injury.
Respiratory Distress Syndrome
Carbonic anhydrase isoenzymes in infants with respiratory distress syndrome.
Respiratory Distress Syndrome
Carbonic anhydrase isoenzymes in the erythrocytes of new-born premature and full-term infants.
Respiratory Insufficiency
Acute respiratory failure precipitated by a carbonic anhydrase inhibitor.
Respiratory Insufficiency
Carbonic anhydrase inhibitors in patients with respiratory failure and metabolic alkalosis: a systematic review and meta-analysis of randomized controlled trials.
Respiratory Insufficiency
Effect of CO2 on carbonic anhydrase activity and isozyme levels in respiratory failure.
Respiratory Insufficiency
Kinetics of CO2 exchange with carbonic anhydrase immobilized on fiber membranes in artificial lungs.
Respiratory Insufficiency
The effect of a new carbonic anhydrase inhibitor (dichlorphenamide) in respiratory insufficiency.
Respiratory Insufficiency
Trial sequential analysis suggested the potential overestimated effect of carbonic anhydrase inhibitor for respiratory failure and metabolic alkalosis.
Respiratory Insufficiency
[A contribution on the treatment of respiratory insufficiency with carbonic anhydrase inhibitors]
Respiratory Insufficiency
[Carbonic anhydrase inhibitors in the treatment of global respiratory insufficiency in patients with chronic bronchopneumathies]
Respiratory Insufficiency
[Comparison between the effects of metabolic acidosis due to ammonium chloride and carbon anhydrase inhibitors in patients with chronic respiratory insufficiency. I. Ventilation, gas exchange, and gas tension in the blood, at rest and during muscular exercise of various intensity]
Respiratory Insufficiency
[Comparison between the effects of metabolic acidosis due to ammonium chloride and carbon anhydrase inhibitors, in patients with chronic respiratory insufficiency. II. Tissue oxygenation and anerobic metabolism during muscular exercise]
Respiratory Insufficiency
[Effects of carbonic anhydrase inhibition and of acidosis due to ammonium chloride on the ventilatory response to CO2 in chronic respiratory insufficiency]
Respiratory Insufficiency
[Effects of carbonic anhydrase inhibition on respiratory function in patients with chronic respiratory insufficiency. During rest]
Respiratory Insufficiency
[Effects of the inhibition of carbonic anhydrase on respiratory function in patients with chronic respiratory insufficiency. During muscular exercise of varying intensity]
Respiratory Insufficiency
[Effects of the inhibition of carbonic anhydrase on respiratory function in patients with chronic respiratory insufficiency. Tissue oxygenation and oxygen debt during muscular exercise of varying intensity]
Respiratory Insufficiency
[Oxygen and carbonic anhydrase inhibitors in the treatment of attacks of respiratory insufficiency.]
Retinal Artery Occlusion
Purulent anterior segment endophthalmitis following paracentesis.
Retinal Degeneration
Efficacy of topical brinzolamide in children with retinal dystrophies.
Retinal Degeneration
Progressive renal injury from transgenic expression of human carbonic anhydrase IV folding mutants is enhanced by deficiency of p58IPK.
Retinal Degeneration
Retinal Dystrophy with Intraretinal Cystoid Spaces Associated with Mutations in the Crumbs Homologue (CRB1) gene.
Retinal Detachment
Rapid changes in the expression of glial cell proteins caused by experimental retinal detachment.
Retinal Diseases
In vivo imaging reveals novel aspects of retinal disease progression in Rs1h(-/Y) mice but no therapeutic effect of carbonic anhydrase inhibition.
Retinal Diseases
Topical Aqueous Suppression and Closure of Idiopathic Full-Thickness Macular Holes.
Retinal Dystrophies
Autoimmune retinopathy associated with monoclonal gammopathy of undetermined significance: a case report.
Retinal Dystrophies
Carbonic anhydrase inhibitors in patients with X-linked retinoschisis: effects on macular morphology and function.
Retinal Dystrophies
Efficacy of topical brinzolamide in children with retinal dystrophies.
Retinal Dystrophies
Macular cysts in retinal dystrophy.
Retinal Dystrophies
Paradoxical response to carbonic anhydrase inhibitors in patients with intraretinal cystoid spaces.
Retinal Dystrophies
Resolution of cystoid macular edema with topical carbonic anhydrase inhibitor in a patient with retinal dystrophy associated with Cohen syndrome.
Retinal Dystrophies
Topical carbonic anhydrase inhibitors in macular edema associated with Alström syndrome.
Retinal Dystrophies
TOPICAL DORZOLAMIDE FOR CYSTOID MACULAR EDEMA IN BIETTI CRYSTALLINE RETINAL DYSTROPHY.
Retinal Hemorrhage
Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation.
Retinal Perforations
Macular Hole Closure with Topical Carbonic Anhydrase Inhibitor.
Retinitis
Retrospective cohort study exploring whether an association exists between spatial distribution of cystoid spaces in cystoid macular oedema secondary to retinitis pigmentosa and response to treatment with carbonic anhydrase inhibitors.
Retinitis
Short-term outcomes of subtenon triamcinolone acetonide injections in patients with retinitis pigmentosa-associated cystoid macular edema unresponsive to carbonic anhydrase inhibitors.
Retinitis Pigmentosa
An efficient method for the synthesis of novel derivatives 4-{5-[4-(4-amino-5-mercapto-4H-[1,2,4]triazol-3-yl)-phenyl]-3-trifluoromethyl-pyrazol-1-yl}-benzenesulfonamide and their anti-inflammatory potential.
Retinitis Pigmentosa
Apoptosis-inducing signal sequence mutation in carbonic anhydrase IV identified in patients with the RP17 form of retinitis pigmentosa.
Retinitis Pigmentosa
Bilateral intravitreal dexamethasone implant for retinitis pigmentosa-related macular edema.
Retinitis Pigmentosa
Chemical chaperones protect from effects of apoptosis-inducing mutation in carbonic anhydrase IV identified in retinitis pigmentosa 17.
Retinitis Pigmentosa
Continued exploration and tail approach synthesis of benzenesulfonamides containing triazole and dual triazole moieties as carbonic anhydrase I, II, IV and IX inhibitors.
Retinitis Pigmentosa
Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa.
Retinitis Pigmentosa
Design and synthesis of novel 1,3-diaryltriazene-substituted sulfonamides as potent and selective carbonic anhydrase II inhibitors.
Retinitis Pigmentosa
Discovery of 4-sulfamoyl-phenyl-?-lactams as a new class of potent carbonic anhydrase isoforms I, II, IV and VII inhibitors: The first example of subnanomolar CA IV inhibitors.
Retinitis Pigmentosa
Discovery of new 2, 5-disubstituted 1,3-selenazoles as selective human carbonic anhydrase IX inhibitors with potent anti-tumor activity.
Retinitis Pigmentosa
Efficacy and prognostic factors of response to carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa.
Retinitis Pigmentosa
Efficacy of additional topical betamethasone in persistent cystoid macular oedema after carbonic anhydrase inhibitor treatments in retinitis pigmentosa.
Retinitis Pigmentosa
Efficacy of carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa: A meta-analysis.
Retinitis Pigmentosa
Efficacy of dorzolamide hydrochloride in the management of chronic cystoid macular edema in patients with retinitis pigmentosa.
Retinitis Pigmentosa
Evaluation of selenide, diselenide and selenoheterocycle derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
Retinitis Pigmentosa
First evaluation of organotellurium derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
Retinitis Pigmentosa
Identification and characterization of a novel mutation in the carbonic anhydrase IV gene that causes retinitis pigmentosa.
Retinitis Pigmentosa
Intravitreal dexamethasone implant for recalcitrant cystoid macular edema secondary to retinitis pigmentosa: a pilot study.
Retinitis Pigmentosa
Intrinsic thermodynamics of high affinity inhibitor binding to recombinant human carbonic anhydrase IV.
Retinitis Pigmentosa
Pathogenesis of retinitis pigmentosa associated with apoptosis-inducing mutations in carbonic anhydrase IV.
Retinitis Pigmentosa
Progressive renal injury from transgenic expression of human carbonic anhydrase IV folding mutants is enhanced by deficiency of p58IPK.
Retinitis Pigmentosa
RECURRENT CENTRAL SEROUS CHORIORETINOPATHY ASSOCIATED WITH RETINITIS PIGMENTOSA TREATED WITH CARBONIC ANHYDRASE INHIBITORS.
Retinitis Pigmentosa
Retrospective cohort study exploring whether an association exists between spatial distribution of cystoid spaces in cystoid macular oedema secondary to retinitis pigmentosa and response to treatment with carbonic anhydrase inhibitors.
Retinitis Pigmentosa
Screening for the carbonic anhydrase IV gene mutations in Chinese retinitis pigmentosa patients.
Retinitis Pigmentosa
Short-term outcomes of subtenon triamcinolone acetonide injections in patients with retinitis pigmentosa-associated cystoid macular edema unresponsive to carbonic anhydrase inhibitors.
Retinitis Pigmentosa
Synthesis and biological evaluation of cyclic imides incorporating benzenesulfonamide moieties as carbonic anhydrase I, II, IV and IX inhibitors.
Retinitis Pigmentosa
Synthesis of novel acyl selenoureido benzensulfonamides as carbonic anhydrase I, II, VII and IX inhibitors.
Retinitis Pigmentosa
The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular oedema.
Retinitis Pigmentosa
THE USE OF CARBONIC ANHYDRASE INHIBITORS IN THE RETREATMENT OF CYSTIC MACULAR LESIONS IN RETINITIS PIGMENTOSA AND X-LINKED RETINOSCHISIS.
Retinitis Pigmentosa
Therapeutic effect of prolonged treatment with topical dorzolamide for cystoid macular oedema in patients with retinitis pigmentosa.
Retinitis Pigmentosa
Topical steroidal and nonsteroidal antiinflammatory drugs for the treatment of cystoid macular edema in retinitis pigmentosa.
Retinitis Pigmentosa
Treatment of cystoid macular edema secondary to retinitis pigmentosa: a systematic review.
Retinitis Pigmentosa
[Antiretinal antibodies associated with cystoid macular edema]
Retinoschisis
A combination of topical and systemic carbonic anhydrase in the treatment of chromosome X-linked retinoschisis.
Retinoschisis
Carbonic anhydrase inhibition in X-linked retinoschisis: An eye on the photoreceptors.
Retinoschisis
Carbonic Anhydrase Inhibitors for the Treatment of Cystic Macular Lesions in Children With X-Linked Juvenile Retinoschisis.
Retinoschisis
Carbonic anhydrase inhibitors in patients with X-linked retinoschisis: effects on macular morphology and function.
Retinoschisis
Papillomacular retinoschisis associated with glaucoma: Response to topical carbonic anhydrase inhibitor.
Retinoschisis
Paradoxical Anatomic Response to Topical Carbonic Anhydrase Inhibitor in X-linked Retinoschisis.
Retinoschisis
Resolution of optic disc pit-associated macular retinoschisis after topical carbonic anhydrase inhibitor treatment: Report of a case.
Retinoschisis
STRUCTURAL AND FUNCTIONAL MONITORING OF EXTRAMACULAR CYSTOID SPACES IN A CASE OF X-LINKED RETINOSCHISIS TREATED WITH ACETAZOLAMIDE.
Retinoschisis
THE USE OF CARBONIC ANHYDRASE INHIBITORS IN THE RETREATMENT OF CYSTIC MACULAR LESIONS IN RETINITIS PIGMENTOSA AND X-LINKED RETINOSCHISIS.
Retinoschisis
Treatment of adult-onset acute macular retinoschisis in enhanced s-cone syndrome with oral acetazolamide.
Retinoschisis
USE OF A CARBONIC ANHYDRASE INHIBITOR IN X-LINKED RETINOSCHISIS: Effect on Cystic-Appearing Macular Lesions and Visual Acuity.
Retinoschisis
Use of dorzolamide for patients with x-linked retinoschisis.
Retinoschisis
X-linked juvenile retinoschisis in females and response to carbonic anhydrase inhibitors: case report and review of the literature.
Rhabdomyolysis
Carbonic anhydrase III as a serum marker for diagnosis of rhabdomyolysis.
Rhabdomyolysis
Determination of carbonic anhydrase III isoenzyme concentration in sera of racehorses with exertional rhabdomyolysis.
Rhabdomyolysis
Exertional rhabdomyolysis in carbonic anhydrase 12 deficiency.
Rhabdomyosarcoma
Tumour expressions of hypoxic markers predict the response to neo-adjuvant chemotherapy in children with inoperable rhabdomyosarcoma.
Rheumatic Diseases
Antibodies to carbonic anhydrase in systemic lupus erythematosus and other rheumatic diseases.
Rheumatic Diseases
[Clinical evaluation of blood catalase and carbonic anhydrase activity in rheumatism in children]
Rheumatic Fever
[Carbonic anhydrase of erythrocytes in acute rheumatic fever in children]
Rickets
[Determination of carbonic anhydrase activity, concentration of 2,3-diphosphoglycerate and several erythrocyte indices in rickets]
Salivary Gland Calculi
Possible Drug-Associated Sialolithiasis From the Bicarbonate Anhydrase Inhibitor Topiramate: A Case Report and Literature Review.
Salivary Gland Neoplasms
Intrinsic binding of 4-substituted-2,3,5,6-tetrafluorobenezenesulfonamides to native and recombinant human carbonic anhydrase VI.
Sarcoidosis
Sarcoidosis patient: an unexpected reaction to carbonic anhydrase enzyme inhibitor.
Sarcoma
An Immunohistochemical Study of the Expression of the Hypoxia Markers Glut-1 and Ca-IX in Canine Sarcomas.
Sarcoma
Can sparsely and heterogeneously expressed proteins be detected using tissue microarrays? A simulation study of the hypoxia marker carbonic anhydrase IX (CA IX) in human soft tissue sarcoma.
Sarcoma
Carbonic anhydrase isozymes II, IX, and XII in uterine tumors.
Sarcoma
Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma.
Sarcoma
Design, synthesis, and structure-activity relationships of 1-ethylpyrazole-3-carboxamide compounds as novel hypoxia-inducible factor (HIF)-1 inhibitors.
Sarcoma
Influence of tumor transplantation methods on tumor growth rate and metastatic potential of solitary tumors derived from metastases.
Sarcoma
Metastatic instability of murine tumor metastases: dependence on tumor type.
Sarcoma
Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1?
Sarcoma
Prognostic impacts of hypoxic markers in soft tissue sarcoma.
Sarcoma
Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin.
Sarcoma, Experimental
[Activity of ceruloplasmin, carbonic anhydrase and saturation of transferrin with iron in blood serum of rats developing experimental sarcoma M-1 against a background of E-avitaminosis]
Schistosomiasis
Serum Carbonic Anhydrase 1 is a Biomarker for Diagnosis of Human Schistosoma mansoni Infection.
Schistosomiasis
Sulfonamide Inhibition Studies of an ?-Carbonic Anhydrase from Schistosoma mansoni, a Platyhelminth Parasite Responsible for Schistosomiasis.
Schistosomiasis mansoni
Serum Carbonic Anhydrase 1 is a Biomarker for Diagnosis of Human Schistosoma mansoni Infection.
Scleroderma, Diffuse
A study of anti-carbonic anhydrase II antibodies in rheumatic autoimmune diseases.
Scleroderma, Diffuse
Serum levels of soluble carbonic anhydrase IX are decreased in patients with diffuse cutaneous systemic sclerosis compared to those with limited cutaneous systemic sclerosis.
Scleroderma, Systemic
Anti-carbonic anhydrase II antibodies in systemic sclerosis: association with lung involvement.
Scleroderma, Systemic
Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status.
Scleroderma, Systemic
Serum levels of soluble carbonic anhydrase IX are decreased in patients with diffuse cutaneous systemic sclerosis compared to those with limited cutaneous systemic sclerosis.
Scleroderma, Systemic
Subgroups of Sjögren syndrome patients according to serological profiles.
Seizures
A single dose of sulthiame induces a selective increase in resting motor threshold in human motor cortex: A transcranial magnetic stimulation study.
Seizures
Acetazolamide impairs fear memory consolidation in rodents.
Seizures
Anticonvulsant sulfonamides/sulfamates/sulfamides with carbonic anhydrase inhibitory activity: drug design and mechanism of action.
Seizures
Carbonic anhydrase inhibitors as anticonvulsant agents.
Seizures
Carbonic anhydrase inhibitors suppress seizures in a rat model of birth asphyxia.
Seizures
Carbonic anhydrase IV on brain capillary endothelial cells: a marker associated with the blood-brain barrier.
Seizures
Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ?50 kg/m2 Prior to Bariatric Surgery.
Seizures
Computer-aided identification of human carbonic anhydrase isoenzyme VII inhibitors as potential antiepileptic agents.
Seizures
Correlation between effects of acute acetazolamide administration to mice on electroshock seizure threshold and maximal electroshock seizure pattern, and on carbonic anhydrase activity in subcellular fractions of brain.
Seizures
Development of seizure patterns in newborn animals; significance of brain carbonic anhydrase.
Seizures
Developmental changes in seizure susceptibility in carbonic anhydrase II-deficient mice and normal littermates.
Seizures
Discovery of Benzenesulfonamide Derivatives as Carbonic Anhydrase Inhibitors with Effective Anticonvulsant Action: Design, Synthesis, and Pharmacological Evaluation.
Seizures
Discovery of potent anti-convulsant carbonic anhydrase inhibitors: Design, synthesis, in vitro and in vivo appraisal.
Seizures
Expression of carbonic anhydrases II, IV, VII, VIII and XII in rat brain after kainic acid induced status epilepticus.
Seizures
Glial contribution to seizure: carbonic anhydrase activity in epileptic mammalian brain.
Seizures
Increased susceptibility of brain slices from carbonic anhydrase II-deficient mice to low [Mg2+]O-induced seizures.
Seizures
Induction of new carbonic anhydrase II following treatment with acetazolamide in DBA and C57 mice.
Seizures
Localization of carbonic anhydrase in the cerebrum and cerebellum of normal and audiogenic seizure mice.
Seizures
Lucky Switcheroo: Dramatic Potency and Selectivity Improvement of Imidazoline Inhibitors of Human Carbonic Anhydrase VII.
Seizures
Mechanisms of tolerance to the anticonvulsant effects of acetazolamide in mice: relation to the activity and amount of carbonic anhydrase in brain.
Seizures
Mutations in the Na(+)/citrate cotransporter NaCT (SLC13A5) in pediatric patients with epilepsy and developmental delay.
Seizures
Neuronal carbonic anhydrase VII provides GABAergic excitatory drive to exacerbate febrile seizures.
Seizures
Novel, Broad-Spectrum Anticonvulsants Containing a Sulfamide Group: Advancement of N-((Benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into Human Clinical Studies.
Seizures
Pharmacological inhibition of brain carbonic anhydrase protects against 4-aminopyridine seizures.
Seizures
Phenyl(thio)phosphon(amid)ate Benzenesulfonamides as Potent and Selective Inhibitors of Human Carbonic Anhydrases II and VII Counteract Allodynia in a Mouse Model of Oxaliplatin-Induced Neuropathy.
Seizures
Reduced susceptibility to seizures in carbonic anhydrase II deficient mutant mice.
Seizures
Resistance of hippocampal synaptic transmission to hypoxia in carbonic anhydrase II-deficient mice.
Seizures
Role of glial cation and anion transport mechanisms in etiology and arrest of seizures.
Seizures
Seizure patterns in young animals; significance of brain carbonic anhydrase. II.
Seizures
Substituted thiadiazolines as inhibitors of central nervous system carbonic anhydrase.
Seizures
Sulthiame in childhood epilepsy.
Seizures
The Many Faces of Glut1 Deficiency Syndrome.
Seizures
The roles of nitric oxide and carbon dioxide gas in the neurotoxic actions of oxygen under pressure.
Seizures
Up-regulation of carbonic anhydrase isozyme IV in CNS myelin of mice genetically deficient in carbonic anhydrase II.
Seizures
Zonisamide: chemistry, mechanism of action, and pharmacokinetics.
Seizures, Febrile
Neuronal carbonic anhydrase VII provides GABAergic excitatory drive to exacerbate febrile seizures.
Seminoma
Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors.
Sepsis
Preferential consumption of heparin cofactor II in disseminated intravascular coagulation associated with acute promyelocytic leukemia.
Sepsis
Proteome analysis of hemofilter adsorbates to identify novel substances of sepsis: a pilot study.
Sepsis
[The state of carbonic anhydrase in the blood of wounded with sepsis; the role of vitaminotherapy].
Sexually Transmitted Diseases
Biochemical and structural characterisation of a protozoan beta-carbonic anhydrase from Trichomonas vaginalis.
Shock, Cardiogenic
Peroxiredoxin 1 induces inflammatory cytokine response and predicts outcome of cardiogenic shock patients necessitating extracorporeal membrane oxygenation: an observational cohort study and translational approach.
Sialadenitis
Induction of experimental autoimmune sialoadenitis by immunization of PL/J mice with carbonic anhydrase II.
Sickle Cell Trait
Carbonic anhydrase activity in sickle cell anemia, sickle cell trait, and pernicious anemia.
Sickle Cell Trait
Reversal of retinal and optic disc ischemia in a patient with sickle cell trait and glaucoma secondary to traumatic hyphema.
Sinus Thrombosis, Intracranial
Use of single-slice thick slab phase-contrast angiography for the diagnosis of dural venous sinus thrombosis.
Sjogren's Syndrome
Antibodies to carbonic anhydrase and IgG4 levels in idiopathic chronic pancreatitis: relevance for diagnosis of autoimmune pancreatitis.
Sjogren's Syndrome
Autoantibodies against carbonic anhydrase II are increased in renal tubular acidosis associated with Sjogren syndrome.
Sjogren's Syndrome
Evaluation of Autoantibodies in Patients with Primary and Secondary Sjogren's Syndrome.
Sjogren's Syndrome
Induction of anti-carbonic-anhydrase-II antibody causes renal tubular acidosis in a mouse model of Sjogren's syndrome.
Sjogren's Syndrome
Novel carbonic anhydrase autoantibodies and renal manifestations in patients with primary Sjogren's syndrome.
Sjogren's Syndrome
Prevalence of Novel Candidate Sjogren Syndrome Autoantibodies in the Dry Eye Assessment and Management (DREAM) Study.
Sjogren's Syndrome
Serum antibodies to carbonic anhydrase IV in patients with autoimmune pancreatitis.
Sleep Apnea Syndromes
Acetazolamide Reduces Blood Pressure and Sleep-Disordered Breathing in Patients With Hypertension and Obstructive Sleep Apnea: A Randomized Controlled Trial.
Sleep Apnea Syndromes
Effects of acetazolamide on the sleep apnea syndrome and its therapeutic mechanism.
Sleep Apnea Syndromes
Increased Carbonic Anhydrase Activity is Associated with Sleep Apnea Severity and Related Hypoxemia.
Sleep Apnea Syndromes
Independent associations between arterial bicarbonate, apnea severity and hypertension in obstructive sleep apnea.
Sleep Apnea Syndromes
Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist: a patent evaluation of CA2958110 and IN6616DEN2012.
Sleep Apnea Syndromes
Zonisamide reduces obstructive sleep apnoea: a randomised placebo-controlled study.
Sleep Apnea Syndromes
[Inhibition of renal carbonic anhydrase as a respiratory stimulant-- an obsolete indication?]
Sleep Apnea, Central
Low-dose acetazolamide does affect respiratory muscle function in spontaneously breathing anesthetized rabbits.
Sleep Apnea, Central
The effects of acetazolamide on arterial pressure variability during REM sleep in the rat.
Sleep Apnea, Obstructive
Acetazolamide Reduces Blood Pressure and Sleep-Disordered Breathing in Patients With Hypertension and Obstructive Sleep Apnea: A Randomized Controlled Trial.
Sleep Apnea, Obstructive
Carbonic Anhydrase II Deficiency: A Rare Case of Severe Obstructive Sleep Apnea.
Sleep Apnea, Obstructive
Carbonic anhydrase, obstructive sleep apnea and hypertension: Effects of intervention.
Sleep Apnea, Obstructive
Increased Carbonic Anhydrase Activity is Associated with Sleep Apnea Severity and Related Hypoxemia.
Sleep Apnea, Obstructive
Independent associations between arterial bicarbonate, apnea severity and hypertension in obstructive sleep apnea.
Small Cell Lung Carcinoma
Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer.
Spinal Muscular Atrophies of Childhood
Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: relationship with creatine kinase.
Splenosis
Renal Splenosis: Renal Mass Biopsy Diagnosis of a Tumor Clinically Mimicking Renal Cell Carcinoma.
Spondylitis, Ankylosing
Carbonic Anhydrase 1-Mediated Calcification Is Associated With Atherosclerosis, and Methazolamide Alleviates Its Pathogenesis.
Spondylitis, Ankylosing
Carbonic anhydrase I is involved in the process of bone formation and is susceptible to ankylosing spondylitis.
Spondylitis, Ankylosing
Increased expression of carbonic anhydrase I in the synovium of patients with ankylosing spondylitis.
Spondylitis, Ankylosing
The role of carbonic anhydrase in the pathogenesis of vascular calcification in humans.
Squamous Cell Carcinoma of Head and Neck
Carbonic Anhydrase III Promotes Cell Migration and Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Carbonic anhydrase IX overexpression regulates the migration and progression in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density.
Squamous Cell Carcinoma of Head and Neck
Clinicopathological significance of carbonic anhydrase 9, glucose transporter-1, Ki-67 and p53 expression in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients.
Squamous Cell Carcinoma of Head and Neck
Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Correlation of carbonic anhydrase 9 (CA9) with pathological T-stage and prognosis in patients with oral tongue squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
Expression of CA IX in dysplasia adjacent to surgical resection margins of oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Expression of CA-IX is associated with advanced stage tumors and poor survival in oral squamous cell carcinoma patients.
Squamous Cell Carcinoma of Head and Neck
Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Expression of carbonic anhydrases I/II and the correlation to clinical aspects of oral squamous cell carcinoma analyzed using tissue microarray.
Squamous Cell Carcinoma of Head and Neck
Galectin-1: a link between tumor hypoxia and tumor immune privilege.
Squamous Cell Carcinoma of Head and Neck
High stromal carbonic anhydrase IX expression is associated with nodal metastasis and decreased survival in patients with surgically-treated oral cavity squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
HPV-associated differential regulation of tumor metabolism in oropharyngeal head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Impact of tumoral carbonic anhydrase IX and Ki-67 expression on survival in oral squamous cell carcinoma patients.
Squamous Cell Carcinoma of Head and Neck
Increased expression of carbonic anhydrase IX in oral submucous fibrosis and oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Investigation of the Prognostic Role of Carbonic Anhydrase 9 (CAIX) of the Cellular mRNA/Protein Level or Soluble CAIX Protein in Patients with Oral Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study.
Squamous Cell Carcinoma of Head and Neck
Microsatellite alterations in head and neck squamous cell carcinoma and relation to expression of pimonidazole, CA IX and GLUT-1.
Squamous Cell Carcinoma of Head and Neck
Overexpression of carbonic anhydrase IX induces cell motility by activating matrix metalloproteinase-9 in human oral squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
PAI-1, CAIX, and VEGFA expressions as prognosis markers in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Prognostic significance of HIF-1a, CA-IX, and OPN in T1-T2 laryngeal carcinoma treated with radiotherapy.
Squamous Cell Carcinoma of Head and Neck
Prognostic value of CAIX expression in oral squamous cell carcinoma: a systematic review and meta-analysis.
Squamous Cell Carcinoma of Head and Neck
Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy.
Squamous Cell Carcinoma of Head and Neck
The prognostic impact of a combined carbonic anhydrase IX and Ki67 signature in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy.
Squamous Cell Carcinoma of Head and Neck
Tumor-associated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis.
Squamous Cell Carcinoma of Head and Neck
[A preliminary study on the relationship between GLUT-1?MCT-4 and CA? in laryngeal squamous cell carcinoma].
Squamous Cell Carcinoma of Head and Neck
[Expression and clinical pathological implications of carbonic anhydrase 9 and P glycoprotein in laryngeal squamous cell carcinoma].
Starvation
Carbonic anhydrases in cytosol, nucleus, and membranes of rat liver.
Stevens-Johnson Syndrome
CD8(+) T-cell activation by methazolamide causes methazolamide-induced Stevens-Johnson syndrome and toxic epidermal necrolysis.
Stevens-Johnson Syndrome
HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
Stevens-Johnson Syndrome
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Associated with Carbonic Anhydrase Inhibitors: Epidemiology, Genetics, and Insights into Mechanisms.
Stevens-Johnson Syndrome
Toxic Epidermal Necrolysis in a Patient with HLA-B*5901 Haplotype Caused by Topical and Oral Carbonic Anhydrase Inhibitors.
Stevens-Johnson Syndrome
Toxic Epidermal Necrolysis Induced by the Topical Carbonic Anhydrase Inhibitors Brinzolamide and Dorzolamide.
Stomach Neoplasms
Cancer-associated splicing variants of the CDCA1 and MSMB genes expressed in cancer cell lines and surgically resected gastric cancer tissues.
Stomach Neoplasms
Carbonic anhydrase IV inhibits cell proliferation in gastric cancer by regulating the cell cycle.
Stomach Neoplasms
CREB is a key negative regulator of carbonic anhydrase IX (CA9) in gastric cancer.
Stomach Neoplasms
Detection of autoantibodies against carbonic anhydrase I and II in the plasma of patients with gastric cancer.
Stomach Neoplasms
Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer.
Stomach Neoplasms
Expression of carbonic anhydrase 9 at the invasion front of gastric cancers.
Stomach Neoplasms
Expression of hypoxic marker CA IX is regulated by site-specific DNA methylation and is associated with the histology of gastric cancer.
Stomach Neoplasms
Implications of carbonic anhydrase IX hypermethylation in gastric cancer pathogenesis.
Stomach Neoplasms
Low CA II expression is associated with tumor aggressiveness and poor prognosis in gastric cancer patients.
Stomach Neoplasms
siRNA-mediated knockdown against CDCA1 and KNTC2, both frequently overexpressed in colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis.
Stomach Neoplasms
[The clinical significance of E-cadherin and alpha-catenin expression in human gastric cancer]
Stomach Ulcer
Effect of ZnSO4 upon gastric acid secretion and carbonic anhydrase.
Stomach Ulcer
Measurement of Carbonic Anhydrase I and II Isozymes in Feces as a Marker of Occult Blood in Horses with Intestinal Tract Bleeding.
Stomach Ulcer
Successful treatment of intractable gastric ulcers with acetazolamide.
Stomach Ulcer
Treatment of gastric ulcer with carbonic anhydrase inhibitors.
Stomatitis, Aphthous
Salivary proteome of aphthous stomatitis reveals the participation of vitamin metabolism, nutrients, and bacteria.
Stroke
Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management.
Stroke
Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study.
Stroke
The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain.
Stroke
Transgenic Expression of Carbonic Anhydrase III in Cardiac Muscle Demonstrates A Mechanism to Tolerate Acidosis.
Stroke
[Juvenile cerebral infarction associated with heparin cofactor II abnormality. A case report]
Taste Disorders
Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
Taste Disorders
The role of zinc in the treatment of taste disorders.
Taste Disorders
Zinc deficiency and taste dysfunction; contribution of carbonic anhydrase, a zinc-metalloenzyme, to normal taste sensation.
Telangiectasis
DECREASED MACULAR THICKNESS IN NONPROLIFERATIVE MACULAR TELANGIECTASIA TYPE 2 WITH ORAL CARBONIC ANHYDRASE INHIBITORS.
Teratoma
Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors.
Testicular Neoplasms
Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors.
Tetany
[Carbonic anhydrase inhibition and spasmophilia.]
Thromboangiitis Obliterans
[Juvenile cerebral infarction associated with heparin cofactor II abnormality. A case report]
Thrombocythemia, Essential
Cytosolic carbonic anhydrase activity in chronic myeloid disorders with different clinical phenotype.
Thromboembolism
Heparin cofactor II deficiency in renal allograft recipients: no correlation with the development of thrombosis.
Thrombophilia
Heparin cofactor II deficiency in renal allograft recipients: no correlation with the development of thrombosis.
Thrombophilia
Heparin cofactor II: experimental approach to a new assay and clinical results.
Thrombophilia
Prevalence of heparin cofactor II deficiency in patients with a history of venous thrombosis.
Thrombosis
Carbonic Anhydrase Inhibitors suppress platelet procoagulant responses and in vivo thrombosis.
Thrombosis
Combined inherited protein S and heparin co-factor II deficiency in a patient with upper limb thrombosis: a family study.
Thrombosis
Constitutional heparin co-factor II deficiency associated with recurrent thrombosis.
Thrombosis
Down-regulation of metabolic proteins in hepatocellular carcinoma with portal vein thrombosis.
Thrombosis
Heparin cofactor II deficiency in renal allograft recipients: no correlation with the development of thrombosis.
Thrombosis
Heparin cofactor II in adults and infants with thrombosis and DIC.
Thrombosis
Heparin cofactor II: experimental approach to a new assay and clinical results.
Thrombosis
Hereditary heparin cofactor II deficiency and coronary artery disease.
Thrombosis
Hereditary heparin cofactor II deficiency and the risk of development of thrombosis.
Thrombosis
Plasma and urinary heparin cofactor II levels in patients with nephrotic syndrome.
Thrombosis
Prevalence of heparin cofactor II deficiency in patients with a history of venous thrombosis.
Thrombosis
Use of single-slice thick slab phase-contrast angiography for the diagnosis of dural venous sinus thrombosis.
Thrombosis
[The second cofactor of heparin]
Thymoma
Carbonic anhydrase 9 expression is associated with poor prognosis, tumor proliferation, and radiosensitivity of thymic carcinomas.
Thymoma
Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms.
Thymoma
The occurrence of hemoglobins Bart's and F associated with carbonic anhydrase deficiency in a patient with alpha-thalassemia and malignant thymoma.
Thyroid Cancer, Papillary
Glycolysis-related protein expression in thyroid cancer.
Thyroid Diseases
Clinical utility of red blood cell carbonic anhydrase I and zinc concentrations in patients with thyroid diseases.
Thyroid Diseases
Effects of thyroid hormone on erythrocyte carbonic anhydrase-I and zinc concentrations in vivo and in vitro: clinical usefulness of carbonic anhydrase-I and zinc concentrations in erythrocytes.
Thyroid Diseases
Increased serum anti-carbonic anhydrase II antibodies in patients with Graves' disease.
Thyroid Diseases
[Erythrocyte carbonic anhydrase I and zinc concentrations in thyrotoxicosis reflect integrated thyroid hormone levels over the previous few months]
Thyroid Neoplasms
Expression Pattern of Carbonic Anhydrase IX in Medullary Thyroid Carcinoma Supports a Role for RET-Mediated Activation of the HIF Pathway.
Thyroid Neoplasms
Relationship between biological marker expression and fluorine-18 fluorodeoxyglucose uptake in incidentally detected thyroid cancer.
Thyroid Nodule
Carbonic anhydrase 4 and crystallin ?-B immunoreactivity may distinguish benign from malignant thyroid nodules in patients with indeterminate thyroid cytology.
Thyroiditis
Sulfonamide drugs: structure, antibacterial property, toxicity, and biophysical interactions.
Thyroiditis, Subacute
Erythrocyte carbonic anhydrase-I concentrations in patients with Graves' disease and subacute thyroiditis reflect integrated thyroid hormone levels over the previous few months.
Thyrotoxicosis
[Erythrocyte carbonic anhydrase I and zinc concentrations in thyrotoxicosis reflect integrated thyroid hormone levels over the previous few months]
Tongue Neoplasms
Brachytherapy for oral tongue cancer: an analysis of treatment results with various biological markers.
Tongue Neoplasms
ZEB1 transcriptionally regulated carbonic anhydrase 9 mediates the chemoresistance of tongue cancer via maintaining intracellular pH.
Toxemia
Carbonic anhydrase inhibitors; their effect on water and electrolyte metabolism in toxemia of pregnancy.
Toxemia
Effects of carbonic anhydrase inhibitors in toxemia of pregnancy.
Tremor
Essential Tremor: What We Can Learn from Current Pharmacotherapy.
Tremor
The effect of acetazolamide on essential tremor: an open-label trial.
Tremor
[Treatment options for nystagmus].
Trichinellosis
Carbonic anhydrase enzyme as a potential therapeutic target for experimental trichinellosis.
Trichomonas Infections
Biochemical and structural characterisation of a protozoan beta-carbonic anhydrase from Trichomonas vaginalis.
Trigeminal Neuralgia
Carbonic anhydrase II in the cerebrospinal fluid: its value as a disease marker.
Triple Negative Breast Neoplasms
A non-catalytic function of carbonic anhydrase IX contributes to the glycolytic phenotype and pH regulation in human breast cancer cells.
Triple Negative Breast Neoplasms
A Novel Inhibitor of Carbonic Anhydrases Prevents Hypoxia-Induced TNBC Cell Plasticity.
Triple Negative Breast Neoplasms
Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients.
Triple Negative Breast Neoplasms
Application of carbonic anhydrase inhibitors to increase the penetration of doxorubicin and its liposomal formulation into 2D and 3D triple negative breast cancer cell cultures.
Triple Negative Breast Neoplasms
Carbonic anhydrase XII expression is linked to suppression of Sonic hedgehog ligand expression in triple negative breast cancer cells.
Triple Negative Breast Neoplasms
Carbonic Anhydrase XII Expression Is Modulated during Epithelial Mesenchymal Transition and Regulated through Protein Kinase C Signaling.
Triple Negative Breast Neoplasms
Depletion of carbonic anhydrase IX abrogates hypoxia-induced overexpression of stanniocalcin-1 in triple negative breast cancer cells.
Triple Negative Breast Neoplasms
Harnessing Induced Essentiality: Targeting Carbonic Anhydrase IX and Angiogenesis Reduces Lung Metastasis of Triple Negative Breast Cancer Xenografts.
Triple Negative Breast Neoplasms
Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer.
Triple Negative Breast Neoplasms
The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
Triple Negative Breast Neoplasms
[Clinicopathologic features of mammary microglandular adenosis with carcinoma: a study of 5 cases].
Tuberculosis
3-Phenyl-1H-Indole-5-Sulfonamides: Structure-Based Drug Design of a Promising Class of Carbonic Anhydrase Inhibitors.
Tuberculosis
3D-QSAR CoMFA studies on sulfonamide inhibitors of the Rv3588c ?-carbonic anhydrase from Mycobacterium tuberculosis and design of not yet synthesized new molecules.
Tuberculosis
Activation of ?- and ?-carbonic anhydrases from pathogenic bacteria with tripeptides.
Tuberculosis
Activation studies with amines and amino acids of the ?-carbonic anhydrase encoded by the Rv3273 gene from the pathogenic bacterium Mycobacterium tuberculosis.
Tuberculosis
Anti-tubercular and antioxidant activities of C-glycosyl carbonic anhydrase inhibitors: towards the development of novel chemotherapeutic agents against Mycobacterium tuberculosis.
Tuberculosis
Bortezomib inhibits bacterial and fungal ?-carbonic anhydrases.
Tuberculosis
Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c.
Tuberculosis
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
Tuberculosis
Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesulfonamides.
Tuberculosis
Click-tailed benzenesulfonamides as potent bacterial carbonic anhydrase inhibitors for targeting Mycobacterium tuberculosis and Vibrio cholerae.
Tuberculosis
Differential chemical and thermal unfolding pattern of Rv3588c and Rv1284 of Mycobacterium tuberculosis - A comparison by fluorescence and circular dichroism spectroscopy.
Tuberculosis
Dihalogenated sulfanilamides and benzolamides are effective inhibitors of the three ?-class carbonic anhydrases from Mycobacterium tuberculosis.
Tuberculosis
Discovery of Low Nanomolar and Subnanomolar Inhibitors of the Mycobacterial beta-Carbonic Anhydrases Rv1284 and Rv3273.
Tuberculosis
Dithiocarbamates strongly inhibit the ?-class carbonic anhydrases from Mycobacterium tuberculosis.
Tuberculosis
Evaluation of sulphonamide derivatives acting as inhibitors of human carbonic anhydrase isoforms I, II and Mycobacterium tuberculosis ?-class enzyme Rv3273.
Tuberculosis
Evaluation of Thio- and Seleno-Acetamides Bearing Benzenesulfonamide as Inhibitor of Carbonic Anhydrases from Different Pathogenic Bacteria.
Tuberculosis
In vitro inhibition of Mycobacterium tuberculosis ?-carbonic anhydrase 3 with Mono- and dithiocarbamates and evaluation of their toxicity using zebrafish developing embryos.
Tuberculosis
Inhibition of ?-, ?-, ?-, ?-, ?- and ?-class carbonic anhydrases from bacteria, fungi, algae, diatoms and protozoans with famotidine.
Tuberculosis
Inhibition of ?-carbonic anhydrases with ureido-substituted benzenesulfonamides.
Tuberculosis
Inhibition of the ?-carbonic anhydrases from Mycobacterium tuberculosis with C-cinnamoyl glycosides: identification of the first inhibitor with anti-mycobacterial activity.
Tuberculosis
Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
Tuberculosis
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.
Tuberculosis
Mycobacterium tuberculosis?-Carbonic Anhydrases: Novel Targets for Developing Antituberculosis Drugs.
Tuberculosis
Natural Product-Based Phenols as Novel Probes for Mycobacterial and Fungal Carbonic Anhydrases.
Tuberculosis
Structural Mechanics of the pH-dependent Activity of beta-Carbonic Anhydrase from Mycobacterium tuberculosis.
Tuberculosis
Structure based drug discovery for designing leads for the non-toxic metabolic targets in multi drug resistant Mycobacterium tuberculosis.
Tuberculosis
Sulfonamides incorporating fluorine and 1,3,5-triazine moieties are effective inhibitors of three ?-class carbonic anhydrases from Mycobacterium tuberculosis.
Tuberculosis
Synthesis and carbonic anhydrase inhibitory properties of sulfamides structurally related to dopamine.
Tuberculosis
The beta-Carbonic Anhydrases from Mycobacterium tuberculosis as Drug Targets.
Tuberculosis
The Carbonic Anhydrase Inhibitor Ethoxzolamide Inhibits the Mycobacterium tuberculosis PhoPR Regulon and Esx-1 Secretion and Attenuates Virulence.
Tuberculosis
[Value of carbonic anhydrase activity in blood in tuberculosis.]
Tuberculosis, Pulmonary
[Effect of oxolamine on respiratory function, carbonic anhydrase and prothrombin level in pulmonary tuberculosis.]
Tuberous Sclerosis
Brain calcification in Kallman's syndrome. Computed tomographic appearance.
Tularemia
Anion inhibitors of the ?-carbonic anhydrase from the pathogenic bacterium responsible of tularemia, Francisella tularensis.
Tularemia
Sulfonamide inhibition profiles of the ?-carbonic anhydrase from the pathogenic bacterium Francisella tularensis responsible of the febrile illness tularemia.
Typhoid Fever
[Carbonic anhydrase in typhoid fever.]
Ureteral Obstruction
Liposome-mediated gene therapy in the kidney.
Urinary Bladder Neoplasms
Analytical validation of ONCURIA a multiplex bead-based immunoassay for the non-invasive bladder cancer detection.
Urinary Bladder Neoplasms
Carbonic anhydrase 2 is a novel invasion-associated factor in urinary bladder cancers.
Urinary Bladder Neoplasms
Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer.
Urinary Bladder Neoplasms
Carbonic anhydrase IX expression and outcome after radiotherapy for muscle-invasive bladder cancer.
Urinary Bladder Neoplasms
Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker.
Urinary Bladder Neoplasms
Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder.
Urinary Bladder Neoplasms
HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Urinary Bladder Neoplasms
Identification of Carbonic Anhydrase IX as a Novel Target for Endoscopic Molecular Imaging of Human Bladder Cancer.
Urinary Bladder Neoplasms
Serum adenosine deaminase, catalase and carbonic anhydrase activities in patients with bladder cancer.
Urinary Bladder Neoplasms
Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN).
Urinary Bladder Neoplasms
Splicing variants of carbonic anhydrase IX in bladder cancer and urine sediments.
Urinary Bladder Neoplasms
The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer.
Urinary Bladder Neoplasms
Vascular Endothelial Growth Factor, Carbonic Anhydrase 9, and Angiogenin as Urinary Biomarkers for Bladder Cancer Detection.
Urinary Calculi
[Urinary lithiasis of medical origin]
Urogenital Neoplasms
Urinary carbonic anhydrase IX splicing messenger RNA variants in urogenital cancers.
Urolithiasis
Immunohistochemical detection of renal carbonic anhydrase of patients with recurrent urolithiasis.
Urolithiasis
Nephrocalcinosis and urolithiasis in carbonic anhydrase II deficiency syndrome.
Urolithiasis
The effect of antiepileptic drugs on the kidney function and structure.
Urolithiasis
Urolithiasis on the ketogenic diet with concurrent topiramate or zonisamide therapy.
Urolithiasis
[Detection of carbonic anhydrase in the human kidney from the viewpoint of acid-base regulation (an immunohistochemical study in urolithiasis patients)]
Urolithiasis
[ON UROLITHIASIS FOLLOWING LONG-TERM ADMINISTRATION OF CARBONIC ANHYDRASE INHIBITORS IN THE THERAPY OF GLAUCOMA.]
Urolithiasis
[Urinary lithiasis of medical origin]
Urolithiasis
[Urolithiasis during treatment of carbonic anhydrase inhibitors]
Uterine Cervical Neoplasms
Additional Prognostic Value of SUVmax Measured by F-18 FDG PET/CT over Biological Marker Expressions in Surgically Resected Cervical Cancer Patients.
Uterine Cervical Neoplasms
Assessment of the antiproliferative and apoptotic roles of sulfonamide carbonic anhydrase IX inhibitors in HeLa cancer cell line.
Uterine Cervical Neoplasms
Association between human papillomavirus DNA load and development of cervical intraepithelial neoplasia and cervical cancer.
Uterine Cervical Neoplasms
Cancer initiating-cells are enriched in the CA9 positive fraction of primary cervix cancer xenografts.
Uterine Cervical Neoplasms
Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer.
Uterine Cervical Neoplasms
Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer.
Uterine Cervical Neoplasms
Carbonic Anhydrase IX Promotes Human Cervical Cancer Cell Motility by Regulating PFKFB4 Expression.
Uterine Cervical Neoplasms
Carbonic anhydrase XII expression is associated with histologic grade of cervical cancer and superior radiotherapy outcome.
Uterine Cervical Neoplasms
Comparative assessment of lymph node micrometastasis in cervical, endometrial and vulvar cancer: insights on the real time qRT-PCR approach versus immunohistochemistry, employing dual molecular markers.
Uterine Cervical Neoplasms
Detection of high risk human papillomavirus cervical infections by the hybrid capture in Asunción, Paraguay.
Uterine Cervical Neoplasms
Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer.
Uterine Cervical Neoplasms
Evaluation of the anticancer potential of a sulphonamide carbonic anhydrase IX inhibitor on cervical cancer cells.
Uterine Cervical Neoplasms
HPV test by Hybrid Capture II for the diagnosis of HR-HPV persistent infection.
Uterine Cervical Neoplasms
Hybrid capture-II and LCR-E7 PCR assays for HPV typing in cervical cytologic samples.
Uterine Cervical Neoplasms
Hypoxia biomarkers in squamous cell carcinoma of the uterine cervix.
Uterine Cervical Neoplasms
Inhibition of Carbonic Anhydrase IX Promotes Apoptosis through Intracellular pH Level Alterations in Cervical Cancer Cells.
Uterine Cervical Neoplasms
Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study.
Uterine Cervical Neoplasms
Prophylactic irradiation of para-aortic lymph nodes for patients with locally advanced cervical cancers with and without high CA9 expression (KROG 07-01): A randomized, open-label, multicenter, phase 2 trial.
Uterine Cervical Neoplasms
Role of hypoxia-inducible factor-1?, carbonic anhydrase-IX, glucose transporter-1 and vascular endothelial growth factor associated with lymph node metastasis and recurrence in patients with locally advanced cervical cancer.
Uterine Cervical Neoplasms
siRNA-mediated knockdown against CDCA1 and KNTC2, both frequently overexpressed in colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis.
Uterine Cervical Neoplasms
Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer.
Uterine Cervical Neoplasms
[Evaluation of genotyping of human papilomavirus by a new DNA liquid chip based on Luminex XMAP]
Uveal Effusion Syndrome
Medical therapy for uveal effusion syndrome.
Uveitis
Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema.
Uveitis
[Therapy of cystoid diffuse macular edema after uveitis and cataract surgery with the carbonic anhydrase inhibitor acetazolamide (Diamox)]
Uveitis, Anterior
Serum Anti-carbonic Anhydrase Antibodies and Oxidant-Antioxidant Balance in Patients with Acute Anterior Uveitis.
Uveomeningoencephalitic Syndrome
Proteomics Profiling of Plasma Exosomes in VKH Patients
Vaccinia
Reconstitution of carbonic anhydrase activity of the cell-surface-binding protein of vaccinia virus.
Vaccinia
Structural and functional characterization of a cell surface binding protein of vaccinia virus.
Vascular Calcification
Mice carrying a CAR-2 null allele lack carbonic anhydrase II immunohistochemically and show vascular calcification.
Vascular Calcification
The role of carbonic anhydrase in the pathogenesis of vascular calcification in humans.
Vasculitis
Anti-carbonic anhydrase III autoantibodies in vasculitis syndrome.
Venous Thromboembolism
Prevalence of heparin cofactor II deficiency in patients with a history of venous thrombosis.
Venous Thrombosis
Hereditary heparin cofactor II deficiency and the risk of development of thrombosis.
Venous Thrombosis
Prevalence of heparin cofactor II deficiency in patients with a history of venous thrombosis.
Ventricular Dysfunction, Right
Carbonic Anhydrase IX in the Prediction of Right Ventricular Dysfunction in Patients With Hemodynamically Stable Acute Pulmonary Embolism.
Vesicular Stomatitis
A novel quasi-viral agent, MaTu, is a two-component system.
Viremia
Clinical evaluation of the digene hybrid capture II test and the COBAS AMPLICOR monitor test for determination of hepatitis B virus DNA levels.
Virus Diseases
Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type-2 inflammation: a patent evaluation (WO2017/058370).
Virus Diseases
Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase I.
von Hippel-Lindau Disease
Expression of hypoxia-inducible carbonic anhydrases in brain tumors.
Vulvar Neoplasms
Hemoglobin level predicts outcome for vulvar cancer patients independent of GLUT-1 and CA-IX expression in tumor tissue.
Vulvar Neoplasms
Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases.
Vulvar Neoplasms
Serum carbonic anhydrase IX and its prognostic relevance in vulvar cancer.
Wasting Syndrome
Carbonic anhydrase XII functions in health and disease.
Wilms Tumor
Establishment of HLA-DR4 transgenic mice for the identification of CD4+ T cell epitopes of tumor-associated antigens.
Wilms Tumor
Overexpression of carbonic anhydrase and HIF-1? in Wilms tumours.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
show
top
